10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____.

Commission file number:  001-36475

Aemetis, Inc.

(Exact name of registrant as specified in its charter)

Delaware	26-1407544
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

20400 Stevens Creek Blvd., Suite 700

Cupertino, CA 95014

(408) 213-0940

(Address and telephone number of principal executive offices)

Securities registered under Section 12(b) of the Exchange Act:

Title of each class of registered securities	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.001 par value	AMTX	NASDAQ

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☐    No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ☐    No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑      No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  (Check one):

Large accelerated filer	☐	Accelerated filer	☑
Non-accelerated filer	☐	Smaller reporting company	☑
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐   No ☑

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $253.2 Million as of June 30, 2023, based on the closing price on the NASDAQ Global Market reported for such date.

The number of shares outstanding of the registrant’s Common Stock on February 29, 2024, was 42,608,698 shares.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the Registrant’s 2024 Annual Meeting of Stockholders which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant's fiscal year ended December 31, 2023, are incorporated by reference in Part III of this Form 10-K.

TABLE OF CONTENTS

	Page
PART I
Special Note Regarding Forward-Looking Statements	2
Item 1.  Business	2
Item 1A.  Risk Factors	8
Item 2.  Properties	21
Item 3.  Legal Proceedings	22
Item 4.  Mine Safety Disclosures	22
PART II
Item 5.  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	22
Item 6.  [Reserved]	22
Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 8.  Financial Statements and Supplementary Data	33
Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	69
Item 9A.  Controls and Procedures	70
Item 9B.  Other Information	71
PART III
Item 10.  Directors, Executive Officers and Corporate Governance	71
Item 11.  Executive Compensation	71
Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	71
Item 13.  Certain Relationships and Related Transactions, and Director Independence	71
Item 14.  Principal Accounting Fees and Services	71
PART IV
Item 15.  Exhibits and Financial Statement Schedules	72
Index to Financial Statements	33
Signatures	78

1

PART I

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

We make forward-looking statements in this Annual Report on Form 10-K, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this Annual Report on Form 10-K include, without limitation, statements regarding management’s plans; trends in market conditions with respect to prices for inputs for our products and prices for our products; our ability to leverage approved feedstock pathways; our ability to leverage our location and infrastructure; our ability to incorporate lower cost, non‑food advanced biofuels feedstock at the Keyes plant; our ability to expand into alternative markets for biodiesel and its byproducts, including continuing to expand our sales into international markets; our ability to maintain and expand strategic relationships with suppliers; our ability to access governmental carbon reduction incentives; our ability to construct and fund diary digesters; our ability to supply gas into the transportation markets; our ability to continue to develop, maintain, and protect new and existing intellectual property rights; our ability to adopt, develop and commercialize new technologies; our ability to refinance our senior debt on more commercial terms or at all; our ability to continue to fund operations and our future sources of liquidity and capital resources; our ability to sell additional notes under our EB‑5 note program and our expectations regarding the release of funds from escrow under our EB-5 note program; our ability to improve margins; and our ability to raise additional debt and equity funding at the parent, subsidiary or project level. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “targets,” “will likely result,” “will continue” or similar expressions are intended to identify forward looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, the risks set forth under the caption “Risk Factors” below, which are incorporated herein by reference as well as those business risks and factors described elsewhere in this report and in our other filings with the Securities and Exchange Commission (the “SEC”).

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  

We obtained the market data used in this report from internal company reports and industry publications. Industry publications generally state that the information contained in those publications has been obtained from sources believed to be reliable, but their accuracy and completeness are not guaranteed, and their reliability cannot be assured.  Although we believe market data used in this Form 10‑K is reliable, it has not been independently verified.

Unless the context requires otherwise, references to “we,” “us,” “our,” and “the Company” refer specifically to Aemetis, Inc. and its subsidiaries.

Item 1.  Business

General

Founded in 2006 and headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis referred to herein as “Aemetis,” the “Company,” “we,” “our” or “us”) is an international renewable natural gas and renewable fuels company focused on the operation, acquisition, development, and commercialization of innovative technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.  We do this by building a local circular bioeconomy using agricultural products and waste to produce low carbon, advanced renewable fuels that reduce greenhouse gas ("GHG") emissions and improve air quality.  Our current operations include:

►  California Ethanol - We own and operate a 65 million gallon per year capacity ethanol production facility in Keyes, California (the “Keyes Plant”). In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains (“WDG”), Distillers Corn Oil (“DCO”), and Condensed Distillers Solubles (“CDS”), all of which are sold as animal feed to local dairies and feedlots.  The Keyes Plant also sells CO₂ that is converted to liquid and sold to food, beverage, and industrial customers. We are implementing several energy efficiency initiatives at the Keyes Plant focused on reducing operating costs and lowering the carbon intensity of our fuel.

►  California Dairy Renewable Natural Gas - We produce Renewable Natural Gas (RNG) in central California.  Our facilities consist of eight anaerobic digesters that produce biogas from dairy waste, a 26-mile biogas collection pipeline leading to a central upgrading hub, and an interconnect to inject the RNG into the utility natural gas pipeline for delivery to customers for use as transportation fuel.  We are actively expanding our RNG production dairies, with several additional digesters under construction, agreements with a total of 43 dairies, and environmental review completed for an additional 24 miles of pipeline.  We are also building our own RNG dispensing station, which is planned to begin operating in 2024.

►  India Biodiesel - We own and operate a plant in Kakinada, India (“Kakinada Plant”) with a capacity to produce about 60 million gallons per year of high-quality distilled biodiesel from a variety of vegetable oil and animal waste feedstocks.  The Kakinada Plant is one of the largest biodiesel production facilities in India.  The Kakinada Plant can also distill the crude glycerin byproduct from the biodiesel refining process into refined glycerin, which is sold to the pharmaceutical, personal care, paint, adhesive, and other industries. 

In addition, we are actively growing our business by seeking to develop or acquire new facilities, including the following key projects:

►  Sustainable Aviation Fuel and Renewable Diesel – We are developing a sustainable aviation fuel and renewable diesel (“SAF/RD”) production plant to be located at the Riverbank Industrial Complex in Riverbank, CA. The plant is currently designed to produce 90 million gallons per year of SAF/RD from renewable oil and fats obtained from the Company’s other biofuels plants and other sources. The plant will use low-carbon hydroelectric electricity and renewable hydrogen that is generated within the plant’s own processes using byproducts of the SAF/RD production. In September 2023, we received approval of the Use Permit and CEQA for the development of the plant, and we are continuing with the engineering and other required development activities for the plant.

2

► Carbon Capture and Underground Sequestration – We are developing Carbon Capture and Underground Sequestration (“CCUS”) facilities that will inject carbon dioxide captured from air emissions deep into the ground for geologic storage to reduce emissions to the atmosphere of greenhouse gases that contribute to global warming.  In May 2023, the Company received a permit from the State of California to build a geologic characterization well that will provide information for the permitting and design of a CCUS well to be located in Riverbank, California. The Company plans to construct that well in 2024 and is at the same time is continuing engineering, permitting and other development activities for the sequestration well.

The Company’s current and planned businesses produce renewable fuels and reduce carbon emissions, while generating valuable Renewable Fuel Standard credits, California Low Carbon Fuel Standard credits, and federal tax credits.

Strategy

Key elements of our strategy include:

California Ethanol

Improve operating margins and cash flow by improving the energy efficiency of the Keyes Plant and continuing to seek alternative feedstocks that minimize cost and carbon emissions.  Over the past 12 years, we have made several improvements to the Keyes plant that allow us to sell substantially all of our byproducts as commercial products into the local agricultural economy.  For the last several years, our strategy has focused on further improvements to reduce the carbon emissions from the plant and to improve the plant's energy efficiency, both of which will lower the carbon intensity and increase the value of the ethanol we produce and sell. We are in the process of designing and procuring a mechanical vapor recompression (MVR) system that is expected to reduce natural gas consumption by 80%. We have installed and are in the final stages of commissioning a 1.9 megawatt solar microgrid with battery backup. In addition, we are continuing to seek out and evaluate potential feedstocks that will reduce cost and carbon intensity, with an emphasis on processes that use cellulosic feedstocks to augment or replace current feedstocks.

California Dairy Renewable Natural Gas

Leverage our position as an established dairy digester owner and operator to continue to build dairy digesters and connected pipeline to increase RNG production. In 2018, we benefited from our established relationship with more than 80 California Central Valley dairies to begin signing leases and raising funds to construct dairy digesters. We now have eight operating dairy digesters that produce biomethane, six additional digesters under construction, and contracts with a total of 43 dairies for supply of feedstock to current and future digesters.  We are currently producing RNG at a rate of about 270,000 MMBtu per year, and we plan to continue to build digesters and expand our upgrading hub over the next several years to be able to produce about 1.6 million MMBtu/year of RNG.

India Biodiesel

Capitalize on recent policy changes by the Government of India. We plan to continue to pursue sales of biodiesel to Oil Marketing Companies (“OMC’s”) that are owned by the India government under the recently adopted cost-plus contract structure, as well as pursing sales to traditional bulk, fleet, industrial, retail, and transportation biodiesel markets in India. These sales are driven in part by the India government's 2022 update to its National Biofuels Policy that targets a blend of 5% biodiesel into fossil diesel.

Diversify our feedstocks.  We have designed and upgraded our Kakinada Plant to be able to produce biodiesel from multiple feedstocks and plan to continue efforts to procure and process these diversified feedstocks where and when economically feasible.  We have developed proprietary technology that allows us to use lower-cost Fatty Acid Distillate as a feedstock. We also now have the ability to use animal tallow to produce biodiesel, so we have begun procuring tallow.  This allows us to acquire tallow that we may use for production while also pursuing opportunities for exports of tallow.

Develop and commercially deploy technologies to produce high-margin products. We plan to continue investing in the conversion of lower quality, waste oils into higher value biofuels in addition to biodiesel, including renewable diesel and sustainable aviation fuels. Additionally, we continue to evaluate improvements to the throughput capacity and efficiency of our production facilities.  We plan to invest in those areas that allow for more efficient and higher throughput for the production of biodiesel and refined glycerin.

Other Initiatives

Leverage technology for the development and production of additional advanced biofuels and renewable chemicals. We continue to evaluate new technologies, develop technologies under our existing patents and conduct research and development to produce low and negative carbon intensity advanced biofuels from renewable feedstocks. Our objective is to continue to commercialize our portfolio of technologies and expand the adoption of these advanced biofuels and bio-chemicals technologies.

Leverage site control of our Keyes and Riverbank properties to construct production plants to produce low and negative carbon intensity products. Initiatives are underway to construct facilities that produce SAF and renewable diesel at our Riverbank location, and to generate LCFS and IRS 45Q credits by injecting CO₂ into wells at both our Keyes Plant and Riverbank locations.

Evaluate and pursue technology and facility acquisition opportunities.  We intend to evaluate and pursue opportunities to acquire technologies and facilities that result in accretive value opportunities as financial resources and business prospects make the acquisition of these technologies, facilities, and processes advisable. In addition, we may also seek to acquire companies, enter into licensing agreements, or form joint ventures with companies that offer prospects for the adoption of technologies that would be accretive to earnings.

3

2023 Highlights

California Ethanol

We produce five products at our California Ethanol plant: denatured fuel ethanol, wet distillers grains (WDG), distillers corn oil (DCO), condensed distillers solubles, and CO₂. The products reflect our primary production and the result of our strategy over the last decade to convert substantially all of the byproducts of the plant into marketable products.  During 2023, we substantially installed a solar microgrid, which is expected to begin operation in early 2024, as a key step in electrifying and further reducing the carbon emissions from the plant.  We shut down the Keyes plant in late 2022 due to high natural gas prices, used the shutdown period to install several improvements, and restarted the plant in June 2023; this shutdown period is the primary reason for the lower output in 2023. The following table shows our production and sales of ethanol and WDG in 2023 and 2022:

	Years ended December 31,				2023 vs 2022 %
	2023		2022		Change
Ethanol
Gallons Sold (in millions)		32.1		59.0		-45.6	%
Average Sales Price/Gallon	$	2.44	$	2.81		-13.2	%
WDG
Tons Sold (in thousands)		225		397		-43.3	%
Average Sales Price/Ton	$	97	$	128		-24.2	%

California Dairy Renewable Natural Gas

During 2023, we delivered Renewable Natural Gas ("RNG") to the market through the regional utility gas pipeline. We used contractual relationships with third-party fuel stations to dispense gas for transportation use.  In connection with dispensing for transportation use, we began generating and inventorying sellable credits under the federal Renewable Fuel Standard (referred to as "D3 RINs") and the California Low Carbon Fuel Standard ("LCFS"). We began selling D3 RINs in the third quarter of 2023 and began selling LCFS credits using the temporary carbon intensity pathway score of negative 150 in the first quarter of 2024. The individual dairy LCFS scores are under review by the California Air Resources Board (CARB).  We are continuing to actively increase our RNG production by constructing additional dairy digesters and pipelines and by engaging in pre-construction development efforts for the contracting, permitting and financing of additional digesters to continue the growth.  The following table shows our production and sales of dairy RNG in 2023 and 2022:

	Years ended December 31,				2023 vs 2022 %
	2023		2022		Change
Dairy Renewable Natural Gas
MMBtu external sales (in thousands)		194.2		8.4		2211.9	%
MMBtu stored as inventory (in thousands)		68.0		9.0		655.6	%
MMBtu intercompany sales (in thousands)		-		48.6		-100.0	%

India Biodiesel

We produce two primary products at the Kakinada Plant: biodiesel and refined glycerin manufactured by further processing of the crude glycerin that is a by‑product of biodiesel production. During 2023, we sold biodiesel to the government Oil Marketing Companies ("OMCs") Hindustan Petroleum, Bharat Petroleum, and Indian Oil Corporation. In the fourth quarter of 2023, we received a new 12-month allocation from the OMCs for the sale of 18,334 metric tons of biodiesel and we began executing this allocation. The following table shows our production and sales of biodiesel and refined glycerin in 2023 and 2022:

	Years ended December 31,				2023 vs 2022 %
	2023		2022		Change
Biodiesel
Metric tons sold (in thousands) (1)		60.5		17.7		241.8	%
Average Sales Price/Ton	$	1,232	$	1,526		-19.3	%
Refined Glycerin
Metric tons sold (in thousands) (1)		4.2		1.2		250.0	%
Average Sales Price/Ton	$	640	$	850		-24.7	%

(1) 1 metric ton is equal to 1,000 kilograms (approximately 2,204 pounds).

4

Competition

California Ethanol – According to the U.S. Energy Information Agency (the “EIA”), on January 1, 2023, there were approximately 187 commercial ethanol production facilities in the U.S. with combined production of approximately 17.7 billion gallons per year. The production of ethanol is a commodity-based business where producers compete on the basis of price. We sell ethanol into the California market. However, since there is insufficient production capacity in California to supply the state’s total fuel ethanol consumption (in excess of 1.5 billion gallons annually), we compete with ethanol transported into California principally from Midwestern producers or imported from other countries, primarily Brazil. Similarly, our co-products, principally WDG and DCO, are sold into local California markets and compete with DDG and DCO imported into California as well as with alternative feed products.

California Dairy Renewable Natural Gas – Dairy renewable natural gas sold for transportation use currently competes with other renewable gas, fossil natural gas, and with fossil based products.  The pricing for our sales of D3 RINs and LCFS credits fluctuates based on the supply and demand for those credits at any given time, and we compete with other credit producers that are participating in those markets.  

India Biodiesel – Biodiesel sold as fuel competes primarily with the producers of petroleum diesel, consisting of the three OMCs and two private oil companies:  Reliance Petroleum and Essar Oil, all of whom have significantly larger market shares for fossil diesel than we do for renewable diesel, and they control a significant share of the distribution network. These companies also purchase our product for blending with fossil-diesel and further sales to their customers.  We compete primarily on the basis of price, quality and reliable delivery, since our plant can produce distilled biodiesel and has historically been a more reliable and high-quality supplier than some other biodiesel producers in India. With respect to crude and refined glycerin, we compete with other glycerin producers and refiners selling products into the personal care, paints and adhesive markets primarily on the basis of price and product quality.

Customers

California Ethanol – We sell 100% of the ethanol, WDG, CDO, and CDS we produce to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement, and J.D. Heiskell resells the products to customers designated by us. We have designated a single fuel marketing company, Murex LLC ("Murex"), to purchase our ethanol, which it resells to fuel blenders. We sell the CO₂ gas from our fermenters through a dedicated pipeline to Messer Gas, which operates a commercial grade CO₂ production plant adjacent to our Keyes plant.

California Dairy Renewable Natural Gas – We deliver Renewable Natural Gas into the regional utility gas pipeline and sell it to transportation customers through a contractual relationship with a fuel dispensing company. We sell the environmental attributes through industry brokers.

India Biodiesel – We sell biodiesel to the three Government OMC’s. During 2023, our Oil Marketing Companies customers accounted for 95% of our biodiesel sales.

Pricing

California Ethanol – The market prices of ethanol, WDG, and DCO vary throughout the year.  Ethanol pricing is influenced by local and national inventory and production levels, imported ethanol, corn prices, regulatory factors, gasoline demand, and government regulations related to renewable fuel volumes and allowed fuel mixes. Our ethanol price is based on quarterly sales contracts entered by Murex with local fuel blenders that typically based delivery prices on indexes of daily spot prices for ethanol. The price for WDG is influenced by the price of corn, the supply and price of dried distillers grains, and demand from the local dairy and feed markets and determined monthly pursuant to a marketing agreement with A.L. Gilbert and is generally determined in reference to the local price of dried distillers grains and other comparable feed products. 

California Dairy Renewable Natural Gas – The price for sales of RNG gas molecules is based on the market price of fossil based natural gas.  The price we receive for sales of D3 RINs and LCFS credits are typically based on spot markets for those credits.  Each of those credit markets is driven by regulatory factors that affect the quantity of credits needed by fossil fuel producers to achieve compliance, and also by the abundance of credits generated by renewable fuel producers.

India Biodiesel – During 2022, the formula for setting the OMC’s offer price was modified to allow biodiesel producers in India to begin production and supply of product at economically viable levels under these contracts, and this pricing mechanism continued in 2023.  The pricing uses a "cost-plus" formula under which the current price for sales is based on the trailing average of several factors of production cost.

Raw Materials and Suppliers

California Ethanol – We procure corn as feedstock for the Keyes Ethanol Plant from J.D. Heiskell. The purchase price is based on spot market prices at the time we process the corn, plus transportation costs and fees.

California Dairy Renewable Natural Gas – We produce Renewable Natural Gas from biogas generated by anerobic digesters located on properties that we lease from dairy operators. We construct and own the dairy digesters and the pipeline that connects the digesters to our upgrading hub located at our California Ethanol plant. Our agreements with each dairy include both a land lease and an agreement by the dairy to supply their manure into our digesters, with payments from us to the dairy based primarily on herd size and the value of environmental attributes that we generate. Generally, these leases have a 25-year term with two five year options to renew.

5

India Biodiesel – Our plant is currently capable of using a broad variety of feedstocks to produce biodiesel, which provides us with flexibility to purchase the least cost feedstocks available in the market.  In 2023 and 2022, we produced a significant amount of our biodiesel from refined palm stearin, which was sourced locally. The byproduct of producing high fat RBD/crude palm stearin is palm fatty acid distillate (PFAD), which we can also process into biodiesel. During 2021, we received approval from the Pollution Control Board of India to use refined animal tallow for production of biodiesel and we began procuring tallow. In addition to feedstock, the Kakinada Plant requires methanol and chemical catalysts for use in the biodiesel production process. These chemicals are also readily available and sourced from a number of suppliers surrounding the Kakinada Plant. We are not dependent on sole source or limited source suppliers for any of our raw materials or chemicals.

Commodity Risk Management Strategies

California Ethanol – The cost of corn and the price of ethanol are volatile and the correlation of the pricing of these commodities determines the profit margin at our Keyes Plant. We are, therefore, exposed to commodity price risk. We monitor prices daily to assess the overall impact of the pricing on profitability. We periodically explore and utilize methods of mitigating the volatility of our commodity prices through hedging strategies. We sold our WDG during 2022 on a month-to-month basis, however, we monitor and periodically sell on a quarterly basis when we believe longer term contracts allow us to better manage commodity and pricing risk. In 2023, we engaged in advance purchases of natural gas supply to obtain longer term benefits of favorable prices.

California Dairy Renewable Natural Gas – The prices for renewable natural gas, D3 RINs, and LCFS credits are volatile. We therefore are exposed to market price risk for our sales of RNG and associated environmental attributes. We mitigate risk by scaling our payments to dairy operators based, in part, upon the market price for credits in order to correlate our costs to market prices.

India Biodiesel –The cost of crude or refined palm stearin and the price of biodiesel are volatile and are generally uncorrelated. We therefore are exposed to ongoing and substantial commodity price risk at our Kakinada plant.  Our risk management strategies are to (i) configure the Kakinada plant to be able to produce biodiesel from a wide variety of feedstocks and (ii) to produce biodiesel only when we believe we can generate positive gross margins and to idle the Kakinada Plant during periods of low or negative gross margins.  Additionally, we currently sell our biodiesel primarily to OMCs using a cost-plus based pricing structure that correlates our product pricing with our feedstock and operating costs. 

Research and Development

Our research and development efforts are targeted towards evaluating, and commercializing technologies for the production of SAF, renewable diesel fuel, cellulosic ethanol, and other renewable biofuels. The objective of this development activity is to identify and develop efficient conversion technologies that will use waste feedstocks to produce renewable biofuels and biochemicals that have low carbon intensity on a large-scale, commercial basis.

Patents and Trademarks

We hold several awarded patents in the United States.  Our patents cover processes to break down plant biomass and a technology to convert carbon chain chemical structures. We intend to develop, maintain and secure further intellectual property rights and pursue new patents to expand upon our current patent base. As an operating company, we do not consider our business, as a whole, to be dependent on the ownership of patents, but we are seeking to develop and/or access them as means to allow our facilities to use lower cost or lower carbon sources of feedstock to produce renewable fuels.  We currently have one issued trademark. We do not consider the success of our business, as a whole, to be dependent on these trademarks.

Environmental and Regulatory Matters

California Ethanol and California Dairy Renewable Natural Gas

We are subject to federal, state and local environmental laws, regulations and permit conditions, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees.  These laws, regulations and permits may, from time to time, require us to incur significant capital costs.  These include, but are not limited to, testing and monitoring plant emissions, and where necessary, obtaining and maintaining mitigation processes to comply with regulations.  They may also require us to make operational changes to limit actual or potential impacts to the environment.  A significant violation of these laws, regulations, permits or license conditions could result in substantial fines, criminal sanctions, permit revocations and/or facility shutdowns.  In addition, environmental laws and regulations change over time, and any such changes, more vigorous enforcement policies or the discovery of currently unknown conditions may require substantial additional environmental expenditures.

6

We are also subject to potential liability for the investigation and cleanup of environmental contamination at each of the properties that we own or operate and at off-site locations where we arrange for the disposal of hazardous wastes.  If significant contamination is identified at our properties in the future, costs to investigate and remediate this contamination as well as costs to investigate or remediate associated damage could be significant.  If any of these sites are subject to investigation and/or remediation requirements, we may be responsible under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 (“CERCLA”) or other environmental laws for all or part of the costs of such investigation and/or remediation, and for damage to natural resources.  We may also be subject to related claims by private parties alleging property damage or personal injury due to exposure to hazardous or other materials at or from such properties.  While costs to address contamination or related third-party claims could be significant, based upon currently available information, we are not aware of any such material contamination or third-party claims.  Based on our current assessment of the environmental and regulatory risks, we have not accrued any amounts for environmental matters as of December 31, 2023 and 2022.  The ultimate costs of any liabilities that may be identified or the discovery of additional contaminants could materially adversely impact our results of operation or financial condition.

In addition, the production and transportation of our products may result in spills or releases of hazardous substances, which could result in claims from governmental authorities or third parties relating to actual or alleged personal injury, property damage, or damage to natural resources.  We maintain insurance coverage against some, but not all, potential losses caused by our operations.  Our general and umbrella liability policy coverage includes, but is not limited to, physical damage to assets, employer’s liability, comprehensive general liability, automobile liability and workers’ compensation.  We do not carry environmental insurance.  We believe that our insurance is adequate for our industry, but losses could occur for uninsurable or uninsured risks or in amounts in excess of existing insurance coverage.  The occurrence of events which result in significant personal injury or damage to our property, natural resources or third parties that is not covered by insurance could have a material adverse impact on our results of operations and financial condition.

Our air emissions are subject to the federal Clean Air Act, and similar state laws, which generally require us to obtain and maintain air emission permits for our ongoing operations as well as for any expansion of existing facilities or any new facilities.  Obtaining and maintaining those permits requires us to incur costs, and any future more stringent standards may result in increased costs and may limit or interfere with our operating flexibility.  These costs could have a material adverse effect on our financial condition and results of operations.  Because other ethanol manufacturers in the U.S. are and will continue to be subject to similar laws and restrictions, we do not currently believe that our costs to comply with current or future environmental laws and regulations will adversely affect our competitive position with other U.S. ethanol producers.  However, because ethanol is produced and traded internationally, these costs could adversely affect us in our efforts to compete with foreign producers who are not subject to such stringent requirements.

New laws or regulations relating to the production, disposal or emission of carbon dioxide and other greenhouse gases may require us to incur significant additional costs with respect to plants that we build or acquire.  We currently conduct our North American commercial activities exclusively in California. Climate change and reduction legislation is a topic of consideration by the U.S. Congress and California State Legislature, which may significantly impact the biofuels industry’s emissions regulations, as will the RFS, California’s LCFS, and other potentially significant changes in existing transportation fuels regulations.

India Biodiesel - We are subject to national, state and local environmental laws, regulations and permits, including with respect to the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees.  These laws may require us to make operational changes to limit actual or potential impacts to the environment.  A violation of these laws, regulations or permits can result in substantial fines, natural resource damages, criminal sanctions, permit revocations and/or facility shutdowns.  In addition, environmental laws and regulations (and interpretations thereof) change over time, and any such changes, more vigorous enforcement policies or the discovery of currently unknown conditions may require substantial additional environmental expenditures.

Employees

As of December 31, 2023, we had a total of 205 full-time equivalent employees, including 16 our corporate offices, 44 at the Keyes Plant, 13 Aemetis Biogas employees, 3 at the Riverbank Industrial Complex, and 129 in India.  We believe that our employees are highly skilled, and our success will depend in part upon our ability to retain our employees and attract new qualified employees, many of whom are in great demand. We have never had a work stoppage or strike, and no employees are presently represented by a labor union or covered by a collective bargaining agreement. We believe relations with our employees are positive.

Available Information

We file reports with the Securities and Exchange Commission (“SEC”). We make available on our website under the “Investors” tab, free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports as soon as reasonably practicable after we electronically file such materials with or furnish them to the SEC. Our website address is www.aemetis.com. Our website address is provided as an inactive textual reference only, and the contents of that website are not incorporated in or otherwise to be regarded as part of this report. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

7

Item 1A.  Risk Factors

We operate in an evolving industry that presents numerous risks beyond our control that are driven by factors that cannot be predicted.  Should any of the risks described in this section or in the documents incorporated by reference in this report actually occur, our business, results of operations, financial condition, or stock price could be materially and adversely affected.  Investors should carefully consider the risk factors discussed below, in addition to the other information in this report, before making any investment in our securities.

Risks Related to our Overall Business

We are currently not profitable and historically, we have incurred significant losses.  If we incur continued losses, we may have to curtail our operations, which may prevent us from successfully operating and expanding our business.

Historically, we have relied upon cash from debt and equity financing activities to fund substantially all of the cash requirements of our activities.  As of December 31, 2023, we had an accumulated deficit of approximately $475.4 million. For our fiscal years ended December 31, 2023 and 2022, we reported a net loss of $46.4 million, and $107.8 million respectively. We may incur losses for an indeterminate period of time and may not achieve consistent profitability.  We expect to rely on cash on hand, cash, if any, generated from our operations, borrowing availability, if any, under our lines of credit and proceeds from future financing activities, if any, to fund all of the cash requirements of our business.  In some market environments, we may have limited access to incremental financing, which could defer or cancel growth projects, reduce business activity or cause us to default on our existing debt agreements if we are unable to meet our payment schedules. An extended period of losses or negative cash flow may prevent us from successfully operating and expanding our business.  

Our indebtedness, preference payments, and interest expense could limit cash flow and adversely affect operations and our ability to make full payment on outstanding debt.

For the year ended December 31, 2023, we recognized $33.0 million in interest rate expense and $25.3 million in accretion of Series A preferred units (excludes debt related fees and amortization expense). 

● Any cash flows after covering our operations, equity raises if any, and any EB-5 funding are used to pay principal and interest on debt, thereby reducing the funds available for working capital, capital expenditures, acquisitions, research and development and other general corporate purposes;

● Any Biogas cash flows are used to pay mandatory redemptions under the Preferred Unit Purchase Agreement and thus reduce the funds available to use by us for operations.

● Insufficient cash flows from operations may force us to sell assets, or seek additional capital, which we may not be able to accomplish on favorable terms, if at all; and

● The level of indebtedness may make us more vulnerable to economic or industry downturns.

Our business is dependent on external financing and cash from operations to service debt and provide future growth.

The adoption of new technologies at our ethanol and biodiesel plants, the development bio-methane digesters at local dairies near our Keyes Plant, a SAF/RD production plant and CCUS projects, and our working capital requirements are financed in part through debt or debt-like facilities.  We may need to seek significant additional financing to continue or grow our operations and to develop our business. However, generally unfavorable credit market conditions may make it difficult to obtain necessary capital or additional debt financing on commercially viable terms or at all.  If we are unable to pay our debt, we may be forced to delay or cancel capital expenditures, sell assets, restructure our indebtedness, seek additional financing, or file for bankruptcy protection.  Debt levels or debt service requirements may limit our ability to borrow additional capital, make us vulnerable to increases in prevailing interest rates, subject our assets to liens, limit our ability to adjust to changing market conditions, or place us at a competitive disadvantage to our competitors.  Should we be unable to generate enough cash from our operations or secure additional financing to fund our operations and debt service requirements, we may be required to postpone or cancel growth projects, reduce our operations, or may be unable to meet our debt repayment schedules.  Any one of these events would likely have a material adverse effect on our operations and financial position.

There can be no assurance that our existing cash flow from operations will be sufficient to sustain operations and to the extent that we are dependent on credit facilities to fund operations or service debt, there can be no assurances that we will be successful at securing funding from our senior lender or significant shareholders. Should we require additional financing, there can be no assurances that the additional financing will be available on terms satisfactory to us.  Our ability to identify and enter into commercial arrangements with feedstock suppliers in India depends on maintaining our operations agreement with Gemini Edibles and Fats India Private Limited (“Gemini”) and Secunderabad Oils Limited (“SOL”).  If we are unable to maintain this strategic relationship, our business may be negatively affected.  In addition, the ability of Gemini and SOL to continue to provide us with working capital depends in part on the financial strength of them and their banking relationships.  If Gemini and SOL are unable or unwilling to continue to provide us with working capital, our business may be negatively affected.  Our ability to enter into commercial arrangements with feedstock suppliers in California depends on maintaining our operations agreement with J.D. Heiskell, who is currently providing us with working capital for our Keyes Plant.  If we are unable to maintain this strategic relationship, our business may be negatively affected.  In addition, the ability of J.D. Heiskell to continue to provide us with working capital depends in part on the financial strength of J.D. Heiskell and its banking relationships.  If J.D. Heiskell is unable or unwilling to continue to provide us with working capital, our business may be negatively affected.  Our consolidated financial statements do not include any adjustments to the classification or carrying values of our assets or liabilities that might be necessary as a result of the outcome of this uncertainty.

8

We may be unable to repay or refinance our Third Eye Capital Notes upon maturity.

Under our note facilities with Third Eye Capital, we owe approximately $181.8 million, excluding debt discounts, as of December 31, 2023.  Our indebtedness and interest payments under these note facilities are currently substantial and may adversely affect our cash flow, cash position and stock price.  The current maturity date on some of these notes was recently extended to April 2025. We have been able to extend our indebtedness in the past, but we may not be able to continue to extend the maturity of these notes.  We may not have sufficient cash available at the time of maturity to repay this indebtedness.  We have default covenants that may accelerate the maturities of these notes.  We may not have sufficient assets or cash flow available to support refinancing these notes at market rates or on terms that are satisfactory to us.  If we are unable to extend the maturity of the notes or refinance on terms satisfactory to us, we may be forced to refinance on terms that are materially less favorable, seek funds through other means such as a sale of some of our assets or otherwise significantly alter our operating plan, any of which could have a material adverse effect on our business, financial condition and results of operations. Additionally, if we are unable to amend our current note purchase agreement with Third Eye Capital, our ability to pay dividends could be restrained.

We are dependent upon our working capital agreements with J.D. Heiskell, Gemini Edibles and Fats India Private Limited and Secunderabad Oils Limited. 

Our ability to operate our Keyes Plant depends on maintaining our working capital agreement with J.D. Heiskell, our marketing agreement with Murex and our ability to operate the Kakinada Plant depends on maintaining our working capital agreements with Gemini and SOL. The Heiskell Agreement provides for an initial term of one year with automatic one-year renewals; provided, however, that J.D. Heiskell may terminate the agreement by notice 30 days prior to the end of the initial term or any renewal term.  In addition, the agreement may be terminated at any time upon an event of default, such as payment default, bankruptcy, acts of fraud or material breach under one of our related agreements with J.D. Heiskell.  The Gemini and SOL agreement may be terminated at any time by either party upon written notice.  If we are unable to maintain these strategic relationships, we will be required to locate alternative sources of working capital and corn supply, which we may be unable to do in a timely manner or at all.  If we are unable to maintain our current working capital arrangements or locate alternative sources of working capital, our ability to operate our plants will be negatively affected.

Our results from operations are primarily dependent on the spread between the feedstock and energy we purchase and the fuel, animal feed and other products we sell.

The results of our ethanol production business in the U.S. are significantly affected by the spread between the cost of corn and natural gas that we purchase and the price of the ethanol, WDG and DCO that we sell. Similarly, in India our biodiesel business is primarily dependent on the price difference between the costs of the feedstock we purchase (principally NRPO and crude glycerin) and the products we sell (principally distilled biodiesel and refined glycerin).  The markets for ethanol, biodiesel, WDG, DCO and glycerin are highly volatile and subject to significant fluctuations.  Any decrease in the spread between prices of the commodities we buy and sell, whether as a result of an increase in feedstock prices or a reduction in ethanol or biodiesel prices, would adversely affect our financial performance and cash flow and may cause us to suspend production at either of our plants.

As of December 31, 2021 we became an “accelerated filer” and are therefore subject to the auditor attestation requirement in the assessment of our internal control over financial reporting.

Because the worldwide market value of our common stock held by non-affiliates exceeded $75 million (but was less than $700 million), as of the last business day of our fiscal quarter ended June 30, 2022, we are an “accelerated filer” as defined by SEC rule. Therefore, we are now subject to the requirement that we include in this Annual Report on Form 10-K for the fiscal year ending December 31, 2022, the auditor’s attestation report on assessment of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. If we do not have a sufficient history for us and our independent registered public accounting firm to test and evaluate our new processes and controls, we may be unable to obtain an unqualified attestation report from our independent registered public accounting firm required under Section 404 of the Sarbanes-Oxley Act. If our independent registered public accounting firm is not able to render an unqualified attestation, it could result in lost investor confidence in the accuracy, reliability, and completeness of our financial reports. We expect that our status as an accelerated filer and compliance with these increased requirements will require management to expend additional time while also condensing the time frame available to comply with certain requirements, which may further increase our legal and financial compliance costs.

The price of ethanol is volatile and subject to large fluctuations, and increased ethanol production may cause a decline in ethanol prices or prevent ethanol prices from rising, either of which could adversely impact our results of operations, cash flows and financial condition.

The market price of ethanol is volatile and subject to large fluctuations. The market price of ethanol is dependent upon many factors, including the supply of ethanol and the demand for gasoline, which is in turn dependent upon the price of petroleum, which is also highly volatile and difficult to forecast.  Fluctuations in the market price of ethanol may cause our profitability or losses to fluctuate significantly.  In addition, domestic ethanol production capacity increased significantly in the last decade.  Demand for ethanol may not increase commensurately with increases in supply, which could lead to lower ethanol prices. Demand for ethanol could be impaired due to a number of factors, including regulatory developments and reduced gasoline consumption. Reduced gasoline consumption has occurred in the past and could occur in the future as a result of increased gasoline or oil prices.

We may be unable to execute our business plan.

The value of our long-lived assets is based on our ability to execute our business plan and generate sufficient cash flow to justify the carrying value of our assets.  Should we fall short of our cash flow projections in the future, we may be required to write down the value of these assets under accounting rules and further reduce the value of our assets.  We can make no assurances that future cash flows will develop and provide us with sufficient cash to maintain the value of these assets, thus avoiding future impairment to our asset carrying values.  As a result, we may need to write down the carrying value of our long-lived assets.

9

In addition, we intend to modify or adapt third party technologies at the Keyes Plant and at the Kakinada Plant to accommodate alternative feedstocks and improve operations.  After we design and engineer a specific integrated upgrade to either or both plants to allow us to produce products other than their existing products, we may not receive permission from the regulatory agencies to install the process at one or both plants.  Additionally, even if we are able to install and begin operations of an integrated advanced fuels and/or bio-chemical plant, we cannot assure you that the technology will work and produce cost effective products because we have never designed, engineered nor built this technology into an existing bio-refinery.  Similarly, our plans to develop the SAF/RD production plant, CCS, the integrated microgrid, the MVR system, or the Mitsubishi dehydration system at the Keyes Plant may not be successful as a result of financing or issues in the design or construction process.  Any inability to execute our business plan may have a material adverse effect on our operations, financial position, ability to pay dividends, and ability to continue as a going concern.

We may not be able to recover the costs of our substantial investments in capital improvements and additions, and the actual cost of such improvements and additions may be significantly higher than we anticipate.

Our strategy calls for continued investment in capital improvements and additions. For example, we are currently developing “Carbon Zero” biofuels production plants designed to produce biofuels, including renewable jet and renewable diesel fuel utilizing hydrogen and non-edible renewable oils.  We are also building carbon capture sequestration wells to generate low-carbon fuel standard credits by injecting CO₂ into sequestration wells that are monitored for emissions to ensure the long-term sequestration of carbon underground, developing the Carbon Zero Facility in Riverbank, CA to utilize licensed technologies to convert local California surplus biomass into ultra-low carbon renewable ethanol.  The construction of these capital improvements and additions involves numerous regulatory, environmental, political and legal uncertainties, many of which are beyond our control and may require the expenditure of significant amounts of capital, which may exceed our estimates and we may require significant debt or equity financing. These projects may not be completed at the planned cost, on schedule or at all due to unavailability of needed financing. The construction of new ethanol and other biofuel facilities is subject to construction cost overruns due to labor costs, costs of equipment and materials such as steel, labor shortages or weather or other delays, inflation or other factors, which could be material. In addition, the construction of these facilities is typically subject to the receipt of approvals and permits from various regulatory agencies. Those agencies may not approve the projects in a timely manner, if at all, or may impose restrictions or conditions on the projects that could potentially prevent a project from proceeding, lengthen its expected completion schedule and/or increase its anticipated cost. Moreover, our revenues and cash flows may not increase immediately upon the expenditure of funds on a particular project. For instance, if we expand an existing facility or construct a new facility, the construction may occur over an extended period of time, and we may not receive any material increases in revenues or cash flows until the project is completed. As a result, the new facilities may not be able to achieve our expected investment return, which could adversely affect our results of operations.

We are in the process of developing SAF/RD, CCUS, dairy digester, and other projects, and the success of such projects depends on many factors; as such, cash flows and revenue projections may not be achieved.

We are actively developing projects designed to reduce emissions of greenhouse gases. These include (i) a biofuels production plant in Riverbank, California designed to produce SAF/RD using renewable fats and oils obtained from existing Aemetis biofuels plants and other sources, (ii) Carbon Capture and Underground Sequestration (“CCUS”) projects designed to compress and inject CO₂ into deep wells for long-term sequestration of carbon underground, (iii) additional dairy digesters at new locations, along with associated infrastructure for transporting and producing biogas and Renewable Natural Gas. We also plan to develop additional projects beyond those listed here.

Each of these development projects depends on completing all necessary development activities, including, but not limited to, obtaining necessary regulatory approvals and permits, acquisition of property rights, contracting, engineering and cost estimating, determination of feasibility, funding of project development costs, construction financing, construction, and startup. There is no certainty that we will successfully complete all the necessary development activities for any particular project, that a project will ultimately be built, that a project will be built or operational according to our planned schedule, or that a project will ultimately generate revenue or contribute to our cash flows, any of which could have a material adverse effect on our business, financial condition, results of operations and cash flow.

We rely on the availability of tax credits, carbon credits, grants, and other regulatory and financial incentives. The expiration, elimination, modification, or reduction of these regulations, credits, and incentives could adversely impact our business.

U.S. and India federal, state, and local governments provide regulations and incentives for operations and projects that are designed to promote renewable fuels and reduce carbon emissions. Each of our currently operating businesses and development projects are expected to generate revenue, cash, and credits from these government programs. In particular, we have used and plan to continue to use the provisions of the Internal Revenue Code (“IRC”) and the Inflation Reduction Act (“IRA”) amendments to the IRC in 2022 that provide Investment Tax Credits, Production Tax Credits, and other credits, and that allow us to either use the credits or to monetize the credits by selling them to third parties. These include certain transferrable IRA tax credits generated from our qualified biogas facilities. We also currently generate and plan to continue to generate credits under the federal Renewable Fuel Standard (“RFS”) and the California Low Carbon Fuel Standard (“LCFS”). Our India plant produces biofuel to help India meet the goals of its National Policy on Biofuels. The IRA, RFS, LCFS and other regulations, as well as our ability to qualify for and monetize the tax credits, carbon credits, grants and other financial incentives available thereunder, are subject to modifications, additional regulatory requirements or limits, varying interpretations, reduction, expiration, and other changes. These can occur with or without advance notice, may affect our past business activities or future plans, and may occur for a variety of reasons resulting from legislation, new or changing regulations, regulatory interpretation, court cases, and other sources. These regulatory programs, credits, and incentives have been and will continue to be material to our business and to our projects under development. Changes to regulations and reductions in or expirations of governmental credits and incentives could adversely impact our revenue, increase cost of materials, and reduce the size of our addressable market, any of which could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

10

We are dependent on, and vulnerable to any difficulties of, our principal suppliers and customers.

We buy all of the feedstock for the Keyes Plant from one supplier, J.D. Heiskell.  Under the Heiskell Supply Agreement, we are only permitted to purchase feedstock from other suppliers upon the satisfaction of certain conditions.  In addition, we have contracted to sell all of the WDG, CDS, and corn oil we produce at the Keyes Plant to J.D. Heiskell.  J.D. Heiskell, in turn, sells all WDG and syrup produced to A.L. Gilbert.  We sell the majority of our fuel ethanol production to one customer, Murex.  If J.D. Heiskell were to fail to deliver adequate feedstock to the Keyes Plant or fail to purchase all the contracted product we produce, if Murex were to fail to purchase the majority of the ethanol we produce, if A.L. Gilbert were to fail to purchase all of the WDG and syrup we produce, or if any of them were otherwise to default on our agreements with them or fail to perform as expected, we may be unable to find replacement suppliers or purchasers, or both, in a reasonable time or on favorable terms, any of which could materially adversely affect our results of operations and financial condition.

We may not receive the funds we expect under our EB-5 program.

Our EB-5 Phase I program allows for the issuance of up to 72 subordinated convertible promissory notes, each in the amount of $0.5 million due and payable four years from the date of the note for a total aggregate principal amount of up to $36.0 million. As of December 31, 2023, $35.5 million have been raised through the EB-5 program and have been released from escrow and $0.5 million remain to be funded to escrow. Additionally, the USCIS could deny approval of the loans, and then we would not receive some or all of the subscribed funds.  If the USCIS takes longer to approve the release of funds in escrow, or does not approve the loans at all, it would have a material adverse effect on our cash flows available for operations, and thus could have a material adverse effect on our results of operations. As of December 31, 2023, $37.9 million of principal and unpaid interest was outstanding on the EB-5 Notes under the EB-5 Phase I funding.

On October 16, 2016, we launched our EB-5 Phase II program, allowing for the issuance of up to 100 subordinated convertible promissory notes, on substantially similar terms and conditions as those issued under our EB-5 Phase I program, for a total aggregate principal amount of up to $50.8 million. On November 21, 2019, the minimum investment was raised from $500,000 per investor to $900,000 per investor.  As of December 31, 2023, $4.0 million has been raised through the EB-5 Phase II program and have been released from escrow and $4.3 million of principal and unpaid interest was outstanding on the EB-5 Notes under the EB-5 Phase II funding.  There can be no assurance that we will be able to successfully raise additional funds under our EB-5 Phase II program or that such funds, if raised, will be approved by USCIS. If we are unable to raise, receive approval for, or receive any funds under our EB-5 Phase II program, our business may be negatively affected.

We face competition for our bio-chemical and transportation fuels products from providers of petroleum-based products and from other companies seeking to provide alternatives to these products, many of whom have greater resources and experience than we do, and if we cannot compete effectively against these companies, we may not be successful.

Our renewable products compete with both the traditional, largely petroleum-based bio-chemical and fuels products that are currently being used in our target markets and with the alternatives to these existing products that established enterprises and new companies are seeking to produce.  The oil companies, large chemical companies and well-established agricultural products companies with whom we compete are much larger than we are, and have, in many cases, well developed distribution systems and networks for their products.

In the transportation fuels market, we compete with independent and integrated oil refiners, advanced biofuels companies, traditional biofuel companies and biodiesel companies. Refiners compete with us by selling traditional fuel products and some are also pursuing hydrocarbon fuel production using non-renewable feedstocks, such as natural gas and coal, as well as processes using renewable feedstocks, such as vegetable oil and biomass. We also expect to compete with companies that are developing the capacity to produce diesel and other transportation fuels from renewable resources in other ways.

With the emergence of many new companies seeking to produce chemicals and fuels from alternative sources, we may face increasing competition from alternative fuels and chemicals companies. As they emerge, some of these companies may be able to establish production capacity and commercial partnerships to compete with us. If we are unable to establish production and sales channels that allow us to offer comparable products at attractive prices, we may not be able to compete effectively with these companies.

We also face competition from international suppliers. Ethanol can be imported into the United States duty-free from some countries, which may undermine the domestic ethanol industry.  Currently, international suppliers produce ethanol primarily from sugar cane and as such, production costs for ethanol in these countries can be significantly less than those in the United States and the import of lower price or lower carbon value ethanol from these countries may reduce the demand for domestic ethanol and depress the price at which we sell our ethanol.

Our operations are subject to environmental, health, and safety laws, regulations, and liabilities.

Our operations are subject to various federal, state and local environmental laws, and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, access to and impacts on water supply, and the health and safety of our employees.  In addition, our operations and sales in India subject us to risks associated with foreign laws, policies and regulations.  Some of these laws and regulations require our facilities to operate under permits or licenses that are subject to renewal or modification.  These laws, regulations and permits can require expensive emissions testing and pollution control equipment or operational changes to limit actual or potential impacts to the environment. Violations of these laws, regulations or permits, or license conditions can result in substantial fines, natural resource damages, criminal sanctions, permit revocations and facility shutdowns.  We may not be at all times in compliance with these laws, regulations, permits or licenses or we may not have all permits or licenses required to operate our business.  We may be subject to legal actions brought by environmental advocacy groups and other parties for actual or alleged violations of environmental laws, permits or licenses. As we enter into new markets such as USP alcohol and hand sanitizer, we may be subject to several regulations and health and safety laws by TTB and Food and Drug Administration (‘FDA”). Failure to comply with these health and safety laws, our license to sell these products may be revoked and we may be subject to certain penalties.  In addition, we may be required to make significant capital expenditures on an ongoing basis to comply with increasingly stringent environmental laws, regulations, and permit and license requirements.

11

We may be liable for the investigation and cleanup of environmental contamination at our facilities and at off-site locations where we arrange for the disposal of hazardous substances.  If hazardous substances have been or are disposed of or released at sites that undergo investigation or remediation by regulatory agencies, we may be responsible under CERCLA or other environmental laws for all or part of the costs of investigation and remediation, and for damage to natural resources.  We also may be subject to related claims by private parties alleging property damage and personal injury due to exposure to hazardous or other materials at or from those properties. Some of these matters may require us to expend significant amounts for investigation, cleanup or other costs.

New laws, new interpretations of existing laws, increased governmental enforcement of environmental laws or other developments could require us to make additional significant expenditures.  Continued government and public emphasis on environmental issues can be expected to result in increased future investments for environmental controls at our production facilities.  Environmental laws and regulations applicable to our operations now or in the future, more vigorous enforcement policies and discovery of currently unknown conditions may require substantial expenditures that could have a negative impact on our results of operations and financial condition.

Our business is affected by greenhouse gas and climate change regulation.

Emissions of carbon dioxide resulting from manufacturing ethanol are subject to permit requirements.  Climate change continues to attract considerable attention globally. Numerous proposals have been made and could continue to be made at the international, federal, state and local levels to monitor and limit existing emissions of GHG, including carbon dioxide, as well as to restrict or eliminate future emissions. At this stage, it is not possible to accurately estimate either a timetable for implementation of any future regulations or our future compliance costs relating to implementation. Under the 2015 Paris Agreement, parties to the United Nations Framework Convention on Climate Change agreed to undertake ambitious efforts to reduce GHG emissions and strengthen adaptation to the effects of climate change. In February 2021, the U.S. recommitted to the Agreement after having withdrawn in August 2017.

In the U.S., the EPA promulgated federal GHG regulations under the Clean Air Act affecting certain sources. The EPA issued mandatory GHG reporting requirements, requirements to obtain GHG permits for certain industrial plants and GHG performance standards for some facilities. Although the EPA recently scaled back certain GHG requirements, addressing climate change is a stated priority of President Biden and as such additional regulations and legislation are likely to be forthcoming at the U.S. federal or state level that could result in increased operating costs for compliance, or required acquisition or trading of emission allowances. Additionally, demand for the products we produce may be reduced.

If new laws or regulations are passed relating to the production, disposal or emissions of carbon dioxide, we may be required to incur significant costs to comply with such new laws or regulations. Compliance with future legislation may require us to take action unknown to us at this time that could be costly, and require the use of working capital, which may or may not be available, preventing us from operating as planned, which may have a material adverse effect on our operations and cash flow.

A change in government policies may cause a decline in the demand for our products.

The domestic ethanol industry is highly dependent upon a myriad of federal and state regulations and legislation, and any changes in legislation or regulation could adversely affect our results of operations and financial position.  Other federal and state programs benefiting ethanol generally are subject to U.S. government obligations under international trade agreements, including those under the World Trade Organization Agreement on Subsidies and Countervailing Measures, and may be the subject of challenges, in whole or in part.  Growth and demand for ethanol and biodiesel is largely driven by federal and state government mandates or blending requirements, such as the RFS, which was implemented pursuant to the Energy Policy Act of 2005 and the Energy Independence and Security Act of 2007 (the “EISA”). The RFS program sets annual quotas for the quantity of renewable fuels (such as ethanol) that must be blended into motor fuels consumed in the United States. However, legislation aimed at reducing or eliminating the renewable fuel use required by the RFS has been introduced in the United States Congress. Any change in government policies could have a material adverse effect on our business and the results of our operations.

Waivers of the RFS minimum levels of renewable fuels included in gasoline or of the requirements by obligated parties to comply with the regulations could have a material adverse effect on our results of operations.  Under the Energy Policy Act, the U.S. Department of Energy, in consultation with the Secretary of Agriculture and the Secretary of Energy, may waive the renewable fuels mandate with respect to one or more states if the Administrator of the EPA determines that implementing the requirements would severely harm the economy or the environment of a state, a region or the nation, or that there is inadequate supply to meet the requirement.  Additionally, the EPA has exercised the authority to waive the requirements of the RFS for certain small refiners.  Any waiver of the RFS with respect to one or more states would reduce demand for ethanol and could cause our results of operations to decline and our financial condition to suffer.  Further activity by the EPA to waive the requirements for small refiners could cause softening of pricing in the industry and cause our results of operations to similarly decline.

A critical state program is California's LCFS, which is designed to reduce greenhouse gas emissions associated with transportation fuels used in California by ensuring that the fuel sold meets declining targets for such emissions. The regulation quantifies lifecycle greenhouse gas emissions by assigning a carbon intensity ("CI") score to each transportation fuel based on that fuel’s lifecycle assessment. Each petroleum fuel provider, generally the fuel’s producer or importer (the “Regulated Party”), is required to ensure that the overall CI score for its fuel pool meets the annual carbon intensity target for a given year. A Regulated Party’s fuel pool can include gasoline, diesel, and their blend stocks and substitutes. This obligation is tracked through credits and deficits. Fuels with a CI score lower than the annual standard earn a credit, and fuels that are higher than the standard result in a deficit. Credits can be traded. Any changes to California’s LCFS could cause our results of operations, particularly in ethanol and biogas, to decline and cause our financial condition to suffer.

12

Concerns regarding the environmental impact of biofuel production could affect public policy which could impair our ability to operate at a profit and substantially harm our revenues and operating margins.

Under the EISA, the EPA is required to produce a study every three years of the environmental impacts associated with current and future biofuel production and use, including effects on air and water quality, soil quality and conservation, water availability, energy recovery from secondary materials, ecosystem health and biodiversity, invasive species and international impacts. Should such EPA triennial studies, or other analyses find that biofuel production and use has resulted in, or could in the future result in, adverse environmental impacts, such findings could also negatively impact public perception and acceptance of biofuel as an alternative fuel, which also could result in the loss of political support. To the extent that state or federal laws are modified or public perception turns against biofuels, use requirements such as RFS and LCFS may not continue, which could materially harm our ability to operate profitably.

We may encounter unanticipated difficulties in converting the Keyes Plant to accommodate alternative feedstocks, new chemicals used in the fermentation and distillation process or new mechanical production equipment.

In order to improve the operations of the Keyes Plant and execute on our business plan, we intend to modify the Keyes Plant to accommodate alternative feedstocks and new chemical and/or mechanical production processes, including an integrated microgrid, an MVR distillation system,  the Mitsubishi dehydration system and other technologies.  We may not be able to successfully implement these modifications, and they may not function as we expect them to. These modifications may cost significantly more to complete than our estimates.  The Keyes Plant may not operate at nameplate capacity once the changes are complete.  If any of these risks materialize, they could have a material adverse effect on our results of operations and financial position.

We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act.

Our operations in countries outside the United States, including our operations in India, are subject to anti-corruption laws and regulations, including restrictions imposed by the U.S. Foreign Corrupt Practices Act (the “FCPA”). The FCPA and similar anti-corruption laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business. We operate in parts of the world that have experienced governmental corruption to some degree and, in certain circumstances, strict compliance with anti-corruption laws may conflict with local customs and practices.

Our employees and agents interact with government officials on our behalf, including interactions necessary to obtain licenses and other regulatory approvals necessary to operate our business. These interactions create a risk that actions may occur that could violate the FCPA or other similar laws.

Although we have policies and procedures designed to promote compliance with local laws and regulations as well as U.S. laws and regulations, including the FCPA, there can be no assurance that all of our employees, consultants, contractors and agents will abide by our policies. If we are found to be liable for violations of the FCPA or similar anti-corruption laws in other jurisdictions, either due to our own acts or out of inadvertence, or due to the acts or inadvertence of others, we could suffer from criminal or civil penalties which could have a material and adverse effect on our results of operations, financial condition and cash flows.

A substantial portion of our assets and operations are located in India, and we are subject to regulatory, economic and political uncertainties in India.

Certain of our principal operating subsidiaries are incorporated in India, and substantial portions of our assets are located in India. We intend to continue to develop and expand our facilities in India.  The Indian government has exercised and continues to exercise significant influence over many aspects of the Indian economy. India’s government has traditionally maintained an artificially low price for certain commodities, including diesel fuel, through subsidies, but has recently begun to reduce such subsidies, which benefits us.  We cannot assure you that liberalization policies will continue. Various factors, such as changes in the current federal government, could trigger significant changes in India’s economic liberalization and deregulation policies and disrupt business and economic conditions in India generally and our business in particular.  In particular, the Indian government’s 2018 National Biofuels Policy stated a plan to increase Biodiesel blending to 5% of the diesel market, equal to more than 1.2 billion gallons per year. We cannot assure you that this policy will continue, nor can we assure you that we will continue to be able to procure biodiesel supply contracts with the Indian state-owned oil marketing companies through the public tender process. Our financial performance may be adversely affected by any such changes or other changes to the general economic conditions and economic and fiscal policy in India, including changes in exchange rates and controls, interest rates and taxation policies, as well as social stability and political, economic or diplomatic developments affecting India in the future.

Currency fluctuations between the Indian rupee and the U.S. dollar could have a material adverse effect on our results of operations.

A substantial portion of our revenues is denominated in Indian rupees. We report our financial results in U.S. dollars. The exchange rates between the Indian rupee and the U.S. dollar have changed substantially in recent years and may fluctuate substantially in the future.  We do not currently engage in any formal currency hedging of our foreign currency exposure, and our results of operations may be adversely affected if the Indian rupee fluctuates significantly against the U.S. dollar.

We could be subject to strict restrictions on the movement of cash and the exchange of foreign currencies which could limit our access to cash held in our Indian subsidiary to fund our U.S. operations or otherwise make investments where needed.

Our Indian operations could be subject to strict restrictions on the movement of cash and the exchange of foreign currencies, which would limit our ability to use this cash across our global operations. For instance, cash and cash equivalents were $2.7 million at December 31, 2023, of which $2.6 million was held in our North American entities and $0.1 million was held in our India subsidiary. Cash held in our Indian subsidiary may not otherwise be available for servicing debt obligations, potential investment or use for operations in the United States. Moreover, even if we were to repatriate this cash back to the United States for use in U.S. investments, this cash could be subject to additional withholding taxes. Due to various methods by which cash could be repatriated to the United States in the future, the amount of taxes attributable to the cash is dependent on circumstances existing if and when remittance occurs. Due to the various methods by which such earnings could be repatriated in the future, it is not practicable to determine the amount of applicable taxes that would result from such repatriation. In addition, Indian regulations may impose restrictions on the movement and exchange of foreign currencies which could further limit our ability to use such funds for repayment of debt, operations or capital or other strategic investments. Our inability to access our cash where and when needed could impede our ability to service our debt obligations, make investments and support our operations.

13

Aemetis, Inc. is a holding and management company and there are significant limitations on our ability to receive distributions from our subsidiaries.

We conduct substantially all of our operations through subsidiaries and are dependent on cash distributions, dividends or other intercompany transfers of funds from our subsidiaries to finance our operations. Our subsidiaries have not made significant distributions to us and may not have funds available for dividends or distributions in the future.  The ability of our subsidiaries to transfer funds to us will be dependent upon their respective abilities to achieve sufficient cash flows after satisfying their respective cash requirements, including subsidiary-level debt service on their respective credit agreements. Our current credit agreement, the Third Eye Capital Note Purchase Agreement, as amended from time to time, as described in the Notes to Consolidated Financial Statements, requires us to obtain the prior consent of Third Eye Capital, as the Administrative Agent of the Note holders, to make cash distributions or any intercompany fund transfers. The ability of our Indian operating subsidiary to transfer funds to us is restricted by Indian laws and may be adversely affected by U.S. federal income tax laws.  Under Indian laws, our capital contributions, or future capital contributions, to our Indian operation cannot be remitted back to the U.S. Remittance of funds by our Indian subsidiary to us may subject us to significant tax liabilities under U.S. federal income tax laws.

Our ability to utilize our NOL carryforwards may be limited.

Under the Internal Revenue Code of 1986, as amended (the “Code”), a corporation is generally allowed a deduction in any taxable year for net operating losses (“NOL”) carried over from prior taxable years. As of December 31, 2023, we had U.S. federal NOL carryforwards of approximately $253.0 million and state NOL carryforwards of approximately $336.0 million. As of December 31, 2023, the federal NOLs of $187.0 million and the state NOLs of $348.0 million expire on various dates between 2027 and 2042.  Due to the 2017 U.S. Tax Reform, U.S. federal NOLs after 2017 in the amount of $85.0 million have no expiration date.

The Section 163(j) excess interest expense carryover does not expire (similar to NOLs).  However, the Section 163(j) excess interest expense carryover is subject to allowed amounts and the Section 382 change of ownership rules, similar to NOLs and tax credits. The annual computation for how much interest expense is allowed includes the prior year interest carry over plus current year interest. The amount allowed is generally 30% (the law was modified for 2019 and 2020 to 50% due to COVID) of adjusted taxable income before the interest. Due to the ongoing interest expense every year, our ability to continue to carry forward the interest expense to next year may be limited.

Our ability to deduct these NOL carryforwards against future taxable income could be limited if we experience an “ownership change,” as defined in Section 382 of the Code.  In general, an ownership change may result from one or more transactions increasing the aggregate ownership of certain persons (or groups of persons) in our stock by more than 50 percentage points over a testing period (generally three years).  Past or future direct or indirect changes in the ownership of our stock, including sales or acquisitions of our stock by certain stockholders and purchases and issuances of our stock by us, some of which are not in our control and/or may occur or have already occurred in the public markets, could result in an ownership change.  Any resulting limitation on the use of our NOL carryforwards could result in the payment of taxes above the amounts currently estimated.

Non-U.S. stockholders of our common stock, in certain situations, could be subject to U.S. federal income tax on the gain from the sale, exchange or other disposition of our common stock.

Our Keyes Plant (which constitutes a U.S. real property interest for purposes of determining whether we are a U.S. real property holding corporation (a “USRPHC”) under the Foreign Investment in Real Property Tax Act (“FIRPTA”)), currently accounts for a significant portion of our assets. The value of our Keyes Plant relative to our real property located outside of the United States and other assets used in our trade or business may be uncertain and may fluctuate over time. Therefore, we may be, now or at any time while a non-U.S. stockholder owns our common stock, a USRPHC. If we are a USRPHC, certain non-U.S. stockholders may be subject to U.S. federal income tax on gain from the disposition of our stock under FIRPTA, in which case such non-U.S. stockholders would also be required to file U.S. federal income tax returns with respect to such gain. Whether the FIRPTA provisions apply depends on the stock that a non-U.S. stockholder owns and whether, at the time such non-U.S. stockholder disposes of our common stock, such common stock is regularly traded on an established securities market within the meaning of the applicable U.S. Treasury regulations. Non-U.S. stockholders should consult with their own tax advisors concerning the U.S. federal income tax consequences of the sale, exchange or other disposition of our common stock.

We are subject to covenants and other operating restrictions under the terms of our debt, which may restrict our ability to engage in some business transactions.

Our debt facilities contain covenants restricting our ability, among others, to:

● incur additional debt;

● make certain capital expenditures;

● incur or permit liens to exist;

● enter into transactions with affiliates;

● guarantee the debt of other entities, including joint ventures;

● pay dividends;

● merge or consolidate or otherwise combine with another company; and

● transfer, sell or lease our assets.

These restrictions may limit our ability to engage in business transactions that may be beneficial to us or may restrict our ability to execute our business plan.

We may be subject to liabilities and losses that may not be covered by insurance.

Our employees and facilities are subject to the hazards associated with producing ethanol and biodiesel.  Operating hazards can cause personal injury and loss of life, damage to, or destruction of, property, plant and equipment and environmental damage.  We maintain insurance coverage in amounts, against the risks that we believe are consistent with industry practice and maintain an active safety program.  However, we could sustain losses for uninsurable or uninsured risks, or in amounts in excess of existing insurance coverage.  Events that result in significant personal injury or damage to our property or to property owned by third parties or other losses that are not fully covered by insurance could have a material adverse effect on our results of operations and financial position.

14

Insurance liabilities are difficult to assess and quantify due to unknown factors, including the severity of an injury, the determination of our liability in proportion to other parties, the number of incidents not reported and the effectiveness of our safety program.  If we were to experience insurance claims or costs above our coverage limits or that are not covered by our insurance, we might be required to use working capital to satisfy these claims rather than to maintain or expand our operations.  To the extent that we experience a material increase in the frequency or severity of accidents or workers’ compensation claims, or unfavorable developments on existing claims, our operating results and financial condition could be materially and adversely affected.

Our mergers, acquisitions, partnerships, and joint ventures may not be as beneficial as we anticipate.

We have increased our operations through mergers, acquisitions, partnerships and joint ventures and intend to continue to explore these opportunities in the future. For example, in December 2020, we announced an investment in Nevo Motors, Inc. pursuant to a Strategic Electric Vehicle Production Facilities Agreement that will utilize our current and future manufacturing facilities and fueling stations, as well as renewable natural gas and electricity produced by us.  The anticipated benefits of these transactions might take longer to realize than expected and these may never be fully realized, or even realized at all.  Furthermore, partnerships and joint ventures generally involve restrictive covenants on the parties involved, which may limit our ability to manage these agreements in a manner that is in our best interest.  Future mergers, acquisitions, partnerships, and joint ventures may involve the issuance of debt or equity, or a combination of the two, as payment for or financing of the business or assets involved, which may dilute ownership interest in our business.  Any failure to adequately evaluate and address the risks of and execute on our mergers, acquisitions, partnerships, and joint ventures could have an adverse material effect on our business, results of operations, and financial condition.  In connection with such acquisitions and strategic transactions, we may incur unanticipated expenses, fail to realize anticipated benefits, have difficulty incorporating the acquired businesses, our management may become distracted from our core business, and we may disrupt relationships with current and new employees, customers and vendors, incur significant debt, or have to delay or not proceed with announced transactions.  The occurrence of any of these events could have an adverse effect on our business.

Our business may be significantly disrupted upon the occurrence of a catastrophic event or cyberattack.

Our Keyes and Kakinada Plants are highly automated and they rely extensively on the availability of our network infrastructure and internal technology systems. The failure of our systems due to a catastrophic event, such as an earthquake, fire, flood, tsunami, weather event, telecommunications failure, power failure, cyberattack or war, could adversely impact our business, results of operations and financial condition.  We have developed disaster recovery plans and maintain backup systems in order to reduce the potential impact of a catastrophic event. However, there can be no assurance that these plans and systems would enable us to return to normal business operations.

Our network infrastructure and internal technology systems may also be subject to other risks such as computer viruses, physical or electronic vandalism or other similar disruptions that could cause system interruptions and loss of critical data. Cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our networks and systems to more sophisticated and targeted measures directed at us or our third-party service providers. Despite the implementation of cybersecurity measures including access controls, data encryption, vulnerability assessments, employee training, continuous monitoring, and maintenance of backup and protective systems, our network infrastructure and internal technology systems may still be vulnerable to cybersecurity threats and other electronic security breaches. While we have taken reasonable efforts to protect ourselves, and to date, we have not experienced any material breaches or material losses related to cyberattacks, we cannot assure that any of our security measures would be sufficient in the future.

Adverse weather conditions, including as a result of climate change, may adversely affect the availability, quality and price of agricultural commodities and agricultural commodity products, as well as our operations and operating results.

Adverse weather conditions have historically caused volatility in the agricultural commodity industry and consequently in our operating results by causing crop failures or significantly reduced harvests, which may affect the supply and pricing of the agricultural commodities that we sell and use in our business and negatively affect the creditworthiness of agricultural producers who do business with us, including corn, feed and dairy producers.

Severe adverse weather conditions, such as hurricanes or severe storms, may also result in extensive property damage, extended business interruption, personal injuries and other loss and damage to us. Our operations also rely on dependable and efficient transportation services. A disruption in transportation services, as a result of weather conditions or otherwise, may also significantly adversely impact our operations.

Additionally, the potential physical impacts of climate change are uncertain and may vary by region. These potential effects could include changes in rainfall patterns, water shortages, changing sea levels, changing storm patterns and intensities, and changing temperature levels that could adversely impact our costs and business operations, the location, costs and competitiveness of global agricultural commodity production and related storage and processing facilities and the supply and demand for agricultural commodities. These effects could be material to our results of operations, liquidity or capital resources. 

We may be unable to protect our intellectual property.

We rely on a combination of patents, trademarks, trade name, confidentiality agreements, and other contractual restrictions on disclosure to protect our intellectual property rights.  We also enter into confidentiality agreements with our employees, consultants, and corporate partners, and control access to and distribution of our confidential information.  These measures may not preclude the disclosure of our confidential or proprietary information.  Despite efforts to protect our proprietary rights, unauthorized parties may attempt to copy or otherwise obtain and use our proprietary information.  Monitoring unauthorized use of our confidential information is difficult, and we cannot be certain that the steps we have taken to prevent unauthorized use of our confidential information, particularly in foreign countries where the laws may not protect proprietary rights as fully as in the U.S., will be effective.

Companies in our industry aggressively protect and pursue their intellectual property rights.  From time to time, we receive notices from competitors and other operating companies, as well as notices from “non-practicing entities,” or NPEs, that claim we have infringed upon, misappropriated or misused other parties’ proprietary rights.  Our success and future revenue growth will depend, in part, on our ability to protect our intellectual property.  It is possible that competitors or other unauthorized third parties may obtain, copy, use or disclose our technologies and processes, or confidential employee, customer or supplier data.  Any of our existing or future patents may be challenged, invalidated or circumvented.

15

We may not be able to successfully develop and commercialize our technologies, which may require us to curtail or cease our research and development activities.

Since 2007, we have been developing patent-pending enzyme technology to enable the production of ethanol from a combination of starch and cellulose, or from cellulose alone. In July 2011, we acquired Zymetis, Inc., a biochemical research and development firm, with several patents pending and in-process R&D utilizing the Z-microbe™ to produce renewable chemicals and advanced fuels from renewable feedstocks.  In 2018, in cooperation with a federally funded agency, we secured a grant from the California Energy Commission to optimize and demonstrate the effectiveness of ionic liquids technologies for breaking down biomass to produce ethanol. To date, we have not completed a large-scale commercial prototype of our technology and are uncertain at this time when completion of a commercial scale prototype or commercial scale production will occur.  Commercialization risks include economic financial feasibility at commercial scale, availability of funding to complete large-scale commercial plant, ability of ionic liquids to function at commercial scale and market acceptance of product.

Technological advances and changes in production methods in the biomass-based biofuel industry and renewable chemical industry could render our plants obsolete and adversely affect our ability to compete.

It is expected that technological advances in biomass-based biofuel production methods will continue to occur and new technologies for biomass-based diesel production may develop. Advances in the process of converting oils and fats into biodiesel and renewable diesel, including co-processing, could allow our competitors to produce advanced biofuels more efficiently and at a substantially lower cost. New standards or production technologies may require us to make additional capital investments in, or modify, plant operations to meet these standards. If we are unable to adapt or incorporate technological advances into our operations, our production facilities could become less competitive or obsolete. Further, it may be necessary for us to make significant expenditures to acquire any new technology and retrofit our plants in order to incorporate new technologies and remain competitive. In order to execute our strategy to expand into the production of renewable chemicals, additional advanced biofuels, next generation feedstocks and related renewable products, we may need to acquire licenses or other rights to technology from third parties. We can provide no assurance that we will be able to obtain such licenses or rights on favorable terms. If we are unable to obtain, implement or finance new technologies, our production facilities could be less efficient than our competitors, and our ability to sell biomass-based diesel may be harmed, negatively impacting our revenues and profitability.

Disruption in the supply chain could materially adversely affect our business.

We rely on our suppliers for our business, including feedstocks and materials for our development and efficiency projects. Future delays or interruptions in the supply chain due may be cause by world events such as the Russian-Ukraine conflict, Gaza war, and Red Sea vessel attacks.  These expose us to various risks that could increase our costs and/or impact our operations or business plans including:

● we or our suppliers may have excess or inadequate inventory of feedstocks for operation of our plants;

● we may face delays in construction or development of our infrastructure projects;

● we may not be able to timely procure parts or equipment to upgrade, replace, or repair our plants and technology system; and

● our suppliers may encounter financial hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.

Failure to remediate a material weakness in, or inherent limitations associated with, internal accounting controls could result in material misstatements in our financial statements.

Our management has identified a material weakness in our internal control over financial reporting related to our complex business transactions processes. See “Item 9A. Controls and Procedures”. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. As a result, management has concluded that, due to such material weakness, our disclosure controls and procedures were not effective as of December 31, 2023.

Our efforts to improve our internal controls are ongoing; however, there are inherent limitations in all control systems and no evaluation of controls can provide absolute assurance that all deficiencies have been detected. If we are unable to maintain effective internal control over financial reporting, or after having remediated such material weakness, fail to maintain the effectiveness of our internal control over financial reporting or our disclosure controls and procedures, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to regulatory  scrutiny, civil or criminal penalties or litigation. Continued or future failure to maintain effective internal control over financial reporting could also result in financial statements that do not accurately reflect our financial condition or results of operations and may also restrict our future access to the capital markets. There can be no assurance that we will not conclude in the future that this material weakness continues to exist or that we will not identify any significant deficiencies or other material weaknesses that will impair our ability to report our financial condition and results of operations accurately or on a timely basis.

16

Risks related to ownership of our stock

Our stock price is highly volatile, which could result in substantial losses for investors purchasing shares of our common stock and in litigation against us.

The market price of our common stock has fluctuated significantly in the past and may continue to fluctuate significantly in the future. The market price of our common stock may continue to fluctuate in response to one or more of the following factors, many of which are beyond our control:

● fluctuations in the market prices of ethanol and its co-products including WDG and corn oil;

● the cost of key inputs to the production of ethanol, including corn and natural gas;

● the volume and timing of the receipt of orders for ethanol from major customers;

● competitive pricing pressures;

● our ability to produce, sell and deliver ethanol on a cost-effective and timely basis;

● the announcement, introduction and market acceptance of one or more alternatives to ethanol;

● losses resulting from adjustments to the fair values of our outstanding warrants to purchase our common stock;

● changes in market valuations of companies similar to us;

● stock market price and volume fluctuations generally;

● regulatory developments or increased enforcement;

● fluctuations in our quarterly or annual operating results;

● additions or departures of key personnel;

● our inability to obtain financing; and

● our financing activities and future sales of our common stock or other securities.

The price at which you purchase shares of our common stock may not be indicative of the price that will prevail in the trading market. You may be unable to sell your shares of common stock at or above your purchase price, which may result in substantial losses to you, and which may include the complete loss of your investment. In the past, securities class action litigation has often been brought against a company following periods of high stock price volatility. We may be the target of similar litigation in the future. Securities litigation could result in substantial costs and divert management’s attention and our resources away from our business.

Any of the risks described above could have a material adverse effect on our results of operations or the price of our common stock, or both.

We do not intend to pay dividends.

We have not paid any cash dividends on any of our securities since inception and we do not anticipate paying any cash dividends on any of our securities in the foreseeable future.

Our principal shareholders hold a substantial amount of our common stock.

Eric A. McAfee, our Chief Executive Officer and Chair of the Board, and our other officers and directors beneficially own, in the aggregate, a portion of our outstanding stock as further described in our proxy that is incorporated by reference into this 10-K. As a result, these shareholders, acting together, may be able to influence matters requiring shareholder approval, including the election of directors and approval of mergers and acquisitions and other significant corporate transactions.  See “Security Ownership of Certain Beneficial Owners and Management.”  The interests of these shareholders may differ from yours and this concentration of ownership enables these shareholders to exercise influence over many matters requiring shareholder approval, may have the effect of delaying, preventing or deterring a change in control, deprive you of an opportunity to receive a premium for your securities as part of a sale of the company and may affect the market price of our securities.

The exercise of outstanding options and warrants to purchase our common stock could substantially dilute your investment and reduce the voting power of your shares, impede our ability to obtain additional financing and cause us to incur additional expenses.

There are outstanding options and warrants to acquire our common stock issued to employees and directors.  Additionally, certain of our financing arrangements, such as our EB-5 notes are convertible into shares of our common stock at fixed prices.  Such securities allow their holders an opportunity to profit from a rise in the market price of our common stock such that conversion of the securities will result in dilution of the equity interests of our common stockholders.  The terms on which we may obtain additional financing may be adversely affected by the existence and potentially dilutive impact of our outstanding convertible securities.

17

Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.

Our certificate of incorporation provides that, with certain limited exceptions, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any stockholder to bring (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any director or officer of the Company owed to us or our stockholders, creditors or other constituents, (iii) any action asserting a claim against us or any director or officer of the Company arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or our bylaws, or (iv) any action asserting a claim against the Company or any director or officer of the Company governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have received notice of and consented to the foregoing provisions. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations.

Provisions in our certificate of incorporation and bylaws may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management.

Our certificate of incorporation and bylaws contain provisions that may discourage unsolicited takeover proposals that stockholders may consider to be in their best interests. Our board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being elected in each year. As a result, at a given annual meeting only a minority of the board of directors may be considered for election. Since our “staggered board” may prevent our stockholders from replacing a majority of our board of directors at any given annual meeting, it may entrench management and discourage unsolicited stockholder proposals that may be in the best interests of stockholders. Moreover, our board of directors has the ability to designate the terms of and issue new series of preferred stock, which could be used to dilute the stock ownership of a potential hostile acquirer. Although we have opted out of the anti-takeover provisions under Section 203 of the Delaware General Corporation Law, we have adopted anti-takeover provisions that are substantially similar to such provisions, which could delay or prevent a change of control. Together these provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.

General Risk Factors

Our success depends in part on recruiting and retaining key personnel and, if we fail to do so, it may be more difficult for us to execute our business strategy.

Our success depends on our continued ability to attract, retain and motivate highly qualified management, manufacturing and scientific personnel, in particular our Chairman and Chief Executive Officer, Eric McAfee. We maintain key person insurance on our Mr. McAfee as our Chief Executive Officer for purposes of loan compliance, but do not maintain any key person insurance on our other executives. Competition for qualified personnel in the renewable fuel and bio-chemicals manufacturing fields is intense.  Our future success will depend on, among other factors, our ability to retain our current key personnel, and attract and retain qualified future key personnel, particularly executive management.  Failure to attract or retain key personnel could have a material adverse effect on our business and results of operations.

Our operations subject us to risks associated with foreign laws, policies, regulations, and markets.

Our sales and manufacturing operations in foreign countries are subject to the laws, policies, regulations, and markets of the countries in which we operate.  As a result, our foreign manufacturing operations and sales are subject to inherent risks associated with the countries in which we operate.  Risks involving our foreign operations include differences or unexpected changes in regulatory requirements, political and economic instability, terrorism and civil unrest, work stoppages or strikes, natural disasters, interruptions in transportation, restrictions on the export or import of technology, difficulties in staffing and managing international operations, variations in tariffs, quotas, taxes, and other market barriers, longer payment cycles, changes in economic conditions in the international markets in which our products are sold, and greater fluctuations in sales to customers in developing countries.  Any inability to effectively manage the risks associated with our foreign operations may have a material adverse effect on our results of operations or financial condition.

Operational difficulties at our facilities may negatively impact our business.

Our operations may experience unscheduled downtimes due to technical or structural failure, political and economic instability, terrorism and civil unrest, natural disasters, and other operational hazards inherent to our operations.  These hazards may cause personal injury or loss of life, severe damage to or destruction of property, equipment, or the environment, and may result in the suspension of operations or the imposition of civil or criminal penalties.  Our insurance may not be adequate to cover such potential hazards and we may not be able to renew our insurance on commercially reasonable terms or at all.  In addition, any reduction in the yield or quality of the products we produce could negatively impact our ability to market our products.  Any decrease in the quality, reduction in volume, or cessation of our operations due to these hazards would have a material adverse effect on the results of our business and financial condition.

18

Our success depends on our ability to manage the growth of our operations.

Our strategy envisions a period of rapid growth that may impose a significant burden on our administrative and operational resources and personnel, which, if not effectively managed, could impair our growth.  The growth of our business will require significant investments of capital and management’s close attention.  If we are unable to successfully manage our growth, our sales may not increase commensurately with capital expenditures and investments.  Our ability to effectively manage our growth will require us to substantially expand the capabilities of our administrative and operational resources and to attract, train, manage and retain qualified management, technicians and other personnel.  In addition to our plans to adopt technologies that expand our operations and product offerings at our biodiesel and ethanol plants, we may seek to enter into strategic business relationships with companies to expand our operations.  If we are unable to successfully manage our growth, we may be unable to achieve our business goals, which may have a material adverse effect on the results of our operations and financial condition.

Our business may be subject to natural forces beyond our control.

Earthquakes, floods, droughts, tsunamis, and other unfavorable weather conditions may affect our operations.  Natural catastrophes may have a detrimental effect on our supply and distribution channels, causing a delay or preventing our receipt of raw materials from our suppliers or delivery of finished goods to our customers.  In addition, weather conditions may adversely impact the planting, growth, harvest, storage, and general availability of any number of the products we may process at our facilities or sell to our customers.  The severity of these occurrences, should they ever occur, will determine the extent to which and if our business is materially and adversely affected.

U.S. tax law changes could materially affect the tax aspects of our business and the industries in which we compete.

Continued developments in U.S. tax reform could adversely affect our results of operations and cash flows. It is also possible that provisions of U.S. tax reform could be subsequently amended in a way that is adverse to the Company. Although we believe that our income tax provisions and accruals are reasonable and in accordance with generally accepted accounting principles in the United States, and that we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any tax audits and any related litigation, could be materially different from our historical income tax provisions and accruals. The results of a tax audit or litigation could materially affect our operating results and cash flows in the periods for which that determination is made. In addition, future period net income may be adversely impacted by litigation costs, settlements, penalties, and interest assessments.

Future sales and issuances of rights to purchase common stock by us could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We may issue equity or convertible securities in the future.  To the extent that we do so, our stockholders may experience substantial dilution.  We may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner, we determine from time to time.  If we sell common stock, convertible securities, or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales and new investors could gain rights superior to our existing stockholders.

Inflation may adversely affect us by increasing costs of our business.

Inflation can adversely affect us by increasing costs of feedstock, equipment, materials, and labor. In addition, inflation is often accompanied by higher interest rates. In an inflationary environment, such as the current economic environment, depending on other economic conditions, we may be unable to raise prices of our fuels or products to keep up with the rate of inflation, which would reduce our profit margins. Given the inflation rates in fiscal year 2022, we have experienced, and continue to experience, increases in prices of feedstock, equipment, materials, and labor. Continued inflationary pressures could impact our profitability.

Interest rates could change substantially, materially impacting our profitability.

Our borrowings expose us to interest rate risk, which could adversely affect our profitability. We monitor and manage this exposure as part of our overall risk management program, but the changes in interest rates cannot always be predicted, hedged, or offset with price increases to eliminate earnings volatility.

Inflation, including as a result of commodity price inflation or supply chain constraints due to the war in Ukraine, may adversely impact our results of operations.

We have experienced inflationary impacts on key production inputs, feedstock, wages and other costs of labor, equipment, services, and other business expenses. Commodity prices in particular have risen significantly over the past year. Inflation and its negative impacts could escalate in future periods. In addition, inflation is often accompanied by higher interest rates.

Ukraine is the third largest exporter of grain in the world. Russia is one of the largest producers of natural gas and oil. The commodity price impact of the war in Ukraine has been a sharp rise in grain and energy prices, including corn and natural gas, two of our primary production input commodities. In addition, the war in Ukraine has and may continue to adversely affect global supply chains resulting in further commodity price inflation for our production inputs. Also, given high global grain prices, U.S. farmers may prefer to lock in prices and export additional volumes, reducing domestic grain supplies and resulting in further inflationary pressures.

In an inflationary environment, such as the current economic environment, depending on other economic conditions, we may be unable to raise prices of our fuels or products to keep up with the rate of inflation, which would reduce our profit margins. As a result, inflation may have a material adverse effect on our results of operations and financial condition.

19

Item 1B. Unresolved Staff Comments.

None.

Item 1C. Cybersecurity.

Risk Management and Strategy

Aemetis' cybersecurity and information security framework includes physical, administrative and technical safeguards, as well as plans and procedures we believe are reasonable to help Aemetis prevent and timely and effectively respond to cybersecurity threats and incidents, including threats or incidents that may impact our operations, facilities and employees.  These plans are based upon our assessment of risk considering our industry, specific operations, cyber perimeter, social exposure, information confidentiality and tertiary stakeholders.

Our efforts focus on protecting and enhancing the security of our information systems, software, networks, and other assets. These efforts are designed to protect against, and mitigate the effects of, among other things, cybersecurity incidents where unauthorized parties attempt to access confidential, sensitive, or personal information; potentially hold such information for ransom; destroy data; disrupt or degrade service or our operations; sabotage systems; or otherwise cause harm to Aemetis, our customers, suppliers, or other key stakeholders. We employ capabilities, processes, and other security measures we believe are designed to reduce and mitigate these risks.

Aemetis contracts with a primary Managed Security Provider (MSP) to provide services that assist us with assessing, enhancing, implementing and monitoring our cybersecurity risk management programs and responding to incidents.  Aemetis maintains cyber recovery plans as well as a cybersecurity insurance policy.

Aemetis utilizes a third-party cybersecurity and information security awareness training programs. Training is administered and tracked through online learning modules and ongoing phishing simulations. Training topics include how to escalate suspicious activities including phishing, viruses, spams, insider threats, suspect human behaviors or safety issues.

In 2023, we did not identify any cybersecurity threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. However, despite the capabilities, processes, and other security measures we employ that we believe our controls are designed to detect, reduce, and mitigate the risk of cybersecurity incidents, we may not be aware of all vulnerabilities or might not accurately assess the risks of incidents, and such preventative measures cannot provide absolute security and may not be sufficient in all circumstances or mitigate all potential risks.

Governance

Role of Management

Aemetis’ cybersecurity initiative is led by its Chief Financial Officer, who is in the unique position of being able to integrate cybersecurity with the financial internal control framework.  He is responsible for administration of the cybersecurity and information security program and risk management, using his experience working with information technology and financial control system during a majority of his career, including over 10 years of overseeing the Aemetis information technology and security program.

We utilize a Managed Security Provider (MSP) who serves as the central point for identifying all cybersecurity incidents and reporting, including incidents that directly target company network, internal information systems and incidents originating from third parties. The MSP provides end-to-end operations for the purpose of monitoring, detecting, alerting and responding to cyber incidents. The MSP is also responsible for activating the containment and resolution efforts where appropriate to support Aemetis through the resolution of the incident.

The MSP escalates incidents with significant impact and pervasiveness to Aemetis’ Chief Financial Officer, who evaluates each incident in terms of its impact on Aemetis and operations, ability to conduct business with customers and suppliers, brand reputation and health, safety or the environment, and the speed and degree to which the incident has been contained.  Our Chief Financial Officer, working with the executive management team, also manages the communication with our Board and outside parties. After initial identification, evaluation and escalation for material events, the MSP monitors all cybersecurity incidents for changes in degree of impact or pervasiveness.

Role of the Board

The Board of Directors ("Board") recognizes the importance of cybersecurity in safeguarding the sensitive data and protecting the perimeter of the computer network. The Board is responsible for overseeing overall risk management for the Corporation, including review of the cybersecurity program.  As part of its oversight responsibilities, the Board receives an annual cybersecurity update from the Chief Financial Officer.  The annual review includes oversight of cyber exposure, risk assessment, incident response, integration with other control activities, internal monitoring, and risk management processes, such as updates to Aemetis’ cybersecurity programs and mitigation strategies, and other cybersecurity developments.

20

Item 2.  Properties.

California Ethanol

Ethanol Plant in Keyes, CA.  The Keyes Plant is situated on approximately 11 acres of land and contains 25,284 square feet of plant building and structures. The property is located adjacent to the Union Pacific Railroad system to facilitate the inbound transportation of feedstock. Our tangible and intangible assets, including the Keyes Plant, are subject to perfected first liens and mortgages as further described in Note 4. Debt, of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.

Real Property in Keyes, CA. We own 5.32 acres of real property located next to our Keyes Plant.  We lease the property to Messer Gas, which receives CO₂ from the Keyes Plant and produces liquid CO₂ for sale into local markets.

California Dairy Renewable Natural Gas

Dairy Biogas Digesters, Central Valley, CA.  Since 2019, we have entered into arrangements with 43 dairies in the Central Valley of California that include leases for land to build anaerobic digesters and/or manure supply agreements. These agreements each have a term of 25 years with two optional 5-year extensions.

Faith Home Road, Ceres, CA. We own 8.5 acres of real property on Faith Home Road near the Keyes Plant. Currently, Aemetis Biogas uses the location for its office headquarters and warehouse.  This corner property is also a strategic location for future operations supporting the Company’s Carbon Zero projects, including CCUS.

India Biodiesel

Biodiesel Plant in Kakinada, India.  The Kakinada Plant is situated on approximately 32,000 square meters of land in Kakinada, India.  The property is located 7.5 kilometers from the local seaport with connectivity through a third-party pipeline to the port jetty. The pipeline facilitates the importing of raw materials and exporting of finished products.  

Pretreatment Plant. During 2022, we acquired 3,683 square meters of land in Remannapalem Village, Kakinada.

India Administrative Office.  On April 2, 2023, we entered into a three-year lease of approximately 1,000 square feet of office space to accommodate our principal administrative, sales and marketing facilities in Hyderabad, India.

Other Properties

Corporate Office, Cupertino, CA. Our corporate headquarters are located in leased office space at 20400 Stevens Creek Blvd., Suite 700, Cupertino, CA. This includes 9,238 square feet of rented space. We extended the lease in June 2020 for an additional eight years with a new termination date of May 31, 2028. 

Riverbank Industrial Complex, Riverbank, CA. On December 14, 2021, we entered into real estate purchase agreements and a lease disposition and development agreement for the Riverbank Industrial Complex in Riverbank, CA. We plan to use the purchased and leased property for the construction of a sustainable aviation fuel and renewable diesel production plant. Pursuant to the lease disposition and development agreement, we serve as the master developer for the property to develop, construct, finance, operate and maintain the leased property.  The lease commenced on April 1, 2022, and the term is for fifteen years, with an option to purchase the property at the end of the lease.  We are also developing a portion of the Riverbank Industrial Complex to be used for a CCUS facility.

Goodland Energy Center, Goodland, KS.  We own a large portion of the Goodland Energy Center in Goodland, Kansas, comprising approximately 93 acres of land, approximately 34,992 square feet of buildings and equipment as part of a partially completed 40 million gallon per year dry-mill ethanol plant.  The ethanol plant is not currently operational.

21

Item 3.  Legal Proceedings.

Not applicable.

Item 4.  Mine Safety Disclosures.

Not Applicable.

PART II

Item 5.  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is traded under the symbol "AMTX" on the NASDAQ Stock Market.

Number of Stockholders

As of March 1, 2024, our common stock was held by 175 holders of record and by approximately 26 thousand stockholders who hold shares in street name.
 

Dividends

We have never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use to operate and expand our business and to reduce our outstanding debt, and therefore do not anticipate paying cash dividends in the foreseeable future.  In addition, we currently have covenants in certain of our debt agreements that prohibit paying dividends without the consent of the applicable lender.

Securities authorized for issuance under equity compensation plans

See Note 9 to the Consolidated Financial Statements contained in Item 8 of this Annual Report.

Sales of Unregistered Equity Securities

In addition to issuances of unregistered securities previously reported in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K, the Company issued the following unregistered securities during 2023:

On October 16, 2023, our senior lender increased the credit limit under one of our debt agreements.  Under the terms of that preexisting debt agreement, this increase automatically revised a previously issued warrant to increase the number of shares issuable under the warrant by 25,000 shares.  The warrant has an exercise price of $10.20 per share and a remaining term of 3.4 years. This issuance was exempt from registration under Section 4 of the Securities Act of 1933 as a transaction by an issuer not involving any public offering.

On December 12, 2023, we issued 126,008 shares of common stock to the holders of our Series B Preferred Stock in an exchange at a 1 for 10 ratio of all outstanding shares of Series B Stock. The issuance of common stock was exempt from registration under Section 3(a)(9) of the Securities Act of 1933 as a security exchange by the issuer with existing security holders for which no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange. In connection with the exchange, we filed a Registration Statement on Form S-1 on December 5, 2023, to register the subsequent resale or other disposition of the common stock in the exchange, and the S-1 was declared effective by the SEC on December 12, 2023.

Stock Repurchases

None.

Item 6.  [Reserved]

Not applicable.

22

Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. MD&A is organized as follows:  

● Overview. Discussion of our business and overall analysis of financial and other highlights affecting us, to provide context for the remainder of MD&A.

● Key Performance Indicators. Discussion of our key performance indicators, to provide context for company operations.

● Results of Operations. An analysis of our financial results comparing the twelve months ended December 31, 2023 and 2022.

● Liquidity and Capital Resources. An analysis of changes in our balance sheets and cash flows and discussion of our financial condition.

● Critical Accounting Estimates. Accounting estimates that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.

The following discussion should be read in conjunction with our consolidated financial statements and accompanying notes included elsewhere in this report.  The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs.  Our actual results could differ materially from those discussed in the forward-looking statements.  Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Report, particularly under “Part I, Item 1A.  Risk Factors,” and in other reports we file with the SEC.  All references to years relate to the calendar year ended December 31 of the particular year.

Overview

Founded in 2006 and headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis referred to herein as, “Aemetis,” the “Company,” “we,” “our” or “us”) is an international renewable natural gas, and renewable fuels company focused on the operation, acquisition, development and commercialization of innovative low and negative carbon intensity products and technologies that replace traditional fossil derived products. We operate in three reportable segments consisting of “California Ethanol,” “California Dairy Renewable Natural Gas,” and “India Biodiesel.” We have other operating segments determined not to be separately reportable that are collectively represented by the “All Other” category. Our mission is to generate sustainable and innovative renewable fuel solutions that benefit communities and restore our environment. We do this by building a local circular bioeconomy utilizing agricultural waste to produce low carbon, advanced renewable fuels that reduce greenhouse gas (“GHG”) emissions and improve air quality by replacing traditional petroleum-based products. For revenue and other information regarding our operating segments, see Note 11 - Segment Information, of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.

Our California Ethanol segment consists of a 65 million gallon per year capacity ethanol production facility located in Keyes, California (the “Keyes Plant”) that we own and operate. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains (“WDG”), Distillers Corn Oil (“DCO”), and Condensed Distillers Solubles (“CDS”), all of which are sold as animal feed to more than 80 local dairies and feedlots.  We also capture the Carbon Dioxide (“CO2”) emissions from our fermenters and sell it to Messer for use to produce liquid CO₂ that it sells to food, beverage, and industrial customers. We are implementing several energy efficiency initiatives focused on lowering the carbon intensity of our fuels, primarily by decreasing the use of fossil natural gas. These energy efficiency projects include high efficiency heat exchangers; a two-megawatt solar microgrid with battery storage; an Allen Bradley Decision Control System (DCS) to manage and optimize energy use and other plant operations; and a Mechanical Vapor Recompression (MVR) system to produce steam using low carbon electricity instead of natural gas.  This changes will lower the carbon intensity (CI) of the ethanol we produce and allow us to sell it for a correspondingly higher price.

Our California Dairy Renewable Natural segment Aemetis Biogas or “ABGL,” operates anaerobic digesters at local dairies near the Keyes Plant (many of whom also purchase WDG produced by the Keyes Plant as animal feed) to produce biogas from dairy waste; transports the biogas by pipeline to the Keyes Plant site; and converts the biogas to Renewable Natural Gas (“RNG”) that is delivered to customers through the PG&E regional natural gas pipeline.  We currently have eight operating digesters that receive dairy waste from nine dairies, and we are actively growing with an additional six digesters under construction that will receive dairy waste from nine dairies.  We have constructed 36 miles of collection pipeline and have received environmental approval to construct an additional 24 miles.  We currently have agreements with a total of 43 dairies and are seeking to increase that.

Our India Biodiesel segment includes a biodiesel production plant in Kakinada, India (“Kakinada Plant”) with a nameplate production capacity of about 60 million gallons per year.  It produces high quality distilled biodiesel and refined glycerin for customers in India. We believe the Kakinada Plant is one of the largest biodiesel production facilities in India on a nameplate capacity basis. Kakinada Plant is capable of processing a variety of vegetable oils and animal fat waste feedstocks into biodiesel that meets applicable product standards. Our Kakinada Plant can also distill the crude glycerin byproduct from the biodiesel refining process into refined glycerin, which is sold to the pharmaceutical, personal care, paint, adhesive, and other industries.

Our All Other segment consists of our projects that are under development, including the planned sustainable aviation fuel and renewable diesel plant in Riverbank, California and our planned Carbon Capture and Underground Sequestration (CCUS) operations.  It also includes our research and development facility in Minneapolis, Minnesota and our corporate offices in Cupertino, California.

23

Our planned sustainable aviation fuel (SAF) and renewable diesel (RD) production plant is currently designed to produce 90 million gallons per year of combined SAF and RD from feedstocks consisting of renewable waste oils and fats. Our initially planned facility will be located at the Riverbank Industrial Complex in Riverbank, California. We signed a lease with purchase to option for the Riverbank Industrial Complex in 2021 and took possession of the site in 2022.  In 2023, we received a Use Permit and CEQA approval for the SAF/RD plant and we are continuing with development activities, including permitting, engineering, and financing. The site has access to low carbon hydroelectric power, and our plant is designed to use renewable hydrogen that will be produced from byproducts of the SAF/RD production process.

Our planned CCUS projects will compress and inject CO₂ into deep wells that are monitored to ensure the long-term sequestration of carbon underground. California’s Central Valley has been identified as one of the world’s most favorable regions for large-scale CO₂ injection projects due to the subsurface geologic formation that absorbs and retains CO₂ gas. The two initial Aemetis CCUS injection projects are being designed to capture and sequester more than two million metric tons per year of CO₂ at the Aemetis biofuels plant sites in Keyes and Riverbank, California. In July 2022, Aemetis purchased 24 acres at the Riverbank Industrial Complex in Riverbank, California to develop a CCUS injection well with more than 1 million metric ton per year of CO₂ sequestration capacity. In 2023, we obtained a permit to construct a geologic characterization well at the Riverbank site to obtain information to support an EPA Class VI CO₂ injection well permit application.  Once operational, these projects will generate revenue by selling California LCFS credits and federal Internal Revenue Code Section 45Q tax credits.

Our Minneapolis, Minnesota research and development laboratory evaluates and develops technologies that would use low carbon intensity and waste feedstocks to produce low or below zero carbon intensity biofuels and biochemicals. We are focused on processes that extract sugar from cellulosic feedstocks and then use the remaining biomass to produce low carbon ethanol, renewable hydrogen, sustainable aviation fuel, and renewable diesel.

Key Performance Indicators (KPI):

Aemetis measures performance based on the utilization of our plants, production of products, and associated pricing and margins. For California ethanol, the key products are ethanol and WDG, measured in millions of gallons sold and tons sold, respectively.  For India Biodiesel, the products are biodiesel and refined glycerin, both measured in metric tons sold.  Since our Keyes Plant currently uses corn as the sole feedstock, the delivered quantity and cost of corn is also a key performance indicator as it indicates high-level operating margin of the plant.  Utilization is measured as the production of transportation fuel produced as a percentage of the nameplate capacity, the engineering specification of the plant. For California RNG, the products are Renewable Gas (RNG), D3 RINs, and LCFS credits.  The RNG quantity measured in MMBtu, and quantity of D3 RINs and LCFS credits generated are based on the quantity of RNG dispensed. Management utilizes these metrics to assess cash generated by each facility on a daily or weekly basis and to make decisions about the appropriate level of operation to balance market demand with plant capabilities and efficiency.

The following table summarized our KPIs:

Production and Price Performance

(Unaudited)

	Years ended December 31,						2023 vs 2022 %
	2023			2022			Change
Ethanol
Gallons Sold (in millions)		32.1			59.0			-45.6	%
Average Sales Price/Gallon	$	2.44		$	2.81			-13.2	%
Percent of nameplate capacity		58	%		107	%		-45.8	%
WDG
Tons Sold (in thousands)		225			397			-43.3	%
Average Sales Price/Ton	$	97		$	128			-24.2	%
Delivered Cost of Corn
Bushels ground (in millions)	11.5				20.2			-43.1	%
Average delivered cost / bushel	$	7.11		$	9.65			-26.3	%
Dairy Renewable Natural Gas
MMBtu external sales (in thousands)		194.2			8.4			2211.9	%
MMBtu stored as inventory (in thousands)		68.0			9.0			655.6	%
MMBtu intercompany sales (in thousands)		-			48.6			-100.0	%
Biodiesel
Metric tons sold (in thousands)		60.5			17.7			241.8	%
Average Sales Price/Metric ton	$	1,232		$	1,526			-19.3	%
Percent of Nameplate Capacity		40	%		12	%
Refined Glycerin
Metric tons sold (in thousands)		4.2			1.2			250.0	%
Average Sales Price/Metric ton	$	640		$	850			-24.7	%

24

Results of Operations

Year Ended December 31, 2023, Compared to Year Ended December 31, 2022

Revenue

We sell all ethanol, WDG, CDO, and CDS produced to J.D. Heiskell, which resells it to customers designated by us.  Our finished ethanol tank is leased by J.D. Heiskell and legal title to the product is transferred when we put our ethanol product into the tank.  We have designated Murex LLC to purchase all of the ethanol and A.L. Gilbert to purchase the WDG. Each company resells to third-party customers.  We sell the CO2 that we capture from our fermenters to Messer Gas.           

Most of our California Dairy Renewable Natural Gas segment revenues during the year ended  December 31, 2023, were from sales of D3 RINs generated from sales of our RNG for transportation use.

Substantially all of our India segment revenues during the years ended December 31, 2023 and 2022, were from sales of biodiesel to OMCs and refined glycerin to other external customers.    

Fiscal Year Ended December 31 (in thousands)

						2023 vs 2022
	2023		2022			Inc/(dec)			% change
California Ethanol	$	104,068	$	228,194		$	(124,126	)		-54.4	%
California Dairy Renewable Natural Gas*		5,455		1,210			4,245			350.8	%
India Biodiesel		77,194		28,111			49,083			174.6	%
Eliminations		-		(1,002	)		1,002			-100.0	%
Total	$	186,717	$	256,513		$	(69,796	)		-27	%

*Most California Dairy Renewable Natural Gas revenue is intercompany in 2022, refer to Item 8, Footnote 11 for the split between intercompany and external sales.

California Ethanol.   For the year ended December 31, 2023, the segment generated 75% of revenue from sales of ethanol, 21% from sales of WDG, and 4% from sales of corn oil, CDS, CO₂, and other sales. During the year ended December 31, 2023, plant production averaged 58% of the 55 million gallon per year nameplate capacity. The decrease in revenues was due to an extended maintenance cycle and acceleration of the implementation of several important ethanol plant energy efficiency upgrades to the Keyes Plant during the first five months of 2023 coupled with decrease in average price of ethanol by 13% and WDG by 24%.

California Dairy Renewable Natural Gas. During the years ended December 31, 2023 and 2022, we produced and sold 194.2 thousand and 8.4 thousand MMBtu ("million British thermal units") of Renewable Natural Gas ("RNG"), to an external party at an average price of $5.12 and $25 per MMBtu, respectively, and we also sold 48.6 MMBtu to an intercompany party during the year ended December 31, 2022.   In addition, we entered into agreement with a marketing partner to dispense RNG into transportation vehicles, which allowed us to begin generating D3 RINs in 2023 as a new revenue stream that did not previously exist. During the year ended December 31, 2023, we generated 1.4 million D3 RINs and sold them at an average price of $3.19 per D3 RIN. 

India Biodiesel.  For the year ended December 31, 2023, the segment generated 97% of revenue from sales of biodiesel, and 3% from other sales, compared to 96% of sales from biodiesel, and 4% from other sales during the year ended December 31, 2022. The increase in revenues for the year ended December 31, 2023, compared to the year ended December 31, 2022, was due to an increase in the sales volume of biodiesel from 17.7 thousand metric tons to 60.5 thousand metric tons offset by decrease in average biodiesel price per metric ton to $1,232 from $1,526 per metric ton during the same period in 2022. The increase in revenues was primarily attributable to the Kakinada Plant obtaining and executing on the India government-sponsored OMC tenders and purchase contracts.

25

Cost of Goods Sold

Cost of goods sold consists primarily of feedstock, chemicals, direct costs (principally labor and labor related costs) and factory overhead. Depending on the costs of these inputs in comparison to the sales price of our end products, our gross margins at any given time can vary from positive to negative. Factory overhead includes direct and indirect costs associated with plant operations, including the cost of repairs and maintenance, consumables, maintenance, on-site security, insurance, depreciation, and inbound freight.

Our feedstock for California Ethanol is procured by J.D. Heiskell pursuant to the Heiskell Supply Agreement. Title to the corn passes to us when the corn is deposited into our weigh bin and entered into the production process. Our cost of feedstock is established by J.D Heiskell based on the Chicago Board of Trade pricing and includes rail, truck or ship transportation, local basis costs, and a handling fee paid to J.D. Heiskell. The credit term for the corn purchased from J.D. Heiskell is one day. Cost of goods sold also includes chemicals, plant overhead and out-bound transportation. Plant overhead includes direct and indirect costs associated with the operation of the Keyes Plant, including the cost of electricity and natural gas, maintenance, insurance, direct labor, depreciation and freight.

The feedstock for producing Renewable Natural Gas is supplied by dairy operators who lease us land and supply our digesters with their manure flush. Our cost of feedstock is established by manure supply agreements based on the value of the environmental attributes and the size of the dairy.

Substantially all of our feedstock for India Biodiesel is procured as crude palm stearin, a non-edible feedstock, from neighboring natural oil processing plants at a discount to refined palm oil or imported from international market when prices are viable.  Raw material is received by truck and title passes when the goods are loaded at our vendors’ facilities.  Credit terms vary by vendor. However, we generally receive 15 days of credit on the purchases. We purchase crude glycerin in the international market on letters of credit or advance payment terms.

The following table shows Cost of Goods Sold:

Fiscal Year Ended December 31 (in thousands)

						2023 vs 2022
	2023		2022			Inc/(dec)			% change
California Ethanol	$	110,670	$	241,211		$	(130,541	)		-54.1	%
California Dairy Renewable Natural Gas		5,786		1,988			3,798			191.0	%
India Biodiesel		68,244		19,838			48,406			244.0	%
All other		-		13			(13	)		-100.0	%
Eliminations		-		(1,002	)		1,002			-100.0	%
Total	$	184,700	$	262,048		$	(77,348	)		-30	%

California Ethanol.  We ground 11.5 million bushels of corn at an average price of $7.11 per bushel during the year ended December 31, 2023, compared to 20.2 million bushels of corn at an average price of $9.65 per bushel during the year ended December 31, 2022. The decrease in cost of goods for the year ended December 31, 2023, is mainly due to the extended shutdown from December 2022 to June 2023, as well as $8.2 million more in natural gas costs and $3.6 million more in transportation costs during 2022.

California Dairy Renewable Natural Gas. Cost of Goods Sold expenses relate to dairy manure payments, maintenance on the dairy digesters, production bonuses, and depreciation. The eliminations in 2022 relate to intercompany sales. 

India Biodiesel.  The increase in cost of goods sold during the year ended December 31, 2023, compared to December 31, 2022, was attributable to an increase in the volume of biodiesel feedstock by 241% to 60.5 thousand metric tons during the year ended December 31, 2023, compared to 17.7 thousand metric tons during the year ended December 31, 2022, offset by a decrease in the average price of biodiesel feedstock by 1% to $838 per metric ton, compared to $843 per metric ton in the same period in 2022. 

26

Gross Profit (loss)

Fiscal Year Ended December 31 (in thousands)

							2023 vs 2022
	2023			2022			Inc/(dec)		% change
California Ethanol	$	(6,602	)	$	(13,017	)	$	6,415		-49.3	%
California Dairy Renewable Natural Gas		(331	)		(778	)		447		-57.5	%
India Biodiesel		8,950			8,273			677		8.2	%
All other		-			(13	)		13		-100.0	%
Total	$	2,017		$	(5,535	)	$	7,552		-136	%

California Ethanol. Gross loss decreased by 49.3% in the year ended December 31, 2023, primarily due to lower volumes of ethanol and WDG sold combined with lower ethanol and WDG prices offset by higher corn costs combined with increased costs in natural gas and transportation in the same period ending  December 31, 2022.

California Dairy Renewable Natural Gas. Gross loss reflects expenses incurred as we begin to ramp up our Dairy Renewable Natural Gas business including dairy manure payments, maintenance on the dairy digesters, production bonuses, and depreciation.

India Biodiesel. The increase in gross profit was attributable to the increase in sales and production of biodiesel to fulfill the government OMC tender offers.

Operating (income)/expense and non-operating (income)/expense

In 2023 and 2022, substantially all of our R&D expenses related to research and development activities in Minnesota. R&D expenses decreased in the year ended December 31, 2023, due to decreases in expenses related to research subcontract work.

SG&A expenses consist primarily of salaries and related expenses for employees, marketing expenses related to sales of ethanol and WDG in California Ethanol and biodiesel and other products in India Biodiesel, as well as professional fees, insurance, other corporate expenses, and related facilities expenses. SG&A expenses as a percentage of revenue were 21% in the year ended December 31, 2023, compared to 11% in the year ended December 31, 2022. The increase in SG&A percentage over sales was due to a decrease in sales and reclass of several cost of goods expenses to SG&A for the period when the plant did not operate during the first five months of 2023.  The increase in SG&A expenses in the year ended December 31, 2023, was primarily due to an increase in headcount, salaries and stock-based compensation of $4.7 million, an increase in professional fees of $0.9 million, an increase in depreciation and amortization of $1.7 million due to a reclass of cost of goods sold to SG&A, an increase in taxes, insurance, rent and utilities of $1.9 million, an increase in supplies and services of $0.6 million, and an increase in other costs of $1.6 million due to the reclass of cost of goods sold to SG&A which was offset by $0.8 million in rental income increase. 

							2023 vs 2022
	2023			2022			Inc/(dec)			% change
Research and development expenses	$	152		$	180		$	(28	)		-16	%
Selling, general and administrative expenses		39,266			28,686		$	10,580			37	%
Other expense (income):
Interest expense
Interest rate expense		32,995			21,407		$	11,588			54	%
Debt related fees and amortization expense		6,524			7,363			(839	)		-11	%
Accretion and other expenses of Series A preferred units		25,313			9,888			15,425			156	%
Loss on debt extinguishment		-			49,386			(49,386	)		-100	%
Gain on litigation		-			(1,400	)		1,400			-100	%
Other income		(2,077	)		(14,340	)		12,263			-86	%

27

Other expense (income) consists primarily of interest and amortization expense attributable to our debt facilities and accretion of biogas Series A preferred units. The cost of debt facilities includes stock or warrants issued as fees. The fair value of stock and warrants are amortized as expenses, except when the extinguishment accounting method is applied, in which case refinanced debt costs are recorded as extinguishment expense. Interest expense and debt related fees and amortization increased in the year ended  December 31, 2023, due to higher variable interest rates and higher debt balances from obtaining the Carbon Revolving line, Fuels Revolving line, and the construction loan with Greater Nevada Credit Union. The decrease in accretion and other expenses of the Series A Preferred Units was due to amendments obtained at lower interest costs and a $30.0 million payment on the Series A preferred units. Gain on litigation reflects the settlement of the EdenIQ lawsuit in the second quarter of 2022. Other expense (income) change r elates to a grant in the amount of $14.2 million received from the USDA's Biofuel Producer Program in 2022, created as part of the CARES Act, to compensate biofuel producers that experienced market losses due to the COVID-19 pandemic.

Liquidity and Capital Resources

Cash and Cash Equivalents

Cash and cash equivalents were $2.7 million at December 31, 2023, of which $2.6 million was held in our North American entities and $0.1 million was held in our India entity. Our current ratio was 0.43 and 0.21, respectively, at December 31, 2023 and 2022. We expect that our future available liquidity resources will consist primarily of cash generated from operations, remaining cash balances, borrowings available, if any, under our senior debt facilities and our subordinated debt facilities, and any additional funds raised through sales of equity. The use of proceeds from all equity raises and debt financings are subject to approval by our senior lender.

Liquidity

Cash and cash equivalents, current assets, current liabilities, and debt at the end of each period were as follows (in thousands):

	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,667	$	4,313
Current assets (including cash, cash equivalents, and deposits)		36,400		18,136
Current and long term liabilities (excluding all debt)		165,662		162,728
Current & long term debt		294,721		246,240

Our principal sources of liquidity have been cash provided by the sale of equity, operations, and borrowings under various debt arrangements.

We operate in a volatile market in which we have limited control over the major components of input costs and product revenues and are making investments in future facilities and facility upgrades that improve the overall margin while lessening the impact of these volatile markets.  As such, we expect cash provided by operating activities to fluctuate in future periods primarily because of changes in the prices for corn, ethanol, WDG, DCO, CDS, biodiesel, waste fats and oils, glycerin, non-refined palm oil, natural gas, LCFS credits, and D3 RINs. To the extent that we experience periods in which the spread between ethanol prices and corn and energy costs narrow or the spread between biodiesel prices and waste fats and oils or palm oil and energy costs narrows, we require additional working capital to fund operations. 

As a result of negative capital and negative operating results, and collateralization of substantially all of the Company assets, we have been reliant on our senior secured lender to provide additional funding and have been required to remit substantially all excess cash from operations to our senior lender. In order to meet obligations during the next twelve months, we will need to either refinance our debt or receive the continued cooperation of its senior lender. We plan to pursue the following strategies to improve the course of the business.

For the Keyes Plant, we plan to operate the plant and continue to improve its financial performance by adopting new technologies or process changes that increase energy efficiency, reduce costs, and enhance revenue, as well as execute upon awarded grants that improve energy and operational efficiencies resulting in lower cost, lower carbon intensity, and overall margin improvement.

For our dairy RNG production, we plan to continue to operate our existing digesters as well as continue to build new dairy digesters and extend the existing pipeline. Funding for continued construction has been based on government guaranteed debt financing and grant programs.  We are seeking multiple sources of additional project funding to allow us to accelerate the addition of new digesters.  We began generating revenue from D3 RIN sales in 2023 and first generated revenue from the sale of LCFS credits in January 2024.  We will have a full year of revenue from both sources in 2024, which will provide significant increased liquidity.

For the Riverbank SAF/RD production plan, we are continuing with permitting, engineering and other development activities and seeking both debt and equity funds needed for development and construction.

For the Kakinada Plant, we plan to continue to enter into cost-plus contracts with the OMCs as our primary customer.  We also plan to continue to upgrade our plant to increase capacity and  expand feedstock flexibility.  We are also evaluating the production of additional products and developing channels for the export of allow. The Kakinada plant has had positive gross income during the last two years and we expect this to continue.  We also rely on our working capital lines with Gemini and Secunderabad Oils in India to fund our commercial arrangements for the acquisitions of feedstock.

28

In addition to the above we plan to continue to locate funding for existing and new business opportunities through a combination of working with our senior lender, restructuring existing loan agreements, selling high yield debt instruments, selling bonds in the taxable and tax-exempt markets, selling equity through the ATM and otherwise, selling the current EB-5 Phase II offering, or by vendor financing arrangements.

As of December 31, 2023, the outstanding balance of principal, interest and fees, net of discounts, on all Third Eye Capital Notes equaled $177.2 million.  The maturity dates for the Third Eye Capital financing arrangements April 1, 2025, for $121.2 million (based on a February 2024 extension); March 1, 2025, for $32.5 million; and March 1, 2026, for $23.5 million. Our senior lender has provided a series of accommodating amendments to the existing and previous loan facilities as described in further detail in Note 4. Debt of the Notes to Consolidated Financial Statements in Item 8 of this Form 10-K. However, future amendments or accommodations will continue to be at the discretion of the lender.

Change in Working Capital and Cash Flows

The following table describes changes in current and long-term debt (in thousands) during the year ended December 31, 2023:

Increases to debt:
Accrued interest	$	33,870
Maturity date extension fee and other fees		2,329
Sub debt extension fees		680
Revolving Notes Series B draw		800
Fuels Revolving Line draw		15,065
Construction Loan draw		21,467
Working capital loan draw		40,040
Change in debt issuance costs, net of amortization		116
Total Increases to debt				$	114,367
Decreases to debt:
Principal, fees, and interest payments to senior lender	$	(26,896	)
Principal and interest payments to EB-5 investors		(213	)
Term loan payments		(9	)
Construction Term loan payments		(2,217	)
Working capital loan payments		(36,551	)
Total Decreases to debt				$	(65,886	)
Change in total debt				$	48,481

Working capital changes reflect (i) a $13.6 million increase in inventories consisting mostly of raw material procurement in India and production of biodiesel, (ii) a $7.4 million increase in accounts receivable, (iii) a $0.9 million decrease in prepaid expenses, (iv) a decrease in other current assets of $0.2 million, and (v) a $1.6 million decrease in cash caused by India segment operational activities.

Cash provided by operating activities was $13.8 million, derived from a net loss of $46.4 million, non-cash charges of $46.2 million, and changes in operating assets and liabilities of $14.1 million. The non-cash charges consisted of: (i) $6.6 million in amortization of debt issuance costs and other intangible assets, (ii) $6.9 million in depreciation expenses, (iii) $7.7 million in stock-based compensation expense, (iv) $25.3 million in preferred unit accretion and other expenses of Series A preferred units, (v) $0.4 million in fair value of warrants issued, and (vi) $25 thousand of impairment loss on intangibles. Net changes in operating assets and liabilities consisted primarily of an increase in (i) inventories of $13.8 million, (ii) accounts receivable of $7.4 million, (iii) other assets of $2.0 million, (iv) an increase in accounts payable of $13.7 million, (v) and an increase in accrued interest and fees of $23.6 million. This was partially offset by (i) a decrease in prepaid expenses of $1.8 million and (ii) a decrease in other liabilities of $1.8 million.

Cash used by investing activities was $23.7 million, of which $5.7 million was used for capital projects in the Keyes Plant, $24.7 million was used for capital projects associated with production of Renewable Natural Gas, $1.3 million for capital projects at the India Plant, and $1.4 million related to all other capital projects. This was partially offset by grant proceeds of $9.4 million.

Cash provided by financing activities was $9.1 million, consisting primarily of $75.5 million proceeds from borrowings, $0.1 million from stock option exercises, and $21.7 million from issuance of common stock, offset by repayments of borrowings of $56.1 million, debt renewal and waiver fee payments of $1.7 million, Series A preferred financing payments of $30.0 million, and payments on finance leases of $0.4 million.

In October 2020, we commenced an at-the-market stock sales program, which allows us to sell and issue shares of our common stock into the publicly traded markets.  During the year ended December 31, 2023, we issued 4.5 million shares of common stock under the at-the-market offering program for net proceeds of $21.7 million net of commissions and offering related expenses.

29

Off-Balance Sheet Arrangements

We had no outstanding off-balance sheet arrangements as of December 31, 2023.

Critical Accounting Policies and Estimates

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of net sales and expenses for each period. We believe that of our most significant accounting policies and estimates, defined as those policies and estimates that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain are: revenue recognition; recoverability of long-lived assets, Series A Preferred unit liability, and debt modification and extinguishment accounting. 

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance on the recognition of revenue. The guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. In March and April 2016, the FASB issued further revenue recognition guidance amending principal versus agent considerations regarding whether an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The Company adopted this guidance on January 1, 2019, using the modified retrospective approach. There was no cumulative impact to retained earnings. We assess all of our revenue streams to identify any differences in the timing, measurement or presentation of revenue recognition.

We derive revenue primarily from sales of ethanol and related co-products, renewable natural gas, and biodiesel pursuant to supply agreements and purchase order contracts. We assess the following criteria under the ASC 606 guidance: (i) identify the contracts with customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when the entity satisfies the performance obligations.

We have elected to adopt the practical expedient that allows for ignoring the significant financing component of a contract when estimating the transaction price when the transfer of promised goods to the customer and customer payment for such goods are expected to be within one year of contract inception. Further, we have elected to adopt the practical expedient in which incremental costs of obtaining a contract are expensed when the amortization period would otherwise be less than one year.

California Ethanol:  On May 25, 2023, we entered into the second amendment to the Aemetis Keyes Grain Procurement and Working Capital Agreement with J.D. Heiskell, the second amendment to the Corn Procurement and Working Capital Agreement with J.D. Heiskell, and the second amendment to the Keyes Ethanol and Corn Tank Lease with J.D. Heiskell. The amendments provide that J.D. Heiskell will buy all ethanol, WDG, CDS, and Corn Oil produced by the Keyes Plant and sell those products to customers designated by us and pay us the same price as it receives, (ii) J.D. Heiskell will lease our ethanol product storage tanks at the Keyes Plant, and (iii) Aemetis will provide J.D. Heiskell with payments sufficient to provide working capital credit sufficient to pay for four days of grain.  Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, the performance obligation was satisfied by delivery of the physical product from our finished goods tank to our customer’s contracted trucks. Effective on May 25, 2023, the performance obligation for ethanol sales is satisfied by delivery of the physical product to the finished goods tank leased by J.D. Heiskell. The transaction price is determined based on daily market prices negotiated by Murex for ethanol and by our marketing partner A.L. Gilbert Company (“A.L. Gilbert”) for WDG. The transaction price is allocated to one performance obligation.

The below table shows our sales in California Ethanol by product category:

California Ethanol	For the twelve months ended December 31,
	2023		2022
Ethanol sales	$	78,403	$	165,876
Wet distiller's grains sales		21,963		50,930
Other sales		3,702		11,388
	$	104,068	$	228,194

30

In addition to selling our products to J.D. Heiskell, we also buy the corn that we use as feedstock to produce ethanol from J.D. Heiskell. We consider the purchase of corn as a cost of goods sold and consider the sale of ethanol as revenue upon transfer to the finished goods tank and consider the sale of WDG, CDO, and CDS as revenue, upon trucks leaving the Keyes Plant with the product. Shipments of ethanol and WDG are billed net of the related transportation and marketing charges. The transportation component is accounted for in cost of goods sold and the marketing component is accounted for in sales, general and administrative expense. Transportation and marketing charges are known within days of the transaction and are recorded at the actual amounts. We have elected an accounting policy under which these charges have been treated as fulfillment activities provided after control has transferred. As a result, these charges are recognized in cost of goods sold and selling, general and administrative expenses, respectively, and revenues are recorded at the gross invoiced amount.

California Renewable Natural Gas:  We recognize revenue from the sale of Renewable Natural Gas, D3 RINs, and LCFS Credits. The RNG is transported through a regional natural gas pipeline to our customer, and we recognize sales of the gas molecules concurrent with the injection into the pipeline.  We have entered into a contract with a regional transportation fuel supply company to dispense the RNG for transportation use in conformance with the book-and-claim accounting rules of the RFS and LCFS programs. We generate D3 RINs concurrent with the dispensing activity. We may hold the D3 RINs or sell them, and we generate associated revenue at the time of sale. We generate LCFS credits on a quarterly basis that are associated with RNG dispensed two quarters prior. We may hold or sell the LCFS credits, and we generate associated revenue at the time of sale.  We first generated revenue from the sale of D3 RINs in the third quarter of 2023 and first generated revenue from the sale of LCFS credits in the first quarter of 2024.

India Biodiesel:  We sell products pursuant to purchase orders (written or verbal) or by contract with governmental or international parties, in which performance is satisfied by delivery and acceptance of the physical product. Given that the contracts are sufficiently similar in nature, we have assessed these contracts as a portfolio of similar contracts as allowed under the practical expedient. Doing so does not result in a materially different outcome compared to individually accounting for each contract. All domestic and international deliveries are subject to certain specifications as identified in contracts. The transaction price is determined based on reference market prices for biodiesel, refined glycerin, and Palm Fatty Acid Distillers (“PFAD”) net of taxes. There is no transaction price allocation needed.

The following table shows our sales in India Biodiesel by product category:

India Biodiesel	For the twelve months ended December 31,
	2023		2022
Biodiesel sales	$	74,503	$	27,041
Other sales		2,691		1,070
	$	77,194	$	28,111

Recoverability of Our Long-Lived Assets

Property and Equipment

Property, plant and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of buildings, furniture, machinery, equipment, land, and plants in North America and India. When property, plant and equipment are acquired as part of an acquisition, the items are recorded at fair value on the purchase date. It is our policy to depreciate capital assets over their estimated useful lives using the straight-line method.

31

Impairment of Long-Lived Assets

Our long-lived assets consist of property, plant and equipment.  We review long-lived asset groups for impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset groups may not be recoverable. We measure recoverability of assets to be held and used by comparing the carrying amount of an asset group to the estimated undiscounted future cash flows expected to be generated by the asset group.  If the carrying amount of an asset group exceeds its estimated future cash flows, we record an impairment charge in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. 

The impairment test for long-lived asset groups requires us to make estimates regarding amount and timing of projected cash flows to be generated by an asset or asset group over an extended period of time.  Management judgment regarding the existence of circumstances that indicate impairment is based on numerous potential factors including, but not limited to, a decline in our future projected cash flows, a decision to suspend operations at a plant for an extended period of time, adoption of our product by the market, a sustained decline in our market capitalization, a sustained decline in market prices for similar assets or businesses, or a significant adverse change in legal or regulatory factors or the business climate.  Significant management judgment is required in determining the fair value of our long-lived assets to measure impairment, including projections of future cash flows. Fair value is determined through various valuation techniques including discounted cash flow models, market values and third-party independent appraisals, as considered necessary.  Changes in estimates of fair value could result in a write-down of the asset in a future period. 

Long-term assets are analyzed based on their line items on the consolidated balance sheet and the lowest level where the asset groups are expected to generate cash flow. We consider the lowest level asset group as one where the value of the asset becomes independent from the other assets and has the ability to operate on an independent basis, and results in a functional unit.  We therefore group the reporting units into the following: the Keyes, California ethanol plant, the Kakinada, India biodiesel plant, the Central California Dairy Digester Network, the Riverbank, California Carbon Zero plant under development, the Goodland Energy Center LLC, which consists of a partially completed dry-mill, and the Carbon Capture Sequestration asset group under development. These asset groups represent our significant long-lived assets. Both the Keyes and Kakinada plants have been operated efficiently and no asset groups showed indicators of impairment, therefore no impairment test was needed for our Company’s long-lived assets.

Series A Preferred unit liability and Testing for Debt Modification or Extinguishment Accounting

During 2023 and 2022, we evaluated amendments to our debt under the ASC 470-50 guidance for modification and extinguishment accounting and under ASC 470-60 for Troubled Debt Restructuring. The evaluation for troubled debt restructuring included assessing whether the Company is experiencing financial difficulties and whether the creditor granted a concession. To determine whether the Company is experiencing financial difficulties, we evaluate if the payments on debt made on time, forecasting of cash flows, and other ways if the Company can meet its upcoming obligations. To determine whether a concession is granted, we calculate the post-restructuring effective interest rate by projecting cash flows on the new terms and calculating a discount rate equal to the carrying amount of pre-restructuring debt and comparing this calculation to the terms of prior amendments.  If the post restructuring effective interest rate is less than the prior terms effective interest rate, we assess this as having been granted a concession. We then apply troubled debt restructuring accounting to any debt in which the creditor granted a concession. The above evaluation determines if there is no troubled debt restructuring, then the evaluation for modification and extinguishment includes comparing the net present value of cash flows of the new debt to the old debt to determine if changes greater than 10 percent occurred. In instances where our future cash flows change more than 10 percent, we record our debt at fair value based on factors available to us for similar borrowings and use the extinguishment accounting method to account for the debt extinguishment. 

Recently Issued Accounting Pronouncements

Refer to Note 1 of the Financial Statements for a description of new accounting pronouncements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

32

Item 8.  Financial Statements and Supplementary Data.

AEMETIS, INC.

Index to Consolidated Financial Statements

	Page Number
Report of Independent Registered Public Accounting Firm (PCAOB ID 49)	34
Consolidated Financial Statements
Consolidated Balance Sheets	37
Consolidated Statements of Operations and Comprehensive Loss	38
Consolidated Statements of Cash Flows	39
Consolidated Statements of Stockholders' Deficit	40
Notes to Consolidated Financial Statements	41

33

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Aemetis, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Aemetis, Inc. and its subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders’ deficit and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. Our report dated March 28, 2024, expressed an opinion that the Company had not maintained effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Liquidity & Management’s Plan

As disclosed in Note 16 of the consolidated financial statements, the Company has been reliant on their senior secured lender for liquidity and has been required to remit substantially all excess cash from operations to the senior secured lender. Management believes, based on the Company’s business plan, that cash flows from operations and established financing arrangements, including financing available under the reserve liquidity facility provided by the Company’s senior secured lender, and potential additional issuances of common stock are sufficient to fund future cash flow requirements and satisfy the Company’s obligations as they come due for at least one year from the financial statement issuance date.

We determined the adequacy of the available commitment on the reserve liquidity facility and the Company's overall cash flow projections to be a critical audit matter because management’s plan includes certain significant assumptions related to the Company's cash flow needs. Auditing management’s assumptions related to the Company's cash flow needs involved a high degree of auditor judgment and increased audit efforts.

Our audit procedures related to the Company’s liquidity evaluation and the adequacy of the commitment on the reserve liquidity facility included the following, among others:

● We evaluated the reasonableness of forecasted cash needs, for at least one year from the financial statement issuance date, by comparing to historical operating results as well as external forecasted market data for both ethanol and corn.

● We evaluated the reasonableness of management’s estimated reduction in current liabilities from the Company's cash needs for a period of greater than a year from the financial statement issuance date by evaluating subordination agreements that are in place and the ability for the company to defer interest payments on various debt agreements.

● We evaluated management’s forecasted cash needs, for at least one year from the financial statement issuance date, in the context of other audit evidence obtained, including, but not limited to, board of director minutes and investor presentation to determine whether the other audit evidence supported or contradicted the forecast.

● We tested the subsequent event activity related to additional cash available or needs to additional funding of working capital.

● We tested the Company's ability to maintain compliance with covenants, for at least one year from the financial statement issuance date, under the existing loan agreements and the ability of the Company's senior lender to provide the additional funding under the amended reserve liquidity facility.

34

Investment Tax Credit Sale

As disclosed in Note 1 of the consolidated financial statements, the Company entered into an investment tax credit sale agreement with a third-party resulting in a $55.2 million income tax benefit recognized for the year ended December 31, 2023.

We determined the Company's investment tax credit sale to be a critical audit matter as there was a high degree of auditor judgment and increased audit effort, including the use of income tax and revenue recognition specialists, when performing procedures to evaluate the appropriateness of the accounting determinations for the investment tax credit sale.

Our audit procedures related to the investment tax credit sale included the following, among others:

● We read the relevant investment tax credit sale documents and compared to the terms to the Company's accounting documentation.

● We evaluated the Company's accounting determination and the application of the relevant accounting guidance, including an evaluation of audit evidence regarding the determination that control of the investment tax credit had been transferred to the purchaser.

/s/ RSM US LLP                          

We have served as the Company's auditor since 2012.

Des Moines, Iowa

March 28, 2024

35

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Aemetis, Inc.

Opinion on the Internal Control Over Financial Reporting

We have audited Aemetis, Inc. and its subsidiaries’ (the Company) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. In our opinion, because of the effect of the material weaknesses described below on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders’ deficit and cash flows for the years then ended, and the related notes to the consolidated financial statements of the Company and our report dated March 28, 2024 expressed an unqualified opinion.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses have been identified and included in management's assessment:

● There were ineffective information technology general controls (ITGCs) and segregation of duties, specifically in the areas of user access, passwords, change-management, and third-party service provider report review over certain information technology systems used in the Company’s financial reporting processes. As a result of the pervasive impact of these controls, automated and manual business process controls that are dependent on ITGCs and appropriate segregation of duties were also ineffective.

● There were ineffective controls relating to the Company maintaining sufficient personnel in the proper roles to allow for timely and precise completion and documentation of the performance of controls. As a result of this deficiency, we note that all financial statement transaction cycles could be impacted such that material misstatements may not be detected in a timely manner. We specifically note the following items impacted by this deficiency that rise to the level of a material weakness:

o Controls over the amount of revenue recognized for ethanol sales and wet distillers grain sales were ineffective due to a lack of verification of prices invoiced.

o Controls over debt covenants, debt classification, and going concern were ineffective due to untimely completion, imprecise review of inputs, and insufficient written documentation regarding the performance of related controls.

o Controls over financial statement tie outs were ineffective due to untimely completion of such review.

o Controls over cash were ineffective due to untimely performance of bank reconciliations performed on related cash accounts.

o Controls over property, plant and equipment and related depreciation expense and accumulated depreciation were ineffective due to the untimely performance of such review and reconciliation of such accounts.

o Controls over income tax disclosures were ineffective due to imprecise review and approval of the income tax provision.

These material weaknesses were considered in determining the nature, timing and extent of audit tests applied in our audit of the 2023 financial statements, and this report does not affect our report dated March 28, 2024 on those financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. 

Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ RSM US LLP

Des Moines, Iowa

March 28, 2024

36

AEMETIS, INC.

CONSOLIDATED BALANCE SHEETS

AS OF December 31, 2023 and 2022

(In thousands except for par value)

	December 31, 2023			December 31, 2022
Assets
Current assets:
Cash and cash equivalents ($1,093 and $165 respectively from VIE)	$	2,667		$	4,313
Accounts receivable ($55 and $165 respectively from VIE)		8,633			1,264
Inventories, net of allowance for excess and obsolete inventory of $1,040 as of December 31, 2023 and 2022		18,291			4,658
Prepaid expenses ($1,438 and $858 respectively from VIE)		3,347			4,248
Other current assets ($289 and $725 respectively from VIE)		3,462			3,653
Total current assets		36,400			18,136
Property, plant and equipment, net ($81,966 and $71,633 respectively from VIE)		195,108			180,441
Operating lease right-of-use assets ($145 and $224 respectively from VIE)		2,056			2,449
Other assets ($4,881 and $3,458 respectively from VIE)		9,842			6,088
Total assets	$	243,406		$	207,114
Liabilities and stockholders' deficit
Current liabilities:
Accounts payable ($3,815 and $9,192 respectively from VIE)	$	32,132		$	26,168
Current portion of long term debt ($190 and $0 from VIE)		13,585			12,465
Short term borrowings ($9 and $19,831 respectively from VIE)		23,443			36,754
Mandatorily redeemable Series B convertible preferred stock		4,521			4,082
Current portion of operating lease liability ($48 and $41 respectively from VIE)		406			338
Other current liabilities ($0 and $645 respectively from VIE)		10,302			8,474
Total current liabilities		84,389			88,281
Long term liabilities:
Senior secured notes and revolving notes		176,476			155,843
EB-5 notes		29,500			29,500
Other long term debt ($40,857 and $31 respectively from VIE)		51,717			11,678
Series A preferred units ($113,189 and $116,000 respectively from VIE)		113,189			116,000
Operating lease liability ($67 and $115 respectively from VIE)		1,783			2,189
Other long term liabilities		3,329			5,477
Total long term liabilities		375,994			320,687
Stockholders' deficit:
Series B convertible preferred stock, $0.001 par value; 7,235 authorized; 0 and 1,270 shares issued and outstanding each period, respectively (aggregate liquidation preference of $0 and $3,810 respectively)		-			1
Common stock, $0.001 par value; 80,000 authorized; 40,966 and 35,869 shares issued and outstanding each period, respectively		41			36
Additional paid-in capital		264,058			232,546
Accumulated deficit		(475,405	)		(428,985	)
Accumulated other comprehensive loss		(5,671	)		(5,452	)
Total stockholders' deficit		(216,977	)		(201,854	)
Total liabilities and stockholders' deficit	$	243,406		$	207,114

The accompanying notes are an integral part of the financial statements.

37

AEMETIS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE YEARS ENDED December 31, 2023 and 2022

(In thousands, except for earnings per share)

	For the years ended December 31,
	2023			2022
Revenues	$	186,717		$	256,513
Cost of goods sold		184,700			262,048
Gross (loss) profit		2,017			(5,535	)
Research and development expenses		152			180
Selling, general and administrative expenses		39,266			28,686
Operating loss		(37,401	)		(34,401	)
Other expense (income):
Interest expense
Interest rate expense		32,995			21,407
Debt related fees and amortization expense		6,524			7,363
Accretion and other expenses of Series A preferred units		25,313			9,888
Loss on debt extinguishment		-			49,386
Gain on litigation		-			(1,400	)
Other income		(2,077	)		(14,340	)
Loss before income taxes		(100,156	)		(106,705	)
Income tax expense (benefit)		(53,736	)		1,053
Net loss	$	(46,420	)	$	(107,758	)
Other comprehensive (loss)
Foreign currency translation loss		(219	)		(1,102	)
Comprehensive loss	$	(46,639	)	$	(108,860	)
Net loss per common share
Basic	$	(1.22	)	$	(3.12	)
Diluted	$	(1.22	)	$	(3.12	)
Weighted average shares outstanding
Basic		38,061			34,585
Diluted		38,061			34,585

The accompanying notes are an integral part of the financial statements.

38

AEMETIS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED December 31, 2023 and 2022

(In thousands)

	For the year ended December 31,
	2023			2022
Operating activities:
Net loss	$	(46,420	)	$	(107,758	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Share-based compensation		7,660			6,410
Depreciation		6,933			5,535
Debt related fees and amortization expense		6,524			7,363
Intangibles and other amortization expense		72			46
Accretion and other expenses of Series A preferred units		25,313			9,888
Warrants issued for working capital agreement		409			-
Loss on asset disposals		-			47
Loss on debt extinguishment		-			49,386
Gain on litigation		-			(1,400	)
Loss on lease termination		-			736
Deferred tax (benefit) expense		(750	)		832
Changes in operating assets and liabilities:
Accounts receivable		(7,422	)		294
Inventories		(13,843	)		360
Prepaid expenses		1,838			1,777
Other assets		(2,016	)		(3,941	)
Accounts payable		13,726			2,183
Accrued interest expense and fees		23,558			15,501
Other liabilities		(1,757	)		(10,125	)
Net cash provided by (used in) operating activities		13,825			(22,866	)
Investing activities:
Capital expenditures		(33,119	)		(39,157	)
Grant proceeds received for capital expenditures		9,432			7,851
Net cash used in investing activities		(23,687	)		(31,306	)
Financing activities:
Proceeds from borrowings		75,482			69,356
Repayments of borrowings		(56,130	)		(26,266	)
Lender debt renewal and waiver fee payments		(1,681	)		(1,169	)
Payments on Series A preferred financing		(30,000	)		-
Payments on finance leases		(428	)		(481	)
Proceeds from issuance of common stock in equity offering		21,718			11,987
Proceeds from the exercise of stock options		133			206
Net cash provided by financing activities		9,094			53,633
Effect of exchange rate changes on cash and cash equivalents		49			(213	)
Net change in cash and cash equivalents for period		(719	)		(752	)
Cash, cash equivalents, and restricted cash at beginning of period		6,999			7,751
Cash, cash equivalents, and restricted cash at end of period		6,280			6,999
Supplemental disclosures of cash flow information, cash paid:
Cash paid for interest	$	9,813		$	19,515
Income taxes paid		20			10
Supplemental disclosures of cash flow information, non-cash transactions:
Subordinated debt extension fees added to debt		680			680
Debt fees added to revolving lines		-			800
Fair value of warrants issued to subordinated debt holders		1,278			1,939
Fair value of stock issued to a related party for guarantee fees		-			2,012
Fair value of warrants issued to lender for debt issuance costs		318			3,158
Fair value of stock issued to lender		-			1,335
Lender debt extension, waiver, and other fees added to debt		-			583
Capital expenditures in accounts payable		7,900			15,411
Payment of debt added to revolving lines		-			16,266
Operating lease liabilities arising from obtaining right of use assets		-			306
Financing lease liabilities arising from obtaining right of use assets		-			2,932
Capital expenditures purchased on financing		-			290

The accompanying notes are an integral part of the financial statements.

39

AEMETIS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED December 31, 2023 and 2022

(In thousands)

	Series B Preferred Stock						Common Stock				Additional Paid-in		Accumulated			Accumulated Other Comprehensive
	Shares			Dollars			Shares		Dollars		Capital		Deficit			Loss			Total
Balance at December 31, 2021		1,275		$	1			33,461	$	33	$	205,305	$	(321,227	)	$	(4,350	)	$	(120,238	)
																				-
Issuance of common stock		-			-			1,885		3		15,530		-			-			15,533
Series B conversion to common stock		(5	)		-			1		-		-		-			-			-
Stock options exercised		-			-			296		-		205		-			-			205
Stock-based compensation		-			-			-		-		6,410		-			-			6,410
Issuance and exercise of warrants		-			-			226		-		5,096		-			-			5,096
Foreign currency translation loss		-			-			-		-		-		-			(1,102	)		(1,102	)
Net loss		-			-			-		-		-		(107,758	)		-			(107,758	)
Balance at December 31, 2022		1,270			1			35,869		36		232,546		(428,985	)		(5,452	)		(201,854	)
Issuance of common stock		-			-			4,499		4		21,714		-			-			21,718
Series B conversion to common stock		(1,270	)		(1	)		127		1		-		-			-			-
Stock options exercised		-			-			183		-		133		-			-			133
Stock-based compensation		-			-			-		-		7,660		-			-			7,660
Issuance and exercise of warrants		-			-			288		-		2,005		-			-			2,005
Foreign currency translation loss		-			-			-		-		-		-			(219	)		(219	)
Net loss		-			-			-		-		-		(46,420	)		-			(46,420	)
Balance at December 31, 2023		-		$	-			40,966	$	41		264,058	$	(475,405	)	$	(5,671	)	$	(216,977	)

The accompanying notes are an integral part of the financial statements.

40

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

1. Nature of Activities and Summary of Significant Accounting Policies

Nature of Activities. These consolidated financial statements include the accounts of Aemetis, Inc. (formerly AE Biofuels, Inc.), a Delaware corporation, and its subsidiaries (collectively, “Aemetis” or the “Company”):

● Aemetis Americas, Inc., a Delaware corporation, and its subsidiary AE Biofuels, Inc., a Delaware corporation;

● Aemetis International, Inc., a Nevada corporation, and its subsidiary International Biofuels Ltd, a Mauritius corporation, and its subsidiary Universal Biofuels Private Limited, an India company;

● Aemetis Technologies, Inc., a Delaware corporation;

● Aemetis Biofuels, Inc., a Delaware corporation, and its subsidiary Energy Enzymes, Inc., a Delaware corporation;

● AE Advanced Fuels, Inc., a Delaware corporation, and its subsidiaries Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, and Aemetis Property Keyes, Inc., a Delaware corporation;

● Aemetis Advanced Fuels, Inc., a Nevada corporation;

● Aemetis Advanced Products Keyes, Inc., a Delaware corporation, and its subsidiaries Aemetis Properties Riverbank, Inc., a Delaware corporation, Aemetis Health Products, Inc., a Delaware corporation; and Aemetis Riverbank, Inc., a Delaware corporation, and its subsidiary Aemetis Advanced Products Riverbank, Inc., a Delaware corporation;

● Aemetis Advanced Biorefinery Keyes, Inc., a Delaware corporation;

● Aemetis Carbon Capture, Inc. a Nevada corporation;

● Aemetis Biogas LLC, a Delaware Limited Liability Company and its subsidiaries Aemetis Biogas Services LLC, a Delaware Limited Liability Company, and Aemetis Biogas Holdings LLC, a Delaware Limited Liability Company, and its subsidiaries Aemetis Biogas 1 LLC, a Delaware Limited Liability Company, Aemetis Biogas 2 LLC, a Delaware Limited Liability Company, Aemetis Biogas 3 LLC, a Delaware Limited Liability Company, Aemetis Biogas 4 LLC, a Delaware Limited Liability Company, Aemetis Biogas 5 LLC, a Delaware Limited Liability Company, Aemetis Biogas 6 LLC, a Delaware Limited Liability Company, Aemetis Biogas 7 LLC, a Delaware Limited Liability Company, and Aemetis Biogas 8 LLC, a Delaware Limited Liability Company;

● Goodland Advanced Fuels, Inc., a Nevada corporation.

Founded in 2006 and headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis referred to herein as, “Aemetis,” the “Company,” “we,” “our” or “us”) is an international renewable natural gas and renewable fuels company focused on the operation, acquisition, development, and commercialization of innovative low and negative carbon intensity products and technologies that replace traditional petroleum-based products. We operate in three reportable segments consisting of “California Ethanol,” “California Dairy Renewable Natural Gas,” and “India Biodiesel.” We have other operating segments determined not to be reportable segments and are collectively represented by the “All Other” category. Our mission is to generate sustainable and innovative renewable fuel solutions that benefit communities and restore our environment. We do this by building a local circular bioeconomy utilizing agricultural waste to produce low and negative carbon, advanced renewable fuels that reduce greenhouse gas ("GHG") emissions and improve air quality by replacing traditional petroleum-based products.

Basis of Presentation and Consolidation. These consolidated financial statements include the accounts of Aemetis, Inc. and its subsidiaries. We consolidate all entities in which we have a controlling financial interest. A controlling financial interest is usually obtained through ownership of a majority of the voting interests. However, an enterprise must consolidate a variable interest entity (“VIE”) if the enterprise is the primary beneficiary of the VIE, even if the enterprise does not own a majority of the voting interests. The primary beneficiary is the party that has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. ABGL was assessed to be a VIE and through the Company's ownership interest in all of the outstanding common stock, the Company has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company.

All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. To the extent there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.

Revenue Recognition. We derive revenue primarily from sales of ethanol and related co-products in California Ethanol segment, renewable natural gas for California Dairy Renewable Natural Gas segment, and biodiesel in India Biodiesel segment pursuant to supply agreements and purchase order contracts. We assess the following criteria under the ASC 606 guidance: (i) identify the contracts with customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when the entity satisfies the performance obligations.  

California Ethanol:  From 2022 until the second quarter of 2023, we sold our ethanol production to Murex who marketed it to oil companies as a gasoline blend stock.  Starting in the second quarter of 2023, we began selling all our ethanol to J.D. Heiskell who sells it to customers designated by us, and we have designated Murex, who continues to market the product.  J.D. Heiskell does not charge a fee for reselling the ethanol but they receive the payments from the ultimate customer.  We also buy our corn feedstock from J.D. Heiskell, and J.D. Heiskell pays us the net balance between ethanol and other product sales and our corn purchases.  Our accounting (i) treats us as the purchaser/customer for corn purchases from J.D. Heiskell and we record the full purchase cost in cost-of-good sold, and (ii) treats us as the seller for ethanol and other product sales, so we treat all sales as revenue.

41

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, the performance obligation was satisfied by delivery of the physical product from our finished goods tank to our customer’s contracted trucks. Effective on May 25, 2023, the performance obligation is satisfied by delivery of the physical product to our finished goods tank leased by J.D. Heiskell. The transaction price is determined based on daily market prices and quarterly contract pricing negotiated by Murex for its customers for ethanol and based on dry distillers' market and local demand by our marketing partner A.L. Gilbert Company (“A.L. Gilbert”) for WDG. The transaction price is allocated to one performance obligation.

During the last two weeks of December 2022, we undertook an extended maintenance cycle and accelerated the implementation of several important ethanol plant energy efficiency upgrades. Our decision was partly driven by the high natural gas prices in California during the period. Furthermore, after monitoring natural gas pricing and margin profitability, we decided to extend the maintenance cycle into the first and second quarters of 2023 and restarted the plant at the end of May 2023.

The following table shows our sales in California Ethanol by product category:

California Ethanol	For the twelve months ended December 31,
	2023		2022
Ethanol sales	$	78,403	$	165,876
Wet distiller's grains sales		21,963		50,930
Other sales		3,702		11,388
	$	104,068	$	228,194

California Dairy Renewable Natural Gas: Our facilities as of December 31, 2023, consist of seven anaerobic digesters that process feedstock from dairies into biogas, a 26-mile collection pipeline leading to a central upgrading hub, and an interconnect to inject the RNG into the utility natural gas pipeline for delivery to customers for use as transportation fuel.  During 2023, Renewable Natural Gas ("RNG") produced at our seven operating dairy digesters was delivered to the regional natural gas pipeline.  In connection with dispensing the RNG, we also began generating and inventorying sellable credits under the federal Renewable Fuel Standard (referred to as "D3 RINs") and the California Low Carbon Fuel Standard credits ("LCFS"). We began selling D3 RINs in the third quarter of 2023 and began selling LCFS credits in the first quarter of 2024. We recognize revenue from sales of RNG concurrent with our production and injection into the transportation pipeline.  We recognize revenue from sales of D3 RINs and LCFS credits at the time we sell the credits. 

Dairy Renewable Natural Gas	For the twelve months ended December 31,
	2023		2022
Molecule and RIN sales	$	5,455	$	208

India Biodiesel: We sell products pursuant to purchase orders (written or verbal) or by contract with governmental or international parties, in which performance is satisfied by delivery and acceptance of the physical product. Given that the contracts are sufficiently similar in nature, we have assessed these contracts as a portfolio of similar contracts as allowed under the practical expedient. Doing so does not result in a materially different outcome compared to individually accounting for each contract. All domestic and international deliveries are subject to certain specifications as identified in contracts. The transaction price is determined based on reference market prices for biodiesel, refined glycerin, and PFAD net of taxes. Transaction price is allocated to one performance obligation.

The following table shows our sales in India by product category:

India Biodiesel	For the twelve months ended December 31,
	2023		2022
Biodiesel sales	$	74,503	$	27,041
Other sales		2,691		1,070
	$	77,194	$	28,111

Cost of Goods Sold. Cost of goods sold includes those costs directly associated with the production of revenues, such as raw material consumed, factory overhead, and other direct production costs.  During periods of idle plant capacity from January to May 2023, costs otherwise charged to cost of goods sold are reclassified to selling, general and administrative expense. 

Shipping and Handling Costs. When incurred, shipping and handling costs are classified as a component of cost of goods sold in the accompanying consolidated statements of operations.

42

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Research and Development. Research and development costs are expensed as incurred, unless they have alternative future uses to the Company.

Cash, Cash Equivalents, and Restricted Cash. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company maintains cash balances at various financial institutions domestically and abroad. The Federal Deposit Insurance Corporation insures domestic cash accounts. The Company’s accounts at these institutions may at times exceed federally insured limits. The Company has not experienced any losses in such accounts. Amounts included in restricted cash represent those required to be set aside by the AB1 and AB2 Loan Agreements with Greater Nevada Credit Union ("GNCU") and Magnolia Bank, respectively, and will be released at times specified in each agreement.

The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same such amounts shown in the statement of cash flows. 

	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,667	$	4,313
Restricted cash included in other current assets		289		725
Restricted cash included in other assets		3,324		1,961
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	6,280	$	6,999

Accounts Receivable.   The Company sells all of its products to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement. Our third-party marketing partners arrange to buy ethanol and WDG generally without requiring collateral and sell directly to customers on a variety of terms including advanced payment terms, based on the size and creditworthiness of the customer. DCO and CDS are marketed and sold to various customers under the J.D. Heiskell Purchasing Agreement. The Company sells biodiesel, glycerin, and processed natural oils to a variety of customers and may require advanced payment based on the size and creditworthiness of the customer. Usually, invoices are due within 30 days on net terms. Accounts receivable mostly consist of product sales made to large creditworthy customers. Trade accounts receivable are presented at original invoice amount, net of any allowance for doubtful accounts.

The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and estimates an allowance for expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may be required. 

Inventories. Finished goods, raw materials, and work-in-process inventories are valued using methods that approximate the lower of cost (first-in, first-out) or net realizable value (NRV).  Distillers’ grains and related products are stated at NRV.  In the valuation of inventories, NRV is determined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.

Other current assets. The other current assets contain input tax credits of $1.6 million, employee advance receivables of $69 thousand, and advances to customers of $1.2 million by our India biodiesel segment. 

Variable Interest Entities. We determine at the inception of each arrangement whether an entity in which we have made an investment or in which we have other interests in is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other interests in a VIE in accordance with applicable GAAP.

Property, Plant and Equipment. Property, plant, and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of buildings, furniture, machinery, equipment, land, biogas dairy digesters, and the Keyes Plant, Goodland Plant and Kakinada Plant. It is the Company’s policy to depreciate capital assets over their estimated useful lives using the straight-line method.

The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 Property Plant and Equipment –Subsequent Measurement, which requires recognition of impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of asset groups may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, based on estimated undiscounted cash flows, the impairment loss would be measured as the difference between the carrying amount of the asset group and its estimated fair value. The Company has not recorded any impairment as of December 31, 2023 and 2022.

43

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Grants Received.

California Energy Commission Low-Carbon Fuel Production Program. The Company has been awarded $4.2 million in matching grants from the California Energy Commission Low-Carbon Fuel Production Program (“LCFPP”). The LCFPP grant reimburses the Company for costs to design, procure, and install processing facility to clean-up, measure and verify negative-carbon intensity dairy renewable natural gas fuel at the production facility in Keyes, California. The Company has received $3.8 million from the LCFPP as of  December 31, 2023, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Department of Food and Agriculture Dairy Digester Research and Development Grant. In 2019, the Company was awarded $3.2 million in matching grants from the California Department of Food and Agriculture (“CDFA”) Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct two of the Company’s biogas capture systems under contract with central California dairies. The Company received all the awarded grant proceeds as of the second quarter of 2021. In  October 2020, the Company was awarded $7.8 million in matching grants from the CDFA Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct six of the Company’s biogas capture systems under contract with central California dairies. The Company has received $6.2 million from the CDFA 2020 grant program as of December 31, 2023, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Energy Commission Low Carbon Advanced Ethanol Grant Program. In  May 2019, the Company was awarded the right to receive reimbursements from the California Energy Commission Community-Scale and Commercial-Scale Advanced Biofuels Production Facilities grant under the Alternative and Renewable Fuel and Vehicle Technology Program in an amount up to $5.0 million (the “CEC Reimbursement Program”) in connection with the Company’s expenditures toward the development of the Riverbank Cellulosic Ethanol Facility. To comply with the guidelines of the CEC Reimbursement Program, the Company must make a minimum of $7.9 million in matching contributions to the Riverbank project. The Company receives funds under the CEC Reimbursement Program for actual expenses incurred up to $5.0 million as long as the Company makes the minimum matching contribution. Given that the Company has not made the minimum matching contribution, the California Energy Commission did not extend the due date and would not move forward with this grant program. Given the nature of the project, the grant for reimbursement of capital expenditures of $1.7 million is presented with other current liabilities as of  December 31, 2023 and 2022 

U.S. Department of Food and Agriculture Forest Service Grant. Aemetis Advanced Products Keyes (“AAPK”) has been awarded $245 thousand in matching grants from the U.S. Department of Food and Agriculture Forest Service (“US Forest Service”) under the Wood Innovation and Community Wood program. The grant reimburses the Company for continued development of technologies and processes to valorize forest waste for the production of cellulosic ethanol.  AAPK has received $166 thousand from the US Forest Service as reimbursement for actual allowable program costs incurred through December 31, 2023.

California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. Aemetis Advanced Fuels Keyes (“AAFK”) has been awarded an $8.0 million grant to design, construct and commission a grid-connected 1.56 MW photovoltaic microgrid and 1.25MW/2.5MWh Battery Energy Storage System integrated with an artificial intelligence-driven distributed control system (DCS). The grant requires $1.6 million in matching contribution in which the Company has made. AAFK received $4.4 million in grant funds from this program as reimbursement for actual expenditures incurred through  December 31, 2023. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Department of Forestry and Fire Protection Grant. AAPK has been awarded $2 million in matching grants from the CAL FIRE Business and Workforce Development Grant Program (“CAL Fire”) in  May 2022. This CAL Fire grant program reimburses AAPK for costs to design, construct, and commission a 2 million gallon per year cellulosic ethanol facility that will convert conifer biomass from forested regions of the Sierra Nevada into an ultra‐low carbon biofuel derived from 100% forest biomass (“CAL Fire Conversion Program”). AAPK must contribute $5.8 million in cost share contributions to the project to receive grant proceeds. AAPK has received no grant funds from the CAL Fire Conversion Program as reimbursement for actual costs through December 31, 2023.

California Department of Forestry and Fire Protection Grant. AAPK has been awarded $500 thousand in grants from CAL Fire in  May 2022. This CAL Fire grant program reimburses AAPK for costs to advance a new‐to‐the world technology that circumvents current limitations surrounding the extraction of cellulosic sugars by pioneering a novel route for deconstructing woody biomass using ionic liquids (“CAL Fire Extraction Program”). AAPK has received no grant funds from the CAL Fire Extraction Program as reimbursement for actual costs through  December 31, 2023.

U.S. Forest Service Community Wood Grant. Aemetis Advanced Products Riverbank (“AAPR”) has been awarded $642 thousand in matching grants from the U.S Forest Service Wood Innovations Program (“USFS”) in  May 2022. The USFS grant program reimburses AAPR for costs to design, construct, and commission a plant to produce cellulosic ethanol using preliminary research and development in partnership with the Joint Bioenergy Institute (JBEI). USFS grant funds will be used to complete the FEL-3 design phase of the entire process, construct a biomass pretreatment unit to extract sugars at the Aemetis Riverbank site and ferment sugars into ethanol at the Keyes Plant. AAPR must contribute $2.4 million in cost share contributions to the project to receive grant proceeds. AAPK has received no grant funds from the USFS grant program as reimbursement for actual costs through  December 31, 2023.

USDA Biofuel Producer Program Grant. During the second quarter of 2022, a grant in the amount of $14.2 million was received from the USDA’s Biofuel Producer Program, created as part of the CARES Act, to compensate biofuel producers who experienced market losses due to the COVID-19 pandemic. This was recorded in the other expense (income) section of the Consolidated Statements of Operations and Comprehensive Loss.

California Energy Commission Grant for Mechanical Vapor Recompression System. Aemetis Advanced Fuels Keyes (“AAFK”) has been awarded a $6.0 million grant to design, construct and commission a mechanical vapor recompression (MVR) system. The additional evaporation stages will eliminate natural gas consumption and related greenhouse gas emissions in the evaporation portion of the process by installing metering equipment and software to monitor and optimize the plant’s energy consumption. The MVR system will compress vapor to a higher pressure and temperature so that it can be recycled multiple times as steam heat in the evaporation process, which will dramatically reduce natural gas use. The grant requires $5.3 million in matching contributions. AAFK has received no grant funds from this program as reimbursement for actual expenditures incurred through  December 31, 2023. Due to the uncertainty associated with the approval process under the grant program, the Company will recognize future grant proceeds received as a reduction of costs in the period when payment is received.

44

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

PG&E A2313 Pipeline Interconnection Recovery Grant. In February 2023, Aemetis Biogas received $5 million from Pacific Gas and Electric (PG&E) as part of qualification under a California Public Utility Commission Biomethane incentive program reimbursing actual Aemetis Biogas costs to interconnect biogas cleanup hub with PG&E utility pipeline. Incentive payment earned after validating renewable natural gas flowed into PG&E interconnect successfully for required period of time.

Pacific Gas and Electric SEM Manufacturer’s Incentive Program. During the fourth quarter of 2022, AAFK received $374 thousand in PG&E SEM Incentive Program reimbursements for installing more efficient beer feed heat exchangers. Third party consultants verified the reduction in natural gas usages from the new heat exchangers to obtain the incentive program funds.

Investment Tax Credits. In the third quarter of 2023, the Company sold to a third-party purchaser certain transferrable Investment Tax Credits (ITCs) that had been generated by the Company from its investments in the California Dairy Renewable Natural Gas segment. The Company accounted for the ITC sale in accordance with ASC 740 by electing the flow-through method. The net value of the tax credits sale of $55.2 million is recorded as an income tax benefit in the income statement for the period ending December 31, 2023. The cash was received in October 2023, and it was used to make certain principal and interest payments on revolving notes and Series A preferred financing.

Income Taxes. The Company recognizes income taxes in accordance with ASC 740 Income Taxes using an asset and liability approach. This approach requires the recognition of taxes payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. The measurement of current and deferred taxes is based on provisions of enacted tax law. ASC 740 provides for recognition of deferred tax assets if the realization of such assets is more likely than not to occur. Otherwise, a valuation allowance is established for the deferred tax assets, which may not be realized. As of December 31, 2023 and 2022, the Company recorded a full valuation allowance against its U.S. federal and state net deferred tax assets due to operating losses incurred since inception. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets were fully offset by a valuation allowance.

The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may have a material impact on the Company’s tax provision in a future period.        

In 2018, the Company adopted certain tax accounting policies related to the new global intangible low-taxed income (“GILTI”) provisions under the Tax Cuts and Jobs Act such that the Company will: (1) account for all GILTI related book-tax differences as period costs and (2) use the Incremental Cash Tax Savings approach in evaluating its valuation allowance assessment related to the GILTI inclusion.

Basic and Diluted Net Income (Loss) per Share.  Basic net loss per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted net loss per share reflects the dilution of common stock equivalents such as options, convertible preferred stock, debt and warrants to the extent the impact is dilutive.  As the Company incurred a net loss for the years ended December 31, 2023 and 2022, potentially dilutive securities have been excluded from the diluted net loss per share computations as their effect would be anti-dilutive.

The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of December 31, 2023 and 2022:

	As of
	December 31, 2023		December 31, 2022
Series B preferred (post split basis)		-		127
Common stock options and warrants		6,056		5,050
Debt with conversion feature at $30 per share of common stock		1,267		1,240
Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation		7,323		6,417

Comprehensive Loss. ASC 220 Comprehensive Income requires that an enterprise report, by major components and as a single total, the change in its net assets from non-owner sources. The Company’s other comprehensive loss and accumulated other comprehensive loss consists solely of cumulative currency translation adjustments resulting from the translation of the financial statements of our India subsidiary. The investment in this subsidiary is considered indefinitely invested overseas, and as a result, deferred income taxes are not recorded related to the currency translation adjustments.

Foreign Currency Translation/Transactions. The Company’s India subsidiary operates in a local currency environment where the local currency is the functional currency used for transactions and accounting. Assets and liabilities of that subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date and the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Income and expense accounts are translated at average exchange rates during the year. Transactional gains and losses from foreign currency transactions are recorded in other (income) loss, net.

Fair Value of Financial Instruments. Financial instruments include accounts receivable, accounts payable, accrued liabilities, current and non-current portion of subordinated debt, notes payable, Series A preferred units, and long-term debt.  Due to the unique terms of our notes payable and long-term debt and the financial condition of the Company, the fair value of the debt is not readily determinable.  The fair value determined using level 3 inputs of all other current financial instruments is estimated to approximate carrying value due to the short-term nature of these instruments.

45

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Share Based Compensation. We recognize share-based compensation expense in accordance with ASC 718 Stock Compensation, which requires the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards over the vesting period, adjusted to reflect only those shares that are expected to vest.

Commitments and Contingencies. We record and/or disclose commitments and contingencies in accordance with ASC 450 Contingencies.  ASC 450 applies to an existing condition, situation, or set of circumstances involving uncertainty as to possible loss that will ultimately be resolved when one or more future events occur or fail to occur.

Convertible Instruments.  The Company evaluates the impacts of convertible instruments based on the underlying conversion features. Convertible Instruments are evaluated for treatment as derivatives that could be bifurcated and recorded separately.  

Debt Issuance Costs. The Company records debt issuance costs related to specific incremental costs directly attributable to issuing, modifying, or extending a debt instrument.  The debt issuance costs are reported as an adjustment to the carrying amount of the debt.  The debt issuance costs are amortized using the interest rate method over the life of the debt instrument.

Troubled Debt Restructuring Accounting. The evaluation for troubled debt restructuring includes assessing whether the creditor granted a concession. To determine this, we calculate the post-restructuring effective interest rate by projecting cash flows on the new terms and calculating a discount rate equal to the carrying amount of pre-restructuring debt and comparing this calculation to the terms of prior amendments.  If the post restructuring effective interest rate is less than the prior terms effective interest rate, we assess this as having been granted a concession.  We then apply troubled debt restructuring accounting to any debt in which the creditor granted a concession.

Debt Modification Accounting. The Company evaluates amendments to its debt in accordance with ASC 540-50 Debt – Modification and Extinguishments for modification and extinguishment accounting.  This evaluation includes comparing the net present value of cash flows of the new debt to the old debt to determine if changes greater than 10 percent occurred.  In instances where the net present value of future cash flows changed more than 10 percent, the Company applies extinguishment accounting and determines the fair value of its debt based on factors available to the Company.

Recently Adopted Accounting Pronouncements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements. 

There were no other recently issued and effective authoritative guidance that are expected to have a material impact on the Company’s Consolidated Financial Statements through the reporting date.

2. Inventories

Inventories consist of the following:

	As of
	December 31, 2023		December 31, 2022
Raw materials	$	9,907	$	2,971
Work-in-progress		1,682		127
Finished goods		6,702		1,560
Total inventories	$	18,291	$	4,658

As of December 31, 2023 and December 31, 2022, the Company recognized a lower of cost or net realizable value of $58 thousand and $0.1 million respectively, related to inventory.

46

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

3. Property, Plant and Equipment

Property, plant and equipment consist of the following:

	As of
	December 31, 2023			December 31, 2022
Land	$	7,345		$	7,344
Plant and buildings		136,318			99,116
Furniture and fixtures		2,266			1,831
Machinery and equipment		14,982			15,209
Construction in progress		73,057			88,990
Property held for development		15,431			15,437
Finance lease right of use assets		2,889			3,045
Total gross property, plant & equipment		252,288			230,972
Less accumulated depreciation		(57,180	)		(50,531	)
Total net property, plant & equipment	$	195,108		$	180,441

Interest capitalized in property, plant, and equipment was $5.6 million and $11.1 million for the years ended December 31, 2023 and 2022, respectively.

Construction in progress includes costs for the biogas construction projects (dairy digesters and pipeline), Riverbank projects (sustainable aviation fuel and renewable diesel plant as well as carbon capture characterization well), and energy efficiency projects at the Keyes Plant. Property held for development is the partially completed Goodland Plant which is not ready for operation. Depreciation will begin for each project when the project is finalized and placed into service. Depreciation on the components of property, plant and equipment is calculated using the straight-line method to allocate their depreciable amounts over their estimated useful lives as follows:

	Years
Plant and buildings		20 - 30
Machinery and equipment		5 - 15
Furniture and fixtures		3 - 5

The Company recorded depreciation expense of approximately $6.9 million and $5.5 million respectively, for the years ended December 31, 2023 and 2022.

4. Debt

Debt consists of the notes from the Company’s senior lender, Third Eye Capital, acting as Agent for the Purchasers (Third Eye Capital), other working capital lenders and subordinated lenders as follows:

	December 31, 2023		December 31, 2022
Third Eye Capital term notes	$	7,159	$	7,141
Third Eye Capital revolving credit facility		20,922		60,602
Third Eye Capital revolving notes Series B		54,412		-
Third Eye Capital revenue participation term notes		12,011		11,963
Third Eye Capital acquisition term notes		26,655		26,578
Third Eye Capital Fuels Revolving Line		32,511		27,410
Third Eye Capital Carbon Revolving Line		23,486		22,710
Construction Loan		41,024		19,820
Cilion shareholder seller notes payable		7,028		6,821
Subordinated notes		17,625		15,931
EB-5 promissory notes		42,211		41,404
Working capital loans		3,827		-
Term loans on capital expenditures		5,850		5,860
Total debt		294,721		246,240
Less current portion of debt		37,028		49,219
Total long term debt	$	257,693	$	197,021

47

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Third Eye Capital Note Purchase Agreement

On July 6, 2012, Aemetis, Inc. and Aemetis Advanced Fuels Keyes, Inc. (“AAFK”), entered into an Amended and Restated Note Purchase Agreement with Third Eye Capital (the “Note Purchase Agreement”).  Pursuant to the Note Purchase Agreement, Third Eye Capital extended credit in the form of (i) senior secured term loans in an aggregate principal amount of approximately $7.2 million to replace existing notes held by Third Eye Capital (the “Term Notes”); (ii) senior secured revolving loans in an aggregate principal amount of $18.0 million (the “Revolving Credit Facility”); (iii) senior secured term loans in the principal amount of $10.0 million to convert the prior revenue participation agreement to a note (the “Revenue Participation Term Notes”); and (iv) senior secured term loans in an aggregate principal amount of $15.0 million (the “Acquisition Term Notes”) used to fund the cash portion of the acquisition of Cilion, Inc. (the Term Notes, Revolving Credit Facility, Revenue Participation Term Notes and Acquisition Term Notes are referred to herein collectively as the “Original Third Eye Capital Notes”).

On  March 8, 2022, Third Eye Capital agreed to the Limited Waiver and Amendment No. 22 to the Note Purchase Agreement (“Amendment No. 22”) to: (i) provide a waiver for the Blocked Account Agreement Violation in which the Borrowers failed to deliver Blocked Account Control Agreements by  December 31, 2021, (ii) provide for a waiver for the Subordinated Debt Violation, in which the Company made a repayment to a Subordinated Debt lender, and (iii) provide for a waiver of the consolidated unfunded capital expenditures covenant for the quarters through  December 31, 2021.  As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash.

On  May 11, 2022, Third Eye Capital agreed to the Limited Waiver and Amendment No. 23 to the Note Purchase Agreement (“Amendment No. 23”) to: (i) provide a waiver for the Blocked Account Agreement Violation in which the Borrowers failed to deliver Blocked Account Control Agreements by  March 31, 2022, (ii) provide for a waiver of the ratio of note indebtedness covenant for the quarter ended  March 31, 2023 and (iii) provide for a waiver of the unfunded capital expenditures covenant for the quarter ended  March 31, 2022 in which the Company exceeded the $100,000 capital expenditures limit. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million.

On  August 8, 2022, Third Eye Capital agreed to Limited Waiver and Amendment No. 24 to the Note Purchase Agreement ("Amendment No. 24") to: (i) provide that the maturity date of the Third Eye Capital Notes  may be further extended at our election to  April 1, 2024 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that such fee  may be added to the outstanding principal balance of each Note on the effective date of each such extension, and (ii) provide for a waiver for certain covenant defaults. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.3 million in cash (the "Amendment No. 24 Fee").

On March 6, 2023, Third Eye Capital agreed to the Limited Waiver and Amendment No. 25 to the Note Purchase Agreement (“Amendment No. 25”) to: provide a waiver for the Keyes Plant Minimum Quarterly Production violation for the quarter ended March 31, 2023, in which the Borrowers did not meet the 10-million-gallon production requirement. As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash.

On  May 4, 2023, Third Eye Capital agreed to the Limited Waiver and Amendment No. 26 to the Note Purchase Agreement (“Amendment No. 26”) to: provide a waiver for (i) the Keyes Plant Minimum Quarterly Production violation for the quarter ended June 30, 2023, in which the Borrowers did not meet the minimum production of 10 million gallons requirement and (ii) the lender agrees to waive the cash payment of certain fees which are required by the Third Eye Capital Notes and allowed these fees to be added to the outstanding balance of the Revolving Notes. As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million. We evaluated the terms of Amendment No. 26 and the maturity date extension in accordance with ASC 470-50 Debt – Modification and Extinguishment and ASC 470-60 Troubled Debt Restructuring and applied modification accounting treatment.

On  May 16, 2023, Third Eye Capital agreed to the Limited Waiver and Amendment No. 27 to the Note Purchase Agreement (“Amendment No. 27”) to: (i) provide that the maturity date of the Third Eye Capital Notes may be further extended at our election to April 1, 2025 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension, (ii) create a new series of Revolving Notes ("Revolving Notes Series B"), and (iii) provide for the issuance of new Revolving Notes Series B to facilitate the funding. As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment fee of $0.5 million, by adding the balance to the Revolving Notes Series B and issued a warrant exercisable for 80,000 shares of the Company's common stock with an exercise price of $2.00 per each share issuable under the warrant. We evaluated the terms of Amendment No. 27 in accordance with ASC 470-50 Debt – Modification and Extinguishment and ASC 470-60 Troubled Debt Restructuring and applied modification accounting treatment. 

According to ASC 470-10-45 Debt–Other Presentation Matters, if it is probable that the Company will not be able to cure the default at measurement dates within 12 months, the related debt needs to be classified as current. To assess this guidance, the Company performed ratio and cash flow analysis using its cash flow forecast and debt levels for plant to debt ratio covenant over the next four quarters. The Company forecasted sufficient cash flows to reduce debt levels of Third Eye Capital and meet the operations of the Company. Based on this analysis, the Company believes that it is reasonably possible that through a combination of cash flows from operations, EB-5 investments, and proceeds from the sale of common stock, it will be able to meet the ratio of the note indebtedness covenant during the relevant period. In addition, in February 2024, Aemetis extended the maturity date by one year to April 1, 2025.  As such, the notes are classified as long-term debt as of December 31, 2023.

48

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

On  March 25, 2024, the Company and Third Eye Capital Corporation entered into a “Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement” (“Amendment No. 28”) that (i) revised the loan covenant related to Keyes plant note indebtedness to exclude certain draws on Third Eye credit facilities and to exclude the "Redemption Fee," as defined in the Amended and Restated Note Purchase Agreement, and (ii) changed the maximum ratio of Note Indebtedness to the Keyes Plant market value to 120%. As consideration for Amendment No. 28, the Company agreed to pay Third Eye Capital an amendment fee of $0.1 million. We will evaluate the terms of Amendment No. 28 in accordance with ASC 470-50 Debt – Modification and Extinguishment.

On March 6, 2020, we entered into a one-year reserve liquidity facility governed by a promissory note, payable to Third Eye Capital Corporation, in the principal amount of $18 million. On March 14, 2021, Third Eye Capital agreed to increase the amount available under the reserve liquidity facility to $70.0 million. On August 9, 2021, Third Eye Capital agreed to decrease the amount available under the reserve liquidity notes governed by a promissory note to $40.0 million. On March 25, 2024, the Company and Third Eye Capital entered into a "Seventh Amended and Restated Promissory Note" that increased the amount available under the Company's reserve liquidity facility to $85 million and extended the maturity date to  April 1, 2025. Borrowings under the Note are available until maturity on April 1, 2025. Interest on borrowed amounts accrues at a rate of 30% per annum, to be paid monthly in arrears, or 40% if an event of default has occurred and continues. Interest payments due may be capitalized into the principal balance of the Note. The Company will pay a standby fee of 2% per annum of the difference between the aggregate principal outstanding under the Note and the commitment, payable monthly arrears in either cash or stock. The Note also requires the Company to pay a fee in the amount of $0.5 million in connection with a request for an advance on the Note, provided that such fee may be added to the principal amount of the Note. The outstanding principal balance of the indebtedness evidenced by the Note, plus any accrued but unpaid interest and any other sums due thereunder, is due and payable in full on April 1, 2025. In addition, the Company must make payments on the Note with funds received from the closing of certain new debt or equity financing or transactions, as described in the Note. The Note is secured by liens and security interests upon the property and assets of the Company.

Terms of Third Eye Capital Notes

A.	Term Notes. As of December 31, 2023, the Company had $7.2 million in principal and interest outstanding under the Term Notes and $45 thousand unamortized debt issuance costs. The Term Notes accrue interest at 14% per annum. The Term Notes mature on April 1, 2025.
B.	Revolving Credit Facility. The Revolving Credit Facility accrues interest at the prime rate plus 13.75% (22.25% as of December 31, 2023), payable monthly in arrears. Interest was accrued and accrued interest from all notes can be capitalized to the Revolving Credit Facility. The Revolving Credit Facility matures on April 1, 2025. As of December 31, 2023, AAFK had $21.9 million in principal and interest and waiver fees outstanding under the Revolving Credit Facility and $0.9 million unamortized discount issuance costs.
C.	Revolving Notes Series B. The Revolving Notes Series B accrues interest at the prime rate plus 13.75% (22.25% as of December 31, 2023) payable monthly in arrears. The Revolving Notes Series B matures on April 1, 2025. As of December 31, 2023, AAFK had $54.8 million in principal and interest and waiver fees outstanding and $0.4 million unamortized debt issuance costs under the Revolving Notes Series B.
D.	Revenue Participation Term Notes. The Revenue Participation Term Note bears interest at 5% per annum and matures on April 1, 2025. As of December 31, 2023, AAFK had $12.1 million in principal and interest outstanding on the Revenue Participation Term Notes and $81 thousand unamortized discount issuance costs.
E.	Acquisition Term Notes. The Acquisition Term Notes accrue interest at the prime rate plus 10.75% (19.25% per annum as of December 31, 2023 and mature on April 1, 2025. As of December 31, 2023, Aemetis Facility Keyes, Inc. had $26.8 million in principal and interest and redemption fees outstanding and unamortized discount issuances costs of $184 thousand. The outstanding principal balance includes a total of $7.5 million in redemption fees on which interest is not charged.
F.	Reserve Liquidity Notes. The Reserve Liquidity Notes, with available borrowing capacity in the amount of $85.0 million, accrues interest at the rate of 30% per annum and are due and payable upon the earlier of: (i) the closing of new debt or equity financings, (ii) receipt from any sale, merger, debt or equity financing, or (iii) April 1, 2025. We have no borrowings outstanding under the Reserve Liquidity Notes as of December 31, 2023.

49

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

The Third Eye Capital Notes contain various covenants, including but not limited to, debt to plant value ratio, minimum production requirements, and restrictions on capital expenditures. The terms of the Notes allow the lender to accelerate the maturity in the event of default that could reasonably be expected to have a material adverse effect, such as any change in the business, operations, or financial condition. The Company has evaluated the likelihood of such an acceleration event and determined such an event to not be probable in the next twelve months.

The Third Eye Capital Notes are secured by first priority liens on all real and personal property of, and assignment of proceeds from all government grants and guarantees from the Company’s North American subsidiaries. The Third Eye Capital Notes all contain cross-collateral and cross-default provisions. McAfee Capital, LLC (“McAfee Capital”), owned by Eric McAfee, the Company’s Chairman and CEO, provided a guaranty of payment and performance secured by all of its Company shares. In addition, Eric McAfee provided a blanket lien on substantially all of his personal assets, and McAfee Capital provided a guarantee in the amount of $8.0 million.

Third Eye Capital Revolving Credit Facility for Fuels and Carbon Lines. On  March 2, 2022, GAFI and Aemetis Carbon Capture, Inc. (“ACCI”) entered into an Amended and Restated Credit Agreement (“Credit Agreement”) with Third Eye Capital , as administrative agent and collateral agent, and the lender party thereto (the “New Credit Facility”). The New Credit Facility provides for two credit facilities with aggregate availability of up to $100 million, consisting of a revolving credit facility with GAFI for up to $50 million (the “Fuels Revolving Line”) and a revolving credit facility with ACCI for up to $50 million (the “Carbon Revolving Line” and together with the Fuels Revolving Line, the “Revolving Lines”). The revolving loans made under the Fuels Revolving Line have a maturity date of  March 1, 2025 and will accrue a rate of interest per annum equal to the greater of (i) the prime rate plus 6.00% and (ii) ten percent (10.0%) (14.50% per annum as of December 31, 2023, and the revolving loans made under the Carbon Revolving Line will have a maturity date of  March 1, 2026 and accrue a rate of interest per annum equal to the greater of (i) the prime rate plus 4.00% and (ii) eight percent (8.0%) (12.50% per annum as of December 31, 2023. The revolving loans made under the Fuels Revolving Line are available for working capital purposes and the revolving loans made under the Carbon Revolving Line are available for projects that reduce, capture, use or sequester carbon with the objective of reducing carbon dioxide emissions. In connection with the New Credit Facility, the Company agreed to issue to the lender under the New Credit Facility: (i) warrants entitling the lender to purchase 50,000 shares of common stock of the Company at an exercise price equal to $10.20 per share, exercisable for a five-year period from March 2, 2022; and (ii) warrants entitling holders thereof to purchase 250,000 shares of common stock of the Company, at an exercise price equal to $20.00 per share, exercisable for a ten-year period from March 2, 2022. In addition, under the Fuels Revolving Line, we issued 100,000 shares of common stock to existing note holders under the GAFI note purchase agreement. The shares were accounted at fair value and are being amortized over the life of the Fuels Revolving Line. Upon closing of the New Credit Facility, the Company drew on the revolving lines to repay $16.0 million on the higher interest rate AAFK Revolving Credit Facility, $6.1 million in property taxes, and to fund the capital projects and working capital projects.

As of  December 31, 2023., GAFI had $33.9 million in principal and interest outstanding and $1.3 million unamortized debt issuance costs. As of  December 31, 2023, ACCI had $25.2 million in principal and interest outstanding and $1.7 million in unamortized debt issuance costs.

Cilion shareholder seller notes payable.  In connection with the Company’s merger with Cilion, Inc., (Cilion) on July 6, 2012, the Company issued $5.0 million in notes payable to Cilion shareholders (Cilion Notes) as merger compensation, subordinated to the Third Eye Capital Notes.  The Cilion Notes bear interest at 3% per annum and are due and payable after the Third Eye Capital Notes have been paid in full.  As of December 31, 2023, Aemetis Facility Keyes, Inc. had $7.0 million in principal and interest outstanding on the Cilion Notes.

Subordinated Notes. On January 6 and January 9, 2012, AAFK entered into Note and Warrant Purchase Agreements with two accredited investors pursuant to which it issued $0.9 million and $2.5 million in original notes to the investors (Subordinated Notes). The Subordinated Notes mature every six months. Upon maturity, the Subordinated Notes are renewable automatically at the Company's election for six month periods with a fee of 10% added to the balance outstanding plus issuance of warrants exercisable at $0.01 with a two-year term. Interest accrues at 10% per annum and is due at maturity. Neither AAFK nor Aemetis may make any principal payments under the Subordinated Notes until all loans made by Third Eye Capital to AAFK are paid in full.

On  January 1, 2023, the maturity on two Subordinated Notes was extended until the earlier of (i)  June 30, 2023; (ii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A $90 thousand and $250 thousand cash extension fee was paid by adding the fee to the balance of the new Subordinated Notes and 113 thousand common stock warrants were granted with a term of two years and an exercise price of $0.01 per share. On  July 1, 2023, the maturity on two Subordinated Notes was extended until the earlier of (i)  December 31, 2023; (ii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A $90 thousand and $250 thousand cash extension fee was paid by adding the fee to the balance of the new Subordinated Notes and 113 thousand common stock warrants were granted with a term of two years and an exercise price of $0.01 per share. The Company evaluated the  January 1, 2023 and  July 1 2023 amendments and the refinancing terms of the notes and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment.

On  January 1, 2024, the maturity on two Subordinated Notes was extended until the earlier of (i)  June 30, 2024; (ii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A $90 thousand and $250 thousand cash extension fee was paid by adding the fee to the balance of the new Subordinated Notes and 113 thousand common stock warrants were granted with a term of two years and an exercise price of $0.01 per share.

50

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

At December 31, 2023 and 2022, the Company had, in aggregate, the amount of $17.6 million and $15.9 million in principal and interest outstanding, respectively, under the Subordinated Notes.

EB-5 promissory notes.  EB-5 is a U.S. government program authorized by the Immigration and Nationality Act designed to foster employment-based visa preference for immigrant investors to encourage the flow of capital into the U.S. economy and to promote employment of U.S. workers. The Company entered into a Note Purchase Agreement dated March 4, 2011 (as further amended on January 19, 2012 and July 24, 2012) with Advanced BioEnergy, LP, a California limited partnership authorized as a Regional Center to receive EB-5 investments, for the issuance of up to 72 subordinated convertible promissory notes (the “EB-5 Notes”) bearing interest at 2-3%. Each note was issued in the principal amount of $0.5 million and due and payable four years from the date of each note, for a total aggregate principal amount of up to $36.0 million (the “EB-5 Phase I funding”). The original maturity date on the promissory notes can be extended automatically for a one or two-year period initially and is eligible for further one-year automatic extensions as long as there is no notice of non-extension from investors and the investors’ immigration process is in progress. On February 27, 2019, Advanced BioEnergy, LP, and the Company entered into an Amendment to the EB-5 Notes which restated the original maturity date on the promissory notes with automatic six-month extensions as long as the investors’ immigration processes are in progress. Except for six early investor EB-5 Notes, the Company was granted 12 months from the date of the completion of immigration process to redeem these EB-5 Notes. Given the COVID-19 situation and processing delays for immigration process, Advanced BioEnergy, LP extended the maturity dates for debt repayment based on their projected processing timings as long as the investors don’t give notice of withdrawal or I-829 gets approved.  Accordingly, the notes have been recognized as long-term debt while investor notes who obtained green card approval have been classified as current debt. The EB-5 Notes are convertible after three years at a conversion price of $30 per share.

Advanced BioEnergy, LP arranges investments with foreign investors, who each make loans to the Keyes Plant in increments of $0.5 million. The Company has sold an aggregate principal amount of $36.0 million of EB-5 Notes under the EB-5 Phase I funding since 2012 to the date of this filing. As of December 31, 2023, $35.5 million has been released from the escrow amount to the Company, with $0.5 million remaining to be funded to escrow.  As of December 31, 2023, $37.9 million in principal and interest was outstanding on the EB-5 Notes sold under the EB-5 Phase I funding.

On October 16, 2016, the Company launched its EB-5 Phase II funding, with plans to issue $50.0 million in additional EB-5 Notes on substantially similar terms and conditions as those issued under the Company’s EB-5 Phase I funding, to refinance indebtedness and capital expenditures of Aemetis, Inc. and GAFI (the “EB-5 Phase II funding”). On November 21, 2019, the minimum investment was raised from $0.5 million per investor to $0.9 million per investor. The Company entered into a Note Purchase Agreement dated with Advanced BioEnergy II, LP, a California limited partnership authorized as a Regional Center to receive EB-5 Phase II funding investments, for the issuance of up to 100 EB-5 Notes bearing interest at 3%. On May 1, 2020 Supplement No. 3 amended the offering documents and lowered the total eligible new EB-5 Phase II funding investors to 60. Eight EB-5 investors have funded at the $0.5 million per investor amount, while 52 new EB-5 Phase II funding investors are eligible at the new $0.9 million per investor amount under the current offering. Job creation studies show additional investors may be possible to increase the total offering amount in the future. Each new note will be issued in the principal amount of $0.9 million and due and payable five years from the date of each note, for a total aggregate principal amount of up to $50.8 million.

The Company has sold an aggregate principal amount of $4.0 million of EB-5 Notes under the EB-5 Phase II funding since 2016 to the date of this filing. As of December 31, 2023, $4.0 million has been released from escrow to the Company and $46.8 million remains to be funded to escrow. As of December 31, 2023, $4.3 million was outstanding on the EB-5 Notes under the EB-5 Phase II funding.

Working capital loans. On July 26, 2022, the Company entered into a short-term loan with Secunderabad Oils Limited in an amount not to exceed $1.88 million. On August 1, 2022, the Company entered into a short-term loan with Leo Edibles & Fats Limited in an amount not to exceed $1.27 million. The loans bears interest at 18% and are payable monthly.  The loans are repayable on demand by the lender or within one year from the date of issuance. The loans are renewable, and the Company can obtain the loan to the extent they paid back.  As of December 31, 2023 and 2022, the Company had $3.8 million and none, respectively, under these agreements.

Secured loans.  In the first quarter of 2023, the Company entered into several short-term loans with IndusInd Bank and HDFC Bank. The loans are secured by fixed deposits made by the Company. The loans bear interest at rates that range from 6% to 8%.  The loans mature between November 15, 2023 and May 3, 2024. As of December 31, 2023, and December 31, 2022, the Company had no balance, respectively, under these agreements.

Aemetis Biogas 1 LLC Construction and Term Loans. On  October 4, 2022, the Company entered into a Construction Loan Agreement (“AB1 Construction Loan”) with Greater Nevada Credit Union (“GNCU”). Pursuant to the AB1 Construction Loan, the lender made available an aggregate principal of $25 million, secured by all personal property collateral and real property collateral of Aemetis Biogas 1 LLC. The AB1 Construction Loan contained certain financial covenants to be measured as of the last day of each fiscal year end, and annually for the term of the loan. Effective as of December 22, 2023, the AB1 Construction Loan was refinanced and replaced with a term loan ("AB1 Term Loan"). The AB1 Term Loan is secured by all personal property collateral and real property collateral of Aemetis Biogas 1 LLC. It bears interest at a rate of 9.25% per annum, to be adjusted every five years thereafter to equal the five-year Treasury Constant Maturity Rate, as published by the Board of Governors of the Federal Reserve System as of the adjustment date, plus 5.00% or (ii) the index floor. Other material terms of the loan include: (i) payments of interest only to be paid in monthly installments beginning January 22, 2024, (ii) payments of equal combined monthly installments of principal and interest beginning on January 22, 2025, and (iii) a maturity date of December 22, 2042, at which time the entire unpaid principal amount, together with accrued and unpaid interest thereon, shall become due and payable. AB1 Term Loan contains certain financial covenants to be measured as of the last day of each fiscal year beginning fiscal year end 2025, and annually for the term of the loan. The AB1 Term Loan also contains other affirmative and negative covenants, representations and warranties and events of default customary for loan agreements of this nature. As of December 31, 2023 and December 31, 2022, the Company had $25.1 million and none, respectively, outstanding under the AB1 Term Loan.

51

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

  Aemetis Biogas 2 Construction Loan. On July 28,  2023, the Company entered into a second Construction and Term Loan Agreement ( “AB2 Loan") with Magnolia Bank, Incorporated. Pursuant to the AB2 Loan, the lender has made available an aggregate principal amount  not to exceed $25 million. The loan is secured by all personal property collateral and real property collateral of Aemetis Biogas 2 LLC. The loan bears interest at a rate of 8.75% per annum, to be adjusted every five years thereafter to equal the five-year Treasury Constant Maturity Rate, as published by the Board of Governors of the Federal Reserve System as of the adjustment date, plus 5.00%. Other material terms of the AB2 Loan include: (i) payments of interest only to be paid in monthly installments beginning August 15, 2023, (ii) payments of equal combined monthly installments of principal and interest beginning on August 15, 2025, and (iii) a maturity date of July 28, 2043, at which time the entire unpaid principal amount, together with accrued and unpaid interest thereon, shall become due and payable. The AB2 Loan contains certain financial covenants to be measured as of the last day of each fiscal year beginning fiscal year end  2025, and annually for the term of the loan. The AB2 Loan also contains other affirmative and negative covenants, representations and warranties and events of default customary for loan agreements of this nature. As of December 31, 2023 and December 31, 2022, the Company had $16.8 million and none, respectively, outstanding and unamortized discount issuances costs of   $0.8 million and none, respectively, under the AB2 Loan. 

Financing Agreement for capital expenditures.  The Company entered into an agreement with Mitsubishi Chemical America, Inc. (“Mitsubishi”) to purchase ZEBREX^TM membrane dehydration equipment to conserve energy and improve operating efficiencies at the Keyes Plant. The Company also entered into a financing agreement with Mitsubishi for $5.7 million for this equipment. Payments pursuant to the financing transaction will commence after the installation date and interest will be charged based on the certain performance metrics after operation of the equipment. After an initial start-up process, process bottlenecks were encountered, and operations were suspended pending further examination and optimization. 

We recorded the asset in property, plant and equipment, net and recorded the related liability of $2.0 million in short term borrowings and $3.8 million in other long-term debt, respectively as of  December 31, 2023.

Debt repayments for the Company’s loan obligations follow:

Twelve months ended December 31,	Debt Repayments
2024	$	37,028
2025		181,464
2026		37,912
2027		4,128
2028		2,108
There after		37,545
Total debt		300,185
Debt issuance costs		(5,464	)
Total debt, net of debt issuance costs	$	294,721

5. Commitments and Contingencies

Leases

The Company is a party to operating leases for the Company's corporate office in Cupertino, modular offices, and laboratory facilities.  We have also entered into several finance leases for mobile equipment and for the Riverbank Industrial Complex.  These finance leases have a purchase option at the end of the term that we are reasonably certain we will exercise, so the leases are classified as finance leases. All of our leases have remaining term of one year to 13 years. We made an accounting policy election to keep leases with an initial term of 12 months or less off the balance sheet. We will recognize those lease payments in the Consolidated Statements of Operations as we incur the expenses.

The Company evaluates leases in accordance with ASC 842 – Lease Accounting. When discount rates implicit in leases cannot be readily determined, we use the applicable incremental borrowing rate at lease commencement to perform lease classification tests on lease components and to measure lease liabilities and right of use (ROU) assets. The incremental borrowing rate used by the Company is based on weighted average baseline rates commensurate with the Company’s secured borrowing rate, over a similar term. At each reporting period when there is a new lease initiated, the rates established for that quarter are used.

52

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

The components of lease expense and sublease income is as follows:

	Twelve Months Ended December 31,
	2023		2022
Operating lease cost
Operating lease expense	$	722	$	673
Short term lease expense		223		176
Variable lease expense		93		91
Total operating lease cost	$	1,038	$	940
Finance lease cost
Amortization of right-of-use assets	$	121	$	179
Interest on lease liabilities		340		310
Total finance lease cost	$	461	$	489

Cash paid for amounts included in the measurement of lease liabilities:

	Twelve Months Ended December 31,
	2023		2022
Operating cash flows used in operating leases	$	668	$	766
Operating cash flows used in finance leases		340		310
Financing cash flows used in finance leases		428		481

Supplemental non-cash flow information related to the operating ROU asset and lease liabilities for the year ended December 31, 2023 and 2022:

	Twelve Months Ended December 31,
	2023			2022
Operating leases
Accretion of the lease liability	$	249		$	340
Amortization of right-of-use assets		293			333
Weighted Average Remaining Lease Term
Operating leases (in years)		4.2			5.2
Finance leases (in years)		13.0			14.0
Weighted Average Discount Rate
Operating leases		14.1	%		14.2	%
Finance leases		13.2	%		13.2	%

53

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Supplemental balance sheet information related to leases was as follows:

	As of
	December 31, 2023			December 31, 2022
Operating leases
Operating lease right-of-use assets	$	2,056		$	2,449
Current portion of operating lease liability		406			338
Long term operating lease liability		1,783			2,189
Total operating lease liabilities		2,189			2,527
Finance leases
Property and equipment, at cost	$	2,889		$	3,045
Accumulated depreciation		(228	)		(112	)
Property and equipment, net		2,661			2,933
Other current liability		30			71
Other long term liabilities		2,687			2,911
Total finance lease liabilities		2,717			2,982

Maturities of operating lease liabilities were as follows:

Year Ended December 31,	Operating leases			Finance leases
2024	$	682		$	179
2025		681			168
2026		626			145
2027		645			145
2028		272			145
There after		-			10,105
Total lease payments		2,906			10,887
Less imputed interest		(717	)		(8,170	)
Total lease liability	$	2,189		$	2,717

The Company acts as sublessor in certain leasing arrangements, primarily related to land and buildings.  Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Sublease income and head lease expense for these transactions are recognized on net basis on the consolidated financial statements. Sublease income is recorded in the other operating income section of the Consolidated Statements of Operations and Comprehensive Loss.

54

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

The components of lease income for the years ended  December 31, 2023 and 2022 were as follows:

	December 31, 2023		December 31, 2022
Lease income	$	2,075	$	1,255

Future lease commitments to be received by the Company as of  December 31, 2023, are as follows:

Year ended December 31,
2024	$	948
2025		773
2026		562
2027		508
2028		508
There after		635
Total future lease commitments	$	3,934

Legal Proceedings

On  August 31, 2016, the Company filed a lawsuit in Santa Clara County Superior Court against defendant EdenIQ, Inc. (“EdenIQ”). The lawsuit was based on EdenIQ’s wrongful termination of a merger agreement that would have effectuated the merger of EdenIQ into a new entity that would be primarily owned by Aemetis. On  July 24, 2019, the court awarded EdenIQ a portion of the fees and costs it had sought in the amount of approximately $6.2 million and the Company recorded these fees based on the court order. On  May 6, 2022 the parties settled the dispute for $4.8 million by entering into a settlement agreement. The settlement was paid and a gain on litigation of $1.4 million was recognized on the income statement in the second quarter of 2022.

The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of these matters is not presently determinable, it is in the opinion of management that the resolution of outstanding claims will not have a material adverse effect on the financial position or results of operations of the Company. Due to the uncertainties in the litigation and settlement process, it is at least reasonably possible that management's view of outcomes will change in the near term.

6. Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity

On December 20, 2018, ABGL entered into a Series A Preferred Unit Purchase Agreement for the sale of Series A Preferred Units to Protair-X Americas, Inc. (Purchaser), with Third Eye Capital acting as an agent for the sale of 6,000,000 preferred units of ABGL.

ABGL is authorized to issue 11,000,000 common units, and up to 6,000,000 convertible, redeemable, secured, preferred membership units (the “Series A Preferred Units”). ABGL issued 6,000,000 common units to the Company at $5.00 per common unit for a total of $30,000,000 in funding. Additionally, 5,000,000 common units of ABGL are held in reserve as potential conversion units issuable to the Purchaser upon certain triggering events discussed below.

Prior to August 8, 2022, the Preferred Unit Purchase Agreement included (i) preference payments of $0.50 per unit on the outstanding Series A Preferred Units commencing on the second anniversary, with any outstanding preference payments subject to interest at 10 percent per annum (ii) conversion rights for up to 1,200,000 common units or up to maximum number of 5,000,000 common units (also at a one Series A Preferred Unit to one common unit basis) if certain triggering events occur, (iii) one board seat of the three available to be elected by Series A Preferred Unit holders, (iv) mandatory redemption value at $15 per unit payable at an amount equal to 75% of free cash flow generated by ABGL, up to $90 million in the aggregate (if all units are issued), (v) full redemption of the units on the sixth anniversary, (vi) minimum cash flow requirements from each digester, and (vii) $0.9 million paid as fees to the Agent from the proceeds. Until paid, the obligations of ABGL under the Preferred Unit Agreement are secured by the assets of ABGL in an amount not to exceed the sum of (i) $30,000,000, plus (ii) all interest, fees, charges, expenses, reimbursement obligations and indemnification obligations of ABGL.

Prior to August 8, 2022, triggering events would be deemed to occur upon ABGL’s failure to redeem units, comply with covenants, any other defaults or cross defaults, or to perform representations or warranties. Upon a triggering event: (i) the obligation of the Purchaser to purchase additional Series A Preferred Units is terminated, (ii) cash flow payments for redemption payments increases from 75% to 100% of free cash flows, and (iii) total number of common units into which preferred units may be converted increases from 1,200,000 common units to 5,000,000 common units on a one for one basis. As of December 31, 2023, ABGL has not generated minimum quarterly operating cash flows by operating the dairies. As a result of the violation of this covenant, free cash flows, when they occur, may be applied for redemption payments at the increased rate of 100% instead of the initial rate of 75% of free cash flows.

55

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

From inception of the agreement to August 8, 2022, ABGL issued 3,200,000 Series A Preferred Units in the first tranche for a value of $16.0 million and also issued 2,800,000 of Series A Preferred Units in a second tranche for a value of $14.0 million, reduced by a redemption of 20,000 Series A Preferred Units for $0.3 million.

On  August 8th, 2022, ABGL entered into a Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Amendment") providing for: (i) a waiver of certain covenants prohibiting the internal reorganization of ABGL subsidiaries and the incurrence of indebtedness by ABGL and its subsidiaries pursuant to a USDA loan; (ii) a waiver of certain operational defaults under the PUPA; and (iii) an amendment which (a) requires ABGL to redeem all of the outstanding Series A Preferred Units by  December 31, 2022, (the “Final Redemption Date”) for $116 million; and (b) provides ABGL the right to redeem all of the outstanding Series A Preferred Units by  September 30, 2022, for $106 million. The PUPA Amendment further provides the failure to redeem the Series A Preferred Units by the Final Redemption Date would constitute a triggering event requiring ABGL to enter into a credit agreement with Protair and Third Eye Capital effective as of  January 1, 2023. We evaluated the terms of the PUPA Amendment and applied extinguishment accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment and recorded a loss on extinguishment of $49.4 million.

On  January 1, 2023, ABGL entered into the Second Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Second Amendment") providing for: (i) a waiver for not redeeming all Series A Preferred Units by  December 31, 2022, and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by  May 31, 2023, for an aggregate redemption price of $125 million. The PUPA Second Amendment further provides that failure to redeem the Series A Preferred Units by the redemption date, ABGL is required to enter into a credit agreement with Protair and Third Eye Capital effective as of  June 1, 2023 and maturing on May 31, 2024, in substantially the form attached to the PUPA Second Amendment. We determined that Third Eye Capital provided a concession to redeem the preferred shares at lower effective borrowing rate than the credit agreement interest rate or prior amendment rate. In accordance with the provisions of ASC 470-60 Troubled Debt Restructuring, we applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. In addition, given that the Company could turn the agreement into a credit agreement, the Company began accreting the redemption price from an initial carrying value at December 31, 2022, of $116.0 million to $159.0 million over the seventeen months ending May 31, 2024. 

On May 31, 2023, ABGL entered into the Third Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Third Amendment") providing: (i) a waiver to ABGL for not redeeming all Series A Preferred Units by May 31, 2023 and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by August 31, 2023, for an aggregate redemption price of $135 million. The PUPA Third Amendment further provides that failure to redeem the Series A Preferred Units by the redemption date, ABGL is required to enter into a credit agreement with Protair and Third Eye Capital effective, as of September 1, 2023 and maturing on August 31, 2024, in substantially the form attached to the PUPA Third Amendment. We determined that Third Eye Capital provided a concession to redeem the preferred shares at lower effective borrowing rate than the credit agreement interest rate or prior amendment rate. In accordance with the provisions of ASC 470-60 Troubled Debt Restructuring, we applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. In addition, given that the Company could turn the agreement into a credit agreement, the Company is accreting these tranches from a carrying value at May 31, 2023 of $127.2 million to $171.7 million over the fifteen months ending August 31, 2024. . 

On October 6, 2023, ABGL partially repaid $30 million of Series A Preferred Units using the partial proceeds from tax credit sale of $55.2 million.

On November 8, 2023, ABGL entered into the Fourth Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Fourth Amendment") providing: (i) a waiver to ABGL for not redeeming all Series A Preferred Units by August 31, 2023 and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by December 31, 2023, for an aggregate redemption price of $108 million which included $5.5 million closing fee. The PUPA fourth Amendment further provides that failure to redeem the Series A Preferred Units by the redemption date, ABGL is required to enter into a credit agreement with Protair and Third Eye Capital effective, as of January 1, 2024 and maturing on December 31, 2024, in substantially the form attached to the PUPA fourth Amendment. We determined that Third Eye Capital provided a concession to redeem the preferred shares at lower effective borrowing rate than the credit agreement interest rate or prior amendment rate. In accordance with the provisions of ASC 470-60 Troubled Debt Restructuring, we applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. In addition, given that the Company could turn the agreement into a credit agreement, the Company began accreting the redemption price from a carrying value at November 8, 2023 of $110.6 million to $130.0 million over the period ending December 31, 2024.

On February 8, 2024, ABGL entered into the Fifth Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Fourth Amendment") providing: (i) a waiver to ABGL for not redeeming all Series A Preferred Units by December 31, 2023 and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by April 30, 2024, for an aggregate redemption price of $111.0 million which includes a closing fee of $5.5 million. The PUPA Fifth Amendment further provides that if ABGL does not redeem the Series A Preferred Units by the redemption date, ABGL will enter into a credit agreement with Protair and Third Eye Capital effective as of May 1, 2024 and maturing April 30, 2025, in substantially the form attached to the PUPA fifth Amendment. We will evaluate the PUPA fifth amendment according to ASC 470.  Based on the terms of the PUPA Fifth Amendment, the deferred PUPA redemption balance is classified as long term liability as of December 31, 2023. 

56

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

The Company recorded carrying value of Series A Preferred Unit liabilities as long-term liabilities of $113.2 million and $116.0 million as of December 31, 2023 and 2022, respectively.

Variable interest entity assessment

After consideration of ABGL’s operations and the above agreement, we concluded that ABGL did not have enough equity to finance its activities without additional subordinated financial support. ABGL is capitalized with Series A Preferred Units that are recorded as liabilities under U.S. GAAP. Hence, we concluded that ABGL is a VIE. Through the Company's ownership interest in all of the outstanding common stock, its current ability to control the board of directors, the management fee paid to Aemetis and control of subordinated financing decisions, Aemetis has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company. Total assets, before intercompany eliminations, of ABGL as of December 31, 2023 were $90.3 million which serve as collateral for the Series A Preferred Units.

7. Stockholders’ Equity

Common Stock

The Company is authorized to issue 80 million shares of common stock, $0.001 par value per share.  

Convertible Preferred Stock

The company is authorized to issue up to 65 million shares of preferred stock, $0.001 par value per share.

Effective as of December 12, 2023, the Company converted all of its outstanding Preferred Stock into by issuing one share of common stock for each 10 shares of preferred stock outstanding. As a result, as of December 31, 2023, the Company has no outstanding shares of preferred stock.  The following table shows the number of preferred shares authorized and outstanding:

			Shares Issued and
	Authorized		Outstanding December 31,
	Shares		2023		2022
Series B preferred stock		7,235		-		1,270
Undesignated		57,765		-		-
		65,000		-		1,270

8. Warrants to Purchase Common Stock

During 2023, the Company granted the following warrants:

●  A warrant issued to a vendor exercisable for the purchase of 100,000 shares at an exercise price of $2.50 per share with a two-year term. This warrant was exercised in 2023 using cashless exercise resulting in the issuance of 62,293 shares of common stock.

●  Warrants issued to the Company's senior lender exercisable for 160,000 shares of the Company's common stock at an exercise price of $2.00 per share with a five-year term. These warrants are outstanding as of December 31, 2023.

●  In connection with a credit line increase, a warrant issued to the Company's senior lender was automatically modified to increase the number of shares that may be purchased by 25,000 shares.  The warrant has an exercise price of $10.20 per share and a remaining term of about 3 years.

●  Warrants issued to subordinated lenders exercisable for 226,666 at an exercise price of $0.01 per share and a term of two years.  These warrants were exercised in 2023 with a combination of cashless exercise and cash payments.

The following table shows the weighted average fair value calculations for warrants granted based on the listed weighted average assumptions:

Description	For the year ended December 31,
	2023			2022
Dividend-yield		0	%		0	%
Risk-free interest rate		3.85	%		1.75	%
Expected volatility		117.90	%		151.41	%
Expected life (years)		5			3
Exercise price per share	$	1.62		$	10.47
Market value per share on grant date	$	4.13		$	11.29
Fair value per share on grant date	$	3.92		$	9.68

57

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

A summary of historical warrant activity for the years ended  December 31, 2023 and 2022 follows:

	Warrants Outstanding & Exercisable			Weighted - Average Exercise Price		Average Remaining Term in Years
Outstanding December 31, 2021		55		$	2.59		4.95
Granted		527			10.47
Exercised		(227	)		0.01
Outstanding December 31, 2022		355		$	15.92		7.48
Granted		511			1.62
Exercised		(336	)		0.83
Outstanding December 31, 2023		530		$	11.70		5.77

All of the above outstanding warrants are vested and exercisable as of December 31, 2023. 

9. Stock-Based Compensation

2019 Stock Plan

On August 26, 2021, the stockholders of the Company approved the Aemetis, Inc. Amended and Restated 2019 Stock Plan (the “2019 Stock Plan”). This plan allows our Board or delegated Board committee to grant Incentive Stock Options, Non-Statutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, Performance Shares, and other stock or cash awards to employees, Directors, and consultants. The 2019 Stock Plan has a term of 10 years from the original version adoption date of April 25, 2019, and supersedes all prior stockholder approved plans with respect to new grants. Options issued under prior plans and the prior version of the 2019 stock plan remain outstanding and exercisable according to their terms. The 2019 Stock Plan authorizes a total pool of 4,558,621 shares as of July 1, 2021, including all outstanding option grants under all plans and all shares then available for issuance under the 2019 Stock Plan as of that date. Shares within this pool that expire or terminate unused become available for a subsequent grant. In addition, the number of shares available for issuance automatically increases on January 1 of each year by an amount equal to 4% of the sum of total common stock outstanding on January 1 and 2,541,823 shares.

Pursuant to the 2019 Stock Plan, the company issued stock options to employees exercisable for 1.3 million and 1.3 million shares during the years ended December 31, 2023 and 2022, each with a 10 year term and 3 year vesting schedule. The Company issued restricted stock award grants with immediate vesting to directors for 244 thousand shares and 89 thousand shares during the years ended December 31, 2023 and 2022, respectively, with a weighted average fair value on date of grant of $3.75 and $10.92 per share, respectively for those same time periods.

The following table summarizes activity under the 2019 Stock Plan during 2022 and 2023:

	Shares Available for Grant			Number of Shares Outstanding			Weighted-Average Exercise Price
Balance as of December 31, 2021		42			3,763		$	2.29
Authorized		1,338			-			-
Options Granted		(1,307	)		1,307			10.97
RSAs Granted		(89	)		-			-
Exercised		-			(295	)		0.93
Forfeited/expired		81			(81	)		11.63
Balance as of December 31, 2022		65			4,694		$	4.63
Authorized		1,644			-			-
Options Granted		(1,278	)		1,278			3.60
RSAs Granted		(244	)		-			-
Exercised		-			(177	)		1.83
Forfeited/expired		269			(269	)		5.93
Balance as of December 31, 2023		456			5,526		$	4.42

58

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

The following table summarizes vested and unvested option awards outstanding as of December 31, 2023 and 2022:

	Number of Shares		Weighted Average Exercise Price		Remaining Contractual Term (In Years)		Aggregate Intrinsic Value1
2023
Vested and Exercisable		3,986	$	3.58		6.47	$	11,695
Unvested		1,540		6.55		8.67		1,621
Total		5,526	$	4.42		7.04	$	13,316
2022
Vested and Exercisable		3,170	$	2.46		6.98	$	7,419
Unvested		1,524		9.13		8.81		647
Total		4,694	$	4.63		7.58	$	8,066

(1)Intrinsic value based on the $5.24 and $3.96 closing price of Aemetis, Inc. common stock on December 31, 2023 and 2022 respectively, as reported on the NASDAQ Exchange.

Inducement Equity Plan Options

In March 2016, the Board of Directors of the Company approved an Inducement Equity Plan authorizing the issuance of 100,000 non-statutory stock options to purchase common stock. As of December 31, 2023, no options were outstanding under the Inducement Equity Plan. This plan was not approved by stockholders so is available only for grants to prospective employees.

Stock-based Compensation Expense

Stock-based compensation is accounted for in accordance with ASC 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors, and consultants based on estimated fair value on the grant date. We estimate the fair value using the Black-Scholes option pricing model and recognize that fair value as an expense over the vesting period of each grant using the straight-line method. We only record compensation cost for vested options. The Black-Scholes valuation model for stock based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, expected dividends, and expected forfeitures. We use the simplified calculation of expected term described in SEC Staff Accounting Bulletin No. 107, Share-Based Payment. Volatility is based on an average of the historical volatility of Aemetis, Inc. common stock during the period of time preceding the date of option issuance that matches the term of the option grant. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the treasury maturity term corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the small number of plan participants. To the extent actual forfeitures occur, the difference is recorded as an adjustment in the scheduled expense during the period of the forfeiture.

The weighted average fair value for options granted during the years ended 2023 and  2022 are based on the following assumptions:

Description	For the year ended December 31,
	2023			2022
Dividend-yield		0	%		0	%
Risk-free interest rate		3.86	%		2.03	%
Expected volatility		124.62	%		117.21	%
Expected life (years)		7.00			7.00
Market value per share on grant date	$	3.60		$	10.97
Fair value per share on grant date	$	3.29		$	9.71

For the years ended December 31, 2023 and 2022, the Company recorded stock-based compensation expense in the amount of $7.7 million, and $6.4 million, respectively. As of December 31, 2023, the Company had $7.3 million of total unrecognized compensation expense for employees that the Company will amortize over the remaining vesting period of each individual option grant.  The outstanding unvested options have a remaining weighted average vesting term of 1.5 years.

59

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

10. Agreements

Working Capital Arrangement. Pursuant to a Corn Procurement and Working Capital Agreement with J.D. Heiskell, the Company procures whole yellow corn from J.D. Heiskell. The Company has the ability to obtain grain from other sources subject to certain conditions; however, in the past all the Company’s grain purchases have been from J.D. Heiskell. Title and risk of loss of the corn pass to the Company when the corn is deposited into the Keyes Plant weigh bin.  Pursuant to a separate agreement entered in May 2023, J.D. Heiskell also purchases all of our ethanol and other products under separate agreements and sells them to customers designated by us.  We have designated Murex to purchase ethanol and WDG and corn oil are sold to A.L Gilbert. The Company’s relationships with J.D. Heiskell, and A.L. Gilbert are well established, and the Company believes that the relationships are beneficial to all parties involved in utilizing the distribution logistics, reaching out to widespread customer base, managing inventory, and providing working capital relationships.

As of December 31, 2023 and 2022, Aemetis made prepayments to J.D. Heiskell of none and $2.4 million, respectively. The J.D. Heiskell purchases and sales activity associated with the Purchasing Agreement, Corn Procurement and Working Capital Agreements during the years ended December 31, 2023 and 2022 were as follows:

	As of and for the twelve months ended December 31,
	2023		2022
Ethanol sales	$	77,359	$	-
Wet distiller's grains sales		21,963		50,930
CDO and CDS sales		3,296		10,168
Corn purchases		83,128		191,401
Accounts receivable		1,073		-
Accounts payable		1,207		27

Ethanol and Wet Distillers Grains Marketing Arrangement.

The Company entered into a Fuel Ethanol Purchase and Sale Agreement with Murex, which matures on October 31, 2023, with automatic one-year renewals thereafter. On May 30, 2023 the Company entered into Amendment No. 1 to the Fuel Ethanol Purchase and Sale Agreement that provides (i) the Company temporarily suspend the agreement for the duration of the Company's Working Capital Agreement with J.D. Heiskell, and (ii) the initial term shall be automatically renewed beginning on October 1, 2023 and ending on March 31, 2025. The Company also entered into a Wet Distillers Grains Marketing Agreement with A.L. Gilbert, with a maturity date of  December 31, 2024, with automatic one-year renewals thereafter.

For the years ended December 31, 2023 and 2022, the Company expensed marketing costs of $1.5 million and $2.9 million, respectively, under the terms of both the Ethanol Marketing Agreement and the Wet Distillers Grains Marketing Agreement and are presented in Selling, General, and Administration expense.

For the years ended December 31, 2023 and 2022, the Company expensed shipping and handling costs related to sales of ethanol $1.7 million and $3.3 million for each period and expensed transportation costs related to sales of WDG of $3.3 million and $5.3 million.

Supply Trade Agreement. On  July 1, 2022, the Company entered into an operating agreement with Gemini Edibles and Fats India Private Limited (“Gemini”). Under this agreement, Gemini agreed to provide the Company with a supply of feedstock up to a credit limit of $12.7 million. If the Company fails to pay the invoice within the ten-day credit period, the outstanding amount will bear interest at 12%. The term of the agreement is for one year. Either party can terminate the agreement by giving one month notice in writing. The agreement was terminated. As of December 31, 2023 and 2022, the Company had no outstanding balance under this agreement.

As of December 31, 2023, the Company has no forward sales commitments.

60

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

11. Segment Information

Aemetis recognizes three reportable segments “California Ethanol,” “California Dairy Renewable Natural Gas,” and “India Biodiesel.”  

The “California Ethanol” reportable segment includes the Company’s 65 million gallon per year ethanol plant in Keyes, California, and the adjacent land leased for the production of CO₂.

The “California Dairy Renewable Natural Gas” reportable segment including the production and sale of Renewable Natural Gas and associated environmental attributes, consisting of anaerobic digesters located at diaries, at 36 mile biogas collection pipeline, and biogas upgrading hub and pipeline interconnect that produces Renewable Natural Gas from the biogas.

The “India Biodiesel” reportable segment includes the Company’s 60 million gallon per year nameplate capacity biodiesel manufacturing plant in Kakinada India, and administrative offices in Hyderabad, India.

The Company has additional operating segments that were determined not to be reportable segments, including our key projects under development which consists of sustainable aviation fuel and renewable diesel production in Riverbank and Carbon Capture and Underground Sequestration wells in California.  Additionally, our corporate offices, Goodland Plant in Kansas, and the research and development facility in Minnesota are included in the “All Other” category.

Summarized financial information by reportable segment for the years ended December 31, 2023 and 2022 follow:

	For the year ended December 31, 2023
	California Ethanol			California Dairy Renewable Natural Gas			India Biodiesel		All other		Total
Revenues from external customers	$	104,068		$	5,455		$	77,194	$	-	$	186,717
Intersegment revenues		-			-			-		-		-
Gross profit (loss)		(6,602	)		(331	)		8,950		-		2,017
Interest expense, including amortization of debt fees		25,258			2,809			447		11,005		39,519
Accretion and other expenses of Series A preferred units		-			25,313			-		-		25,313
Loss on
Income tax expense (benefit)		-			(55,159	)		1,416		7		(53,736	)
Capital expenditures		5,695			24,744			1,281		1,399		33,119
Depreciation		3,995			2,116			576		246		6,933
Total Assets		67,991			92,794			34,769		47,852		243,406

	For the year ended December 31, 2022
	California Ethanol			California Dairy Renewable Natural Gas			India Biodiesel		All other			Total
Revenues from external customers	$	228,194		$	208		$	28,111	$	-		$	256,513
Intersegment revenues		-			1,002			-		-			1,002
Gross profit (loss)		(13,017	)		(778	)		8,273		(13	)		(5,535	)
Interest expense, including amortization of debt fees		20,637			742			119		7,272			28,770
Accretion and other expenses of Series A preferred units		-			9,888			-		-			9,888
Income tax expense		-			6			1,040		7			1,053
Loss on debt extinguishment		-			49,386			-		-			49,386
Capital expenditures		8,399			22,884			129		7,745			39,157
Depreciation		4,148			615			650		122			5,535
Total Assets		66,794			77,714			16,120		46,486			207,114

61

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

A reconciliation of reportable segment revenues to consolidated totals for the years 2023 and 2022 follow:

Revenues
	2023		2022
Total revenues for reportable segments	$	186,717	$	257,515
Elimination of intersegment revenues		-		(1,002	)
Total consolidated revenues	$	186,717	$	256,513

California Ethanol: During the year ended December 31, 2023 and 2022, the Company amended the Corn Procurement and Working Capital Agreement and the J.D. Heiskell Purchasing Agreement to procure corn from J.D. Heiskell and sell all ethanol, WDG, CDO, and CDS the Company produces to J.D. Heiskell. Sales of ethanol, WDG, CDO, and CDS to one customer accounted for 100% of the California Ethanol segment’s revenue for the year ended December 31, 2023.  Sales of ethanol to one customer accounted for 73% of the California Ethanol segment’s revenue for the year ended  December 31, 2022. Sales of WDG, and corn oil to one customer accounted for 26% of the Company’s California Ethanol segment revenues for the year ended   December 31, 2022.

California Dairy Renewable Natural Gas: 100% of our sales of renewable natural gas during the twelve months ended December 31, 2023 were from sales to one customer.  In the third quarter of 2023, we started selling D3 RINs and one customer accounted for 98% of the 2023 sales.  For the twelve months ended December 31, 2022, all sales were associated with intercompany sales to the Keyes Plant for use in boilers.

India Biodiesel: During the year ended  December 31, 2023, three biodiesel customers accounted for 47%, 25% and 23% of the Company’s India Biodiesel segment revenues. During the year ended  December 31, 2022, three biodiesel customers accounted for 48%, 29%, 12% of the Company’s India Biodiesel segment revenues.

12. Related Party Transactions

The Company owes Eric McAfee, the Company’s Chairman and CEO, and McAfee Capital LLC (“McAfee Capital”), owned by Eric McAfee and his wife, $0.4 million in connection with employment agreements and expense reimbursements. The balance accrued related to these employment agreements was $0.4 million as of December 31, 2023.  On February 28, 2023, the Audit Committee of the Company approved a one-time fee of $350 thousand payable to McAfee Capital in connection with McAfee Capital’s guarantees of the Company’s indebtedness with Third Eye Capital. As of December 31, 2023, the outstanding balance is $175 thousand.

The Company owes various members of its Board of Directors amounts totaling $0.3 million as of December 31, 2023 and December 31, 2022, for each period, in connection with board compensation fees, which are included in accounts payable on the balance sheet. For the years ended December 31, 2023 and 2022 the Company expensed $0.4 million, and $0.4 million, respectively, in connection with board compensation fees. 

13. Income Tax

The Company files a consolidated federal income tax return including all its domestic subsidiaries except for Aemetis Biogas LLC, which files its own returns. State tax returns are filed on a consolidated, combined or separate basis depending on the applicable laws relating to the Company and its subsidiaries.

Components of tax expense consist of the following:

	2023			2022
Current:
Federal	$	(55,164	)	$	-
State and Local		13			13
Foreign		1,489			230
		(53,662	)		243
Deferred:
Federal		-			-
State and Local		-			-
Foreign		(74	)		810
Income tax (benefit) expense	$	(53,736	)	$	1,053

The Company records deferred tax liability in other long term liabilities in the Consolidated Balance Sheets. The deferred tax liability resulted as India subsidiary had income for the year ended  December 31, 2023. U.S. loss and foreign income (loss) before income taxes are as follows:

	Year Ended December 31,
	2023			2022
United States	$	(107,191	)	$	(112,959	)
Foreign		7,035			6,254
Pretax loss	$	(100,156	)	$	(106,705	)

62

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Income tax benefit differs from the amounts computed by applying the statutory U.S. federal income tax rate (21%) to loss before income taxes as a result of the following:

	Year Ended December 31,
	2023			2022
Income tax benefit at the federal statutory rate	$	(21,033	)	$	(22,408	)
State tax benefit		(999	)		(496	)
Sale of tax credits		(55,164	)		-
Foreign tax differential		11			168
Stock-based compensation		2,048			295
Interest Expense		92			58
GILTI Inclusion		-			1,126
Prior year true-ups		(18,031	)		55
Non-includible US Entities		-			13,499
Other		67			46
Credits		(869	)		(2,373	)
Valuation Allowance		40,142			11,083
Income Tax Expense (Benefit)		(53,736	)		1,053
Effective Tax Rate		53.65	%		(0.99	)%

The components of the net deferred tax asset or (liability) are as follows:

	Year Ended December 31,
	2023			2022
Deferred Tax Assets
Organizational Costs, Start-up and Intangible Assets	$	34,217		$	2,309
Stock Based Compensation		1,239			1,842
NOLs, Unabsorbed Depreciation and R&D Credits C/F's		67,621			68,201
Interest expense carryover		29,066			22,374
Ethanol Credits		1,500			1,500
Carbon Oxide Sequestration Credit		6,696			5,827
Accrued Expenses		2,249			2,001
Operating Lease Liability		1,282			1,512
Other, net		248			113
Total Deferred Tax Assets		144,118			105,679
Valuation Allowance		(135,354	)		(95,214	)
Net Deferred Tax Assets		8,764			10,465
Deferred Tax Liabilities
Right of Use Asset		(1,230	)		(1,477	)
Property, Plant & Equipment		(8,266	)		(9,788	)
Other, net		(3	)		(10	)
Total Deferred Tax Liabilities		(9,499	)		(11,275	)
Net Deferred Tax Liabilities	$	(735	)	$	(810	)

Based on the Company’s evaluation of current and anticipated future taxable income, the Company believes it is more likely than not that insufficient taxable income will be generated to realize the net deferred tax assets, and accordingly, a valuation allowance has been set against these net deferred tax assets. The $0.8 million deferred tax liability is recorded in other long-term liabilities on the balance sheet.

63

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

We do not provide for U.S. income taxes for any undistributed earnings of the Company’s foreign subsidiaries, as the Company considers these to be permanently reinvested in the operations of such subsidiaries and have a cumulative foreign loss. At December 31, 2023 and 2022 these undistributed earnings totaled $1.3 million compared to undistributed losses of $2.5 million for  December 31, 2022. If any earnings were distributed, some countries may impose withholding taxes. However, due to the Company’s overall deficit in foreign cumulative earnings and its U.S. loss position, the Company does not believe a material net unrecognized U.S. deferred tax liability exists.

ASC 740 Income Taxes provides that the tax effects from an uncertain tax position can be recognized in the Company’s financial statements only if the position is more-likely-than-not of being sustained on audit, based on the technical merits of the position. Tax positions that meet the recognition threshold are reported at the largest amount that is more-likely-than-not to be realized. This determination requires a high degree of judgment and estimation. The Company periodically analyzes and adjusts amounts recorded for the Company’s uncertain tax positions, as events occur to warrant adjustment, such as when the statutory period for assessing tax on a given tax return or period expires or if tax authorities provide administrative guidance or a decision is rendered in the courts. The Company does not reasonably expect the total amount of uncertain tax positions to significantly increase or decrease within the next 12 months. As of December 31, 2023, the Company’s uncertain tax positions were not significant for income tax purposes.

The following describes the open tax years, by major tax jurisdiction, as of December 31, 2023:

United States — Federal	2007 – present
United States — State	2008 – present
India	2013 – present
Mauritius	2006 – present

As of December 31, 2023, the Company had U.S. federal NOL carryforwards of approximately $253.0 million and state NOL carryforwards of approximately $336.0 million.  The Company also has approximately $1.5 million of alcohol and cellulosic biofuel credit and $6.7 million of carbon oxide sequestration credit carry forwards. The federal net operating loss and other tax credit carryforwards expire on various dates between 2027 and 2043. The state net operating loss carryforwards expire on various dates between 2027 through 2042. Under the current tax law, net operating loss and credit carryforwards available to offset future income in any given year may be limited by US or India statute regarding net operating loss carryovers and timing of expirations or upon the occurrence of certain events, including significant changes in ownership interests. As of  December 31, 2023, the Company's India subsidiary had no loss carryforwards.

64

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

14. Parent Company Financial Statements (Unaudited)

We conduct substantially all of our operations through subsidiaries and are dependent on cash distributions, dividends and other intercompany transfers of funds from our operations. Our subsidiaries have not made significant distributions to us and may not have funds available for dividends or distributions in the future. The ability of our subsidiaries to transfer funds to us will be dependent upon their respective abilities to achieve sufficient cash flows after satisfying their respective cash requirements, including subsidiary level debt service on their respective credit agreements. The following is a summary of the Parent Company Financial statements.

Aemetis, Inc. (Parent Company)

Balance Sheets

As of December 31, 2023 and 2022

	2023			2022
Assets
Current assets
Cash and cash equivalents	$	1,454		$	286
Receivables due from subsidiaries		110,083			98,780
Prepaid expenses		437			611
Other current assets		12			7
Total current assets		111,986			99,684
Investment in Aemetis Property Keyes, Inc.		1,556			1,274
Investment in Aemetis International, Inc.		12,059			6,659
Investment in Aemetis Advanced Products Riverbank, Inc.		638			173
Investment in AE Advanced Products Keyes , Inc.		246			-
Total investments in Subsidiaries, net of advances		14,499			8,106
Property, plant and equipment, net		149			135
Other assets		2,096			2,377
Total Assets	$	128,730		$	110,302
Liabilities & stockholders' deficit
Current liabilities
Accounts payable	$	3,633		$	2,934
Mandatorily redeemable Series B convertible preferred		4,521			4,082
Other current liabilities		5,031			4,269
Total current liabilities		13,185			11,285
Long term liabilities:
Operating lease liability		1,716			2,047
Subsidiary obligation in excess of investment
Investment in AE Advanced Fuels, Inc.		220,571			177,856
Investment in Aemetis Americas, Inc		202			205
Investment in Aemetis Biofuels, Inc.		2,721			2,738
Investment in Aemetis Technologies, Inc.		4,868			4,716
Investment in AE Advanced Products Keyes , Inc.		-			270
Investment in Aemetis Health Products, Inc.		2,084			2,076
Investment in Goodland Advanced Fuels, Inc.		22,982			16,869
Investment in Aemetis Biogas LLC		70,471			91,292
Investment in Aemetis Carbon Capture Inc		5,895			2,323
Investment in Aemetis Properties Riverbank, Inc.		1,012			479
Total subsidiary obligation in excess of investment		330,806			298,824
Total long term liabilities		332,522			300,871
Stockholders' deficit
Series B Preferred convertible stock		-			1
Common stock		41			36
Additional paid-in capital		264,058			232,546
Accumulated deficit		(475,405	)		(428,985	)
Accumulated other comprehensive loss		(5,671	)		(5,452	)
Total stockholders' deficit		(216,977	)		(201,854	)
Total liabilities & stockholders' deficit	$	128,730		$	110,302

65

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Aemetis, Inc. (Parent Company)

Statements of Operations and Comprehensive Loss

For the Years Ended December 31, 2023 and 2022

	2023			2022
Equity in subsidiary losses	$	(25,370	)	$	(91,561	)
Selling, general and administrative expenses		19,218			15,203
Operating loss		(44,588	)		(106,764	)
Other (income) expense
Interest expense		1,073			806
Debt related fees and amortization expense		781			1,581
Other income		(30	)		(1,400	)
Loss before income taxes		(46,412	)		(107,751	)
Income tax expense		8			7
Net loss		(46,420	)		(107,758	)
Other comprehensive loss
Foreign currency translation adjustment		(219	)		(1,102	)
Comprehensive loss	$	(46,639	)	$	(108,860	)

66

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

Aemetis, Inc. (Parent Company)

Statements of Cash Flows

For the years ended December 31, 2023 and 2022

	2023			2022
Operating activities:
Net loss		(46,420	)		(107,758	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		7,660			6,410
Depreciation		51			29
Debt related fees and amortization expense		782			1,776
Subsidiary portion of net losses		25,370			91,561
Gain on litigation		-			(1,400	)
Warrants issued for working capital agreement		409			-
Changes in assets and liabilities:
Prepaid expenses		(608	)		111
Accounts payable		699			(90	)
Accrued interest expense		785			778
Other liabilities		85			(4,625	)
Other assets		276			207
Net cash used in operating activities		(10,911	)		(13,001	)
Investing activities:
Capital expenditures		(65	)		(128	)
Subsidiary advances, net		(9,707	)		1,222
Net cash provided by (used in) investing activities		(9,772	)		1,094
Financing activities:
Proceeds from the exercise of stock options		133			206
Proceeds from issuance of common stock in equity offering		21,718			11,987
Net cash provided by financing activities		21,851			12,193
Net increase in cash, cash equivalents, and restricted cash		1,168			286
Cash, cash equivalents and restricted cash at beginning of period		286			-
Cash, cash equivalents, and restricted cash at end of period	$	1,454		$	286
Supplemental disclosures of cash flow information, cash paid:
Income taxes paid		7			7
Supplemental disclosures of cash flow information, non-cash transactions:
Fair value of warrants issued to subordinated debt holders		1,278			1,939
Fair value of stock issued to a related party for guarantee fees		-			2,012
Fair value of warrants issued for capital expenditures		318			-
Fair value of warrants issued to lender for debt issuance costs		-			3,158
Fair value of stock issued to lender		-			1,335

67

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

15. Subsequent Events

Subordinated Notes

On January 1, 2024, the maturity on two accredited investor's Subordinated Notes was extended until the earlier of (i) June 30, 2024; (ii) completion of an equity financing by AAFK or Aemetis in an amount of not less than $25 million; (iii) the completion of an Initial Public Offering by AAFK or Aemetis; or (iv) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants.  A $90 thousand and $250 thousand extension fee was paid by adding the fee to the balance of the new Subordinated Note and Aemetis issued the lenders warrants exercisable for 113 thousand shares of common stock with a term of two years and an exercise price of $0.01 per share.  The warrants have been fully exercised.

Series A Preferred Unit Purchase Agreement

On February 8, 2024, ABGL entered into a Fifth Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Fifth Amendment").  The PUPA Fifth Amendment: (i) provides an extension of time for ABGL to redeem all of the outstanding Series A Preferred Units until April 30, 2024, and changes the redemption price to $111 million, including fees, (ii) requires ABGL to enter into a twelve-month credit agreement in the amount of $111 million with the lenders if the Series A Preferred Units are not redeemed by such date, and specifies that entry of the credit agreement will satisfy the obligation to redeem the units; and (iii) provides ABGL with a waiver of the obligations of prior agreements to redeem the Series A Preferred Units by any prior dates. 

Third Eye Capital Reserve Liquidity Facility

On March 25, 2024, the Company and Third Eye Capital Corporation entered into a "Seventh Amended and Restated Promissory Note" that increased the amount available under the Company's reserve liquidity facility to $85 million and extended the maturity date to  April 1, 2025. Borrowings under the Note are available until maturity on April 1, 2025. Interest on borrowed amounts accrues at a rate of 30% per annum, to be paid monthly in arrears, or 40% if an event of default has occurred and continues. Interest payments due may be capitalized into the principal balance of the Note. The Company will pay a standby fee of 2% per annum of the difference between the aggregate principal outstanding under the Note and the commitment, payable monthly arrears in either cash or stock. The Note also requires the Company to pay a fee in the amount of $0.5 million in connection with a request for an advance on the Note, provided that such fee may be added to the principal amount of the Note. The outstanding principal balance of the indebtedness evidenced by the Note, plus any accrued but unpaid interest and any other sums due thereunder, is due and payable in full on April 1, 2025. In addition, the Company must make payments on the Note with funds received from the closing of certain new debt or equity financing or transactions, as described in the Note. The Note is secured by liens and security interests upon the property and assets of the Company.

Third Eye Capital Limited Waiver and Amendment No. 28

On  March 25, 2024, the Company and Third Eye Capital Corporation entered into a “Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement” (“Amendment No. 28”) that (i) revised the loan covenant related to Keyes plant note indebtedness to exclude certain draws on Third Eye credit facilities and to exclude the "Redemption Fee," as defined in the Amended and Restated Note Purchase Agreement, and (ii) changed the maximum ratio of Note Indebtedness to the Keyes Plant market value to 120%. As consideration for Amendment No. 28, the Company agreed to pay Third Eye Capital an amendment fee of $0.1 million.

68

AEMETIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except par value and per share data)

 

16.  Liquidity

The accompanying financial statements have been prepared contemplating the realization of assets and satisfaction of liabilities in the normal course of business. As a result of negative capital, negative operating results, and collateralization of substantially all of the Company assets, the Company has been reliant on its senior secured lender to provide additional funding and has been required to remit substantially all excess cash from operations to the senior secured lender. In order to meet our obligations during the next twelve months, we have extended our reserve liquidity credit facility through April 1, 2025, at an amount of up to $85 million, and we plan to refinance debt with our senior lender for amounts becoming due in the next twelve months and sell equity through our at-the-market registration at levels consistent with the year ended December 31, 2023. We believe these plans alleviate substantial doubt about our ability to continue as a going concern. While the Company believes we will be able to implement these plans to provide sufficient liquidity, there are inherent risks and uncertainties regarding our ability to execute our plans. In addition, we plan to pursue the following strategies to improve liquidity:

Operations and Project Development

For the Keyes Plant, we plan to operate the plant and continue to improve its financial performance by adopting new technologies or process changes that allow for energy efficiency, cost reduction, or revenue enhancements, as well as, execute upon awarded grants that improve energy and operational efficiencies resulting in lower cost, lower carbon emissions, and overall margin improvement.

For Aemetis Biogas, we plan to operate our existing biogas digesters to produce and sell Renewable Natural Gas (RNG) and the associated Federal D3 RINs and California LCFS credits.  We are continuing to build new dairy digesters and pipeline extensions.  We began generating revenue from biogas operations in 2023 and this revenue will continue for the full year 2024, as well as increase as we build new digesters.  We also expect revenue to increase when the California Air Resource Board processes our LCFS pathway applications and approves a provisional carbon intensity that is lower than the temporary carbon intensity we currently use to calculate the quantity of LCFS credits that we generate.  We are seeking debt from a variety of sources to accelerate the construction of additional digesters.

For the Kakinada Plant, we plan to continue to sell our biodiesel to OMCs pursuant to cost-plus contracts.  We are also continuing to upgrade the plant to increase feedstock flexibility (and thereby lower feedstock costs), increase production capacity, and produce new products. Additionally, we are in the process of obtaining approval and contractual arrangements for the export of refined animal tallow into international markets.

Financing

We plan to continue to locate funding for existing and new business opportunities through a combination of working with our senior lender, restructuring existing loan agreements, entering into additional debt agreements for specific projects, obtaining project specific equity and debt for development projects, and obtaining additional debt from the current EB-5 Phase II offering.

Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

69

Item 9A.  Controls and Procedures.

The information contained in this section covers management’s evaluation of our disclosure controls and procedures and our assessment of our internal control over financial reporting for the year ended December 31, 2023.

Evaluation of Disclosure Controls and Procedures

Management, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act).  Based on this evaluation, our CEO and CFO concluded that, although remediation plans were initiated to address the material weakness over financial reporting as identified in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the disclosure controls and procedures along with the related internal controls over financial reporting were not effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Inherent Limitations on Effectiveness of Controls

Our management, including the CEO and CFO, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud.  A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Our controls and procedures are designed to provide reasonable assurance that our control system’s objective will be met, and our CEO and CFO have concluded that our disclosure controls and procedures are ineffective at the reasonable assurance level.  The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.  Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected.  These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.  Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.  The design of any system of controls is based in part on certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.  Projections of any evaluation of the effectiveness of controls in future periods are subject to risks.  Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.  Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with GAAP.  Our internal control over financial reporting includes those policies and procedures that:  (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures by us are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.

Under the supervision and with the participation of our management, including our CEO and CFO, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of the period covered by this report based on the criteria for effective internal control described in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Tread way Commission - 2013.  Based on the results of management’s assessment and evaluation, and that our internal control over financial reporting was ineffective due to not maintaining sufficient information technology general controls (ITGCs) and segregation of duties in the areas of user access, passwords, change-management, and third-party service provider report review over certain information technology systems used in the Company’s financial reporting processes. As a result of the pervasive impact of these controls, automated and manual business process controls that are dependent on ITGCs and appropriate segregation of duties were also ineffective. Additionally, the Company did not maintain sufficient personnel in the proper roles to allow for timely and precise completion and documentation leading to control deficiencies associated with:   1) lack of review and documentation of pricing for revenue recognized over ethanol sales and wet distillers grain sales, 2) documentation and reviews over debt covenants, debt classification, going concern analyses, and tax provision, 3) timeliness and reviews related to financial statement tie outs, bank reconciliations, and property, plant and equipment, including depreciation expense. Additionally, as a result of this deficiency, we note that all financial statement transaction cycles could be impacted. 

70

Changes in Internal Control over Financial Reporting

Discussed below are changes made to our internal control over financial reporting during the year ended December 31, 2023 in response to an identified material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Management implemented a new Enterprise Resource Planning system (ERP) during the third quarter of 2023 which included a reassessment of automated and manual controls. The complexity of this implementation created additional challenges in maintaining the operational effectiveness of internal controls, resulting in the material weaknesses explained above. During the fourth quarter, the accounting and finance function was enhanced through the training of newly hired and existing team members. Management believes these changes will enable the company to effectively address the material weaknesses identified in the year ended December 31, 2024. There are, however, inherent limitations in all control systems and no evaluation of controls can provide absolute assurance that all deficiencies have been detected.  While these actions and planned actions are subject to ongoing management evaluation and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles, we are committed to the continuous improvement of our internal control over financial reporting and will continue to diligently review our internal control over financial reporting.

Our independent registered public accounting firm, RSM US LLP, has issued an audit report on the effectiveness of our internal control over financial reporting and their report is included herein.

Item 9B.  Other Information.

(a) Current Reports

On March 25, 2024, the Company entered into two agreements with Third Eye Capital entitled "Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement" and "Seventh Amended and Restated Promissory Note."  These agreements are described in Note 4, Debt, and Note 15, Subsequent Events, to the Consolidated Financial Reports in Item 8 of this Report.  Copies of the two agreements are included in this Report as Exhibits 10.36 and 10.37, respectively.  The descriptions of the two documents in Item 8 are only a summary and are qualified by the terms of the documents included in Exhibits 10.36 and 10.37.

(b) Adoption and Termination of Rule 10b5-1 Stock Trading Plans by Officers and Directors

On September 15, 2023, Francis P. Barton, a member of the Company's Board of Directors, adopted a trading arrangement for the sale of the Company's common stock (a "Rule 10b5-1 Trading Plan") that (i) became effective December 15, 2023, (ii) has a term lasting until December 31, 2024, (iii) provides for the sale of up to 126,000 shares of common stock to be issued upon exercise of options currently held by Mr. Barton, (iv) sets a limit order designating the minimum price upon which sales may occur, and (v) is intended to satisfy the affirmative defense of Securities Exchange Act Rule 10b5-1(c).

On September 15, 2023, Todd A. Waltz, Executive Vice President and Chief Financial Officer of the Company, adopted a Rule 10b5-1 Trading Plan that (i) took effect January 1, 2024, (ii) terminates June 15, 2025, (iii) provides for the sale of up to 475,000 shares of common stock to be issued upon the exercise of options currently held by Mr. Waltz, (iv) contains multiple limit orders designating the minimum prices upon which sales may occur, and (v) is intended to satisfy the affirmative defense of Securities Exchange Act Rule 10b5-1(c). Mr. Waltz's newly adopted plan replaces a previously adopted plan that expired on December 31, 2023, and provided for the sale of up to 475,000 shares on limit order terms. No shares were transacted under the expired plan. 

On November 13, 2023, Andrew B. Foster, Executive Vice President and Chief Operating Officer of the Company, adopted a Rule 10b5-1 Trading Plan that (i) took effect February 14, 2024, (ii) has a term lasting until December 31, 2024, (iii) provides for the sale of up to 199,616 shares of common stock to be issued upon exercise of options currently held by Mr. Foster, (iv) contains multiple limit orders designating the minimum prices upon which sales may occur, and (v) is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c).  Mr. Foster's newly adopted Rule 10b5-1 Trading Plan replaces a previously adopted plan that expired on December 31, 2023, and provided for the sale of 96,000 shares of common stock on limit order terms. No shares were transacted under the expired plan.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

PART III

Item 10.  Directors, Executive Officers and Governance.

The information required by this Item 10 will be included in our Proxy Statement for our 2024 Annual Meeting of Stockholders to be filed no later than 120 days after December 31, 2023, and is incorporated herein by reference.

Item 11.  Executive Compensation.

The information required by this Item 11 will be included in our Proxy Statement for our 2024 Annual Meeting of Stockholders to be filed no later than 120 days after December 31, 2023, and is incorporated herein by reference.

Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item 12 will be included in our Proxy Statement for our 2024 Annual Meeting of Stockholders to be filed no later than 120 days after December 31, 2023, and is incorporated herein by reference.

Item 13.  Certain Relationships and Related Transactions, and Director Independence.

The information required by this Item 13 will be included in our Proxy Statement for our 2024 Annual Meeting of Stockholders to be filed no later than 120 days after December 31, 2023, and is incorporated herein by reference.

Item 14.  Principal Accounting Fees and Services.

The information required by this Item 14 will be included in our Proxy Statement for our 2024 Annual Meeting of Stockholders to be filed no later than 120 days after December 31, 2023, and is incorporated herein by reference.

71

PART IV

Item 15.  Exhibit and Financial Statement Schedules

Financial Statements

The following consolidated financial statements are included in this Annual Report:

● Report of Independent Registered Public Accounting Firm (PCAOB ID 49)

● Consolidated Balance Sheets

● Consolidated Statements of Operations and Comprehensive Loss

● Consolidated Statements of Cash Flows

● Consolidated Statements of Stockholders’ Deficit

● Notes to Consolidated Financial Statements

Financial Statement Schedules

All financial statement schedules have been omitted because they are not applicable or are not required, or because the information is included in the Consolidated Financial Statements or notes thereto under Item 8 in Part II of this Form 10-K.

72

Exhibits

		Incorporated by Reference
Exhibit No.	Description	Form	File No.	Exhibit	Filing Date	Filed Herewith
3(i)	Certificate of Incorporation	8-K	001-35475	3.1	Nov. 2, 2021
3(ii)	Amended and Restated Bylaws	8-K	001-35475	3.1	Aug. 30, 2023
10.1	Amended and Restated 2019 Stock Plan	14A	001-36475		July 23, 2021
10.2	Executive Employment Agreement, dated April 25, 2020, with Eric A. McAfee	8-K	001-36475	10.1	Apr. 28, 2020
10.3	Executive Employment Agreement, dated April 25, 2020, with Todd Waltz	8-K	001-36475	10.2	Apr. 28, 2020
10.4	Executive Employment Agreement, dated April 25, 2020, with Andrew Foster	8-K	001-36475	10.3	Apr. 28, 2020
10.5	Executive Employment Agreement, dated April 25, 2020, with Sanjeev Gupta	8-K	001-36475	10.4	Apr. 28, 2020
10.6	Employment Agreement, dated August 28, 2023, with J. Michael Rockett.	8-K	001-36475	10.1	Aug. 28, 2023
10.7	Amended and Restated Note Purchase Agreement, dated July 6, 2012, among Aemetis Advanced Fuels Keyes, Inc., Keyes Facility Acquisition Corp., Aemetis, Inc., Third Eye Capital Corporation, as Administrative Agent, and the Note holders	8-K	000-51354	10.2	July 10, 2012
10.8	Amended and Restated Guaranty, dated July 6, 2012, among Aemetis, Inc., certain subsidiaries of Aemetis and Third Eye Capital Corporation, as Agent.	8-K	000-51354	10.3	July 10, 2012
10.9	Amended and Restated Security Agreement, dated July 6, 2012, among Aemetis, Inc., certain subsidiaries of Aemetis and Third Eye Capital Corporation, as Agent.	8-K	000-51354	10.4	July 10, 2012
10.10	Limited Waiver and Amendment No. 1 to Amended and Restated Note Purchase Agreement dated as of October 18, 2012, by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, Third Eye Capital Corporation, an Ontario corporation as agent, Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.	8-K	000-51354	10.1	Oct. 23, 2012
10.11	Limited Waiver and Amendment No. 2 to Amended and Restated Note Purchase Agreement dated as of February 27, 2013, by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, Third Eye Capital Corporation, an Ontario corporation as agent, Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.	8-K	000-51354	10.1	Mar. 11, 2013
10.12	Limited Waiver and Amendment No.3 to Amended and Restated Note Purchase Agreement dated as of April 15, 2013, by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, Third Eye Capital Corporation, an Ontario corporation as agent, Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.	8-K	000-51354	10.1	Apr. 16, 2013
10.13	Amendment No. 4 to Amended and Restated Note Purchase Agreement dated as of April 19, 2013, by and among Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, Aemetis, Inc., a Nevada corporation, and Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Insight Fund	8-K/A	000-51354	10.2	May 14, 2013
10.14	Limited Waiver and Amendment No.5 to Amended and Restated Note Purchase Agreement, dated as of July 26, 2013, by and among Aemetis, Inc., Aemetis Advanced Fuels Keyes, Inc. Aemetis Facility Keyes, Inc., Third Eye Capital Corporation, an Ontario corporation, as agent, Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust	8-K	000-51354	10.1	July 31, 2013
10.15	Limited Waiver and Amendment No.6 to Amended and Restated Note Purchase Agreement, dated as of October 28, 2013, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.	8-K	000-51354	10.1	Nov. 1, 2013

73

10.16	Limited Waiver and Amendment No.7 to Amended and Restated Note Purchase Agreement, dated as of May 14, 2014, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.	10-Q	001-36475	10.1	Mar. 31, 2014
10.17	Limited Waiver and Amendment No. 8 to Amended and Restated Note Purchase Agreement, dated as of November 7, 2014, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.	10-Q/A	001-36475	10.1	Nov. 13, 2014
10.18	Limited Waiver and Amendment No. 9 to Amended and Restated Note Purchase Agreement, dated as of March 12, 2015, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.	10K	001-36475	10.1	Mar. 12,2015
10.19	Limited Waiver and Amendment No. 10 to Amended and Restated Note Purchase Agreement, dated as of April 30, 2015, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.	10-Q	001-36475	10.1	May 7, 2015
10.20	Limited Waiver and Amendment No. 11 to Amended and Restated Note Purchase Agreement, dated as of August 6, 2015, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust (incorporated by reference to Exhibit 10.2 of the Quarterly Report on Form 10-Q filed on August 7, 2015).	10-Q	001-36475	10.1	Nov. 5, 2015
10.21	Limited Waiver and Amendment No. 12 to Amended and Restated Note Purchase Agreement, dated as of March 21, 2016, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.	10-K	001-36475	10.68	Mar. 28, 2016
10.22	Limited Waiver and Amendment No. 13 to Amended and Restated Note Purchase Agreement, dated as of March 1, 2017, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Sprott PC Trust.	10-K	001-36475	10.7	Mar. 16, 2017
10.23	Limited Waiver and Amendment No. 14 to Amended and Restated Note Purchase Agreement, dated as of March 27, 2018, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.	10-K	001-36475	10.71	Mar. 27, 2018
10.24	Limited Waiver and Amendment No. 15 to Amended and Restated Note Purchase Agreement, dated as of March 11, 2019, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.	10-K	001-36475	10.74	Mar. 14, 2019
10.25	Limited Waiver and Amendment No. 17 to Amended and Restated Note Purchase Agreement, dated as of August 11, 2020, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.	10-Q	001-36475	10.1	Aug. 13, 2020
10.26	Limited Waiver and Amendment No. 18 to Amended and Restated Note Purchase Agreement, dated as of November 5, 2020, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund – Insight Fund, and Sprott PC Trust.	10-Q	001-36475	99.1	Nov. 12, 2020

74

10.27	Limited Waiver and Amendment No. 19 to Amended and Restated Note Purchase Agreement, dated as of March 14, 2021, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit  Opportunities Fund – Insight Fund and Ninepoint.	10-K	001-36475	10.8	Mar. 14, 2021
10.28	Limited Waiver and Amendment No. 20 to Amended and Restated Note Purchase Agreement, dated as of August 9, 2021, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund - Insight Fund, and Ninepoint Third Eye Capital Private Credit Fund.	10-Q	001-36475	10.1	Aug. 12, 2021

10.29	Limited Waiver and Amendment No. 22 to Amended and Restated Note Purchase Agreement dated as of March 8, 2022, by and Among Aemetis Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund- Insight Fund, and Ninepoint Third Eye Capital Private Credit Fund.	10-K	001-36475	10.94	Dec. 31, 2021
10.30	Limited Waiver and Amendment No. 23 to Amended and Restated Note Purchase Agreement, dated as of May 11, 2022, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; and Third Eye Capital Corporation, an Ontario corporation, as agent for Ninepoint - TEC Private Credit Fund and Third Eye Capital Credit Opportunities Fund - Insight Fund.	10-Q	001-36475	10.1	May 16, 2022
10.31	Limited Waiver and Amendment No. 24 to Amended and Restated Note Purchase Agreement, dated as of August 8, 2022, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; and Third Eye Capital Corporation, an Ontario corporation, as agent for Ninepoint - TEC Private Credit Fund and Third Eye Capital Credit Opportunities Fund - Insight Fund.	10-Q	001-36475	10.1	Aug. 8, 2022
10.32	Limited Waiver and Amendment No. 25 to Amended and Restated Note Purchase Agreement, dated as of March 6, 2023, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; and Third Eye Capital Corporation, an Ontario corporation, as agent for Ninepoint - TEC Private Credit Fund and Third Eye Capital Credit Opportunities Fund - Insight Fund.	10-K	001-36475	10.101	Mar. 9, 2023
10.33	Sixth Amended and Restated Promissory Note, dated as of March 6, 2023, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation including Third Eye Capital Management Inc.	10-K	001-36475	10.100	Mar. 9, 2023
10.34	Limited Waiver and Amendment No. 26 to Amended and Restated Note Purchase Agreement, dated as of May 4, 2023, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; and Third Eye Capital Corporation, an Ontario corporation, as agent for Ninepoint - TEC Private Credit Fund and Third Eye Capital Credit Opportunities Fund - Insight Fund.	10-Q	001-36475	10.1	May 5, 2023
10.35	Limited Waiver and Amendment No. 27 to Amended and Restated Note Purchase Agreement, dated as of May 16, 2023, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation, an Ontario corporation, as agent for Third Eye Capital Credit Opportunities Fund – Insight Fund, Ninepoint – TEC Private Credit Fund, Ninepoint – TEC Private Credit Fund II, and MBI/TEC Private Debt Open-End Trust Fund.	10-Q	001-36475	10.1	Aug. 4, 2023
10.36	Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement, dated as of March 25, 2024, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; and Third Eye Capital Corporation					X
10.37	Seventh Amended and Restated Promissory Note, dated March 25, 2024, by and among Aemetis, Inc.; Aemetis Advanced Fuels Keyes, Inc.; Aemetis Facility Keyes, Inc.; Third Eye Capital Corporation; and Third Eye Capital Management Inc.					X
10.38	Note Purchase Agreement effective as of March 4, 2011, amended January 19, 2012, and July 24, 2012 by and among AE Advanced Fuels, Inc., a Delaware corporation, and Advanced BioEnergy, LP a California limited partnership and Advanced BioEnergy GP, LLC, a California limited liability company.	8-K	001-36475	10.3	Oct. 23, 2012
10.39	Form of Convertible Subordinated Promissory Note by and among AE Advanced Fuels, Inc., a Delaware corporation and Advanced BioEnergy, LP, a California limited partnership.	8-K	001-36475	10.4	Oct. 23, 2012
10.40	Amended and Restated Aemetis Keyes Corn Procurement and Working Capital Agreement, dated May 2, 2013, by and between Aemetis Advanced Fuels Keyes, Inc., and J.D. Heiskell Holdings, LLC	8-K	001-36475	10.2	May 23, 2013

75

10.41 Second Amendment to the Amended and Restated Aemetis Keyes Grain Procurement and Working Capital Agreement, dated as of May 25, 2023, by and between J.D. Heiskell Holdings, LLC and Aemetis Advanced Fuels Keyes, Inc. 8-K 001-36475 10.1 May 26, 2023

10.42	Amended and Restated Heiskell Purchasing Agreement dated May 16, 2013, by and between Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation and a wholly-owned subsidiary of Aemetis, Inc. and J.D. Heiskell Holdings, LLC, a California limited liability company doing business as J.D. Heiskell & Co.*	8-K	001-36475	10.1	May 23, 2023
10.43	Second Amendment to the Amended and Restated Heiskell Purchase Agreement, dated as of May 25, 2023, by and between J.D. Heiskell Holdings, LLC and Aemetis Advanced Fuels Keyes, Inc.	8-K	001-36475	10.2	May 26, 2023
10.44	Second Amendment to the Keyes Ethanol and Corn Tank Lease, dated as of May 25, 2023, by and between J.D. Heiskell Holdings, LLC and Aemetis Advanced Fuels Keyes, Inc.	8-K	001-36475	10.3	May 26, 2023
10.45	WDG Purchase and Sale Agreement dated March 23, 2011 between A.L. Gilbert Company and Aemetis Advanced Fuels Keyes, Inc.	10-K	001-36475	10.66	Oct. 31, 2012

10.46	Keyes Corn Handling Agreement dated March 23, 2011 among A. L. Gilbert Company, AE Advanced Fuels Keyes, Inc., and J.D. Heiskell Holdings, LLC	10-K	001-36475	10.67	Oct. 31, 2012
10.47	Waiver and Amendment to Series A Preferred Unit Purchase Agreement, dated as of August 8, 2022, by and among Aemetis Biogas LLC, Protair-X Americas, Inc., and Third Eye Capital Corporation.	10-Q	001-36475	10.2	Aug. 8, 2022
10.48	Second Waiver and Amendment to Series A Preferred Unit Purchase Agreement, dated as of February 6, 2023, by and among Aemetis Biogas LLC, Protair-X Americas, Inc. and Third Eye Capital Corporation.	8-K	001-36475	10.1	Feb. 6, 2023
10.49	Third Waiver and Amendment to Series A Preferred Unit Purchase Agreement, dated as of May 31, 2023, by and among Aemetis Biogas LLC, Protair-X Americas, Inc. and Third Eye Capital Corporation.	8-K	001-36475	10.1	July 5, 2023
10.50	Fourth Waiver and Amendment to Series A Preferred Unit Purchase Agreement, effective as of November 8, 2023, by and among Aemetis Biogas LLC, Protair X Americas, Inc., and Third Eye Capital Corporation.	10-Q	001-36475	10.1	Nov. 9, 2023
10.51	Fifth Waiver and Amendment to Series A Preferred Unit Purchase Agreement, effective as of February 8, 2024, by and among Aemetis Biogas LLC, Protair X Americas, Inc., and Third Eye Capital Corporation.	8-K	001-36475	10.1	Feb. 14, 2024
10.52	Fuel Ethanol Purchase and Sale Agreement, effective as of June 9, 2021, by and between Aemetis Advanced Fuel Keyes, Inc. and Murex LLC.	8-K	001-36475	10.1	June 14, 2021
10.53	Amendment No. 1 to the Fuel Ethanol Purchase and Sale Agreement, effective as of May 30, 2023, by and between Aemetis Advanced Fuel Keyes, Inc. and Murex LLC.	10-Q	001-36475	10.2	Aug. 4, 2023
10.54	Lease Disposition and Development Agreement, dated as of December 14, 2021, by and between Aemetis Properties Riverbank, Inc. and City of Riverbank, California	8-K	001-36475	10.2	Dec. 21, 2021
10.55	Guaranty Agreement, dated as of December 14, 2021, by and between Aemetis, Inc. and City of Riverbank, California	8-K	001-36475	10.3	Dec. 21, 2021
10.56	Real Estate Purchase and Sale Agreement, dated as of December 14, 2021, by and between Aemetis Properties Riverbank, Inc. and City of Riverbank, California	8-K	001-36475	10.4	Dec. 21, 2021
10.57	Amended and Restated Credit Agreement, dated as of March 2, 2022	8-K	001-36475	10.1	Mar. 4, 2022
10.58	Warrant to Purchase Stock, dated as of March 2, 2022 ("Fuels Revolving Line Warrant")	8-K	001-36475	4.1	Mar. 4, 2022
10.59	Warrant to Purchase Stock, dated as of March 2, 2022 ("Carbon Revolving Line Warrant")	8-K	001-36475	4.2	Mar. 4, 2022
10.60	Amended and Restated General Security Agreement, dated as of  March 2, 2022	8-K	001-36475	10.2	Mar. 4, 2022
10.61	Intellectual Property Security Agreement Supplement, dated as of March 2, 2022	8-K	001-36475	10.3	Mar. 4, 2022
10.62	Third Amended and Restated Guaranty, dated as of March 2, 2022	8-K	001-36475	10.4	Mar. 4, 2022
10.63	Amended and Restated Pledge Agreement, dated as of March 2, 2022	8-K	001-36475	10.5	Mar. 4, 2022

76

10.64	Amendment and Waiver No. 2 to Credit Agreement, effective as of August 1, 2023, by and among Goodland Advanced Fuels, Inc., Aemetis Carbon Capture, Inc., and Third Eye Capital Corporation, as agent for MBI/TEC Private Debt Opportunities Fund II, LP, and acknowledged and agreed by the guarantors listed on the signature page thereto.	10-Q	001-36475	10.3	Aug. 4, 2023
10.65	Construction and Term Loan Agreement, dated as of July 28, 2023, by and among Magnolia Bank Incorporated, Aemetis Biogas 2 LLC, and Aemetis Biogas Holdings LLC.	8-K	001-36475	10.1	July 31, 2023
10.66	Term Loan Agreement dated as of December 22, 2023, by and among Aemetis Biogas 1 LLC, Aemetis Biogas Holdings LLC, and Greater Nevada Credit Union.	8-K	001-36475	10.1	Dec. 29, 2023
14	Code of Ethics	10-K	000-51354	14	May 20, 2009
21	Subsidiaries of the Registrant					X
23	Consent of Independent Registered Public Accounting Firm					X
24	Power of Attorney (included on the signature page)					X
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002					X
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002					X
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X
97	Policy Relating to Recovery of Erroneously Awarded Compensation					X
101.INS *	Inline XBRL Instance Document
101.SCH *	Inline XBRL Taxonomy Extension Schema
101.CAL *	Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF *	Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB *	Inline XBRL Taxonomy Extension Label Linkbase
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*Confidential treatment has been requested for portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

77

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aemetis, Inc.
Date: March 28, 2024	By:	/s/ Eric A. McAfee
		Eric A. McAfee
		Chief Executive Officer
		(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each undersigned person whose signature appears below constitutes and appoints Eric A. McAfee and Todd A. Waltz, and each of them, as their true and lawful attorneys-in-fact, each with full power of substitution, for the undersigned in any and all capacities, to sign any amendments to this report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Name	Title	Date
/s/ Eric A. McAfee	Chair of the Board and Chief Executive Officer	March 28, 2024
Eric A. McAfee	(Principal Executive Officer and Director)
/s/ Todd A. Waltz	Chief Financial Officer	March 28, 2024
Todd A. Waltz	(Principal Financial Officer)
/s/ Francis P. Barton	Director	March 28, 2024
Francis P. Barton
/s/ Lydia I. Beebe	Director	March 28, 2024
Lydia I. Beebe
/s/ John R. Block	Director	March 28, 2024
John R. Block
/s/ Naomi L Boness	Director	March 28, 2024
Naomi L. Boness
/s/ Timothy A. Simon	Director	March 28, 2024
Timothy A. Simon

78

EX-10.36

Exhibit 10.36

LIMITED WAIVER AND AMENDMENT NO. 28 TO

AMENDED AND RESTATED NOTE PURCHASE AGREEMENT

This Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement (this “Amendment”), is dated as of March 25, 2024, is made by and among (i) AEMETIS ADVANCED FUELS KEYES, INC., a Delaware corporation (“AEFK”), AEMETIS FACILITY KEYES, INC., a Delaware corporation (“Keyes Facility”, together with AEFK, the “Borrowers”), AEMETIS, INC., a Delaware corporation (“Parent”), and (ii) THIRD EYE CAPITAL CORPORATION, an Ontario corporation, as agent for the Noteholders (“Administrative Agent”).

RECITALS

A.    The Borrowers, Administrative Agent and Noteholders entered into the Amended and Restated Note Purchase Agreement dated as of July 6, 2012, as amended from time to time including most recently by an Amendment No. 27 dated as of May 16, 2023 (as the same may be amended, restated, supplemented, revised or replaced from time to time, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meaning given to them in the Agreement.

B.    The Borrowers have requested, and the Administrative Agent has agreed to waive certain financial covenants included in the Agreement, in each case on the terms and conditions contained herein.

AGREEMENT

SECTION 1.       Reaffirmation of Indebtedness. The Borrowers hereby confirm that as of February 29, 2024, the outstanding principal balance of the Notes (including accrued interest but excluding certain other fees) is $119,042,086.12.

SECTION 2.        Recitals Part of Agreement. The foregoing recitals are hereby incorporated into and made a part of the Agreement, including all defined terms referenced therein.

SECTION 3.        Note Indebtedness to Keyes Plant Values Amendment.

Subsection 6.2(b) of the Agreement is hereby deleted and replaced with the following:

“Ratios of Note Indebtedness to Keyes Plant Values. The Parent will not permit the ratio of Note Indebtedness (excluding, for purposes of this covenant only, the Redemption Fee and any draws under any Agent Advances including that Seventh Amended and Restated Promissory Note dated March 25, 2024) to the Keyes Plant Market Value to exceed 120%, tested quarterly as of the last day of each Fiscal Quarter, and commencing with the Fiscal Quarter ending March 31, 2024; and”

SECTION 4.          Conditions to Effectiveness.

This Amendment shall be effective on the date first written above but subject to satisfaction of the following conditions precedent:

(A)         Administrative Agent shall have been paid an amendment fee in the amount of $100,000 in cash on or before April 15, 2024, which fee shall be deemed fully earned and nonrefundable on the effective date of this Amendment.

(B)          Borrowers shall, and will cause the other Company Parties to, have performed and complied with all of the covenants and conditions required by this Amendment and the Note Purchase Documents to be performed and complied with upon the effective date of this Amendment.

(C)         Administrative Agent shall have received all other approvals, opinions, documents, agreements, instruments, certificates, schedules and materials as Administrative Agent may reasonably request.         

Each Borrower acknowledges and agrees that the failure to perform, or to cause the performance of, the covenants and agreements in this Amendment will constitute an Event of Default under the Agreement and Administrative Agent and Noteholders shall have the right to demand the immediate repayment in full in cash of all outstanding Indebtedness owing to Administrative Agent and Noteholders under the Agreement, the Notes and the other Note Purchase Documents. In consideration of the foregoing and the transactions contemplated by this Amendment, each Borrower hereby: (i) ratifies and confirms all of the obligations and liabilities of such Borrower owing pursuant to the Agreement and the other Note Purchase Documents, and (ii) agrees to pay all costs, fees and expenses of Administrative Agent and Noteholders in connection with this Amendment.

SECTION 5.         Agreement in Full Force and Effect as Amended.

Except as specifically amended or waived hereby, the Agreement and other Note Purchase Documents shall remain in full force and effect and are hereby ratified and confirmed as so amended. Except as expressly set forth herein, this Amendment shall not be deemed to be a waiver, amendment or modification of, or consent to or departure from, any provisions of the Agreement or any other Note Purchase Document or any right, power or remedy of Administrative Agent or Noteholders thereunder, nor constitute a course of dealing or other basis for altering any obligation of the Borrowers, or a waiver of any provision of the Agreement or any other Note Purchase Document, or any other document, instrument or agreement executed or delivered in connection therewith or of any Default or Event of Default under any of the foregoing, in each case whether arising before or after the execution date of this Amendment or as a result of performance hereunder or thereunder. This Amendment shall not preclude the future exercise of any right, remedy, power, or privilege available to Administrative Agent or Noteholders whether under the Agreement, the other Note Purchase Documents, at law or otherwise. All references to the Agreement shall be deemed to mean the Agreement as modified hereby. This Amendment shall not constitute a novation or satisfaction and accord of the Agreement or any other Note Purchase Documents, but rather shall constitute an amendment thereof. The parties hereto agree to be bound by the terms and conditions of the Agreement and Note Purchase Documents as amended by this Amendment, as though such terms and conditions were set forth herein. Each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of similar import shall mean and be a reference to the Agreement as amended by this Amendment, and each reference herein or in any other Note Purchase Documents to “the Agreement” shall mean and be a reference to the Agreement as amended and modified by this Amendment.

SECTION 6.         Representations by Parent and Borrowers.

Each of the Parent and the Borrowers hereby represents and warrants to Administrative Agent and Noteholders as of the execution date of this Amendment as follows: (A) it is duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation; (B) the execution, delivery and performance by it of this Amendment and all other Note Purchase Documents executed and delivered in connection herewith are within its powers, have been duly authorized, and do not contravene (i) its articles of incorporation, bylaws or other organizational documents, or (ii) any applicable law; (C) no consent, license, permit, approval or authorization of, or registration, filing or declaration with any Governmental Entity or other Person, is required in connection with the execution, delivery, performance, validity or enforceability of this Amendment or any other Note Purchase Documents executed and delivered in connection herewith by or against it; (D) this Amendment and all other Note Purchase Documents executed and delivered in connection herewith have been duly executed and delivered by it; (E) this Amendment and all other Note Purchase Documents executed and delivered in connection herewith constitute its legal, valid and binding obligation enforceable against it in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity; (F) it is not in default under the Agreement or any other Note Purchase Documents and no Event of Default exists, has occurred and is continuing or would result by the execution, delivery or performance of this Amendment; and (G) the representations and warranties contained in the Agreement and the other Note Purchase Documents are true and correct in all material respects as of the execution date of this Amendment as if then made, except for such representations and warranties limited by their terms to a specific date.

SECTION 7.          Miscellaneous.

(A)         This Amendment may be executed in any number of counterparts (including by facsimile or email), and by the different parties hereto on the same or separate counterparts, each of which shall be deemed to be an original instrument but all of which together shall constitute one and the same agreement. Whenever the context and construction so require, all words herein in the singular number herein shall be deemed to have been used in the plural, and vice versa. The use of the word “including” in this Amendment shall be by way of example rather than by limitation. The use of the words “and” or “or” shall not be inclusive or exclusive.

(B)         This Amendment may not be changed, amended, restated, waived, supplemented, discharged, canceled, terminated or otherwise modified without the written consent of the Borrowers and Administrative Agent. This Amendment shall be considered part of the Agreement and shall be a Note Purchase Document for all purposes under the Agreement and other Note Purchase Documents.

(C)         This Amendment, the Agreement and the Note Purchase Documents constitute the final, entire agreement and understanding between the parties with respect to the subject matter hereof and thereof and may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements between the parties, and shall be binding upon and inure to the benefit of the successors and assigns of the parties hereto and thereto. There are no unwritten oral agreements between the parties with respect to the subject matter hereof and thereof.

(D)         This Amendment and the rights and obligations of the parties under this Amendment shall be governed by and construed and interpreted in accordance with the choice of law provisions set forth in the Agreement and shall be subject to the waiver of jury trial and notice provisions of the Agreement.

(E)         Neither the Parent nor any Borrower may assign, delegate or transfer this Amendment or any of their rights or obligations hereunder. No rights are intended to be created under this Amendment for the benefit of any third party donee, creditor or incidental beneficiary of the Borrowers or any Company Party. Nothing contained in this Amendment shall be construed as a delegation to Administrative Agent or Noteholders of the Borrowers or any Company Party’s duty of performance, including any duties under any account or contract in which Administrative Agent or Noteholders have a security interest or lien. This Amendment shall be binding upon the Borrowers, the Parent and their respective successors and assigns.

(F)         All representations and warranties made in this Amendment shall survive the execution and delivery of this Amendment and no investigation by Administrative Agent or Noteholders shall affect such representations or warranties or the right of Administrative Agent or Noteholders to rely upon them.

(G)         THE BORROWERS AND THE PARENT ACKNOWLEDGE THAT SUCH PERSON’S PAYMENT OBLIGATIONS ARE ABSOLUTE AND UNCONDITIONAL WITHOUT ANY RIGHT OF RECISSION, SETOFF, COUNTERCLAIM, DEFENSE, OFFSET, CROSS-COMPLAINT, CLAIM OR DEMAND OF ANY KIND OR NATURE WHATSOEVER THAT CAN BE ASSERTED TO REDUCE OR ELIMINATE ALL OR ANY PART OF ITS LIABILITY TO REPAY THE “OBLIGATIONS” OR TO SEEK AFFIRMATIVE RELIEF OR DAMAGES OF ANY KIND OR NATURE FROM ADMINISTRATIVE AGENT OR ANY NOTEHOLDER. THE BORROWERS AND THE PARENT HEREBY VOLUNTARILY AND KNOWINGLY RELEASE AND FOREVER DISCHARGE ADMINISTRATIVE AGENT AND EACH NOTEHOLDER AND THEIR RESPECTIVE PREDECESSORS, ADMINISTRATIVE AGENTS, EMPLOYEES, SUCCESSORS AND ASSIGNS (COLLECTIVELY, THE “RELEASED PARTIES”), FROM ALL POSSIBLE CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION, DAMAGES, COSTS, EXPENSES, AND LIABILITIES WHATSOEVER, KNOWN OR UNKNOWN, ANTICIPATED OR UNANTICIPATED, SUSPECTED OR UNSUSPECTED, FIXED, CONTINGENT, OR CONDITIONAL, AT LAW OR IN EQUITY, ORIGINATING IN WHOLE OR IN PART ON OR BEFORE THE DATE THIS AMENDMENT IS EXECUTED, WHICH SUCH PERSON MAY NOW OR HEREAFTER HAVE AGAINST THE RELEASED PARTIES, IF ANY, AND IRRESPECTIVE OF WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION OF LAW OR REGULATIONS, OR OTHERWISE, AND ARISING FROM ANY “LOANS”, INCLUDING ANY CONTRACTING FOR, CHARGING, TAKING, RESERVING, COLLECTING OR RECEIVING INTEREST IN EXCESS OF THE HIGHEST LAWFUL RATE APPLICABLE, THE EXERCISE OF ANY RIGHTS AND REMEDIES UNDER THE AGREEMENT OR OTHER NOTE PURCHASE DOCUMENTS, AND NEGOTIATION FOR AND EXECUTION OF THIS AMENDMENT.

{Signatures appear on following pages.}

IN WITNESS WHEREOF, the parties hereto have executed this Amendment effective as of the date first noted above.

BORROWERS:                                    

AEMETIS ADVANCED FUELS KEYES, INC.

By:  ______________________________
Name: Eric A. McAfee
Title: Chief Executive Officer

AEMETIS FACILITY KEYES, INC.

By:  ______________________________
Name: Eric A. McAfee
Title: Chief Executive Officer

PARENT:

AEMETIS, INC.

By:  _____________________________
Name: Eric A. McAfee
Title: Chief Executive Officer

ADMINISTRATIVE AGENT:

THIRD EYE CAPITAL CORPORATION

By:  ____________________________
Name: Arif N. Bhalwani
Title: Managing Director

EX-10.37

Exhibit 10.37

SEVENTH AMENDED AND RESTATED PROMISSORY NOTE

March 25, 2024

FOR VALUE RECEIVED, the undersigned, AEMETIS ADVANCED FUELS KEYES, INC., a Delaware corporation (“AAFK”), AEMETIS FACILITY KEYES, INC., a Delaware corporation (“Keyes Facility”, and together with AAFK, “Borrowers”) and AEMETIS, INC., a Delaware corporation (“Parent”, and together with Borrowers, the “Obligors”) jointly and severally promise to pay to the order of THIRD EYE CAPITAL CORPORATION and/or its affiliates including THIRD EYE CAPITAL MANAGEMENT INC. (the “Lender”) the Aggregate Principal Amount as set forth below, at its offices or such other place as the Lender may designate in writing.

This Amended and Restated Promissory Note (the “Note”) is an amendment and restatement of that original Promissory Note dated March 27, 2018 (the “Original Note”). All debts and other obligations under the Original Note shall be continuing with the only terms thereof being modified as provided in this Note and previous amendments, and this Note shall not be deemed to evidence or result in a novation of such debt or other obligations. This Note is being issued to the Lender in connection with the Amended and Restated Note Purchase Agreement made as of July 6, 2012 (as amended, restated, supplemented, revised, or replaced from time to time, the “NPA”) by and among the Obligors, Third Eye Capital Corporation, as agent for the Noteholders (the “Agent”) and the Noteholders. Capitalized terms used but not defined herein shall have the meaning given to them in the NPA. Notwithstanding anything indicated herein or in the NPA, this Note is deemed to be one of the Notes under the NPA, is a Note Purchase Document and this Note and the obligations hereunder are subject to the provisions of the NPA.

1. Availability. Subject to all of the terms and conditions of this Note, the Lender agrees to make available, for the Borrowers’ use during the term and prior to the Maturity Date (defined below), total credit of up to, but not exceeding, Eighty-Five Million ($85,000,000) Dollars (the “Commitment”) plus Capitalized Interest and Capitalized Fee (each defined below).

2. Use of Proceeds. The principal amount of this Note advanced to the Obligors (the “Principal Amount”) shall be used for working capital purposes, the repayment of outstanding indebtedness (whether secured or unsecured and owed to the Lender or third party) and to pay the Fee (as defined below).

3. Advances. The Obligors may receive advances under this Note up to the Commitment at their discretion (each, an “Advance”) by providing five (5) Business Days’ prior written notice of their request for an Advance hereunder and the proposed use of proceeds of such Advance, provided that such Advances shall be in a minimum amount of $100,000 and in increments of $50,000.

4. Interest. From the date hereof until the repayment of this Note in full, interest on the Principal Amount plus any accrued or Capitalized Interest and Capitalized Fee (the aggregate being the “Aggregate Principal Amount”) outstanding shall be calculated at the rate of 30% per annum, and paid monthly in arrears on the last day of each month (each, an “Interest Calculation Date”); provided, however, that upon and during the occurrence of an Event of Default under the NPA or this Note or the non-payment of this Note by the Maturity Date, the interest rate shall be increased to 40% per annum.  At the election of the Obligors, on each Interest Calculation Date, all of the interest accrued on the then Aggregate Principal Amount and not previously capitalized as of such Interest Calculation Date (all such interest being referred to in this Agreement as “Capitalized Interest”), will be added to the Aggregate Principal Amount advanced to the Borrower hereunder as of such Interest Calculation Date. The Aggregate Principal Amount (as so increased by such Capitalized Interest) will bear interest at the interest rate indicated herein from and after such Interest Calculation Date.

5. Standby Fee. From the date hereof until the earlier of: (i) the early termination of this Note by the parties hereto; and (ii) the Maturity Date, the Borrowers hereunder shall pay to the Lender a standby fee calculated at the rate per annum equal to two percent (2%) of the difference between the average of the Aggregate Principal Amount outstanding and the Commitment, calculated and payable monthly in arrears either in cash or in common stock of the Parent (at the equivalent of 110% of the cash amount of such fee on the date of issuance of such stock) on the first Business Day following the end of each month and on the Maturity Date.

6. Maturity Date.  The outstanding principal balance of the indebtedness evidenced hereby, plus any accrued but unpaid interest, obligations, fees and any other sums owing hereunder, shall be due and payable in full on April 1, 2025 (the “Maturity Date”). The Obligors shall be required to repay the indebtedness under any Advances hereunder from: (a) the proceeds of the closing of any new debt or equity financings, refinancing or other similar transaction between the Lender or any fund or entity arranged by the Lender and any Obligor or any Affiliate thereof; and (b) the receipt by an Obligor or Affiliate thereof of proceeds from any sale, merger, equity or debt financing (including without limitation any EB-5 financing), refinancing or other similar transaction from any third party, after the repayment of the indebtedness outstanding pursuant to the NPA. The Obligors may reborrow any amounts so repaid up until the Maturity Date upon the terms and conditions hereof.

7. Advance Fee.  Upon any Obligor making a request for an Advance, the Obligor shall pay to the Lender a one-time fee (the “Fee”) in the amount of $500,000 which shall be deemed earned and non-refundable on the date of such initial Advance, provided that such Fee may be added to the Principal Amount on the date of such initial Advance made pursuant to this Note (the “Capitalized Fee”).

8. Conditions to Advances.  Administrative Agent shall have received from Aemetis all other approvals, opinions, documents, agreements, instruments, certificates, schedules and materials as Administrative Agent may request with respect to each proposed Advance.

9. Acknowledgement of Security. The Obligors hereby acknowledge, confirm and agree that this Note, and the obligations hereunder, are secured by valid and enforceable liens and security interests upon and in the property and assets of the Obligors as described in the NPA and the other Note Purchase Documents and reaffirm their obligations pursuant to all applicable Note Purchase Documents to which they are a party.

10. Additional Obligations of the Obligors. As further consideration of the Lender providing the funds contemplated under this Note, the Obligors hereby agree, upon the request of the Lender, to take such action, and execute and deliver such further documents as may be reasonably necessary or appropriate to give effect to the provisions and intent of this Note.

11. Waivers. Each Obligor hereby waives demand, presentment for payment, notice of dishonor, protest, and notice of protest and diligence in collection or bringing suit. Time is of the essence.

12. Attorneys’ Fees. Each Obligor agrees to pay the reasonable attorneys’ fees and costs incurred by the Lender in collecting on or enforcing the terms of this Note, whether by suit or otherwise.

13. Paramountcy.  In the event of any conflicts between the provisions of this Note and any provisions of the NPA, solely in connection with this Note, the provisions of this Note shall prevail and be paramount.

14. Severability. In the event any one or more of the provisions of this Note shall for any reason be held to be invalid, illegal, or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this Note operate or would prospectively operate to invalidate this Note, then and in any such event, such provision(s) only shall be deemed null and void and shall not affect any other provision of this Note and the remaining provisions of this Note shall remain operative and in full force and effect and in no way shall be affected, prejudiced, or disturbed thereby.

15. Miscellaneous. This Note and the obligations hereunder may not be assigned by Obligors without the prior written consent of the Lender. This Note and the rights hereunder may be assigned by Lender without the consent of the Obligors. As used herein, the terms “Obligors” and “Lender” shall be deemed to include their respective successors, legal representatives and assigns, whether by voluntary action of the parties or by operation of law. Each Obligor hereby submits to jurisdiction in the State of Delaware and this Note shall be governed by and be construed in accordance with the laws of the State of Delaware. This Note may not be modified except by written agreement signed by the Obligors and the Lender.

[Signature Page Follows]

IN WITNESS WHEREOF, each Obligor has caused this Note to be executed and delivered under seal as of the date first set forth above.

BORROWERS:

AEMETIS ADVANCED FUELS KEYES, INC.

By:          
Name: Eric A. McAfee
Title: Chief Executive Officer

AEMETIS FACILITY KEYES, INC.

By:          
Name: Eric A. McAfee
Title: Chief Executive Officer

PARENT:

AEMETIS, INC.

By:          
Name: Eric A. McAfee
Title: Chief Executive Officer

Accepted and Acknowledged by:

THIRD EYE CAPITAL CORPORATION

THIRD EYE CAPITAL MANAGEMENT INC.

By:                                                      

Name: Arif N. Bhalwani

Title: Managing Director

EX-21

Exhibit 21.1

List of Subsidiaries (Name and State of Formation)

Aemetis Advanced Biorefinery Keyes, Inc. (Delaware)

Aemetis Advanced Fuels, Inc. (Nevada)

Aemetis Advanced Products Keyes, Inc. (Delaware)

Aemetis Health Products, Inc. (Delaware)

Aemetis Properties Riverbank, Inc. (Delaware)

Aemetis Riverbank, Inc. (Delaware)

Aemetis Advanced Products Riverbank, Inc. (Delaware)

Aemetis Americas, Inc. (Nevada)

AE Biofuels, Inc. (Delaware)

Aemetis Biofuels, Inc. (Delaware)

Energy Enzymes, Inc. (Delaware)

Aemetis Biogas LLC (Delaware)

Aemetis Biogas Holdings LLC (Delaware)

Aemetis Biogas 1 LLC (Delaware)

Aemetis Biogas 2 LLC (Delaware)

Aemetis Biogas 3 LLC (Delaware)

Aemetis Biogas 4 LLC (Delaware)

Aemetis Biogas 5 LLC (Delaware)

Aemetis Biogas 6 LLC (Delaware)

Aemetis Biogas 7 LLC (Delaware)

Aemetis Biogas 8 LLC (Delaware)

Aemetis Biogas Services LLC (Delaware)

Aemetis Carbon Capture, Inc. (Nevada)

Aemetis International, Inc. (Nevada)

International Biofuels Ltd (Mauritius)

Universal Biofuels Private Limited (India)

Aemetis Technologies, Inc. (Delaware)

AE Advanced Fuels, Inc. (Delaware)

Aemetis Advanced Fuels Keyes, Inc. (Delaware)

Aemetis Facility Keyes, Inc. (Delaware)

Aemetis Property Keyes, Inc. (Delaware)

EdenIQ Acquisition Corp (Delaware)

Goodland Advanced Fuels, Inc. (Delaware)

EX-23

Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Nos. 333‑248492 and 333‑258322) on Form S‑3 and (Nos. 333‑159556, 333‑194423, 333‑194429, 333‑202327, 333‑209620, 333‑216762, 333‑224002, 333‑230293, 333‑237101, 333‑248489, 333‑249188, 333‑254267, 333‑263452, and 333‑270388) on Form S‑8 of Aemetis, Inc. of our reports dated March 28, 2024, relating to the consolidated financial statements of Aemetis, Inc. (the Company) and the effectiveness of the Company's internal control over financial reporting (on which our report expresses an adverse opinion on the effectiveness of the Company's internal control over financial reporting because of material weaknesses), appearing in this Annual Report on Form 10‑K of Aemetis, Inc. for the year ended December 31, 2023.

/s/ RSM US LLP

Des Moines, Iowa

March 28, 2024

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Eric A. McAfee, certify that:

1.	I have reviewed this Annual Report on Form 10-K of Aemetis, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 28, 2024

/s/ Eric A. McAfee

Eric A. McAfee

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Todd Waltz, certify that:

1.	I have reviewed this Annual Report on Form 10-K of Aemetis, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 28, 2024

/s/ Todd Waltz

Todd Waltz

Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Aemetis, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report “), I, Eric A. McAfee, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Eric A. McAfee
Eric A. McAfee
Chief Executive Officer
Date: March 28, 2024

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Aemetis, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report“), I, Todd Waltz, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Todd Waltz
Todd Waltz
Chief Financial Officer
Date: March 28, 2024

EX-97

Exhibit 97

Aemetis, Inc.

Policy for the Recovery of

Erroneously Awarded Compensation

(“Clawback Policy”)

Adopted January 18, 2024

A. Overview

In accordance with the applicable rules of The Nasdaq Stock Market (the “Nasdaq Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Board of Directors (the “Board”) of Aemetis, Inc. (“Company”) has adopted this Policy (“Policy”) to provide for the recovery of erroneously awarded Incentive-based Compensation from Executive Officers. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H, below.

B. Recovery Of Erroneously Awarded Compensation

(1)    In the event of an Accounting Restatement, the Company will reasonably promptly recover the Erroneously Awarded Compensation Received in accordance with Nasdaq Rules and Rule 10D-1 as follows:

(i) After an Accounting Restatement, the Governance, Compensation, and Nominating Committee (if composed entirely of independent directors, or in the absence of such a committee, a majority of independent directors serving on the Board) (the “Committee”) shall determine the amount of any Erroneously Awarded Compensation Received by each Executive Officer and shall promptly notify each Executive Officer with a written notice containing the amount of any Erroneously Awarded Compensation and a demand for repayment or return of such compensation, as applicable.

For Incentive-based Compensation based on (or derived from) the Company’s stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement:

(a) The amount to be repaid or returned shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the Company’s stock price or total shareholder return upon which the Incentive-based Compensation was Received; and

(b) The Company shall maintain documentation of the determination of such reasonable estimate and provide the relevant documentation as required to Nasdaq.

(ii) The Committee shall have discretion to determine the appropriate means of recovering Erroneously Awarded Compensation based on the particular facts and circumstances. Notwithstanding the foregoing, except as set forth in Section B(2) below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer’s obligations hereunder.

(iii) To the extent that the Executive Officer has already reimbursed the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Erroneously Awarded Compensation that is subject to recovery under this Policy.

(iv) To the extent that an Executive Officer fails to repay all Erroneously Awarded Compensation to the Company when due, the Company shall take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer. The applicable Executive Officer shall be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.

(2)    Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section B(1) above if the Committee (which, as specified above, is composed entirely of independent directors or in the absence of such a committee, a majority of the independent directors serving on the Board) determines that recovery would be impracticable and either of the following two conditions are met:

(i) The Committee has determined that the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making this determination, the Company must make a reasonable attempt to recover the Erroneously Awarded Compensation, documented such attempt(s) and provided such documentation to the Nasdaq;

(ii) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.

C. Disclosure Requirements

The Company shall file all disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission (“SEC”) filings and rules.

D. Prohibition of Indemnification

The Company shall not be permitted to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company’s enforcement of its rights under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted, paid or awarded to an Executive Officer from the application of this Policy or that waives the Company’s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date of this Policy).

E. Administration and Interpretation

This Policy shall be administered by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy and for the Company’s compliance with Nasdaq Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith.

F. Amendment; Termination

The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or Nasdaq rule.

G. Other Recovery Rights

This Policy shall be binding and enforceable against all Executive Officers and, to the extent required by applicable law or guidance from the SEC or Nasdaq, their beneficiaries, heirs, executors, administrators or other legal representatives. The Committee intends that this Policy will be applied to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement.

H. Definitions

For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.

(1)  “Accounting Restatement” means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a “Big R” restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a “little r” restatement).

(2)  “Clawback Eligible Incentive Compensation” means all Incentive-based Compensation Received by an Executive Officer (i) on or after the effective date of the applicable Nasdaq rules, (ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (v) during the applicable Clawback Period (as defined below).

(3)  “Clawback Period” means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date (as defined below),and if the Company changes its fiscal year, any transition period of less than nine months within or immediately following those three completed fiscal years.

(4)  “Erroneously Awarded Compensation” means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.

(5)  “Executive Officer” means each individual who is currently or was previously designated as an “officer” of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).

(6)  “Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company’s financial statements or included in a filing with the SEC.

(7)  “Incentive-based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.

(8)   “Nasdaq” means The Nasdaq Stock Market.

(9)  “Received” means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if the payment or grant of the Incentive-based Compensation to the Executive Officer occurs after the end of that period.

(10)  “Restatement Date” means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

* * *

Exhibit A

Attestation and Acknowledgement of Policy for the Recovery

of Erroneously Awarded Compensation

By my signature below, I acknowledge and agree that:

● I have received and read the attached Policy for the Recovery of Erroneously Awarded Compensation (this “Policy”).

● I hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any Erroneously Awarded Compensation to the Company as determined in accordance with this Policy.

Signature:                                                     

Printed Name:                                              

Date:                                                           

XML

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 29, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0000738214
Entity Registrant Name	AEMETIS, INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-36475
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1407544
Entity Address, Address Line One	20400 Stevens Creek Blvd., Suite 700
Entity Address, City or Town	Cupertino
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95014
City Area Code	408
Local Phone Number	213-0940
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	AMTX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 253,200,000
Entity Common Stock, Shares Outstanding		42,608,698
Auditor Firm ID	49
Auditor Name	RSM US LLP
Auditor Location	Des Moines, Iowa

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,667	$ 4,313
Accounts receivable	8,633	1,264
Inventories, net of allowance for excess and obsolete inventory of $1,040 as of December 31, 2023 and 2022	18,291	4,658
Prepaid expenses	3,347	4,248
Other current assets	3,462	3,653
Total current assets	36,400	18,136
Property, plant and equipment, net	195,108	180,441
Operating lease right-of-use assets	2,056	2,449
Other assets	9,842	6,088
Total assets	243,406	207,114
Current liabilities:
Accounts payable	32,132	26,168
Current portion of long term debt	13,585	12,465
Short term borrowings	23,443	36,754
Current portion of operating lease liability	406	338
Other current liabilities	10,302	8,474
Total current liabilities	84,389	88,281
Long term liabilities:
Senior secured notes and revolving notes	176,476	155,843
EB-5 notes	29,500	29,500
Other long term debt	51,717	11,678
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	113,200	116,000
Operating lease liability	1,783	2,189
Other long term liabilities	3,329	5,477
Total long term liabilities	375,994	320,687
Stockholders' deficit:
Common stock, $0.001 par value; 80,000 authorized; 40,966 and 35,869 shares issued and outstanding each period, respectively	41	36
Additional paid-in capital	264,058	232,546
Accumulated deficit	(475,405)	(428,985)
Accumulated other comprehensive loss	(5,671)	(5,452)
Total stockholders' deficit	(216,977)	(201,854)
Total liabilities and stockholders' deficit	243,406	207,114
Series B Convertible Preferred Stock [Member]
Stockholders' deficit:
Series B convertible preferred stock, $0.001 par value; 7,235 authorized; 0 and 1,270 shares issued and outstanding each period, respectively (aggregate liquidation preference of $0 and $3,810 respectively)	0	1
Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member]
Current liabilities:
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current	4,521	4,082
Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member]
Long term liabilities:
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	$ 113,189	$ 116,000

XML

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 2,667	$ 4,313
Accounts receivable	8,633	1,264
Inventory Valuation Reserves	1,040	1,040
Prepaid expenses	3,347	4,248
Other current assets	3,462	3,653
Property, plant and equipment, net	195,108	180,441
Operating lease right-of-use assets	2,056	2,449
Other assets	9,842	6,088
Accounts payable	32,132	26,168
Current portion of long term debt	13,585	12,465
Short term borrowings	23,443	36,754
Current portion of operating lease liability	406	338
Other current liabilities	10,302	8,474
Other long term debt	51,717	11,678
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	113,200	116,000
Operating lease liability	$ 1,783	$ 2,189
Series B Preferred Stock, Authorized (in shares)	65,000
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	80,000	80,000
Common Stock, Shares Issued (in shares)	40,966	35,869
Common Stock, Shares Outstanding (in shares)	40,966	35,869
Series B Convertible Preferred Stock [Member]
Series B Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Series B Preferred Stock, Authorized (in shares)	7,235	7,235
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Series B Preferred Stock, Shares Outstanding (in shares)	0	1,270
Aggregate Liquidation Preference	$ 0	$ 3,810
Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member]
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	113,189	116,000
Variable Interest Entity, Primary Beneficiary [Member]
Cash and cash equivalents	1,093	165
Accounts receivable	55	165
Prepaid expenses	1,438	858
Other current assets	289	725
Property, plant and equipment, net	81,966	71,633
Operating lease right-of-use assets	145	224
Other assets	4,881	3,458
Accounts payable	3,815	9,192
Current portion of long term debt	190	0
Short term borrowings	9	19,831
Current portion of operating lease liability	48	41
Other current liabilities	0	645
Other long term debt	40,857	31
Operating lease liability	67	115
Variable Interest Entity, Primary Beneficiary [Member] | Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member]
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	$ 113,189	$ 116,000

XML

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Cost of goods sold	184,700	262,048
Gross (loss) profit	2,017	(5,535)
Research and development expenses	152	180
Selling, general and administrative expenses	39,266	28,686
Operating loss	(37,401)	(34,401)
Other expense (income):
Interest rate expense	32,995	21,407
Debt related fees and amortization expense	6,524	7,363
Accretion and other expenses of Series A preferred units	25,313	9,888
Loss on debt extinguishment	0	49,386
Gain on litigation	0	(1,400)
Other income	(2,077)	(14,340)
Loss before income taxes	(100,156)	(106,705)
Income tax expense (benefit)	(53,736)	1,053
Net loss	(46,420)	(107,758)
Other comprehensive (loss)
Foreign currency translation loss	(219)	(1,102)
Comprehensive loss	$ (46,639)	$ (108,860)
Net loss per common share
Basic (in dollars per share)	$ (1.22)	$ (3.12)
Diluted (in dollars per share)	$ (1.22)	$ (3.12)
Weighted average shares outstanding
Basic (in shares)	38,061	34,585
Diluted (in shares)	38,061	34,585

XML

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (46,420)	$ (107,758)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Share-based compensation	7,660	6,410
Depreciation	6,933	5,535
Debt related fees and amortization expense	6,524	7,363
Intangibles and other amortization expense	72	46
Accretion and other expenses of Series A preferred units	25,313	9,888
Warrants issued for working capital agreement	409	0
Loss on asset disposals	0	47
Loss on debt extinguishment	0	49,386
Gain on litigation	0	(1,400)
Loss on lease termination	0	736
Deferred tax (benefit) expense	(750)	832
Changes in operating assets and liabilities:
Accounts receivable	(7,422)	294
Inventories	(13,843)	360
Prepaid expenses	1,838	1,777
Other assets	(2,016)	(3,941)
Accounts payable	13,726	2,183
Accrued interest expense and fees	23,558	15,501
Other liabilities	(1,757)	(10,125)
Net cash provided by (used in) operating activities	13,825	(22,866)
Investing activities:
Capital expenditures	(33,119)	(39,157)
Grant proceeds received for capital expenditures	9,432	7,851
Net cash used in investing activities	(23,687)	(31,306)
Financing activities:
Proceeds from borrowings	75,482	69,356
Repayments of borrowings	(56,130)	(26,266)
Lender debt renewal and waiver fee payments	(1,681)	(1,169)
Payments on Series A preferred financing	(30,000)	0
Payments on finance leases	(428)	(481)
Proceeds from issuance of common stock in equity offering	21,718	11,987
Proceeds from the exercise of stock options	133	206
Net cash provided by financing activities	9,094	53,633
Effect of exchange rate changes on cash and cash equivalents	49	(213)
Net change in cash and cash equivalents for period	(719)	(752)
Cash, cash equivalents, and restricted cash at beginning of period	6,999	7,751
Cash, cash equivalents, and restricted cash at end of period	6,280	6,999
Supplemental disclosures of cash flow information, cash paid:
Cash paid for interest	9,813	19,515
Income taxes paid	20	10
Supplemental disclosures of cash flow information, non-cash transactions:
Subordinated debt extension fees added to debt	680	680
Debt fees added to revolving lines	0	800
Fair value of warrants issued to subordinated debt holders	1,278	1,939
Fair value of stock issued to a related party for guarantee fees	0	2,012
Fair value of warrants issued to lender for debt issuance costs	318	3,158
Fair value of stock issued to lender	0	1,335
Lender debt extension, waiver, and other fees added to debt	0	583
Capital expenditures in accounts payable	7,900	15,411
Payment of debt added to revolving lines	0	16,266
Operating lease liabilities arising from obtaining right of use assets	0	306
Financing lease liabilities arising from obtaining right of use assets	0	2,932
Capital expenditures purchased on financing	$ 0	$ 290

XML

Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2021	1,275	33,461
Balance at Dec. 31, 2021	$ 1	$ 33	$ 205,305	$ (321,227)	$ (4,350)	$ (120,238)
Issuance of common stock (in shares)	0	1,885
Issuance of common stock	$ 0	$ 3	15,530	0	0	15,533
Series B conversion to common stock (in shares)	(5)	(1)
Series B conversion to common stock	$ 0	$ 0	0	0	0	0
Series B conversion to common stock (in shares)	5	1
Stock options exercised (in shares)	0	296
Stock options exercised	$ 0	$ 0	205	0	0	205
Stock-based compensation	$ 0	$ 0	6,410	0	0	6,410
Issuance and exercise of warrants (in shares)	0	226
Issuance and exercise of warrants	$ 0	$ 0	5,096	0	0	5,096
Foreign currency translation loss	0	0	0	0	(1,102)	(1,102)
Net loss	$ 0	$ 0	0	(107,758)	0	(107,758)
Series B conversion to common stock (in shares)	5	1
Balance (in shares) at Dec. 31, 2022	1,270	35,869
Balance at Dec. 31, 2022	$ 1	$ 36	232,546	(428,985)	(5,452)	(201,854)
Issuance of common stock (in shares)	0	4,499
Issuance of common stock	$ 0	$ 4	21,714	0	0	21,718
Series B conversion to common stock (in shares)	(1,270)	(127)
Series B conversion to common stock	$ (1)	$ 1	0	0	0	0
Series B conversion to common stock (in shares)	1,270	127
Stock options exercised (in shares)	0	183
Stock options exercised	$ 0	$ 0	133	0	0	133
Stock-based compensation	$ 0	$ 0	7,660	0	0	7,660
Issuance and exercise of warrants (in shares)	0	288
Issuance and exercise of warrants	$ 0	$ 0	2,005	0	0	2,005
Foreign currency translation loss	0	0	0	0	(219)	(219)
Net loss	$ 0	$ 0	0	(46,420)	0	(46,420)
Series B conversion to common stock (in shares)	1,270	127
Balance (in shares) at Dec. 31, 2023	0	40,966
Balance at Dec. 31, 2023	$ 0	$ 41	$ 264,058	$ (475,405)	$ (5,671)	$ (216,977)

XML

Note 1 - Nature of Activities and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

1. Nature of Activities and Summary of Significant Accounting Policies

Nature of Activities. These consolidated financial statements include the accounts of Aemetis, Inc. (formerly AE Biofuels, Inc.), a Delaware corporation, and its subsidiaries (collectively, “Aemetis” or the “Company”):

● Aemetis Americas, Inc., a Delaware corporation, and its subsidiary AE Biofuels, Inc., a Delaware corporation;

● Aemetis International, Inc., a Nevada corporation, and its subsidiary International Biofuels Ltd, a Mauritius corporation, and its subsidiary Universal Biofuels Private Limited, an India company;

● Aemetis Technologies, Inc., a Delaware corporation;

● Aemetis Biofuels, Inc., a Delaware corporation, and its subsidiary Energy Enzymes, Inc., a Delaware corporation;

● AE Advanced Fuels, Inc., a Delaware corporation, and its subsidiaries Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, and Aemetis Property Keyes, Inc., a Delaware corporation;

● Aemetis Advanced Fuels, Inc., a Nevada corporation;

● Aemetis Advanced Products Keyes, Inc., a Delaware corporation, and its subsidiaries Aemetis Properties Riverbank, Inc., a Delaware corporation, Aemetis Health Products, Inc., a Delaware corporation; and Aemetis Riverbank, Inc., a Delaware corporation, and its subsidiary Aemetis Advanced Products Riverbank, Inc., a Delaware corporation;

● Aemetis Advanced Biorefinery Keyes, Inc., a Delaware corporation;

● Aemetis Carbon Capture, Inc. a Nevada corporation;

● Aemetis Biogas LLC, a Delaware Limited Liability Company and its subsidiaries Aemetis Biogas Services LLC, a Delaware Limited Liability Company, and Aemetis Biogas Holdings LLC, a Delaware Limited Liability Company, and its subsidiaries Aemetis Biogas 1 LLC, a Delaware Limited Liability Company, Aemetis Biogas 2 LLC, a Delaware Limited Liability Company, Aemetis Biogas 3 LLC, a Delaware Limited Liability Company, Aemetis Biogas 4 LLC, a Delaware Limited Liability Company, Aemetis Biogas 5 LLC, a Delaware Limited Liability Company, Aemetis Biogas 6 LLC, a Delaware Limited Liability Company, Aemetis Biogas 7 LLC, a Delaware Limited Liability Company, and Aemetis Biogas 8 LLC, a Delaware Limited Liability Company;

● Goodland Advanced Fuels, Inc., a Nevada corporation.

Founded in 2006 and headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis referred to herein as, “Aemetis,” the “Company,” “we,” “our” or “us”) is an international renewable natural gas and renewable fuels company focused on the operation, acquisition, development, and commercialization of innovative low and negative carbon intensity products and technologies that replace traditional petroleum-based products. We operate in three reportable segments consisting of “California Ethanol,” “California Dairy Renewable Natural Gas,” and “India Biodiesel.” We have other operating segments determined not to be reportable segments and are collectively represented by the “All Other” category. Our mission is to generate sustainable and innovative renewable fuel solutions that benefit communities and restore our environment. We do this by building a local circular bioeconomy utilizing agricultural waste to produce low and negative carbon, advanced renewable fuels that reduce greenhouse gas ("GHG") emissions and improve air quality by replacing traditional petroleum-based products.

Basis of Presentation and Consolidation. These consolidated financial statements include the accounts of Aemetis, Inc. and its subsidiaries. We consolidate all entities in which we have a controlling financial interest. A controlling financial interest is usually obtained through ownership of a majority of the voting interests. However, an enterprise must consolidate a variable interest entity (“VIE”) if the enterprise is the primary beneficiary of the VIE, even if the enterprise does not own a majority of the voting interests. The primary beneficiary is the party that has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. ABGL was assessed to be a VIE and through the Company's ownership interest in all of the outstanding common stock, the Company has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company.

All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. To the extent there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.

Revenue Recognition. We derive revenue primarily from sales of ethanol and related co-products in California Ethanol segment, renewable natural gas for California Dairy Renewable Natural Gas segment, and biodiesel in India Biodiesel segment pursuant to supply agreements and purchase order contracts. We assess the following criteria under the ASC 606 guidance: (i) identify the contracts with customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when the entity satisfies the performance obligations.  

California Ethanol:  From 2022 until the second quarter of 2023, we sold our ethanol production to Murex who marketed it to oil companies as a gasoline blend stock.  Starting in the second quarter of 2023, we began selling all our ethanol to J.D. Heiskell who sells it to customers designated by us, and we have designated Murex, who continues to market the product.  J.D. Heiskell does not charge a fee for reselling the ethanol but they receive the payments from the ultimate customer.  We also buy our corn feedstock from J.D. Heiskell, and J.D. Heiskell pays us the net balance between ethanol and other product sales and our corn purchases.  Our accounting (i) treats us as the purchaser/customer for corn purchases from J.D. Heiskell and we record the full purchase cost in cost-of-good sold, and (ii) treats us as the seller for ethanol and other product sales, so we treat all sales as revenue.

Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, the performance obligation was satisfied by delivery of the physical product from our finished goods tank to our customer’s contracted trucks. Effective on May 25, 2023, the performance obligation is satisfied by delivery of the physical product to our finished goods tank leased by J.D. Heiskell. The transaction price is determined based on daily market prices and quarterly contract pricing negotiated by Murex for its customers for ethanol and based on dry distillers' market and local demand by our marketing partner A.L. Gilbert Company (“A.L. Gilbert”) for WDG. The transaction price is allocated to one performance obligation.

During the last two weeks of December 2022, we undertook an extended maintenance cycle and accelerated the implementation of several important ethanol plant energy efficiency upgrades. Our decision was partly driven by the high natural gas prices in California during the period. Furthermore, after monitoring natural gas pricing and margin profitability, we decided to extend the maintenance cycle into the first and second quarters of 2023 and restarted the plant at the end of May 2023.

The following table shows our sales in California Ethanol by product category:

California Ethanol	For the twelve months ended December 31,
	2023		2022
Ethanol sales	$	78,403	$	165,876
Wet distiller's grains sales		21,963		50,930
Other sales		3,702		11,388
	$	104,068	$	228,194

California Dairy Renewable Natural Gas: Our facilities as of December 31, 2023, consist of seven anaerobic digesters that process feedstock from dairies into biogas, a 26-mile collection pipeline leading to a central upgrading hub, and an interconnect to inject the RNG into the utility natural gas pipeline for delivery to customers for use as transportation fuel.  During 2023, Renewable Natural Gas ("RNG") produced at our seven operating dairy digesters was delivered to the regional natural gas pipeline.  In connection with dispensing the RNG, we also began generating and inventorying sellable credits under the federal Renewable Fuel Standard (referred to as "D3 RINs") and the California Low Carbon Fuel Standard credits ("LCFS"). We began selling D3 RINs in the third quarter of 2023 and began selling LCFS credits in the first quarter of 2024. We recognize revenue from sales of RNG concurrent with our production and injection into the transportation pipeline.  We recognize revenue from sales of D3 RINs and LCFS credits at the time we sell the credits. 

Dairy Renewable Natural Gas	For the twelve months ended December 31,
	2023		2022
Molecule and RIN sales	$	5,455	$	208

India Biodiesel: We sell products pursuant to purchase orders (written or verbal) or by contract with governmental or international parties, in which performance is satisfied by delivery and acceptance of the physical product. Given that the contracts are sufficiently similar in nature, we have assessed these contracts as a portfolio of similar contracts as allowed under the practical expedient. Doing so does not result in a materially different outcome compared to individually accounting for each contract. All domestic and international deliveries are subject to certain specifications as identified in contracts. The transaction price is determined based on reference market prices for biodiesel, refined glycerin, and PFAD net of taxes. Transaction price is allocated to one performance obligation.

The following table shows our sales in India by product category:

India Biodiesel	For the twelve months ended December 31,
	2023		2022
Biodiesel sales	$	74,503	$	27,041
Other sales		2,691		1,070
	$	77,194	$	28,111

Cost of Goods Sold. Cost of goods sold includes those costs directly associated with the production of revenues, such as raw material consumed, factory overhead, and other direct production costs.  During periods of idle plant capacity from January to May 2023, costs otherwise charged to cost of goods sold are reclassified to selling, general and administrative expense. 

Shipping and Handling Costs. When incurred, shipping and handling costs are classified as a component of cost of goods sold in the accompanying consolidated statements of operations.

Research and Development. Research and development costs are expensed as incurred, unless they have alternative future uses to the Company.

Cash, Cash Equivalents, and Restricted Cash. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company maintains cash balances at various financial institutions domestically and abroad. The Federal Deposit Insurance Corporation insures domestic cash accounts. The Company’s accounts at these institutions may at times exceed federally insured limits. The Company has not experienced any losses in such accounts. Amounts included in restricted cash represent those required to be set aside by the AB1 and AB2 Loan Agreements with Greater Nevada Credit Union ("GNCU") and Magnolia Bank, respectively, and will be released at times specified in each agreement.

The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same such amounts shown in the statement of cash flows. 

	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,667	$	4,313
Restricted cash included in other current assets		289		725
Restricted cash included in other assets		3,324		1,961
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	6,280	$	6,999

Accounts Receivable.   The Company sells all of its products to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement. Our third-party marketing partners arrange to buy ethanol and WDG generally without requiring collateral and sell directly to customers on a variety of terms including advanced payment terms, based on the size and creditworthiness of the customer. DCO and CDS are marketed and sold to various customers under the J.D. Heiskell Purchasing Agreement. The Company sells biodiesel, glycerin, and processed natural oils to a variety of customers and may require advanced payment based on the size and creditworthiness of the customer. Usually, invoices are due within 30 days on net terms. Accounts receivable mostly consist of product sales made to large creditworthy customers. Trade accounts receivable are presented at original invoice amount, net of any allowance for doubtful accounts.

The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and estimates an allowance for expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may be required. 

Inventories. Finished goods, raw materials, and work-in-process inventories are valued using methods that approximate the lower of cost (first-in, first-out) or net realizable value (NRV).  Distillers’ grains and related products are stated at NRV.  In the valuation of inventories, NRV is determined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.

Other current assets. The other current assets contain input tax credits of $1.6 million, employee advance receivables of $69 thousand, and advances to customers of $1.2 million by our India biodiesel segment. 

Variable Interest Entities. We determine at the inception of each arrangement whether an entity in which we have made an investment or in which we have other interests in is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other interests in a VIE in accordance with applicable GAAP.

Property, Plant and Equipment. Property, plant, and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of buildings, furniture, machinery, equipment, land, biogas dairy digesters, and the Keyes Plant, Goodland Plant and Kakinada Plant. It is the Company’s policy to depreciate capital assets over their estimated useful lives using the straight-line method.

The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 Property Plant and Equipment –Subsequent Measurement, which requires recognition of impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of asset groups may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, based on estimated undiscounted cash flows, the impairment loss would be measured as the difference between the carrying amount of the asset group and its estimated fair value. The Company has not recorded any impairment as of December 31, 2023 and 2022.

Grants Received.

California Energy Commission Low-Carbon Fuel Production Program. The Company has been awarded $4.2 million in matching grants from the California Energy Commission Low-Carbon Fuel Production Program (“LCFPP”). The LCFPP grant reimburses the Company for costs to design, procure, and install processing facility to clean-up, measure and verify negative-carbon intensity dairy renewable natural gas fuel at the production facility in Keyes, California. The Company has received $3.8 million from the LCFPP as of  December 31, 2023, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Department of Food and Agriculture Dairy Digester Research and Development Grant. In 2019, the Company was awarded $3.2 million in matching grants from the California Department of Food and Agriculture (“CDFA”) Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct two of the Company’s biogas capture systems under contract with central California dairies. The Company received all the awarded grant proceeds as of the second quarter of 2021. In  October 2020, the Company was awarded $7.8 million in matching grants from the CDFA Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct six of the Company’s biogas capture systems under contract with central California dairies. The Company has received $6.2 million from the CDFA 2020 grant program as of December 31, 2023, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Energy Commission Low Carbon Advanced Ethanol Grant Program. In  May 2019, the Company was awarded the right to receive reimbursements from the California Energy Commission Community-Scale and Commercial-Scale Advanced Biofuels Production Facilities grant under the Alternative and Renewable Fuel and Vehicle Technology Program in an amount up to $5.0 million (the “CEC Reimbursement Program”) in connection with the Company’s expenditures toward the development of the Riverbank Cellulosic Ethanol Facility. To comply with the guidelines of the CEC Reimbursement Program, the Company must make a minimum of $7.9 million in matching contributions to the Riverbank project. The Company receives funds under the CEC Reimbursement Program for actual expenses incurred up to $5.0 million as long as the Company makes the minimum matching contribution. Given that the Company has not made the minimum matching contribution, the California Energy Commission did not extend the due date and would not move forward with this grant program. Given the nature of the project, the grant for reimbursement of capital expenditures of $1.7 million is presented with other current liabilities as of  December 31, 2023 and 2022 

U.S. Department of Food and Agriculture Forest Service Grant. Aemetis Advanced Products Keyes (“AAPK”) has been awarded $245 thousand in matching grants from the U.S. Department of Food and Agriculture Forest Service (“US Forest Service”) under the Wood Innovation and Community Wood program. The grant reimburses the Company for continued development of technologies and processes to valorize forest waste for the production of cellulosic ethanol.  AAPK has received $166 thousand from the US Forest Service as reimbursement for actual allowable program costs incurred through December 31, 2023.

California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. Aemetis Advanced Fuels Keyes (“AAFK”) has been awarded an $8.0 million grant to design, construct and commission a grid-connected 1.56 MW photovoltaic microgrid and 1.25MW/2.5MWh Battery Energy Storage System integrated with an artificial intelligence-driven distributed control system (DCS). The grant requires $1.6 million in matching contribution in which the Company has made. AAFK received $4.4 million in grant funds from this program as reimbursement for actual expenditures incurred through  December 31, 2023. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Department of Forestry and Fire Protection Grant. AAPK has been awarded $2 million in matching grants from the CAL FIRE Business and Workforce Development Grant Program (“CAL Fire”) in  May 2022. This CAL Fire grant program reimburses AAPK for costs to design, construct, and commission a 2 million gallon per year cellulosic ethanol facility that will convert conifer biomass from forested regions of the Sierra Nevada into an ultra‐low carbon biofuel derived from 100% forest biomass (“CAL Fire Conversion Program”). AAPK must contribute $5.8 million in cost share contributions to the project to receive grant proceeds. AAPK has received no grant funds from the CAL Fire Conversion Program as reimbursement for actual costs through December 31, 2023.

California Department of Forestry and Fire Protection Grant. AAPK has been awarded $500 thousand in grants from CAL Fire in  May 2022. This CAL Fire grant program reimburses AAPK for costs to advance a new‐to‐the world technology that circumvents current limitations surrounding the extraction of cellulosic sugars by pioneering a novel route for deconstructing woody biomass using ionic liquids (“CAL Fire Extraction Program”). AAPK has received no grant funds from the CAL Fire Extraction Program as reimbursement for actual costs through  December 31, 2023.

U.S. Forest Service Community Wood Grant. Aemetis Advanced Products Riverbank (“AAPR”) has been awarded $642 thousand in matching grants from the U.S Forest Service Wood Innovations Program (“USFS”) in  May 2022. The USFS grant program reimburses AAPR for costs to design, construct, and commission a plant to produce cellulosic ethanol using preliminary research and development in partnership with the Joint Bioenergy Institute (JBEI). USFS grant funds will be used to complete the FEL-3 design phase of the entire process, construct a biomass pretreatment unit to extract sugars at the Aemetis Riverbank site and ferment sugars into ethanol at the Keyes Plant. AAPR must contribute $2.4 million in cost share contributions to the project to receive grant proceeds. AAPK has received no grant funds from the USFS grant program as reimbursement for actual costs through  December 31, 2023.

USDA Biofuel Producer Program Grant. During the second quarter of 2022, a grant in the amount of $14.2 million was received from the USDA’s Biofuel Producer Program, created as part of the CARES Act, to compensate biofuel producers who experienced market losses due to the COVID-19 pandemic. This was recorded in the other expense (income) section of the Consolidated Statements of Operations and Comprehensive Loss.

California Energy Commission Grant for Mechanical Vapor Recompression System. Aemetis Advanced Fuels Keyes (“AAFK”) has been awarded a $6.0 million grant to design, construct and commission a mechanical vapor recompression (MVR) system. The additional evaporation stages will eliminate natural gas consumption and related greenhouse gas emissions in the evaporation portion of the process by installing metering equipment and software to monitor and optimize the plant’s energy consumption. The MVR system will compress vapor to a higher pressure and temperature so that it can be recycled multiple times as steam heat in the evaporation process, which will dramatically reduce natural gas use. The grant requires $5.3 million in matching contributions. AAFK has received no grant funds from this program as reimbursement for actual expenditures incurred through  December 31, 2023. Due to the uncertainty associated with the approval process under the grant program, the Company will recognize future grant proceeds received as a reduction of costs in the period when payment is received.

PG&E A2313 Pipeline Interconnection Recovery Grant. In February 2023, Aemetis Biogas received $5 million from Pacific Gas and Electric (PG&E) as part of qualification under a California Public Utility Commission Biomethane incentive program reimbursing actual Aemetis Biogas costs to interconnect biogas cleanup hub with PG&E utility pipeline. Incentive payment earned after validating renewable natural gas flowed into PG&E interconnect successfully for required period of time.

Pacific Gas and Electric SEM Manufacturer’s Incentive Program. During the fourth quarter of 2022, AAFK received $374 thousand in PG&E SEM Incentive Program reimbursements for installing more efficient beer feed heat exchangers. Third party consultants verified the reduction in natural gas usages from the new heat exchangers to obtain the incentive program funds.

Investment Tax Credits. In the third quarter of 2023, the Company sold to a third-party purchaser certain transferrable Investment Tax Credits (ITCs) that had been generated by the Company from its investments in the California Dairy Renewable Natural Gas segment. The Company accounted for the ITC sale in accordance with ASC 740 by electing the flow-through method. The net value of the tax credits sale of $55.2 million is recorded as an income tax benefit in the income statement for the period ending December 31, 2023. The cash was received in October 2023, and it was used to make certain principal and interest payments on revolving notes and Series A preferred financing.

Income Taxes. The Company recognizes income taxes in accordance with ASC 740 Income Taxes using an asset and liability approach. This approach requires the recognition of taxes payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. The measurement of current and deferred taxes is based on provisions of enacted tax law. ASC 740 provides for recognition of deferred tax assets if the realization of such assets is more likely than not to occur. Otherwise, a valuation allowance is established for the deferred tax assets, which may not be realized. As of December 31, 2023 and 2022, the Company recorded a full valuation allowance against its U.S. federal and state net deferred tax assets due to operating losses incurred since inception. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets were fully offset by a valuation allowance.

The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may have a material impact on the Company’s tax provision in a future period.        

In 2018, the Company adopted certain tax accounting policies related to the new global intangible low-taxed income (“GILTI”) provisions under the Tax Cuts and Jobs Act such that the Company will: (1) account for all GILTI related book-tax differences as period costs and (2) use the Incremental Cash Tax Savings approach in evaluating its valuation allowance assessment related to the GILTI inclusion.

Basic and Diluted Net Income (Loss) per Share.  Basic net loss per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted net loss per share reflects the dilution of common stock equivalents such as options, convertible preferred stock, debt and warrants to the extent the impact is dilutive.  As the Company incurred a net loss for the years ended December 31, 2023 and 2022, potentially dilutive securities have been excluded from the diluted net loss per share computations as their effect would be anti-dilutive.

The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of December 31, 2023 and 2022:

	As of
	December 31, 2023		December 31, 2022
Series B preferred (post split basis)		-		127
Common stock options and warrants		6,056		5,050
Debt with conversion feature at $30 per share of common stock		1,267		1,240
Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation		7,323		6,417

Comprehensive Loss. ASC 220 Comprehensive Income requires that an enterprise report, by major components and as a single total, the change in its net assets from non-owner sources. The Company’s other comprehensive loss and accumulated other comprehensive loss consists solely of cumulative currency translation adjustments resulting from the translation of the financial statements of our India subsidiary. The investment in this subsidiary is considered indefinitely invested overseas, and as a result, deferred income taxes are not recorded related to the currency translation adjustments.

Foreign Currency Translation/Transactions. The Company’s India subsidiary operates in a local currency environment where the local currency is the functional currency used for transactions and accounting. Assets and liabilities of that subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date and the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Income and expense accounts are translated at average exchange rates during the year. Transactional gains and losses from foreign currency transactions are recorded in other (income) loss, net.

Fair Value of Financial Instruments. Financial instruments include accounts receivable, accounts payable, accrued liabilities, current and non-current portion of subordinated debt, notes payable, Series A preferred units, and long-term debt.  Due to the unique terms of our notes payable and long-term debt and the financial condition of the Company, the fair value of the debt is not readily determinable.  The fair value determined using level 3 inputs of all other current financial instruments is estimated to approximate carrying value due to the short-term nature of these instruments.

Share Based Compensation. We recognize share-based compensation expense in accordance with ASC 718 Stock Compensation, which requires the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards over the vesting period, adjusted to reflect only those shares that are expected to vest.

Commitments and Contingencies. We record and/or disclose commitments and contingencies in accordance with ASC 450 Contingencies.  ASC 450 applies to an existing condition, situation, or set of circumstances involving uncertainty as to possible loss that will ultimately be resolved when one or more future events occur or fail to occur.

Convertible Instruments.  The Company evaluates the impacts of convertible instruments based on the underlying conversion features. Convertible Instruments are evaluated for treatment as derivatives that could be bifurcated and recorded separately.  

Debt Issuance Costs. The Company records debt issuance costs related to specific incremental costs directly attributable to issuing, modifying, or extending a debt instrument.  The debt issuance costs are reported as an adjustment to the carrying amount of the debt.  The debt issuance costs are amortized using the interest rate method over the life of the debt instrument.

Troubled Debt Restructuring Accounting. The evaluation for troubled debt restructuring includes assessing whether the creditor granted a concession. To determine this, we calculate the post-restructuring effective interest rate by projecting cash flows on the new terms and calculating a discount rate equal to the carrying amount of pre-restructuring debt and comparing this calculation to the terms of prior amendments.  If the post restructuring effective interest rate is less than the prior terms effective interest rate, we assess this as having been granted a concession.  We then apply troubled debt restructuring accounting to any debt in which the creditor granted a concession.

Debt Modification Accounting. The Company evaluates amendments to its debt in accordance with ASC 540-50 Debt – Modification and Extinguishments for modification and extinguishment accounting.  This evaluation includes comparing the net present value of cash flows of the new debt to the old debt to determine if changes greater than 10 percent occurred.  In instances where the net present value of future cash flows changed more than 10 percent, the Company applies extinguishment accounting and determines the fair value of its debt based on factors available to the Company.

Recently Adopted Accounting Pronouncements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements. 

There were no other recently issued and effective authoritative guidance that are expected to have a material impact on the Company’s Consolidated Financial Statements through the reporting date.

XML

Note 2 - Inventories

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Inventory Disclosure [Text Block]

2. Inventories

Inventories consist of the following:

	As of
	December 31, 2023		December 31, 2022
Raw materials	$	9,907	$	2,971
Work-in-progress		1,682		127
Finished goods		6,702		1,560
Total inventories	$	18,291	$	4,658

As of December 31, 2023 and December 31, 2022, the Company recognized a lower of cost or net realizable value of $58 thousand and $0.1 million respectively, related to inventory.

XML

Note 3 - Property, Plant and Equipment

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

3. Property, Plant and Equipment

Property, plant and equipment consist of the following:

	As of
	December 31, 2023			December 31, 2022
Land	$	7,345		$	7,344
Plant and buildings		136,318			99,116
Furniture and fixtures		2,266			1,831
Machinery and equipment		14,982			15,209
Construction in progress		73,057			88,990
Property held for development		15,431			15,437
Finance lease right of use assets		2,889			3,045
Total gross property, plant & equipment		252,288			230,972
Less accumulated depreciation		(57,180	)		(50,531	)
Total net property, plant & equipment	$	195,108		$	180,441

Interest capitalized in property, plant, and equipment was $5.6 million and $11.1 million for the years ended December 31, 2023 and 2022, respectively.

Construction in progress includes costs for the biogas construction projects (dairy digesters and pipeline), Riverbank projects (sustainable aviation fuel and renewable diesel plant as well as carbon capture characterization well), and energy efficiency projects at the Keyes Plant. Property held for development is the partially completed Goodland Plant which is not ready for operation. Depreciation will begin for each project when the project is finalized and placed into service. Depreciation on the components of property, plant and equipment is calculated using the straight-line method to allocate their depreciable amounts over their estimated useful lives as follows:

	Years
Plant and buildings		20 - 30
Machinery and equipment		5 - 15
Furniture and fixtures		3 - 5

The Company recorded depreciation expense of approximately $6.9 million and $5.5 million respectively, for the years ended December 31, 2023 and 2022.

XML

Note 4 - Debt

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Debt Disclosure [Text Block]

4. Debt

Debt consists of the notes from the Company’s senior lender, Third Eye Capital, acting as Agent for the Purchasers (Third Eye Capital), other working capital lenders and subordinated lenders as follows:

	December 31, 2023		December 31, 2022
Third Eye Capital term notes	$	7,159	$	7,141
Third Eye Capital revolving credit facility		20,922		60,602
Third Eye Capital revolving notes Series B		54,412		-
Third Eye Capital revenue participation term notes		12,011		11,963
Third Eye Capital acquisition term notes		26,655		26,578
Third Eye Capital Fuels Revolving Line		32,511		27,410
Third Eye Capital Carbon Revolving Line		23,486		22,710
Construction Loan		41,024		19,820
Cilion shareholder seller notes payable		7,028		6,821
Subordinated notes		17,625		15,931
EB-5 promissory notes		42,211		41,404
Working capital loans		3,827		-
Term loans on capital expenditures		5,850		5,860
Total debt		294,721		246,240
Less current portion of debt		37,028		49,219
Total long term debt	$	257,693	$	197,021

Third Eye Capital Note Purchase Agreement

On July 6, 2012, Aemetis, Inc. and Aemetis Advanced Fuels Keyes, Inc. (“AAFK”), entered into an Amended and Restated Note Purchase Agreement with Third Eye Capital (the “Note Purchase Agreement”).  Pursuant to the Note Purchase Agreement, Third Eye Capital extended credit in the form of (i) senior secured term loans in an aggregate principal amount of approximately $7.2 million to replace existing notes held by Third Eye Capital (the “Term Notes”); (ii) senior secured revolving loans in an aggregate principal amount of $18.0 million (the “Revolving Credit Facility”); (iii) senior secured term loans in the principal amount of $10.0 million to convert the prior revenue participation agreement to a note (the “Revenue Participation Term Notes”); and (iv) senior secured term loans in an aggregate principal amount of $15.0 million (the “Acquisition Term Notes”) used to fund the cash portion of the acquisition of Cilion, Inc. (the Term Notes, Revolving Credit Facility, Revenue Participation Term Notes and Acquisition Term Notes are referred to herein collectively as the “Original Third Eye Capital Notes”).

On  March 8, 2022, Third Eye Capital agreed to the Limited Waiver and Amendment No. 22 to the Note Purchase Agreement (“Amendment No. 22”) to: (i) provide a waiver for the Blocked Account Agreement Violation in which the Borrowers failed to deliver Blocked Account Control Agreements by  December 31, 2021, (ii) provide for a waiver for the Subordinated Debt Violation, in which the Company made a repayment to a Subordinated Debt lender, and (iii) provide for a waiver of the consolidated unfunded capital expenditures covenant for the quarters through  December 31, 2021.  As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash.

On  May 11, 2022, Third Eye Capital agreed to the Limited Waiver and Amendment No. 23 to the Note Purchase Agreement (“Amendment No. 23”) to: (i) provide a waiver for the Blocked Account Agreement Violation in which the Borrowers failed to deliver Blocked Account Control Agreements by  March 31, 2022, (ii) provide for a waiver of the ratio of note indebtedness covenant for the quarter ended  March 31, 2023 and (iii) provide for a waiver of the unfunded capital expenditures covenant for the quarter ended  March 31, 2022 in which the Company exceeded the $100,000 capital expenditures limit. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million.

On  August 8, 2022, Third Eye Capital agreed to Limited Waiver and Amendment No. 24 to the Note Purchase Agreement ("Amendment No. 24") to: (i) provide that the maturity date of the Third Eye Capital Notes  may be further extended at our election to  April 1, 2024 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that such fee  may be added to the outstanding principal balance of each Note on the effective date of each such extension, and (ii) provide for a waiver for certain covenant defaults. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.3 million in cash (the "Amendment No. 24 Fee").

On March 6, 2023, Third Eye Capital agreed to the Limited Waiver and Amendment No. 25 to the Note Purchase Agreement (“Amendment No. 25”) to: provide a waiver for the Keyes Plant Minimum Quarterly Production violation for the quarter ended March 31, 2023, in which the Borrowers did not meet the 10-million-gallon production requirement. As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash.

On  May 4, 2023, Third Eye Capital agreed to the Limited Waiver and Amendment No. 26 to the Note Purchase Agreement (“Amendment No. 26”) to: provide a waiver for (i) the Keyes Plant Minimum Quarterly Production violation for the quarter ended June 30, 2023, in which the Borrowers did not meet the minimum production of 10 million gallons requirement and (ii) the lender agrees to waive the cash payment of certain fees which are required by the Third Eye Capital Notes and allowed these fees to be added to the outstanding balance of the Revolving Notes. As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million. We evaluated the terms of Amendment No. 26 and the maturity date extension in accordance with ASC 470-50 Debt – Modification and Extinguishment and ASC 470-60 Troubled Debt Restructuring and applied modification accounting treatment.

On  May 16, 2023, Third Eye Capital agreed to the Limited Waiver and Amendment No. 27 to the Note Purchase Agreement (“Amendment No. 27”) to: (i) provide that the maturity date of the Third Eye Capital Notes may be further extended at our election to April 1, 2025 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension, (ii) create a new series of Revolving Notes ("Revolving Notes Series B"), and (iii) provide for the issuance of new Revolving Notes Series B to facilitate the funding. As consideration for such waivers, the borrowers also agreed to pay Third Eye Capital an amendment fee of $0.5 million, by adding the balance to the Revolving Notes Series B and issued a warrant exercisable for 80,000 shares of the Company's common stock with an exercise price of $2.00 per each share issuable under the warrant. We evaluated the terms of Amendment No. 27 in accordance with ASC 470-50 Debt – Modification and Extinguishment and ASC 470-60 Troubled Debt Restructuring and applied modification accounting treatment. 

According to ASC 470-10-45 Debt–Other Presentation Matters, if it is probable that the Company will not be able to cure the default at measurement dates within 12 months, the related debt needs to be classified as current. To assess this guidance, the Company performed ratio and cash flow analysis using its cash flow forecast and debt levels for plant to debt ratio covenant over the next four quarters. The Company forecasted sufficient cash flows to reduce debt levels of Third Eye Capital and meet the operations of the Company. Based on this analysis, the Company believes that it is reasonably possible that through a combination of cash flows from operations, EB-5 investments, and proceeds from the sale of common stock, it will be able to meet the ratio of the note indebtedness covenant during the relevant period. In addition, in February 2024, Aemetis extended the maturity date by one year to April 1, 2025.  As such, the notes are classified as long-term debt as of December 31, 2023.

On  March 25, 2024, the Company and Third Eye Capital Corporation entered into a “Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement” (“Amendment No. 28”) that (i) revised the loan covenant related to Keyes plant note indebtedness to exclude certain draws on Third Eye credit facilities and to exclude the "Redemption Fee," as defined in the Amended and Restated Note Purchase Agreement, and (ii) changed the maximum ratio of Note Indebtedness to the Keyes Plant market value to 120%. As consideration for Amendment No. 28, the Company agreed to pay Third Eye Capital an amendment fee of $0.1 million. We will evaluate the terms of Amendment No. 28 in accordance with ASC 470-50 Debt – Modification and Extinguishment.

On March 6, 2020, we entered into a one-year reserve liquidity facility governed by a promissory note, payable to Third Eye Capital Corporation, in the principal amount of $18 million. On March 14, 2021, Third Eye Capital agreed to increase the amount available under the reserve liquidity facility to $70.0 million. On August 9, 2021, Third Eye Capital agreed to decrease the amount available under the reserve liquidity notes governed by a promissory note to $40.0 million. On March 25, 2024, the Company and Third Eye Capital entered into a "Seventh Amended and Restated Promissory Note" that increased the amount available under the Company's reserve liquidity facility to $85 million and extended the maturity date to  April 1, 2025. Borrowings under the Note are available until maturity on April 1, 2025. Interest on borrowed amounts accrues at a rate of 30% per annum, to be paid monthly in arrears, or 40% if an event of default has occurred and continues. Interest payments due may be capitalized into the principal balance of the Note. The Company will pay a standby fee of 2% per annum of the difference between the aggregate principal outstanding under the Note and the commitment, payable monthly arrears in either cash or stock. The Note also requires the Company to pay a fee in the amount of $0.5 million in connection with a request for an advance on the Note, provided that such fee may be added to the principal amount of the Note. The outstanding principal balance of the indebtedness evidenced by the Note, plus any accrued but unpaid interest and any other sums due thereunder, is due and payable in full on April 1, 2025. In addition, the Company must make payments on the Note with funds received from the closing of certain new debt or equity financing or transactions, as described in the Note. The Note is secured by liens and security interests upon the property and assets of the Company.

Terms of Third Eye Capital Notes

A.	Term Notes. As of December 31, 2023, the Company had $7.2 million in principal and interest outstanding under the Term Notes and $45 thousand unamortized debt issuance costs. The Term Notes accrue interest at 14% per annum. The Term Notes mature on April 1, 2025.
B.	Revolving Credit Facility. The Revolving Credit Facility accrues interest at the prime rate plus 13.75% (22.25% as of December 31, 2023), payable monthly in arrears. Interest was accrued and accrued interest from all notes can be capitalized to the Revolving Credit Facility. The Revolving Credit Facility matures on April 1, 2025. As of December 31, 2023, AAFK had $21.9 million in principal and interest and waiver fees outstanding under the Revolving Credit Facility and $0.9 million unamortized discount issuance costs.
C.	Revolving Notes Series B. The Revolving Notes Series B accrues interest at the prime rate plus 13.75% (22.25% as of December 31, 2023) payable monthly in arrears. The Revolving Notes Series B matures on April 1, 2025. As of December 31, 2023, AAFK had $54.8 million in principal and interest and waiver fees outstanding and $0.4 million unamortized debt issuance costs under the Revolving Notes Series B.
D.	Revenue Participation Term Notes. The Revenue Participation Term Note bears interest at 5% per annum and matures on April 1, 2025. As of December 31, 2023, AAFK had $12.1 million in principal and interest outstanding on the Revenue Participation Term Notes and $81 thousand unamortized discount issuance costs.
E.	Acquisition Term Notes. The Acquisition Term Notes accrue interest at the prime rate plus 10.75% (19.25% per annum as of December 31, 2023 and mature on April 1, 2025. As of December 31, 2023, Aemetis Facility Keyes, Inc. had $26.8 million in principal and interest and redemption fees outstanding and unamortized discount issuances costs of $184 thousand. The outstanding principal balance includes a total of $7.5 million in redemption fees on which interest is not charged.
F.	Reserve Liquidity Notes. The Reserve Liquidity Notes, with available borrowing capacity in the amount of $85.0 million, accrues interest at the rate of 30% per annum and are due and payable upon the earlier of: (i) the closing of new debt or equity financings, (ii) receipt from any sale, merger, debt or equity financing, or (iii) April 1, 2025. We have no borrowings outstanding under the Reserve Liquidity Notes as of December 31, 2023.

The Third Eye Capital Notes contain various covenants, including but not limited to, debt to plant value ratio, minimum production requirements, and restrictions on capital expenditures. The terms of the Notes allow the lender to accelerate the maturity in the event of default that could reasonably be expected to have a material adverse effect, such as any change in the business, operations, or financial condition. The Company has evaluated the likelihood of such an acceleration event and determined such an event to not be probable in the next twelve months.

The Third Eye Capital Notes are secured by first priority liens on all real and personal property of, and assignment of proceeds from all government grants and guarantees from the Company’s North American subsidiaries. The Third Eye Capital Notes all contain cross-collateral and cross-default provisions. McAfee Capital, LLC (“McAfee Capital”), owned by Eric McAfee, the Company’s Chairman and CEO, provided a guaranty of payment and performance secured by all of its Company shares. In addition, Eric McAfee provided a blanket lien on substantially all of his personal assets, and McAfee Capital provided a guarantee in the amount of $8.0 million.

Third Eye Capital Revolving Credit Facility for Fuels and Carbon Lines. On  March 2, 2022, GAFI and Aemetis Carbon Capture, Inc. (“ACCI”) entered into an Amended and Restated Credit Agreement (“Credit Agreement”) with Third Eye Capital , as administrative agent and collateral agent, and the lender party thereto (the “New Credit Facility”). The New Credit Facility provides for two credit facilities with aggregate availability of up to $100 million, consisting of a revolving credit facility with GAFI for up to $50 million (the “Fuels Revolving Line”) and a revolving credit facility with ACCI for up to $50 million (the “Carbon Revolving Line” and together with the Fuels Revolving Line, the “Revolving Lines”). The revolving loans made under the Fuels Revolving Line have a maturity date of  March 1, 2025 and will accrue a rate of interest per annum equal to the greater of (i) the prime rate plus 6.00% and (ii) ten percent (10.0%) (14.50% per annum as of December 31, 2023, and the revolving loans made under the Carbon Revolving Line will have a maturity date of  March 1, 2026 and accrue a rate of interest per annum equal to the greater of (i) the prime rate plus 4.00% and (ii) eight percent (8.0%) (12.50% per annum as of December 31, 2023. The revolving loans made under the Fuels Revolving Line are available for working capital purposes and the revolving loans made under the Carbon Revolving Line are available for projects that reduce, capture, use or sequester carbon with the objective of reducing carbon dioxide emissions. In connection with the New Credit Facility, the Company agreed to issue to the lender under the New Credit Facility: (i) warrants entitling the lender to purchase 50,000 shares of common stock of the Company at an exercise price equal to $10.20 per share, exercisable for a five-year period from March 2, 2022; and (ii) warrants entitling holders thereof to purchase 250,000 shares of common stock of the Company, at an exercise price equal to $20.00 per share, exercisable for a ten-year period from March 2, 2022. In addition, under the Fuels Revolving Line, we issued 100,000 shares of common stock to existing note holders under the GAFI note purchase agreement. The shares were accounted at fair value and are being amortized over the life of the Fuels Revolving Line. Upon closing of the New Credit Facility, the Company drew on the revolving lines to repay $16.0 million on the higher interest rate AAFK Revolving Credit Facility, $6.1 million in property taxes, and to fund the capital projects and working capital projects.

As of  December 31, 2023., GAFI had $33.9 million in principal and interest outstanding and $1.3 million unamortized debt issuance costs. As of  December 31, 2023, ACCI had $25.2 million in principal and interest outstanding and $1.7 million in unamortized debt issuance costs.

Cilion shareholder seller notes payable.  In connection with the Company’s merger with Cilion, Inc., (Cilion) on July 6, 2012, the Company issued $5.0 million in notes payable to Cilion shareholders (Cilion Notes) as merger compensation, subordinated to the Third Eye Capital Notes.  The Cilion Notes bear interest at 3% per annum and are due and payable after the Third Eye Capital Notes have been paid in full.  As of December 31, 2023, Aemetis Facility Keyes, Inc. had $7.0 million in principal and interest outstanding on the Cilion Notes.

Subordinated Notes. On January 6 and January 9, 2012, AAFK entered into Note and Warrant Purchase Agreements with two accredited investors pursuant to which it issued $0.9 million and $2.5 million in original notes to the investors (Subordinated Notes). The Subordinated Notes mature every six months. Upon maturity, the Subordinated Notes are renewable automatically at the Company's election for six month periods with a fee of 10% added to the balance outstanding plus issuance of warrants exercisable at $0.01 with a two-year term. Interest accrues at 10% per annum and is due at maturity. Neither AAFK nor Aemetis may make any principal payments under the Subordinated Notes until all loans made by Third Eye Capital to AAFK are paid in full.

On  January 1, 2023, the maturity on two Subordinated Notes was extended until the earlier of (i)  June 30, 2023; (ii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A $90 thousand and $250 thousand cash extension fee was paid by adding the fee to the balance of the new Subordinated Notes and 113 thousand common stock warrants were granted with a term of two years and an exercise price of $0.01 per share. On  July 1, 2023, the maturity on two Subordinated Notes was extended until the earlier of (i)  December 31, 2023; (ii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A $90 thousand and $250 thousand cash extension fee was paid by adding the fee to the balance of the new Subordinated Notes and 113 thousand common stock warrants were granted with a term of two years and an exercise price of $0.01 per share. The Company evaluated the  January 1, 2023 and  July 1 2023 amendments and the refinancing terms of the notes and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment.

On  January 1, 2024, the maturity on two Subordinated Notes was extended until the earlier of (i)  June 30, 2024; (ii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A $90 thousand and $250 thousand cash extension fee was paid by adding the fee to the balance of the new Subordinated Notes and 113 thousand common stock warrants were granted with a term of two years and an exercise price of $0.01 per share.

At December 31, 2023 and 2022, the Company had, in aggregate, the amount of $17.6 million and $15.9 million in principal and interest outstanding, respectively, under the Subordinated Notes.

EB-5 promissory notes.  EB-5 is a U.S. government program authorized by the Immigration and Nationality Act designed to foster employment-based visa preference for immigrant investors to encourage the flow of capital into the U.S. economy and to promote employment of U.S. workers. The Company entered into a Note Purchase Agreement dated March 4, 2011 (as further amended on January 19, 2012 and July 24, 2012) with Advanced BioEnergy, LP, a California limited partnership authorized as a Regional Center to receive EB-5 investments, for the issuance of up to 72 subordinated convertible promissory notes (the “EB-5 Notes”) bearing interest at 2-3%. Each note was issued in the principal amount of $0.5 million and due and payable four years from the date of each note, for a total aggregate principal amount of up to $36.0 million (the “EB-5 Phase I funding”). The original maturity date on the promissory notes can be extended automatically for a one or two-year period initially and is eligible for further one-year automatic extensions as long as there is no notice of non-extension from investors and the investors’ immigration process is in progress. On February 27, 2019, Advanced BioEnergy, LP, and the Company entered into an Amendment to the EB-5 Notes which restated the original maturity date on the promissory notes with automatic six-month extensions as long as the investors’ immigration processes are in progress. Except for six early investor EB-5 Notes, the Company was granted 12 months from the date of the completion of immigration process to redeem these EB-5 Notes. Given the COVID-19 situation and processing delays for immigration process, Advanced BioEnergy, LP extended the maturity dates for debt repayment based on their projected processing timings as long as the investors don’t give notice of withdrawal or I-829 gets approved.  Accordingly, the notes have been recognized as long-term debt while investor notes who obtained green card approval have been classified as current debt. The EB-5 Notes are convertible after three years at a conversion price of $30 per share.

Advanced BioEnergy, LP arranges investments with foreign investors, who each make loans to the Keyes Plant in increments of $0.5 million. The Company has sold an aggregate principal amount of $36.0 million of EB-5 Notes under the EB-5 Phase I funding since 2012 to the date of this filing. As of December 31, 2023, $35.5 million has been released from the escrow amount to the Company, with $0.5 million remaining to be funded to escrow.  As of December 31, 2023, $37.9 million in principal and interest was outstanding on the EB-5 Notes sold under the EB-5 Phase I funding.

On October 16, 2016, the Company launched its EB-5 Phase II funding, with plans to issue $50.0 million in additional EB-5 Notes on substantially similar terms and conditions as those issued under the Company’s EB-5 Phase I funding, to refinance indebtedness and capital expenditures of Aemetis, Inc. and GAFI (the “EB-5 Phase II funding”). On November 21, 2019, the minimum investment was raised from $0.5 million per investor to $0.9 million per investor. The Company entered into a Note Purchase Agreement dated with Advanced BioEnergy II, LP, a California limited partnership authorized as a Regional Center to receive EB-5 Phase II funding investments, for the issuance of up to 100 EB-5 Notes bearing interest at 3%. On May 1, 2020 Supplement No. 3 amended the offering documents and lowered the total eligible new EB-5 Phase II funding investors to 60. Eight EB-5 investors have funded at the $0.5 million per investor amount, while 52 new EB-5 Phase II funding investors are eligible at the new $0.9 million per investor amount under the current offering. Job creation studies show additional investors may be possible to increase the total offering amount in the future. Each new note will be issued in the principal amount of $0.9 million and due and payable five years from the date of each note, for a total aggregate principal amount of up to $50.8 million.

The Company has sold an aggregate principal amount of $4.0 million of EB-5 Notes under the EB-5 Phase II funding since 2016 to the date of this filing. As of December 31, 2023, $4.0 million has been released from escrow to the Company and $46.8 million remains to be funded to escrow. As of December 31, 2023, $4.3 million was outstanding on the EB-5 Notes under the EB-5 Phase II funding.

Working capital loans. On July 26, 2022, the Company entered into a short-term loan with Secunderabad Oils Limited in an amount not to exceed $1.88 million. On August 1, 2022, the Company entered into a short-term loan with Leo Edibles & Fats Limited in an amount not to exceed $1.27 million. The loans bears interest at 18% and are payable monthly.  The loans are repayable on demand by the lender or within one year from the date of issuance. The loans are renewable, and the Company can obtain the loan to the extent they paid back.  As of December 31, 2023 and 2022, the Company had $3.8 million and none, respectively, under these agreements.

Secured loans.  In the first quarter of 2023, the Company entered into several short-term loans with IndusInd Bank and HDFC Bank. The loans are secured by fixed deposits made by the Company. The loans bear interest at rates that range from 6% to 8%.  The loans mature between November 15, 2023 and May 3, 2024. As of December 31, 2023, and December 31, 2022, the Company had no balance, respectively, under these agreements.

Aemetis Biogas 1 LLC Construction and Term Loans. On  October 4, 2022, the Company entered into a Construction Loan Agreement (“AB1 Construction Loan”) with Greater Nevada Credit Union (“GNCU”). Pursuant to the AB1 Construction Loan, the lender made available an aggregate principal of $25 million, secured by all personal property collateral and real property collateral of Aemetis Biogas 1 LLC. The AB1 Construction Loan contained certain financial covenants to be measured as of the last day of each fiscal year end, and annually for the term of the loan. Effective as of December 22, 2023, the AB1 Construction Loan was refinanced and replaced with a term loan ("AB1 Term Loan"). The AB1 Term Loan is secured by all personal property collateral and real property collateral of Aemetis Biogas 1 LLC. It bears interest at a rate of 9.25% per annum, to be adjusted every five years thereafter to equal the five-year Treasury Constant Maturity Rate, as published by the Board of Governors of the Federal Reserve System as of the adjustment date, plus 5.00% or (ii) the index floor. Other material terms of the loan include: (i) payments of interest only to be paid in monthly installments beginning January 22, 2024, (ii) payments of equal combined monthly installments of principal and interest beginning on January 22, 2025, and (iii) a maturity date of December 22, 2042, at which time the entire unpaid principal amount, together with accrued and unpaid interest thereon, shall become due and payable. AB1 Term Loan contains certain financial covenants to be measured as of the last day of each fiscal year beginning fiscal year end 2025, and annually for the term of the loan. The AB1 Term Loan also contains other affirmative and negative covenants, representations and warranties and events of default customary for loan agreements of this nature. As of December 31, 2023 and December 31, 2022, the Company had $25.1 million and none, respectively, outstanding under the AB1 Term Loan.

Aemetis Biogas 2 Construction Loan. On July 28,  2023, the Company entered into a second Construction and Term Loan Agreement ( “AB2 Loan") with Magnolia Bank, Incorporated. Pursuant to the AB2 Loan, the lender has made available an aggregate principal amount  not to exceed $25 million. The loan is secured by all personal property collateral and real property collateral of Aemetis Biogas 2 LLC. The loan bears interest at a rate of 8.75% per annum, to be adjusted every five years thereafter to equal the five-year Treasury Constant Maturity Rate, as published by the Board of Governors of the Federal Reserve System as of the adjustment date, plus 5.00%. Other material terms of the AB2 Loan include: (i) payments of interest only to be paid in monthly installments beginning August 15, 2023, (ii) payments of equal combined monthly installments of principal and interest beginning on August 15, 2025, and (iii) a maturity date of July 28, 2043, at which time the entire unpaid principal amount, together with accrued and unpaid interest thereon, shall become due and payable. The AB2 Loan contains certain financial covenants to be measured as of the last day of each fiscal year beginning fiscal year end  2025, and annually for the term of the loan. The AB2 Loan also contains other affirmative and negative covenants, representations and warranties and events of default customary for loan agreements of this nature. As of December 31, 2023 and December 31, 2022, the Company had $16.8 million and none, respectively, outstanding and unamortized discount issuances costs of   $0.8 million and none, respectively, under the AB2 Loan. 

Financing Agreement for capital expenditures.  The Company entered into an agreement with Mitsubishi Chemical America, Inc. (“Mitsubishi”) to purchase ZEBREX^TM membrane dehydration equipment to conserve energy and improve operating efficiencies at the Keyes Plant. The Company also entered into a financing agreement with Mitsubishi for $5.7 million for this equipment. Payments pursuant to the financing transaction will commence after the installation date and interest will be charged based on the certain performance metrics after operation of the equipment. After an initial start-up process, process bottlenecks were encountered, and operations were suspended pending further examination and optimization. 

We recorded the asset in property, plant and equipment, net and recorded the related liability of $2.0 million in short term borrowings and $3.8 million in other long-term debt, respectively as of  December 31, 2023.

Debt repayments for the Company’s loan obligations follow:

Twelve months ended December 31,	Debt Repayments
2024	$	37,028
2025		181,464
2026		37,912
2027		4,128
2028		2,108
There after		37,545
Total debt		300,185
Debt issuance costs		(5,464	)
Total debt, net of debt issuance costs	$	294,721

XML

Note 5 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

5. Commitments and Contingencies

Leases

The Company is a party to operating leases for the Company's corporate office in Cupertino, modular offices, and laboratory facilities.  We have also entered into several finance leases for mobile equipment and for the Riverbank Industrial Complex.  These finance leases have a purchase option at the end of the term that we are reasonably certain we will exercise, so the leases are classified as finance leases. All of our leases have remaining term of one year to 13 years. We made an accounting policy election to keep leases with an initial term of 12 months or less off the balance sheet. We will recognize those lease payments in the Consolidated Statements of Operations as we incur the expenses.

The Company evaluates leases in accordance with ASC 842 – Lease Accounting. When discount rates implicit in leases cannot be readily determined, we use the applicable incremental borrowing rate at lease commencement to perform lease classification tests on lease components and to measure lease liabilities and right of use (ROU) assets. The incremental borrowing rate used by the Company is based on weighted average baseline rates commensurate with the Company’s secured borrowing rate, over a similar term. At each reporting period when there is a new lease initiated, the rates established for that quarter are used.

The components of lease expense and sublease income is as follows:

	Twelve Months Ended December 31,
	2023		2022
Operating lease cost
Operating lease expense	$	722	$	673
Short term lease expense		223		176
Variable lease expense		93		91
Total operating lease cost	$	1,038	$	940
Finance lease cost
Amortization of right-of-use assets	$	121	$	179
Interest on lease liabilities		340		310
Total finance lease cost	$	461	$	489

Cash paid for amounts included in the measurement of lease liabilities:

	Twelve Months Ended December 31,
	2023		2022
Operating cash flows used in operating leases	$	668	$	766
Operating cash flows used in finance leases		340		310
Financing cash flows used in finance leases		428		481

Supplemental non-cash flow information related to the operating ROU asset and lease liabilities for the year ended December 31, 2023 and 2022:

	Twelve Months Ended December 31,
	2023			2022
Operating leases
Accretion of the lease liability	$	249		$	340
Amortization of right-of-use assets		293			333
Weighted Average Remaining Lease Term
Operating leases (in years)		4.2			5.2
Finance leases (in years)		13.0			14.0
Weighted Average Discount Rate
Operating leases		14.1	%		14.2	%
Finance leases		13.2	%		13.2	%

Supplemental balance sheet information related to leases was as follows:

	As of
	December 31, 2023			December 31, 2022
Operating leases
Operating lease right-of-use assets	$	2,056		$	2,449
Current portion of operating lease liability		406			338
Long term operating lease liability		1,783			2,189
Total operating lease liabilities		2,189			2,527
Finance leases
Property and equipment, at cost	$	2,889		$	3,045
Accumulated depreciation		(228	)		(112	)
Property and equipment, net		2,661			2,933
Other current liability		30			71
Other long term liabilities		2,687			2,911
Total finance lease liabilities		2,717			2,982

Maturities of operating lease liabilities were as follows:

Year Ended December 31,	Operating leases			Finance leases
2024	$	682		$	179
2025		681			168
2026		626			145
2027		645			145
2028		272			145
There after		-			10,105
Total lease payments		2,906			10,887
Less imputed interest		(717	)		(8,170	)
Total lease liability	$	2,189		$	2,717

The Company acts as sublessor in certain leasing arrangements, primarily related to land and buildings.  Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Sublease income and head lease expense for these transactions are recognized on net basis on the consolidated financial statements. Sublease income is recorded in the other operating income section of the Consolidated Statements of Operations and Comprehensive Loss.

The components of lease income for the years ended  December 31, 2023 and 2022 were as follows:

	December 31, 2023		December 31, 2022
Lease income	$	2,075	$	1,255

Future lease commitments to be received by the Company as of  December 31, 2023, are as follows:

Year ended December 31,
2024	$	948
2025		773
2026		562
2027		508
2028		508
There after		635
Total future lease commitments	$	3,934

Legal Proceedings

On  August 31, 2016, the Company filed a lawsuit in Santa Clara County Superior Court against defendant EdenIQ, Inc. (“EdenIQ”). The lawsuit was based on EdenIQ’s wrongful termination of a merger agreement that would have effectuated the merger of EdenIQ into a new entity that would be primarily owned by Aemetis. On  July 24, 2019, the court awarded EdenIQ a portion of the fees and costs it had sought in the amount of approximately $6.2 million and the Company recorded these fees based on the court order. On  May 6, 2022 the parties settled the dispute for $4.8 million by entering into a settlement agreement. The settlement was paid and a gain on litigation of $1.4 million was recognized on the income statement in the second quarter of 2022.

The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of these matters is not presently determinable, it is in the opinion of management that the resolution of outstanding claims will not have a material adverse effect on the financial position or results of operations of the Company. Due to the uncertainties in the litigation and settlement process, it is at least reasonably possible that management's view of outcomes will change in the near term.

XML

Note 6 - Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Variable Interest Entity Disclosure [Text Block]

6. Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity

On December 20, 2018, ABGL entered into a Series A Preferred Unit Purchase Agreement for the sale of Series A Preferred Units to Protair-X Americas, Inc. (Purchaser), with Third Eye Capital acting as an agent for the sale of 6,000,000 preferred units of ABGL.

ABGL is authorized to issue 11,000,000 common units, and up to 6,000,000 convertible, redeemable, secured, preferred membership units (the “Series A Preferred Units”). ABGL issued 6,000,000 common units to the Company at $5.00 per common unit for a total of $30,000,000 in funding. Additionally, 5,000,000 common units of ABGL are held in reserve as potential conversion units issuable to the Purchaser upon certain triggering events discussed below.

Prior to August 8, 2022, the Preferred Unit Purchase Agreement included (i) preference payments of $0.50 per unit on the outstanding Series A Preferred Units commencing on the second anniversary, with any outstanding preference payments subject to interest at 10 percent per annum (ii) conversion rights for up to 1,200,000 common units or up to maximum number of 5,000,000 common units (also at a one Series A Preferred Unit to one common unit basis) if certain triggering events occur, (iii) one board seat of the three available to be elected by Series A Preferred Unit holders, (iv) mandatory redemption value at $15 per unit payable at an amount equal to 75% of free cash flow generated by ABGL, up to $90 million in the aggregate (if all units are issued), (v) full redemption of the units on the sixth anniversary, (vi) minimum cash flow requirements from each digester, and (vii) $0.9 million paid as fees to the Agent from the proceeds. Until paid, the obligations of ABGL under the Preferred Unit Agreement are secured by the assets of ABGL in an amount not to exceed the sum of (i) $30,000,000, plus (ii) all interest, fees, charges, expenses, reimbursement obligations and indemnification obligations of ABGL.

Prior to August 8, 2022, triggering events would be deemed to occur upon ABGL’s failure to redeem units, comply with covenants, any other defaults or cross defaults, or to perform representations or warranties. Upon a triggering event: (i) the obligation of the Purchaser to purchase additional Series A Preferred Units is terminated, (ii) cash flow payments for redemption payments increases from 75% to 100% of free cash flows, and (iii) total number of common units into which preferred units may be converted increases from 1,200,000 common units to 5,000,000 common units on a one for one basis. As of December 31, 2023, ABGL has not generated minimum quarterly operating cash flows by operating the dairies. As a result of the violation of this covenant, free cash flows, when they occur, may be applied for redemption payments at the increased rate of 100% instead of the initial rate of 75% of free cash flows.

From inception of the agreement to August 8, 2022, ABGL issued 3,200,000 Series A Preferred Units in the first tranche for a value of $16.0 million and also issued 2,800,000 of Series A Preferred Units in a second tranche for a value of $14.0 million, reduced by a redemption of 20,000 Series A Preferred Units for $0.3 million.

On  August 8th, 2022, ABGL entered into a Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Amendment") providing for: (i) a waiver of certain covenants prohibiting the internal reorganization of ABGL subsidiaries and the incurrence of indebtedness by ABGL and its subsidiaries pursuant to a USDA loan; (ii) a waiver of certain operational defaults under the PUPA; and (iii) an amendment which (a) requires ABGL to redeem all of the outstanding Series A Preferred Units by  December 31, 2022, (the “Final Redemption Date”) for $116 million; and (b) provides ABGL the right to redeem all of the outstanding Series A Preferred Units by  September 30, 2022, for $106 million. The PUPA Amendment further provides the failure to redeem the Series A Preferred Units by the Final Redemption Date would constitute a triggering event requiring ABGL to enter into a credit agreement with Protair and Third Eye Capital effective as of  January 1, 2023. We evaluated the terms of the PUPA Amendment and applied extinguishment accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment and recorded a loss on extinguishment of $49.4 million.

On  January 1, 2023, ABGL entered into the Second Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Second Amendment") providing for: (i) a waiver for not redeeming all Series A Preferred Units by  December 31, 2022, and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by  May 31, 2023, for an aggregate redemption price of $125 million. The PUPA Second Amendment further provides that failure to redeem the Series A Preferred Units by the redemption date, ABGL is required to enter into a credit agreement with Protair and Third Eye Capital effective as of  June 1, 2023 and maturing on May 31, 2024, in substantially the form attached to the PUPA Second Amendment. We determined that Third Eye Capital provided a concession to redeem the preferred shares at lower effective borrowing rate than the credit agreement interest rate or prior amendment rate. In accordance with the provisions of ASC 470-60 Troubled Debt Restructuring, we applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. In addition, given that the Company could turn the agreement into a credit agreement, the Company began accreting the redemption price from an initial carrying value at December 31, 2022, of $116.0 million to $159.0 million over the seventeen months ending May 31, 2024. 

On May 31, 2023, ABGL entered into the Third Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Third Amendment") providing: (i) a waiver to ABGL for not redeeming all Series A Preferred Units by May 31, 2023 and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by August 31, 2023, for an aggregate redemption price of $135 million. The PUPA Third Amendment further provides that failure to redeem the Series A Preferred Units by the redemption date, ABGL is required to enter into a credit agreement with Protair and Third Eye Capital effective, as of September 1, 2023 and maturing on August 31, 2024, in substantially the form attached to the PUPA Third Amendment. We determined that Third Eye Capital provided a concession to redeem the preferred shares at lower effective borrowing rate than the credit agreement interest rate or prior amendment rate. In accordance with the provisions of ASC 470-60 Troubled Debt Restructuring, we applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. In addition, given that the Company could turn the agreement into a credit agreement, the Company is accreting these tranches from a carrying value at May 31, 2023 of $127.2 million to $171.7 million over the fifteen months ending August 31, 2024. . 

On October 6, 2023, ABGL partially repaid $30 million of Series A Preferred Units using the partial proceeds from tax credit sale of $55.2 million.

On November 8, 2023, ABGL entered into the Fourth Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Fourth Amendment") providing: (i) a waiver to ABGL for not redeeming all Series A Preferred Units by August 31, 2023 and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by December 31, 2023, for an aggregate redemption price of $108 million which included $5.5 million closing fee. The PUPA fourth Amendment further provides that failure to redeem the Series A Preferred Units by the redemption date, ABGL is required to enter into a credit agreement with Protair and Third Eye Capital effective, as of January 1, 2024 and maturing on December 31, 2024, in substantially the form attached to the PUPA fourth Amendment. We determined that Third Eye Capital provided a concession to redeem the preferred shares at lower effective borrowing rate than the credit agreement interest rate or prior amendment rate. In accordance with the provisions of ASC 470-60 Troubled Debt Restructuring, we applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. In addition, given that the Company could turn the agreement into a credit agreement, the Company began accreting the redemption price from a carrying value at November 8, 2023 of $110.6 million to $130.0 million over the period ending December 31, 2024.

On February 8, 2024, ABGL entered into the Fifth Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Fourth Amendment") providing: (i) a waiver to ABGL for not redeeming all Series A Preferred Units by December 31, 2023 and (ii) the right by ABGL to redeem all of the outstanding Series A Preferred Units by April 30, 2024, for an aggregate redemption price of $111.0 million which includes a closing fee of $5.5 million. The PUPA Fifth Amendment further provides that if ABGL does not redeem the Series A Preferred Units by the redemption date, ABGL will enter into a credit agreement with Protair and Third Eye Capital effective as of May 1, 2024 and maturing April 30, 2025, in substantially the form attached to the PUPA fifth Amendment. We will evaluate the PUPA fifth amendment according to ASC 470.  Based on the terms of the PUPA Fifth Amendment, the deferred PUPA redemption balance is classified as long term liability as of December 31, 2023. 

The Company recorded carrying value of Series A Preferred Unit liabilities as long-term liabilities of $113.2 million and $116.0 million as of December 31, 2023 and 2022, respectively.

Variable interest entity assessment

After consideration of ABGL’s operations and the above agreement, we concluded that ABGL did not have enough equity to finance its activities without additional subordinated financial support. ABGL is capitalized with Series A Preferred Units that are recorded as liabilities under U.S. GAAP. Hence, we concluded that ABGL is a VIE. Through the Company's ownership interest in all of the outstanding common stock, its current ability to control the board of directors, the management fee paid to Aemetis and control of subordinated financing decisions, Aemetis has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company. Total assets, before intercompany eliminations, of ABGL as of December 31, 2023 were $90.3 million which serve as collateral for the Series A Preferred Units.

XML

Note 7 - Stockholders' Equity

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Equity [Text Block]

7. Stockholders’ Equity

Common Stock

The Company is authorized to issue 80 million shares of common stock, $0.001 par value per share.  

Convertible Preferred Stock

The company is authorized to issue up to 65 million shares of preferred stock, $0.001 par value per share.

Effective as of December 12, 2023, the Company converted all of its outstanding Preferred Stock into by issuing one share of common stock for each 10 shares of preferred stock outstanding. As a result, as of December 31, 2023, the Company has no outstanding shares of preferred stock.  The following table shows the number of preferred shares authorized and outstanding:

			Shares Issued and
	Authorized		Outstanding December 31,
	Shares		2023		2022
Series B preferred stock		7,235		-		1,270
Undesignated		57,765		-		-
		65,000		-		1,270

XML

Note 8 - Warrants to Purchase Common Stocks

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Outstanding Warrants [Text Block]

8. Warrants to Purchase Common Stock

During 2023, the Company granted the following warrants:

●  A warrant issued to a vendor exercisable for the purchase of 100,000 shares at an exercise price of $2.50 per share with a two-year term. This warrant was exercised in 2023 using cashless exercise resulting in the issuance of 62,293 shares of common stock.

●  Warrants issued to the Company's senior lender exercisable for 160,000 shares of the Company's common stock at an exercise price of $2.00 per share with a five-year term. These warrants are outstanding as of December 31, 2023.

●  In connection with a credit line increase, a warrant issued to the Company's senior lender was automatically modified to increase the number of shares that may be purchased by 25,000 shares.  The warrant has an exercise price of $10.20 per share and a remaining term of about 3 years.

●  Warrants issued to subordinated lenders exercisable for 226,666 at an exercise price of $0.01 per share and a term of two years.  These warrants were exercised in 2023 with a combination of cashless exercise and cash payments.

The following table shows the weighted average fair value calculations for warrants granted based on the listed weighted average assumptions:

Description	For the year ended December 31,
	2023			2022
Dividend-yield		0	%		0	%
Risk-free interest rate		3.85	%		1.75	%
Expected volatility		117.90	%		151.41	%
Expected life (years)		5			3
Exercise price per share	$	1.62		$	10.47
Market value per share on grant date	$	4.13		$	11.29
Fair value per share on grant date	$	3.92		$	9.68

A summary of historical warrant activity for the years ended  December 31, 2023 and 2022 follows:

	Warrants Outstanding & Exercisable			Weighted - Average Exercise Price		Average Remaining Term in Years
Outstanding December 31, 2021		55		$	2.59		4.95
Granted		527			10.47
Exercised		(227	)		0.01
Outstanding December 31, 2022		355		$	15.92		7.48
Granted		511			1.62
Exercised		(336	)		0.83
Outstanding December 31, 2023		530		$	11.70		5.77

All of the above outstanding warrants are vested and exercisable as of December 31, 2023. 

XML

Note 9 - Stock-based Compensation

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

9. Stock-Based Compensation

2019 Stock Plan

On August 26, 2021, the stockholders of the Company approved the Aemetis, Inc. Amended and Restated 2019 Stock Plan (the “2019 Stock Plan”). This plan allows our Board or delegated Board committee to grant Incentive Stock Options, Non-Statutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, Performance Shares, and other stock or cash awards to employees, Directors, and consultants. The 2019 Stock Plan has a term of 10 years from the original version adoption date of April 25, 2019, and supersedes all prior stockholder approved plans with respect to new grants. Options issued under prior plans and the prior version of the 2019 stock plan remain outstanding and exercisable according to their terms. The 2019 Stock Plan authorizes a total pool of 4,558,621 shares as of July 1, 2021, including all outstanding option grants under all plans and all shares then available for issuance under the 2019 Stock Plan as of that date. Shares within this pool that expire or terminate unused become available for a subsequent grant. In addition, the number of shares available for issuance automatically increases on January 1 of each year by an amount equal to 4% of the sum of total common stock outstanding on January 1 and 2,541,823 shares.

Pursuant to the 2019 Stock Plan, the company issued stock options to employees exercisable for 1.3 million and 1.3 million shares during the years ended December 31, 2023 and 2022, each with a 10 year term and 3 year vesting schedule. The Company issued restricted stock award grants with immediate vesting to directors for 244 thousand shares and 89 thousand shares during the years ended December 31, 2023 and 2022, respectively, with a weighted average fair value on date of grant of $3.75 and $10.92 per share, respectively for those same time periods.

The following table summarizes activity under the 2019 Stock Plan during 2022 and 2023:

	Shares Available for Grant			Number of Shares Outstanding			Weighted-Average Exercise Price
Balance as of December 31, 2021		42			3,763		$	2.29
Authorized		1,338			-			-
Options Granted		(1,307	)		1,307			10.97
RSAs Granted		(89	)		-			-
Exercised		-			(295	)		0.93
Forfeited/expired		81			(81	)		11.63
Balance as of December 31, 2022		65			4,694		$	4.63
Authorized		1,644			-			-
Options Granted		(1,278	)		1,278			3.60
RSAs Granted		(244	)		-			-
Exercised		-			(177	)		1.83
Forfeited/expired		269			(269	)		5.93
Balance as of December 31, 2023		456			5,526		$	4.42

The following table summarizes vested and unvested option awards outstanding as of December 31, 2023 and 2022:

	Number of Shares		Weighted Average Exercise Price		Remaining Contractual Term (In Years)		Aggregate Intrinsic Value1
2023
Vested and Exercisable		3,986	$	3.58		6.47	$	11,695
Unvested		1,540		6.55		8.67		1,621
Total		5,526	$	4.42		7.04	$	13,316
2022
Vested and Exercisable		3,170	$	2.46		6.98	$	7,419
Unvested		1,524		9.13		8.81		647
Total		4,694	$	4.63		7.58	$	8,066

(1)Intrinsic value based on the $5.24 and $3.96 closing price of Aemetis, Inc. common stock on December 31, 2023 and 2022 respectively, as reported on the NASDAQ Exchange.

Inducement Equity Plan Options

In March 2016, the Board of Directors of the Company approved an Inducement Equity Plan authorizing the issuance of 100,000 non-statutory stock options to purchase common stock. As of December 31, 2023, no options were outstanding under the Inducement Equity Plan. This plan was not approved by stockholders so is available only for grants to prospective employees.

Stock-based Compensation Expense

Stock-based compensation is accounted for in accordance with ASC 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors, and consultants based on estimated fair value on the grant date. We estimate the fair value using the Black-Scholes option pricing model and recognize that fair value as an expense over the vesting period of each grant using the straight-line method. We only record compensation cost for vested options. The Black-Scholes valuation model for stock based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, expected dividends, and expected forfeitures. We use the simplified calculation of expected term described in SEC Staff Accounting Bulletin No. 107, Share-Based Payment. Volatility is based on an average of the historical volatility of Aemetis, Inc. common stock during the period of time preceding the date of option issuance that matches the term of the option grant. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the treasury maturity term corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the small number of plan participants. To the extent actual forfeitures occur, the difference is recorded as an adjustment in the scheduled expense during the period of the forfeiture.

The weighted average fair value for options granted during the years ended 2023 and  2022 are based on the following assumptions:

Description	For the year ended December 31,
	2023			2022
Dividend-yield		0	%		0	%
Risk-free interest rate		3.86	%		2.03	%
Expected volatility		124.62	%		117.21	%
Expected life (years)		7.00			7.00
Market value per share on grant date	$	3.60		$	10.97
Fair value per share on grant date	$	3.29		$	9.71

For the years ended December 31, 2023 and 2022, the Company recorded stock-based compensation expense in the amount of $7.7 million, and $6.4 million, respectively. As of December 31, 2023, the Company had $7.3 million of total unrecognized compensation expense for employees that the Company will amortize over the remaining vesting period of each individual option grant.  The outstanding unvested options have a remaining weighted average vesting term of 1.5 years.

XML

Note 10 - Agreements

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Collaborative Arrangement Disclosure [Text Block]

10. Agreements

Working Capital Arrangement. Pursuant to a Corn Procurement and Working Capital Agreement with J.D. Heiskell, the Company procures whole yellow corn from J.D. Heiskell. The Company has the ability to obtain grain from other sources subject to certain conditions; however, in the past all the Company’s grain purchases have been from J.D. Heiskell. Title and risk of loss of the corn pass to the Company when the corn is deposited into the Keyes Plant weigh bin.  Pursuant to a separate agreement entered in May 2023, J.D. Heiskell also purchases all of our ethanol and other products under separate agreements and sells them to customers designated by us.  We have designated Murex to purchase ethanol and WDG and corn oil are sold to A.L Gilbert. The Company’s relationships with J.D. Heiskell, and A.L. Gilbert are well established, and the Company believes that the relationships are beneficial to all parties involved in utilizing the distribution logistics, reaching out to widespread customer base, managing inventory, and providing working capital relationships.

As of December 31, 2023 and 2022, Aemetis made prepayments to J.D. Heiskell of none and $2.4 million, respectively. The J.D. Heiskell purchases and sales activity associated with the Purchasing Agreement, Corn Procurement and Working Capital Agreements during the years ended December 31, 2023 and 2022 were as follows:

	As of and for the twelve months ended December 31,
	2023		2022
Ethanol sales	$	77,359	$	-
Wet distiller's grains sales		21,963		50,930
CDO and CDS sales		3,296		10,168
Corn purchases		83,128		191,401
Accounts receivable		1,073		-
Accounts payable		1,207		27

Ethanol and Wet Distillers Grains Marketing Arrangement.

The Company entered into a Fuel Ethanol Purchase and Sale Agreement with Murex, which matures on October 31, 2023, with automatic one-year renewals thereafter. On May 30, 2023 the Company entered into Amendment No. 1 to the Fuel Ethanol Purchase and Sale Agreement that provides (i) the Company temporarily suspend the agreement for the duration of the Company's Working Capital Agreement with J.D. Heiskell, and (ii) the initial term shall be automatically renewed beginning on October 1, 2023 and ending on March 31, 2025. The Company also entered into a Wet Distillers Grains Marketing Agreement with A.L. Gilbert, with a maturity date of  December 31, 2024, with automatic one-year renewals thereafter.

For the years ended December 31, 2023 and 2022, the Company expensed marketing costs of $1.5 million and $2.9 million, respectively, under the terms of both the Ethanol Marketing Agreement and the Wet Distillers Grains Marketing Agreement and are presented in Selling, General, and Administration expense.

For the years ended December 31, 2023 and 2022, the Company expensed shipping and handling costs related to sales of ethanol $1.7 million and $3.3 million for each period and expensed transportation costs related to sales of WDG of $3.3 million and $5.3 million.

Supply Trade Agreement. On  July 1, 2022, the Company entered into an operating agreement with Gemini Edibles and Fats India Private Limited (“Gemini”). Under this agreement, Gemini agreed to provide the Company with a supply of feedstock up to a credit limit of $12.7 million. If the Company fails to pay the invoice within the ten-day credit period, the outstanding amount will bear interest at 12%. The term of the agreement is for one year. Either party can terminate the agreement by giving one month notice in writing. The agreement was terminated. As of December 31, 2023 and 2022, the Company had no outstanding balance under this agreement.

As of December 31, 2023, the Company has no forward sales commitments.

XML

Note 11 - Segment Information

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

11. Segment Information

Aemetis recognizes three reportable segments “California Ethanol,” “California Dairy Renewable Natural Gas,” and “India Biodiesel.”  

The “California Ethanol” reportable segment includes the Company’s 65 million gallon per year ethanol plant in Keyes, California, and the adjacent land leased for the production of CO₂.

The “California Dairy Renewable Natural Gas” reportable segment including the production and sale of Renewable Natural Gas and associated environmental attributes, consisting of anaerobic digesters located at diaries, at 36 mile biogas collection pipeline, and biogas upgrading hub and pipeline interconnect that produces Renewable Natural Gas from the biogas.

The “India Biodiesel” reportable segment includes the Company’s 60 million gallon per year nameplate capacity biodiesel manufacturing plant in Kakinada India, and administrative offices in Hyderabad, India.

The Company has additional operating segments that were determined not to be reportable segments, including our key projects under development which consists of sustainable aviation fuel and renewable diesel production in Riverbank and Carbon Capture and Underground Sequestration wells in California.  Additionally, our corporate offices, Goodland Plant in Kansas, and the research and development facility in Minnesota are included in the “All Other” category.

Summarized financial information by reportable segment for the years ended December 31, 2023 and 2022 follow:

	For the year ended December 31, 2023
	California Ethanol			California Dairy Renewable Natural Gas			India Biodiesel		All other		Total
Revenues from external customers	$	104,068		$	5,455		$	77,194	$	-	$	186,717
Intersegment revenues		-			-			-		-		-
Gross profit (loss)		(6,602	)		(331	)		8,950		-		2,017
Interest expense, including amortization of debt fees		25,258			2,809			447		11,005		39,519
Accretion and other expenses of Series A preferred units		-			25,313			-		-		25,313
Loss on
Income tax expense (benefit)		-			(55,159	)		1,416		7		(53,736	)
Capital expenditures		5,695			24,744			1,281		1,399		33,119
Depreciation		3,995			2,116			576		246		6,933
Total Assets		67,991			92,794			34,769		47,852		243,406

	For the year ended December 31, 2022
	California Ethanol			California Dairy Renewable Natural Gas			India Biodiesel		All other			Total
Revenues from external customers	$	228,194		$	208		$	28,111	$	-		$	256,513
Intersegment revenues		-			1,002			-		-			1,002
Gross profit (loss)		(13,017	)		(778	)		8,273		(13	)		(5,535	)
Interest expense, including amortization of debt fees		20,637			742			119		7,272			28,770
Accretion and other expenses of Series A preferred units		-			9,888			-		-			9,888
Income tax expense		-			6			1,040		7			1,053
Loss on debt extinguishment		-			49,386			-		-			49,386
Capital expenditures		8,399			22,884			129		7,745			39,157
Depreciation		4,148			615			650		122			5,535
Total Assets		66,794			77,714			16,120		46,486			207,114

A reconciliation of reportable segment revenues to consolidated totals for the years 2023 and 2022 follow:

Revenues
	2023		2022
Total revenues for reportable segments	$	186,717	$	257,515
Elimination of intersegment revenues		-		(1,002	)
Total consolidated revenues	$	186,717	$	256,513

California Ethanol: During the year ended December 31, 2023 and 2022, the Company amended the Corn Procurement and Working Capital Agreement and the J.D. Heiskell Purchasing Agreement to procure corn from J.D. Heiskell and sell all ethanol, WDG, CDO, and CDS the Company produces to J.D. Heiskell. Sales of ethanol, WDG, CDO, and CDS to one customer accounted for 100% of the California Ethanol segment’s revenue for the year ended December 31, 2023.  Sales of ethanol to one customer accounted for 73% of the California Ethanol segment’s revenue for the year ended  December 31, 2022. Sales of WDG, and corn oil to one customer accounted for 26% of the Company’s California Ethanol segment revenues for the year ended   December 31, 2022.

California Dairy Renewable Natural Gas: 100% of our sales of renewable natural gas during the twelve months ended December 31, 2023 were from sales to one customer.  In the third quarter of 2023, we started selling D3 RINs and one customer accounted for 98% of the 2023 sales.  For the twelve months ended December 31, 2022, all sales were associated with intercompany sales to the Keyes Plant for use in boilers.

India Biodiesel: During the year ended  December 31, 2023, three biodiesel customers accounted for 47%, 25% and 23% of the Company’s India Biodiesel segment revenues. During the year ended  December 31, 2022, three biodiesel customers accounted for 48%, 29%, 12% of the Company’s India Biodiesel segment revenues.

XML

Note 12 - Related Party Transactions

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

12. Related Party Transactions

The Company owes Eric McAfee, the Company’s Chairman and CEO, and McAfee Capital LLC (“McAfee Capital”), owned by Eric McAfee and his wife, $0.4 million in connection with employment agreements and expense reimbursements. The balance accrued related to these employment agreements was $0.4 million as of December 31, 2023.  On February 28, 2023, the Audit Committee of the Company approved a one-time fee of $350 thousand payable to McAfee Capital in connection with McAfee Capital’s guarantees of the Company’s indebtedness with Third Eye Capital. As of December 31, 2023, the outstanding balance is $175 thousand.

The Company owes various members of its Board of Directors amounts totaling $0.3 million as of December 31, 2023 and December 31, 2022, for each period, in connection with board compensation fees, which are included in accounts payable on the balance sheet. For the years ended December 31, 2023 and 2022 the Company expensed $0.4 million, and $0.4 million, respectively, in connection with board compensation fees. 

XML

Note 13 - Income Tax

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Income Tax Disclosure [Text Block]

13. Income Tax

The Company files a consolidated federal income tax return including all its domestic subsidiaries except for Aemetis Biogas LLC, which files its own returns. State tax returns are filed on a consolidated, combined or separate basis depending on the applicable laws relating to the Company and its subsidiaries.

Components of tax expense consist of the following:

	2023			2022
Current:
Federal	$	(55,164	)	$	-
State and Local		13			13
Foreign		1,489			230
		(53,662	)		243
Deferred:
Federal		-			-
State and Local		-			-
Foreign		(74	)		810
Income tax (benefit) expense	$	(53,736	)	$	1,053

The Company records deferred tax liability in other long term liabilities in the Consolidated Balance Sheets. The deferred tax liability resulted as India subsidiary had income for the year ended  December 31, 2023. U.S. loss and foreign income (loss) before income taxes are as follows:

	Year Ended December 31,
	2023			2022
United States	$	(107,191	)	$	(112,959	)
Foreign		7,035			6,254
Pretax loss	$	(100,156	)	$	(106,705	)

Income tax benefit differs from the amounts computed by applying the statutory U.S. federal income tax rate (21%) to loss before income taxes as a result of the following:

	Year Ended December 31,
	2023			2022
Income tax benefit at the federal statutory rate	$	(21,033	)	$	(22,408	)
State tax benefit		(999	)		(496	)
Sale of tax credits		(55,164	)		-
Foreign tax differential		11			168
Stock-based compensation		2,048			295
Interest Expense		92			58
GILTI Inclusion		-			1,126
Prior year true-ups		(18,031	)		55
Non-includible US Entities		-			13,499
Other		67			46
Credits		(869	)		(2,373	)
Valuation Allowance		40,142			11,083
Income Tax Expense (Benefit)		(53,736	)		1,053
Effective Tax Rate		53.65	%		(0.99	)%

The components of the net deferred tax asset or (liability) are as follows:

	Year Ended December 31,
	2023			2022
Deferred Tax Assets
Organizational Costs, Start-up and Intangible Assets	$	34,217		$	2,309
Stock Based Compensation		1,239			1,842
NOLs, Unabsorbed Depreciation and R&D Credits C/F's		67,621			68,201
Interest expense carryover		29,066			22,374
Ethanol Credits		1,500			1,500
Carbon Oxide Sequestration Credit		6,696			5,827
Accrued Expenses		2,249			2,001
Operating Lease Liability		1,282			1,512
Other, net		248			113
Total Deferred Tax Assets		144,118			105,679
Valuation Allowance		(135,354	)		(95,214	)
Net Deferred Tax Assets		8,764			10,465
Deferred Tax Liabilities
Right of Use Asset		(1,230	)		(1,477	)
Property, Plant & Equipment		(8,266	)		(9,788	)
Other, net		(3	)		(10	)
Total Deferred Tax Liabilities		(9,499	)		(11,275	)
Net Deferred Tax Liabilities	$	(735	)	$	(810	)

Based on the Company’s evaluation of current and anticipated future taxable income, the Company believes it is more likely than not that insufficient taxable income will be generated to realize the net deferred tax assets, and accordingly, a valuation allowance has been set against these net deferred tax assets. The $0.8 million deferred tax liability is recorded in other long-term liabilities on the balance sheet.

We do not provide for U.S. income taxes for any undistributed earnings of the Company’s foreign subsidiaries, as the Company considers these to be permanently reinvested in the operations of such subsidiaries and have a cumulative foreign loss. At December 31, 2023 and 2022 these undistributed earnings totaled $1.3 million compared to undistributed losses of $2.5 million for  December 31, 2022. If any earnings were distributed, some countries may impose withholding taxes. However, due to the Company’s overall deficit in foreign cumulative earnings and its U.S. loss position, the Company does not believe a material net unrecognized U.S. deferred tax liability exists.

ASC 740 Income Taxes provides that the tax effects from an uncertain tax position can be recognized in the Company’s financial statements only if the position is more-likely-than-not of being sustained on audit, based on the technical merits of the position. Tax positions that meet the recognition threshold are reported at the largest amount that is more-likely-than-not to be realized. This determination requires a high degree of judgment and estimation. The Company periodically analyzes and adjusts amounts recorded for the Company’s uncertain tax positions, as events occur to warrant adjustment, such as when the statutory period for assessing tax on a given tax return or period expires or if tax authorities provide administrative guidance or a decision is rendered in the courts. The Company does not reasonably expect the total amount of uncertain tax positions to significantly increase or decrease within the next 12 months. As of December 31, 2023, the Company’s uncertain tax positions were not significant for income tax purposes.

The following describes the open tax years, by major tax jurisdiction, as of December 31, 2023:

United States — Federal	2007 – present
United States — State	2008 – present
India	2013 – present
Mauritius	2006 – present

As of December 31, 2023, the Company had U.S. federal NOL carryforwards of approximately $253.0 million and state NOL carryforwards of approximately $336.0 million.  The Company also has approximately $1.5 million of alcohol and cellulosic biofuel credit and $6.7 million of carbon oxide sequestration credit carry forwards. The federal net operating loss and other tax credit carryforwards expire on various dates between 2027 and 2043. The state net operating loss carryforwards expire on various dates between 2027 through 2042. Under the current tax law, net operating loss and credit carryforwards available to offset future income in any given year may be limited by US or India statute regarding net operating loss carryovers and timing of expirations or upon the occurrence of certain events, including significant changes in ownership interests. As of  December 31, 2023, the Company's India subsidiary had no loss carryforwards.

XML

Note 14 - Parent Company Financial Statements (Unaudited)

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Condensed Financial Information of Parent Company Only Disclosure [Text Block]

14. Parent Company Financial Statements (Unaudited)

We conduct substantially all of our operations through subsidiaries and are dependent on cash distributions, dividends and other intercompany transfers of funds from our operations. Our subsidiaries have not made significant distributions to us and may not have funds available for dividends or distributions in the future. The ability of our subsidiaries to transfer funds to us will be dependent upon their respective abilities to achieve sufficient cash flows after satisfying their respective cash requirements, including subsidiary level debt service on their respective credit agreements. The following is a summary of the Parent Company Financial statements.

Aemetis, Inc. (Parent Company)

Balance Sheets

As of December 31, 2023 and 2022

	2023			2022
Assets
Current assets
Cash and cash equivalents	$	1,454		$	286
Receivables due from subsidiaries		110,083			98,780
Prepaid expenses		437			611
Other current assets		12			7
Total current assets		111,986			99,684
Investment in Aemetis Property Keyes, Inc.		1,556			1,274
Investment in Aemetis International, Inc.		12,059			6,659
Investment in Aemetis Advanced Products Riverbank, Inc.		638			173
Investment in AE Advanced Products Keyes , Inc.		246			-
Total investments in Subsidiaries, net of advances		14,499			8,106
Property, plant and equipment, net		149			135
Other assets		2,096			2,377
Total Assets	$	128,730		$	110,302
Liabilities & stockholders' deficit
Current liabilities
Accounts payable	$	3,633		$	2,934
Mandatorily redeemable Series B convertible preferred		4,521			4,082
Other current liabilities		5,031			4,269
Total current liabilities		13,185			11,285
Long term liabilities:
Operating lease liability		1,716			2,047
Subsidiary obligation in excess of investment
Investment in AE Advanced Fuels, Inc.		220,571			177,856
Investment in Aemetis Americas, Inc		202			205
Investment in Aemetis Biofuels, Inc.		2,721			2,738
Investment in Aemetis Technologies, Inc.		4,868			4,716
Investment in AE Advanced Products Keyes , Inc.		-			270
Investment in Aemetis Health Products, Inc.		2,084			2,076
Investment in Goodland Advanced Fuels, Inc.		22,982			16,869
Investment in Aemetis Biogas LLC		70,471			91,292
Investment in Aemetis Carbon Capture Inc		5,895			2,323
Investment in Aemetis Properties Riverbank, Inc.		1,012			479
Total subsidiary obligation in excess of investment		330,806			298,824
Total long term liabilities		332,522			300,871
Stockholders' deficit
Series B Preferred convertible stock		-			1
Common stock		41			36
Additional paid-in capital		264,058			232,546
Accumulated deficit		(475,405	)		(428,985	)
Accumulated other comprehensive loss		(5,671	)		(5,452	)
Total stockholders' deficit		(216,977	)		(201,854	)
Total liabilities & stockholders' deficit	$	128,730		$	110,302

Aemetis, Inc. (Parent Company)

Statements of Operations and Comprehensive Loss

For the Years Ended December 31, 2023 and 2022

	2023			2022
Equity in subsidiary losses	$	(25,370	)	$	(91,561	)
Selling, general and administrative expenses		19,218			15,203
Operating loss		(44,588	)		(106,764	)
Other (income) expense
Interest expense		1,073			806
Debt related fees and amortization expense		781			1,581
Other income		(30	)		(1,400	)
Loss before income taxes		(46,412	)		(107,751	)
Income tax expense		8			7
Net loss		(46,420	)		(107,758	)
Other comprehensive loss
Foreign currency translation adjustment		(219	)		(1,102	)
Comprehensive loss	$	(46,639	)	$	(108,860	)

Aemetis, Inc. (Parent Company)

Statements of Cash Flows

For the years ended December 31, 2023 and 2022

	2023			2022
Operating activities:
Net loss		(46,420	)		(107,758	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		7,660			6,410
Depreciation		51			29
Debt related fees and amortization expense		782			1,776
Subsidiary portion of net losses		25,370			91,561
Gain on litigation		-			(1,400	)
Warrants issued for working capital agreement		409			-
Changes in assets and liabilities:
Prepaid expenses		(608	)		111
Accounts payable		699			(90	)
Accrued interest expense		785			778
Other liabilities		85			(4,625	)
Other assets		276			207
Net cash used in operating activities		(10,911	)		(13,001	)
Investing activities:
Capital expenditures		(65	)		(128	)
Subsidiary advances, net		(9,707	)		1,222
Net cash provided by (used in) investing activities		(9,772	)		1,094
Financing activities:
Proceeds from the exercise of stock options		133			206
Proceeds from issuance of common stock in equity offering		21,718			11,987
Net cash provided by financing activities		21,851			12,193
Net increase in cash, cash equivalents, and restricted cash		1,168			286
Cash, cash equivalents and restricted cash at beginning of period		286			-
Cash, cash equivalents, and restricted cash at end of period	$	1,454		$	286
Supplemental disclosures of cash flow information, cash paid:
Income taxes paid		7			7
Supplemental disclosures of cash flow information, non-cash transactions:
Fair value of warrants issued to subordinated debt holders		1,278			1,939
Fair value of stock issued to a related party for guarantee fees		-			2,012
Fair value of warrants issued for capital expenditures		318			-
Fair value of warrants issued to lender for debt issuance costs		-			3,158
Fair value of stock issued to lender		-			1,335

XML

Note 15 - Subsequent Events

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Subsequent Events [Text Block]

15. Subsequent Events

Subordinated Notes

On January 1, 2024, the maturity on two accredited investor's Subordinated Notes was extended until the earlier of (i) June 30, 2024; (ii) completion of an equity financing by AAFK or Aemetis in an amount of not less than $25 million; (iii) the completion of an Initial Public Offering by AAFK or Aemetis; or (iv) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants.  A $90 thousand and $250 thousand extension fee was paid by adding the fee to the balance of the new Subordinated Note and Aemetis issued the lenders warrants exercisable for 113 thousand shares of common stock with a term of two years and an exercise price of $0.01 per share.  The warrants have been fully exercised.

Series A Preferred Unit Purchase Agreement

On February 8, 2024, ABGL entered into a Fifth Waiver and Amendment to Series A Preferred Unit Purchase Agreement (“PUPA Fifth Amendment").  The PUPA Fifth Amendment: (i) provides an extension of time for ABGL to redeem all of the outstanding Series A Preferred Units until April 30, 2024, and changes the redemption price to $111 million, including fees, (ii) requires ABGL to enter into a twelve-month credit agreement in the amount of $111 million with the lenders if the Series A Preferred Units are not redeemed by such date, and specifies that entry of the credit agreement will satisfy the obligation to redeem the units; and (iii) provides ABGL with a waiver of the obligations of prior agreements to redeem the Series A Preferred Units by any prior dates. 

Third Eye Capital Reserve Liquidity Facility

On March 25, 2024, the Company and Third Eye Capital Corporation entered into a "Seventh Amended and Restated Promissory Note" that increased the amount available under the Company's reserve liquidity facility to $85 million and extended the maturity date to  April 1, 2025. Borrowings under the Note are available until maturity on April 1, 2025. Interest on borrowed amounts accrues at a rate of 30% per annum, to be paid monthly in arrears, or 40% if an event of default has occurred and continues. Interest payments due may be capitalized into the principal balance of the Note. The Company will pay a standby fee of 2% per annum of the difference between the aggregate principal outstanding under the Note and the commitment, payable monthly arrears in either cash or stock. The Note also requires the Company to pay a fee in the amount of $0.5 million in connection with a request for an advance on the Note, provided that such fee may be added to the principal amount of the Note. The outstanding principal balance of the indebtedness evidenced by the Note, plus any accrued but unpaid interest and any other sums due thereunder, is due and payable in full on April 1, 2025. In addition, the Company must make payments on the Note with funds received from the closing of certain new debt or equity financing or transactions, as described in the Note. The Note is secured by liens and security interests upon the property and assets of the Company.

Third Eye Capital Limited Waiver and Amendment No. 28

On  March 25, 2024, the Company and Third Eye Capital Corporation entered into a “Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement” (“Amendment No. 28”) that (i) revised the loan covenant related to Keyes plant note indebtedness to exclude certain draws on Third Eye credit facilities and to exclude the "Redemption Fee," as defined in the Amended and Restated Note Purchase Agreement, and (ii) changed the maximum ratio of Note Indebtedness to the Keyes Plant market value to 120%. As consideration for Amendment No. 28, the Company agreed to pay Third Eye Capital an amendment fee of $0.1 million.

XML

Note 16 - Liquidity

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

16.  Liquidity

The accompanying financial statements have been prepared contemplating the realization of assets and satisfaction of liabilities in the normal course of business. As a result of negative capital, negative operating results, and collateralization of substantially all of the Company assets, the Company has been reliant on its senior secured lender to provide additional funding and has been required to remit substantially all excess cash from operations to the senior secured lender. In order to meet our obligations during the next twelve months, we have extended our reserve liquidity credit facility through April 1, 2025, at an amount of up to $85 million, and we plan to refinance debt with our senior lender for amounts becoming due in the next twelve months and sell equity through our at-the-market registration at levels consistent with the year ended December 31, 2023. We believe these plans alleviate substantial doubt about our ability to continue as a going concern. While the Company believes we will be able to implement these plans to provide sufficient liquidity, there are inherent risks and uncertainties regarding our ability to execute our plans. In addition, we plan to pursue the following strategies to improve liquidity:

Operations and Project Development

For the Keyes Plant, we plan to operate the plant and continue to improve its financial performance by adopting new technologies or process changes that allow for energy efficiency, cost reduction, or revenue enhancements, as well as, execute upon awarded grants that improve energy and operational efficiencies resulting in lower cost, lower carbon emissions, and overall margin improvement.

For Aemetis Biogas, we plan to operate our existing biogas digesters to produce and sell Renewable Natural Gas (RNG) and the associated Federal D3 RINs and California LCFS credits.  We are continuing to build new dairy digesters and pipeline extensions.  We began generating revenue from biogas operations in 2023 and this revenue will continue for the full year 2024, as well as increase as we build new digesters.  We also expect revenue to increase when the California Air Resource Board processes our LCFS pathway applications and approves a provisional carbon intensity that is lower than the temporary carbon intensity we currently use to calculate the quantity of LCFS credits that we generate.  We are seeking debt from a variety of sources to accelerate the construction of additional digesters.

For the Kakinada Plant, we plan to continue to sell our biodiesel to OMCs pursuant to cost-plus contracts.  We are also continuing to upgrade the plant to increase feedstock flexibility (and thereby lower feedstock costs), increase production capacity, and produce new products. Additionally, we are in the process of obtaining approval and contractual arrangements for the export of refined animal tallow into international markets.

Financing

We plan to continue to locate funding for existing and new business opportunities through a combination of working with our senior lender, restructuring existing loan agreements, entering into additional debt agreements for specific projects, obtaining project specific equity and debt for development projects, and obtaining additional debt from the current EB-5 Phase II offering.

XML

Insider Trading Arrangements

12 Months Ended

Dec. 31, 2023

shares

ecd_TradingArrByIndTable

Material Terms of Trading Arrangement [Text Block]

Item 9B.  Other Information.

(a) Current Reports

On March 25, 2024, the Company entered into two agreements with Third Eye Capital entitled "Limited Waiver and Amendment No. 28 to Amended and Restated Note Purchase Agreement" and "Seventh Amended and Restated Promissory Note."  These agreements are described in Note 4, Debt, and Note 15, Subsequent Events, to the Consolidated Financial Reports in Item 8 of this Report.  Copies of the two agreements are included in this Report as Exhibits 10.36 and 10.37, respectively.  The descriptions of the two documents in Item 8 are only a summary and are qualified by the terms of the documents included in Exhibits 10.36 and 10.37.

(b) Adoption and Termination of Rule 10b5-1 Stock Trading Plans by Officers and Directors

On September 15, 2023, Francis P. Barton, a member of the Company's Board of Directors, adopted a trading arrangement for the sale of the Company's common stock (a "Rule 10b5-1 Trading Plan") that (i) became effective December 15, 2023, (ii) has a term lasting until December 31, 2024, (iii) provides for the sale of up to 126,000 shares of common stock to be issued upon exercise of options currently held by Mr. Barton, (iv) sets a limit order designating the minimum price upon which sales may occur, and (v) is intended to satisfy the affirmative defense of Securities Exchange Act Rule 10b5-1(c).

On September 15, 2023, Todd A. Waltz, Executive Vice President and Chief Financial Officer of the Company, adopted a Rule 10b5-1 Trading Plan that (i) took effect January 1, 2024, (ii) terminates June 15, 2025, (iii) provides for the sale of up to 475,000 shares of common stock to be issued upon the exercise of options currently held by Mr. Waltz, (iv) contains multiple limit orders designating the minimum prices upon which sales may occur, and (v) is intended to satisfy the affirmative defense of Securities Exchange Act Rule 10b5-1(c). Mr. Waltz's newly adopted plan replaces a previously adopted plan that expired on December 31, 2023, and provided for the sale of up to 475,000 shares on limit order terms. No shares were transacted under the expired plan. 

On November 13, 2023, Andrew B. Foster, Executive Vice President and Chief Operating Officer of the Company, adopted a Rule 10b5-1 Trading Plan that (i) took effect February 14, 2024, (ii) has a term lasting until December 31, 2024, (iii) provides for the sale of up to 199,616 shares of common stock to be issued upon exercise of options currently held by Mr. Foster, (iv) contains multiple limit orders designating the minimum prices upon which sales may occur, and (v) is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c).  Mr. Foster's newly adopted Rule 10b5-1 Trading Plan replaces a previously adopted plan that expired on December 31, 2023, and provided for the sale of 96,000 shares of common stock on limit order terms. No shares were transacted under the expired plan.

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Rule 10b5-1 Arrangement Terminated [Flag]

false

AMTX_Francis P. Barton [Member]

ecd_TradingArrByIndTable

Trading Arrangement, Securities Aggregate Available Amount

126,000

Trading Arrangement Adoption Date

September 15, 2023

Trading Arrangement, Individual Name

Francis P. Barton

Trading Arrangement, Individual Title

Board of Directors Member

Rule 10b5-1 Arrangement Adopted [Flag]

true

AMTX, Todd A. Waltz [Member]

ecd_TradingArrByIndTable

Trading Arrangement, Securities Aggregate Available Amount

475,000

Trading Arrangement Adoption Date

September 15, 2023

Trading Arrangement, Individual Name

Todd A. Waltz

Trading Arrangement, Individual Title

Executive Vice President and Chief Financial Officer

Rule 10b5-1 Arrangement Adopted [Flag]

true

AMTX_Andrew B. Foster [Member]

ecd_TradingArrByIndTable

Trading Arrangement, Securities Aggregate Available Amount

199,616

Trading Arrangement Adoption Date

November 13, 2023

Trading Arrangement, Individual Name

Andrew B. Foster

Trading Arrangement, Individual Title

Executive Vice President and Chief Operating Officer

Rule 10b5-1 Arrangement Adopted [Flag]

true

XML

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation and Consolidation. These consolidated financial statements include the accounts of Aemetis, Inc. and its subsidiaries. We consolidate all entities in which we have a controlling financial interest. A controlling financial interest is usually obtained through ownership of a majority of the voting interests. However, an enterprise must consolidate a variable interest entity (“VIE”) if the enterprise is the primary beneficiary of the VIE, even if the enterprise does not own a majority of the voting interests. The primary beneficiary is the party that has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. ABGL was assessed to be a VIE and through the Company's ownership interest in all of the outstanding common stock, the Company has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company.

All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. To the extent there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.

Revenue [Policy Text Block]

Revenue Recognition. We derive revenue primarily from sales of ethanol and related co-products in California Ethanol segment, renewable natural gas for California Dairy Renewable Natural Gas segment, and biodiesel in India Biodiesel segment pursuant to supply agreements and purchase order contracts. We assess the following criteria under the ASC 606 guidance: (i) identify the contracts with customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when the entity satisfies the performance obligations.  

California Ethanol:  From 2022 until the second quarter of 2023, we sold our ethanol production to Murex who marketed it to oil companies as a gasoline blend stock.  Starting in the second quarter of 2023, we began selling all our ethanol to J.D. Heiskell who sells it to customers designated by us, and we have designated Murex, who continues to market the product.  J.D. Heiskell does not charge a fee for reselling the ethanol but they receive the payments from the ultimate customer.  We also buy our corn feedstock from J.D. Heiskell, and J.D. Heiskell pays us the net balance between ethanol and other product sales and our corn purchases.  Our accounting (i) treats us as the purchaser/customer for corn purchases from J.D. Heiskell and we record the full purchase cost in cost-of-good sold, and (ii) treats us as the seller for ethanol and other product sales, so we treat all sales as revenue.

Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, the performance obligation was satisfied by delivery of the physical product from our finished goods tank to our customer’s contracted trucks. Effective on May 25, 2023, the performance obligation is satisfied by delivery of the physical product to our finished goods tank leased by J.D. Heiskell. The transaction price is determined based on daily market prices and quarterly contract pricing negotiated by Murex for its customers for ethanol and based on dry distillers' market and local demand by our marketing partner A.L. Gilbert Company (“A.L. Gilbert”) for WDG. The transaction price is allocated to one performance obligation.

During the last two weeks of December 2022, we undertook an extended maintenance cycle and accelerated the implementation of several important ethanol plant energy efficiency upgrades. Our decision was partly driven by the high natural gas prices in California during the period. Furthermore, after monitoring natural gas pricing and margin profitability, we decided to extend the maintenance cycle into the first and second quarters of 2023 and restarted the plant at the end of May 2023.

The following table shows our sales in California Ethanol by product category:

California Ethanol	For the twelve months ended December 31,
	2023		2022
Ethanol sales	$	78,403	$	165,876
Wet distiller's grains sales		21,963		50,930
Other sales		3,702		11,388
	$	104,068	$	228,194

California Dairy Renewable Natural Gas: Our facilities as of December 31, 2023, consist of seven anaerobic digesters that process feedstock from dairies into biogas, a 26-mile collection pipeline leading to a central upgrading hub, and an interconnect to inject the RNG into the utility natural gas pipeline for delivery to customers for use as transportation fuel.  During 2023, Renewable Natural Gas ("RNG") produced at our seven operating dairy digesters was delivered to the regional natural gas pipeline.  In connection with dispensing the RNG, we also began generating and inventorying sellable credits under the federal Renewable Fuel Standard (referred to as "D3 RINs") and the California Low Carbon Fuel Standard credits ("LCFS"). We began selling D3 RINs in the third quarter of 2023 and began selling LCFS credits in the first quarter of 2024. We recognize revenue from sales of RNG concurrent with our production and injection into the transportation pipeline.  We recognize revenue from sales of D3 RINs and LCFS credits at the time we sell the credits. 

Dairy Renewable Natural Gas	For the twelve months ended December 31,
	2023		2022
Molecule and RIN sales	$	5,455	$	208

India Biodiesel: We sell products pursuant to purchase orders (written or verbal) or by contract with governmental or international parties, in which performance is satisfied by delivery and acceptance of the physical product. Given that the contracts are sufficiently similar in nature, we have assessed these contracts as a portfolio of similar contracts as allowed under the practical expedient. Doing so does not result in a materially different outcome compared to individually accounting for each contract. All domestic and international deliveries are subject to certain specifications as identified in contracts. The transaction price is determined based on reference market prices for biodiesel, refined glycerin, and PFAD net of taxes. Transaction price is allocated to one performance obligation.

The following table shows our sales in India by product category:

India Biodiesel	For the twelve months ended December 31,
	2023		2022
Biodiesel sales	$	74,503	$	27,041
Other sales		2,691		1,070
	$	77,194	$	28,111

Cost of Goods and Service [Policy Text Block]

Cost of Goods Sold. Cost of goods sold includes those costs directly associated with the production of revenues, such as raw material consumed, factory overhead, and other direct production costs.  During periods of idle plant capacity from January to May 2023, costs otherwise charged to cost of goods sold are reclassified to selling, general and administrative expense. 

Shipping and Handling Costs [Policy Text Block]

Shipping and Handling Costs. When incurred, shipping and handling costs are classified as a component of cost of goods sold in the accompanying consolidated statements of operations.

Research and Development Expense, Policy [Policy Text Block]

Research and Development. Research and development costs are expensed as incurred, unless they have alternative future uses to the Company.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash, Cash Equivalents, and Restricted Cash. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company maintains cash balances at various financial institutions domestically and abroad. The Federal Deposit Insurance Corporation insures domestic cash accounts. The Company’s accounts at these institutions may at times exceed federally insured limits. The Company has not experienced any losses in such accounts. Amounts included in restricted cash represent those required to be set aside by the AB1 and AB2 Loan Agreements with Greater Nevada Credit Union ("GNCU") and Magnolia Bank, respectively, and will be released at times specified in each agreement.

The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same such amounts shown in the statement of cash flows. 

	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,667	$	4,313
Restricted cash included in other current assets		289		725
Restricted cash included in other assets		3,324		1,961
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	6,280	$	6,999

Receivable [Policy Text Block]

Accounts Receivable.   The Company sells all of its products to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement. Our third-party marketing partners arrange to buy ethanol and WDG generally without requiring collateral and sell directly to customers on a variety of terms including advanced payment terms, based on the size and creditworthiness of the customer. DCO and CDS are marketed and sold to various customers under the J.D. Heiskell Purchasing Agreement. The Company sells biodiesel, glycerin, and processed natural oils to a variety of customers and may require advanced payment based on the size and creditworthiness of the customer. Usually, invoices are due within 30 days on net terms. Accounts receivable mostly consist of product sales made to large creditworthy customers. Trade accounts receivable are presented at original invoice amount, net of any allowance for doubtful accounts.

The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and estimates an allowance for expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may be required. 

Inventory, Policy [Policy Text Block]

Inventories. Finished goods, raw materials, and work-in-process inventories are valued using methods that approximate the lower of cost (first-in, first-out) or net realizable value (NRV).  Distillers’ grains and related products are stated at NRV.  In the valuation of inventories, NRV is determined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.

Other Current Assets Policy [Policy Text Block]

Other current assets. The other current assets contain input tax credits of $1.6 million, employee advance receivables of $69 thousand, and advances to customers of $1.2 million by our India biodiesel segment. 

Consolidation, Variable Interest Entity, Policy [Policy Text Block]

Variable Interest Entities. We determine at the inception of each arrangement whether an entity in which we have made an investment or in which we have other interests in is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other interests in a VIE in accordance with applicable GAAP.

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment. Property, plant, and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of buildings, furniture, machinery, equipment, land, biogas dairy digesters, and the Keyes Plant, Goodland Plant and Kakinada Plant. It is the Company’s policy to depreciate capital assets over their estimated useful lives using the straight-line method.

The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 Property Plant and Equipment –Subsequent Measurement, which requires recognition of impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of asset groups may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, based on estimated undiscounted cash flows, the impairment loss would be measured as the difference between the carrying amount of the asset group and its estimated fair value. The Company has not recorded any impairment as of December 31, 2023 and 2022.

Government Assistance [Policy Text Block]

Grants Received.

California Energy Commission Low-Carbon Fuel Production Program. The Company has been awarded $4.2 million in matching grants from the California Energy Commission Low-Carbon Fuel Production Program (“LCFPP”). The LCFPP grant reimburses the Company for costs to design, procure, and install processing facility to clean-up, measure and verify negative-carbon intensity dairy renewable natural gas fuel at the production facility in Keyes, California. The Company has received $3.8 million from the LCFPP as of  December 31, 2023, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Department of Food and Agriculture Dairy Digester Research and Development Grant. In 2019, the Company was awarded $3.2 million in matching grants from the California Department of Food and Agriculture (“CDFA”) Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct two of the Company’s biogas capture systems under contract with central California dairies. The Company received all the awarded grant proceeds as of the second quarter of 2021. In  October 2020, the Company was awarded $7.8 million in matching grants from the CDFA Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct six of the Company’s biogas capture systems under contract with central California dairies. The Company has received $6.2 million from the CDFA 2020 grant program as of December 31, 2023, as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Energy Commission Low Carbon Advanced Ethanol Grant Program. In  May 2019, the Company was awarded the right to receive reimbursements from the California Energy Commission Community-Scale and Commercial-Scale Advanced Biofuels Production Facilities grant under the Alternative and Renewable Fuel and Vehicle Technology Program in an amount up to $5.0 million (the “CEC Reimbursement Program”) in connection with the Company’s expenditures toward the development of the Riverbank Cellulosic Ethanol Facility. To comply with the guidelines of the CEC Reimbursement Program, the Company must make a minimum of $7.9 million in matching contributions to the Riverbank project. The Company receives funds under the CEC Reimbursement Program for actual expenses incurred up to $5.0 million as long as the Company makes the minimum matching contribution. Given that the Company has not made the minimum matching contribution, the California Energy Commission did not extend the due date and would not move forward with this grant program. Given the nature of the project, the grant for reimbursement of capital expenditures of $1.7 million is presented with other current liabilities as of  December 31, 2023 and 2022 

U.S. Department of Food and Agriculture Forest Service Grant. Aemetis Advanced Products Keyes (“AAPK”) has been awarded $245 thousand in matching grants from the U.S. Department of Food and Agriculture Forest Service (“US Forest Service”) under the Wood Innovation and Community Wood program. The grant reimburses the Company for continued development of technologies and processes to valorize forest waste for the production of cellulosic ethanol.  AAPK has received $166 thousand from the US Forest Service as reimbursement for actual allowable program costs incurred through December 31, 2023.

California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. Aemetis Advanced Fuels Keyes (“AAFK”) has been awarded an $8.0 million grant to design, construct and commission a grid-connected 1.56 MW photovoltaic microgrid and 1.25MW/2.5MWh Battery Energy Storage System integrated with an artificial intelligence-driven distributed control system (DCS). The grant requires $1.6 million in matching contribution in which the Company has made. AAFK received $4.4 million in grant funds from this program as reimbursement for actual expenditures incurred through  December 31, 2023. Due to the uncertainty associated with the approval process under the grant program, the Company recognized the grant as a reduction of costs in the period when payment is received.

California Department of Forestry and Fire Protection Grant. AAPK has been awarded $2 million in matching grants from the CAL FIRE Business and Workforce Development Grant Program (“CAL Fire”) in  May 2022. This CAL Fire grant program reimburses AAPK for costs to design, construct, and commission a 2 million gallon per year cellulosic ethanol facility that will convert conifer biomass from forested regions of the Sierra Nevada into an ultra‐low carbon biofuel derived from 100% forest biomass (“CAL Fire Conversion Program”). AAPK must contribute $5.8 million in cost share contributions to the project to receive grant proceeds. AAPK has received no grant funds from the CAL Fire Conversion Program as reimbursement for actual costs through December 31, 2023.

California Department of Forestry and Fire Protection Grant. AAPK has been awarded $500 thousand in grants from CAL Fire in  May 2022. This CAL Fire grant program reimburses AAPK for costs to advance a new‐to‐the world technology that circumvents current limitations surrounding the extraction of cellulosic sugars by pioneering a novel route for deconstructing woody biomass using ionic liquids (“CAL Fire Extraction Program”). AAPK has received no grant funds from the CAL Fire Extraction Program as reimbursement for actual costs through  December 31, 2023.

U.S. Forest Service Community Wood Grant. Aemetis Advanced Products Riverbank (“AAPR”) has been awarded $642 thousand in matching grants from the U.S Forest Service Wood Innovations Program (“USFS”) in  May 2022. The USFS grant program reimburses AAPR for costs to design, construct, and commission a plant to produce cellulosic ethanol using preliminary research and development in partnership with the Joint Bioenergy Institute (JBEI). USFS grant funds will be used to complete the FEL-3 design phase of the entire process, construct a biomass pretreatment unit to extract sugars at the Aemetis Riverbank site and ferment sugars into ethanol at the Keyes Plant. AAPR must contribute $2.4 million in cost share contributions to the project to receive grant proceeds. AAPK has received no grant funds from the USFS grant program as reimbursement for actual costs through  December 31, 2023.

USDA Biofuel Producer Program Grant. During the second quarter of 2022, a grant in the amount of $14.2 million was received from the USDA’s Biofuel Producer Program, created as part of the CARES Act, to compensate biofuel producers who experienced market losses due to the COVID-19 pandemic. This was recorded in the other expense (income) section of the Consolidated Statements of Operations and Comprehensive Loss.

California Energy Commission Grant for Mechanical Vapor Recompression System. Aemetis Advanced Fuels Keyes (“AAFK”) has been awarded a $6.0 million grant to design, construct and commission a mechanical vapor recompression (MVR) system. The additional evaporation stages will eliminate natural gas consumption and related greenhouse gas emissions in the evaporation portion of the process by installing metering equipment and software to monitor and optimize the plant’s energy consumption. The MVR system will compress vapor to a higher pressure and temperature so that it can be recycled multiple times as steam heat in the evaporation process, which will dramatically reduce natural gas use. The grant requires $5.3 million in matching contributions. AAFK has received no grant funds from this program as reimbursement for actual expenditures incurred through  December 31, 2023. Due to the uncertainty associated with the approval process under the grant program, the Company will recognize future grant proceeds received as a reduction of costs in the period when payment is received.

PG&E A2313 Pipeline Interconnection Recovery Grant. In February 2023, Aemetis Biogas received $5 million from Pacific Gas and Electric (PG&E) as part of qualification under a California Public Utility Commission Biomethane incentive program reimbursing actual Aemetis Biogas costs to interconnect biogas cleanup hub with PG&E utility pipeline. Incentive payment earned after validating renewable natural gas flowed into PG&E interconnect successfully for required period of time.

Pacific Gas and Electric SEM Manufacturer’s Incentive Program. During the fourth quarter of 2022, AAFK received $374 thousand in PG&E SEM Incentive Program reimbursements for installing more efficient beer feed heat exchangers. Third party consultants verified the reduction in natural gas usages from the new heat exchangers to obtain the incentive program funds.

Regulatory Income Taxes, Policy [Policy Text Block]

Investment Tax Credits. In the third quarter of 2023, the Company sold to a third-party purchaser certain transferrable Investment Tax Credits (ITCs) that had been generated by the Company from its investments in the California Dairy Renewable Natural Gas segment. The Company accounted for the ITC sale in accordance with ASC 740 by electing the flow-through method. The net value of the tax credits sale of $55.2 million is recorded as an income tax benefit in the income statement for the period ending December 31, 2023. The cash was received in October 2023, and it was used to make certain principal and interest payments on revolving notes and Series A preferred financing.

Income Tax, Policy [Policy Text Block]

Income Taxes. The Company recognizes income taxes in accordance with ASC 740 Income Taxes using an asset and liability approach. This approach requires the recognition of taxes payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. The measurement of current and deferred taxes is based on provisions of enacted tax law. ASC 740 provides for recognition of deferred tax assets if the realization of such assets is more likely than not to occur. Otherwise, a valuation allowance is established for the deferred tax assets, which may not be realized. As of December 31, 2023 and 2022, the Company recorded a full valuation allowance against its U.S. federal and state net deferred tax assets due to operating losses incurred since inception. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets were fully offset by a valuation allowance.

The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may have a material impact on the Company’s tax provision in a future period.        

In 2018, the Company adopted certain tax accounting policies related to the new global intangible low-taxed income (“GILTI”) provisions under the Tax Cuts and Jobs Act such that the Company will: (1) account for all GILTI related book-tax differences as period costs and (2) use the Incremental Cash Tax Savings approach in evaluating its valuation allowance assessment related to the GILTI inclusion.

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted Net Income (Loss) per Share.  Basic net loss per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted net loss per share reflects the dilution of common stock equivalents such as options, convertible preferred stock, debt and warrants to the extent the impact is dilutive.  As the Company incurred a net loss for the years ended December 31, 2023 and 2022, potentially dilutive securities have been excluded from the diluted net loss per share computations as their effect would be anti-dilutive.

The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of December 31, 2023 and 2022:

	As of
	December 31, 2023		December 31, 2022
Series B preferred (post split basis)		-		127
Common stock options and warrants		6,056		5,050
Debt with conversion feature at $30 per share of common stock		1,267		1,240
Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation		7,323		6,417

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Loss. ASC 220 Comprehensive Income requires that an enterprise report, by major components and as a single total, the change in its net assets from non-owner sources. The Company’s other comprehensive loss and accumulated other comprehensive loss consists solely of cumulative currency translation adjustments resulting from the translation of the financial statements of our India subsidiary. The investment in this subsidiary is considered indefinitely invested overseas, and as a result, deferred income taxes are not recorded related to the currency translation adjustments.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation/Transactions. The Company’s India subsidiary operates in a local currency environment where the local currency is the functional currency used for transactions and accounting. Assets and liabilities of that subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date and the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Income and expense accounts are translated at average exchange rates during the year. Transactional gains and losses from foreign currency transactions are recorded in other (income) loss, net.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments. Financial instruments include accounts receivable, accounts payable, accrued liabilities, current and non-current portion of subordinated debt, notes payable, Series A preferred units, and long-term debt.  Due to the unique terms of our notes payable and long-term debt and the financial condition of the Company, the fair value of the debt is not readily determinable.  The fair value determined using level 3 inputs of all other current financial instruments is estimated to approximate carrying value due to the short-term nature of these instruments.

Share-Based Payment Arrangement [Policy Text Block]

Share Based Compensation. We recognize share-based compensation expense in accordance with ASC 718 Stock Compensation, which requires the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards over the vesting period, adjusted to reflect only those shares that are expected to vest.

Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies. We record and/or disclose commitments and contingencies in accordance with ASC 450 Contingencies.  ASC 450 applies to an existing condition, situation, or set of circumstances involving uncertainty as to possible loss that will ultimately be resolved when one or more future events occur or fail to occur.

Debt, Policy [Policy Text Block]

Convertible Instruments.  The Company evaluates the impacts of convertible instruments based on the underlying conversion features. Convertible Instruments are evaluated for treatment as derivatives that could be bifurcated and recorded separately.  

Debt Issuance Costs. The Company records debt issuance costs related to specific incremental costs directly attributable to issuing, modifying, or extending a debt instrument.  The debt issuance costs are reported as an adjustment to the carrying amount of the debt.  The debt issuance costs are amortized using the interest rate method over the life of the debt instrument.

Troubled Debt Restructuring Accounting. The evaluation for troubled debt restructuring includes assessing whether the creditor granted a concession. To determine this, we calculate the post-restructuring effective interest rate by projecting cash flows on the new terms and calculating a discount rate equal to the carrying amount of pre-restructuring debt and comparing this calculation to the terms of prior amendments.  If the post restructuring effective interest rate is less than the prior terms effective interest rate, we assess this as having been granted a concession.  We then apply troubled debt restructuring accounting to any debt in which the creditor granted a concession.

Debt Modification Accounting. The Company evaluates amendments to its debt in accordance with ASC 540-50 Debt – Modification and Extinguishments for modification and extinguishment accounting.  This evaluation includes comparing the net present value of cash flows of the new debt to the old debt to determine if changes greater than 10 percent occurred.  In instances where the net present value of future cash flows changed more than 10 percent, the Company applies extinguishment accounting and determines the fair value of its debt based on factors available to the Company.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements. 

There were no other recently issued and effective authoritative guidance that are expected to have a material impact on the Company’s Consolidated Financial Statements through the reporting date.

XML

Note 1 - Nature of Activities and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Disaggregation of Revenue [Table Text Block]

California Ethanol	For the twelve months ended December 31,
	2023		2022
Ethanol sales	$	78,403	$	165,876
Wet distiller's grains sales		21,963		50,930
Other sales		3,702		11,388
	$	104,068	$	228,194

Dairy Renewable Natural Gas	For the twelve months ended December 31,
	2023		2022
Molecule and RIN sales	$	5,455	$	208

India Biodiesel	For the twelve months ended December 31,
	2023		2022
Biodiesel sales	$	74,503	$	27,041
Other sales		2,691		1,070
	$	77,194	$	28,111

Schedule of Cash and Cash Equivalents [Table Text Block]

	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,667	$	4,313
Restricted cash included in other current assets		289		725
Restricted cash included in other assets		3,324		1,961
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	6,280	$	6,999

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	As of
	December 31, 2023		December 31, 2022
Series B preferred (post split basis)		-		127
Common stock options and warrants		6,056		5,050
Debt with conversion feature at $30 per share of common stock		1,267		1,240
Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation		7,323		6,417

XML

Note 2 - Inventories (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	As of
	December 31, 2023		December 31, 2022
Raw materials	$	9,907	$	2,971
Work-in-progress		1,682		127
Finished goods		6,702		1,560
Total inventories	$	18,291	$	4,658

XML

Note 3 - Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Property, Plant and Equipment [Table Text Block]

	As of
	December 31, 2023			December 31, 2022
Land	$	7,345		$	7,344
Plant and buildings		136,318			99,116
Furniture and fixtures		2,266			1,831
Machinery and equipment		14,982			15,209
Construction in progress		73,057			88,990
Property held for development		15,431			15,437
Finance lease right of use assets		2,889			3,045
Total gross property, plant & equipment		252,288			230,972
Less accumulated depreciation		(57,180	)		(50,531	)
Total net property, plant & equipment	$	195,108		$	180,441

Depreciation Of Property, Plant, and Equipment [Table Text Block]

	Years
Plant and buildings		20 - 30
Machinery and equipment		5 - 15
Furniture and fixtures		3 - 5

XML

Note 4 - Debt (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Debt [Table Text Block]

	December 31, 2023		December 31, 2022
Third Eye Capital term notes	$	7,159	$	7,141
Third Eye Capital revolving credit facility		20,922		60,602
Third Eye Capital revolving notes Series B		54,412		-
Third Eye Capital revenue participation term notes		12,011		11,963
Third Eye Capital acquisition term notes		26,655		26,578
Third Eye Capital Fuels Revolving Line		32,511		27,410
Third Eye Capital Carbon Revolving Line		23,486		22,710
Construction Loan		41,024		19,820
Cilion shareholder seller notes payable		7,028		6,821
Subordinated notes		17,625		15,931
EB-5 promissory notes		42,211		41,404
Working capital loans		3,827		-
Term loans on capital expenditures		5,850		5,860
Total debt		294,721		246,240
Less current portion of debt		37,028		49,219
Total long term debt	$	257,693	$	197,021

Schedule of Maturities of Long-Term Debt [Table Text Block]

Twelve months ended December 31,	Debt Repayments
2024	$	37,028
2025		181,464
2026		37,912
2027		4,128
2028		2,108
There after		37,545
Total debt		300,185
Debt issuance costs		(5,464	)
Total debt, net of debt issuance costs	$	294,721

XML

Note 5 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Lease, Cost [Table Text Block]

	Twelve Months Ended December 31,
	2023		2022
Operating lease cost
Operating lease expense	$	722	$	673
Short term lease expense		223		176
Variable lease expense		93		91
Total operating lease cost	$	1,038	$	940
Finance lease cost
Amortization of right-of-use assets	$	121	$	179
Interest on lease liabilities		340		310
Total finance lease cost	$	461	$	489

	Twelve Months Ended December 31,
	2023		2022
Operating cash flows used in operating leases	$	668	$	766
Operating cash flows used in finance leases		340		310
Financing cash flows used in finance leases		428		481

Supplemental Non-cash Flow Information Related to Leases [Table Text Block]

	Twelve Months Ended December 31,
	2023			2022
Operating leases
Accretion of the lease liability	$	249		$	340
Amortization of right-of-use assets		293			333
Weighted Average Remaining Lease Term
Operating leases (in years)		4.2			5.2
Finance leases (in years)		13.0			14.0
Weighted Average Discount Rate
Operating leases		14.1	%		14.2	%
Finance leases		13.2	%		13.2	%

Supplemental Balance Sheet Information Related to Leases [Table Text Block]

	As of
	December 31, 2023			December 31, 2022
Operating leases
Operating lease right-of-use assets	$	2,056		$	2,449
Current portion of operating lease liability		406			338
Long term operating lease liability		1,783			2,189
Total operating lease liabilities		2,189			2,527
Finance leases
Property and equipment, at cost	$	2,889		$	3,045
Accumulated depreciation		(228	)		(112	)
Property and equipment, net		2,661			2,933
Other current liability		30			71
Other long term liabilities		2,687			2,911
Total finance lease liabilities		2,717			2,982

Lease Term [Table Text Block]

Year Ended December 31,	Operating leases			Finance leases
2024	$	682		$	179
2025		681			168
2026		626			145
2027		645			145
2028		272			145
There after		-			10,105
Total lease payments		2,906			10,887
Less imputed interest		(717	)		(8,170	)
Total lease liability	$	2,189		$	2,717

Operating Lease, Lease Income [Table Text Block]

	December 31, 2023		December 31, 2022
Lease income	$	2,075	$	1,255

Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]

Year ended December 31,
2024	$	948
2025		773
2026		562
2027		508
2028		508
There after		635
Total future lease commitments	$	3,934

XML

Note 7 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Stock by Class [Table Text Block]

			Shares Issued and
	Authorized		Outstanding December 31,
	Shares		2023		2022
Series B preferred stock		7,235		-		1,270
Undesignated		57,765		-		-
		65,000		-		1,270

XML

Note 8 - Warrants to Purchase Common Stocks (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Warrants, Valuation Assumptions [Table Text Block]

Description	For the year ended December 31,
	2023			2022
Dividend-yield		0	%		0	%
Risk-free interest rate		3.85	%		1.75	%
Expected volatility		117.90	%		151.41	%
Expected life (years)		5			3
Exercise price per share	$	1.62		$	10.47
Market value per share on grant date	$	4.13		$	11.29
Fair value per share on grant date	$	3.92		$	9.68

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Warrants Outstanding & Exercisable			Weighted - Average Exercise Price		Average Remaining Term in Years
Outstanding December 31, 2021		55		$	2.59		4.95
Granted		527			10.47
Exercised		(227	)		0.01
Outstanding December 31, 2022		355		$	15.92		7.48
Granted		511			1.62
Exercised		(336	)		0.83
Outstanding December 31, 2023		530		$	11.70		5.77

XML

Note 9 - Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]

	Shares Available for Grant			Number of Shares Outstanding			Weighted-Average Exercise Price
Balance as of December 31, 2021		42			3,763		$	2.29
Authorized		1,338			-			-
Options Granted		(1,307	)		1,307			10.97
RSAs Granted		(89	)		-			-
Exercised		-			(295	)		0.93
Forfeited/expired		81			(81	)		11.63
Balance as of December 31, 2022		65			4,694		$	4.63
Authorized		1,644			-			-
Options Granted		(1,278	)		1,278			3.60
RSAs Granted		(244	)		-			-
Exercised		-			(177	)		1.83
Forfeited/expired		269			(269	)		5.93
Balance as of December 31, 2023		456			5,526		$	4.42

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]

	Number of Shares		Weighted Average Exercise Price		Remaining Contractual Term (In Years)		Aggregate Intrinsic Value1
2023
Vested and Exercisable		3,986	$	3.58		6.47	$	11,695
Unvested		1,540		6.55		8.67		1,621
Total		5,526	$	4.42		7.04	$	13,316
2022
Vested and Exercisable		3,170	$	2.46		6.98	$	7,419
Unvested		1,524		9.13		8.81		647
Total		4,694	$	4.63		7.58	$	8,066

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Description	For the year ended December 31,
	2023			2022
Dividend-yield		0	%		0	%
Risk-free interest rate		3.86	%		2.03	%
Expected volatility		124.62	%		117.21	%
Expected life (years)		7.00			7.00
Market value per share on grant date	$	3.60		$	10.97
Fair value per share on grant date	$	3.29		$	9.71

XML

Note 10 - Agreements (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]

	As of and for the twelve months ended December 31,
	2023		2022
Ethanol sales	$	77,359	$	-
Wet distiller's grains sales		21,963		50,930
CDO and CDS sales		3,296		10,168
Corn purchases		83,128		191,401
Accounts receivable		1,073		-
Accounts payable		1,207		27

XML

Note 11 - Segment Information (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	For the year ended December 31, 2023
	California Ethanol			California Dairy Renewable Natural Gas			India Biodiesel		All other		Total
Revenues from external customers	$	104,068		$	5,455		$	77,194	$	-	$	186,717
Intersegment revenues		-			-			-		-		-
Gross profit (loss)		(6,602	)		(331	)		8,950		-		2,017
Interest expense, including amortization of debt fees		25,258			2,809			447		11,005		39,519
Accretion and other expenses of Series A preferred units		-			25,313			-		-		25,313
Loss on
Income tax expense (benefit)		-			(55,159	)		1,416		7		(53,736	)
Capital expenditures		5,695			24,744			1,281		1,399		33,119
Depreciation		3,995			2,116			576		246		6,933
Total Assets		67,991			92,794			34,769		47,852		243,406

	For the year ended December 31, 2022
	California Ethanol			California Dairy Renewable Natural Gas			India Biodiesel		All other			Total
Revenues from external customers	$	228,194		$	208		$	28,111	$	-		$	256,513
Intersegment revenues		-			1,002			-		-			1,002
Gross profit (loss)		(13,017	)		(778	)		8,273		(13	)		(5,535	)
Interest expense, including amortization of debt fees		20,637			742			119		7,272			28,770
Accretion and other expenses of Series A preferred units		-			9,888			-		-			9,888
Income tax expense		-			6			1,040		7			1,053
Loss on debt extinguishment		-			49,386			-		-			49,386
Capital expenditures		8,399			22,884			129		7,745			39,157
Depreciation		4,148			615			650		122			5,535
Total Assets		66,794			77,714			16,120		46,486			207,114

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

Revenues
	2023		2022
Total revenues for reportable segments	$	186,717	$	257,515
Elimination of intersegment revenues		-		(1,002	)
Total consolidated revenues	$	186,717	$	256,513

XML

Note 13 - Income Tax (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	2023			2022
Current:
Federal	$	(55,164	)	$	-
State and Local		13			13
Foreign		1,489			230
		(53,662	)		243
Deferred:
Federal		-			-
State and Local		-			-
Foreign		(74	)		810
Income tax (benefit) expense	$	(53,736	)	$	1,053

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	Year Ended December 31,
	2023			2022
United States	$	(107,191	)	$	(112,959	)
Foreign		7,035			6,254
Pretax loss	$	(100,156	)	$	(106,705	)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Year Ended December 31,
	2023			2022
Income tax benefit at the federal statutory rate	$	(21,033	)	$	(22,408	)
State tax benefit		(999	)		(496	)
Sale of tax credits		(55,164	)		-
Foreign tax differential		11			168
Stock-based compensation		2,048			295
Interest Expense		92			58
GILTI Inclusion		-			1,126
Prior year true-ups		(18,031	)		55
Non-includible US Entities		-			13,499
Other		67			46
Credits		(869	)		(2,373	)
Valuation Allowance		40,142			11,083
Income Tax Expense (Benefit)		(53,736	)		1,053
Effective Tax Rate		53.65	%		(0.99	)%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	Year Ended December 31,
	2023			2022
Deferred Tax Assets
Organizational Costs, Start-up and Intangible Assets	$	34,217		$	2,309
Stock Based Compensation		1,239			1,842
NOLs, Unabsorbed Depreciation and R&D Credits C/F's		67,621			68,201
Interest expense carryover		29,066			22,374
Ethanol Credits		1,500			1,500
Carbon Oxide Sequestration Credit		6,696			5,827
Accrued Expenses		2,249			2,001
Operating Lease Liability		1,282			1,512
Other, net		248			113
Total Deferred Tax Assets		144,118			105,679
Valuation Allowance		(135,354	)		(95,214	)
Net Deferred Tax Assets		8,764			10,465
Deferred Tax Liabilities
Right of Use Asset		(1,230	)		(1,477	)
Property, Plant & Equipment		(8,266	)		(9,788	)
Other, net		(3	)		(10	)
Total Deferred Tax Liabilities		(9,499	)		(11,275	)
Net Deferred Tax Liabilities	$	(735	)	$	(810	)

Summary of Income Tax Examinations [Table Text Block]

United States — Federal	2007 – present
United States — State	2008 – present
India	2013 – present
Mauritius	2006 – present

XML

Note 14 - Parent Company Financial Statements (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Condensed Balance Sheet [Table Text Block]

	2023			2022
Assets
Current assets
Cash and cash equivalents	$	1,454		$	286
Receivables due from subsidiaries		110,083			98,780
Prepaid expenses		437			611
Other current assets		12			7
Total current assets		111,986			99,684
Investment in Aemetis Property Keyes, Inc.		1,556			1,274
Investment in Aemetis International, Inc.		12,059			6,659
Investment in Aemetis Advanced Products Riverbank, Inc.		638			173
Investment in AE Advanced Products Keyes , Inc.		246			-
Total investments in Subsidiaries, net of advances		14,499			8,106
Property, plant and equipment, net		149			135
Other assets		2,096			2,377
Total Assets	$	128,730		$	110,302
Liabilities & stockholders' deficit
Current liabilities
Accounts payable	$	3,633		$	2,934
Mandatorily redeemable Series B convertible preferred		4,521			4,082
Other current liabilities		5,031			4,269
Total current liabilities		13,185			11,285
Long term liabilities:
Operating lease liability		1,716			2,047
Subsidiary obligation in excess of investment
Investment in AE Advanced Fuels, Inc.		220,571			177,856
Investment in Aemetis Americas, Inc		202			205
Investment in Aemetis Biofuels, Inc.		2,721			2,738
Investment in Aemetis Technologies, Inc.		4,868			4,716
Investment in AE Advanced Products Keyes , Inc.		-			270
Investment in Aemetis Health Products, Inc.		2,084			2,076
Investment in Goodland Advanced Fuels, Inc.		22,982			16,869
Investment in Aemetis Biogas LLC		70,471			91,292
Investment in Aemetis Carbon Capture Inc		5,895			2,323
Investment in Aemetis Properties Riverbank, Inc.		1,012			479
Total subsidiary obligation in excess of investment		330,806			298,824
Total long term liabilities		332,522			300,871
Stockholders' deficit
Series B Preferred convertible stock		-			1
Common stock		41			36
Additional paid-in capital		264,058			232,546
Accumulated deficit		(475,405	)		(428,985	)
Accumulated other comprehensive loss		(5,671	)		(5,452	)
Total stockholders' deficit		(216,977	)		(201,854	)
Total liabilities & stockholders' deficit	$	128,730		$	110,302

Condensed Income Statement [Table Text Block]

	2023			2022
Equity in subsidiary losses	$	(25,370	)	$	(91,561	)
Selling, general and administrative expenses		19,218			15,203
Operating loss		(44,588	)		(106,764	)
Other (income) expense
Interest expense		1,073			806
Debt related fees and amortization expense		781			1,581
Other income		(30	)		(1,400	)
Loss before income taxes		(46,412	)		(107,751	)
Income tax expense		8			7
Net loss		(46,420	)		(107,758	)
Other comprehensive loss
Foreign currency translation adjustment		(219	)		(1,102	)
Comprehensive loss	$	(46,639	)	$	(108,860	)

Condensed Cash Flow Statement [Table Text Block]

	2023			2022
Operating activities:
Net loss		(46,420	)		(107,758	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		7,660			6,410
Depreciation		51			29
Debt related fees and amortization expense		782			1,776
Subsidiary portion of net losses		25,370			91,561
Gain on litigation		-			(1,400	)
Warrants issued for working capital agreement		409			-
Changes in assets and liabilities:
Prepaid expenses		(608	)		111
Accounts payable		699			(90	)
Accrued interest expense		785			778
Other liabilities		85			(4,625	)
Other assets		276			207
Net cash used in operating activities		(10,911	)		(13,001	)
Investing activities:
Capital expenditures		(65	)		(128	)
Subsidiary advances, net		(9,707	)		1,222
Net cash provided by (used in) investing activities		(9,772	)		1,094
Financing activities:
Proceeds from the exercise of stock options		133			206
Proceeds from issuance of common stock in equity offering		21,718			11,987
Net cash provided by financing activities		21,851			12,193
Net increase in cash, cash equivalents, and restricted cash		1,168			286
Cash, cash equivalents and restricted cash at beginning of period		286			-
Cash, cash equivalents, and restricted cash at end of period	$	1,454		$	286
Supplemental disclosures of cash flow information, cash paid:
Income taxes paid		7			7
Supplemental disclosures of cash flow information, non-cash transactions:
Fair value of warrants issued to subordinated debt holders		1,278			1,939
Fair value of stock issued to a related party for guarantee fees		-			2,012
Fair value of warrants issued for capital expenditures		318			-
Fair value of warrants issued to lender for debt issuance costs		-			3,158
Fair value of stock issued to lender		-			1,335

XML

Note 1 - Nature of Activities and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
	Feb. 28, 2023 USD ($)	May 31, 2022 USD ($)	Oct. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2019 USD ($)
Number of Operating Segments						3
U.S. Department of Food And Agriculture Forest Service [Member]
Awarded Grants						$ 245
Proceeds from Grantors						166,000
LCFPP [Member]
Awarded Grants						4,200
Proceeds from Grantors						3,800
CDFAs[Member]
Awarded Grants			$ 7,800					$ 3,200
Proceeds from Grantors						6,200
CEC [Member]
Matching Contribution								7,900
Actual Expenses Incurred								5,000
Unearned Grant Proceeds						1,700	$ 1,700
CEC [Member] | Maximum [Member]
Awarded Grants								$ 5,000
California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System [Member]
Awarded Grants						8,000
Proceeds from Grantors						4,400
Matching Contribution						1,600
CAL FIRE Business and Workforce Development Grant Program [Member]
Awarded Grants		$ 2,000
Proceeds from Grantors						0
Matching Contribution		5,800
CAL Fire [Member]
Awarded Grants		500
Proceeds from Grantors						0
US Forest Service [Member]
Awarded Grants		642
USDA Bioguel Producer Program [Member]
Proceeds from Grantors					$ 14,200
Matching Contribution		$ 2,400
California Energy Commission Grant for Mechanical Vapor Recompression System [Member]
Awarded Grants						6,000
Proceeds from Grantors						0
Matching Contribution						5,300
CEC PG&E Pipeline Interconnect [Member]
Proceeds from Grantors	$ 5,000
PG&E SEM Incentive Program [Member]
Proceeds from Grantors				$ 374
Other Receivable [Member]
Accumulated Deferred Investment Tax Credit						55,200
India Biodiesel [Member] | Other Current Assets [Member]
Tax Credit Carryforward, Amount						1,600
Nontrade Receivables, Current						69
Accounts and Other Receivables, Net, Current						$ 1,200

XML

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of America By Product Category (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Sales	$ 77,194	$ 28,111
California Ethanol [Member]
Sales	104,068	228,194
California Ethanol [Member] | Alternative Energy, Ethanol [Member]
Sales	78,403	165,876
California Ethanol [Member] | Wet Distillers Grains [Member]
Sales	21,963	50,930
California Ethanol [Member] | Product and Service, Other [Member]
Sales	3,702	11,388
California Dairy Renewable Natural Gas [Member] | Gas Molecules and RIN Credits [Member]
Sales	5,455	208
India Biodiesel [Member] | Renewable Energy, Biodiesel [Member]
Sales	74,503	27,041
India Biodiesel [Member] | Product and Service, Other [Member]
Sales	$ 2,691	$ 1,070

XML

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 2,667	$ 4,313
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	6,280	6,999
Other Current Assets [Member]
Restricted cash	289	725
Other Assets [Member]
Restricted cash	$ 3,324	$ 1,961

XML

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	7,323	6,417
Series B Convertible Preferred Stock [Member]
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	0	127
Common Stock Options and Warrants [Member]
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	6,056	5,050
Debt with Conversion Feature [Member]
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	1,267	1,240

XML

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Debt with Conversion Feature [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 30	$ 30

XML

Note 2 - Inventories (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Inventory Write-down	$ 58	$ 100

XML

Note 2 - Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Raw materials	$ 9,907	$ 2,971
Work-in-progress	1,682	127
Finished goods	6,702	1,560
Total inventories	$ 18,291	$ 4,658

XML

Note 3 - Property, Plant and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Capitalized Interest Costs, Including Allowance for Funds Used During Construction	$ 5,600	$ 11,100
Depreciation	$ 6,933	$ 5,535

XML

Note 3 - Property, Plant and Equipment - Schedule of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Land	$ 7,345	$ 7,344
Plant and buildings	136,318	99,116
Furniture and fixtures	2,266	1,831
Machinery and equipment	14,982	15,209
Construction in progress	73,057	88,990
Property held for development	15,431	15,437
Total gross property, plant & equipment	252,288	230,972
Less accumulated depreciation	(57,180)	(50,531)
Total net property, plant & equipment	195,108	180,441
Property, Plant and Equipment [Member]
Finance lease right of use assets	$ 2,889	$ 3,045

XML

Note 3 - Property, Plant and Equipment - Depreciation of Property, Plant, and Equipment (Details)	Dec. 31, 2023
Minimum [Member] | Building [Member]
Useful life (Year)	20 years
Minimum [Member] | Machinery and Equipment [Member]
Useful life (Year)	5 years
Minimum [Member] | Furniture and Fixtures [Member]
Useful life (Year)	3 years
Maximum [Member] | Building [Member]
Useful life (Year)	30 years
Maximum [Member] | Machinery and Equipment [Member]
Useful life (Year)	15 years
Maximum [Member] | Furniture and Fixtures [Member]
Useful life (Year)	5 years

XML

Note 4 - Debt (Details Textual) $ / shares in Units, gal in Millions	Jan. 01, 2024 USD ($) $ / shares shares	Jul. 28, 2023 USD ($)	Jul. 01, 2023 USD ($) $ / shares shares	May 16, 2023 USD ($) $ / shares shares	Jan. 01, 2023 USD ($) $ / shares shares	Oct. 04, 2022 USD ($)	Mar. 02, 2022 USD ($) $ / shares shares	Mar. 06, 2020 USD ($)	Jul. 06, 2012 USD ($)	Mar. 04, 2011 USD ($)	Mar. 25, 2024 USD ($)	Mar. 22, 2024 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Sep. 30, 2023 USD ($)	May 04, 2023 USD ($) gal	Mar. 31, 2023	Mar. 06, 2023 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Aug. 08, 2022 USD ($)	Aug. 01, 2022 USD ($)	Jul. 26, 2022 USD ($)	May 11, 2022 USD ($)	Mar. 08, 2022 USD ($)	Dec. 31, 2021 $ / shares	Aug. 09, 2021 USD ($)	Mar. 14, 2021 USD ($)	May 01, 2020 USD ($)	Nov. 21, 2019 USD ($)	Feb. 27, 2019 $ / shares	Oct. 16, 2016 USD ($)	Jan. 09, 2012 USD ($) $ / shares	Jan. 06, 2012 USD ($)
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 11.7					$ 15.92						$ 2.59
Long-Term Debt, Total													$ 294,721,000
Warrants and Rights Outstanding, Term (Year)													5 years 9 months 7 days					7 years 5 months 23 days						4 years 11 months 12 days
Short-Term Debt													$ 23,443,000					$ 36,754,000
Debt, Long-Term and Short-Term, Combined Amount													294,721,000					246,240,000
Other Long-Term Debt, Noncurrent													51,717,000					11,678,000
Stock Issued Under Fuels Revolving Line [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares							100,000
Five Year Warrants in Connection With New Credit Facility [Member] | Third Eye Capital [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares							50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 10.2
Ten Year Warrants in Connection With New Credit Facility [Member] | Third Eye Capital [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares							250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 20
Warrants in Connection With Subordinated Notes [Member] | AAFK [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.01		$ 0.01																										$ 0.01
Warrants and Rights Outstanding, Term (Year)			2 years		2 years																										2 years
Class of Warrant or Right, Issued (in shares) | shares			113,000		113,000
Warrants in Connection With Subordinated Notes [Member] | Subsequent Event [Member] | AAFK [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	113,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.01
Warrants and Rights Outstanding, Term (Year)	2 years
Class of Warrant or Right, Issued (in shares) | shares	113
Revolving Credit Facility [Member]
Repayments of Long-Term Lines of Credit							$ 16,000,000
Property Taxes Payment							6,100,000
Capital Revolving Credit Facility Fuels And Carbon Lines [Member] | GAFI and ACCI [Member]
Line of Credit Facility, Maximum Borrowing Capacity							100,000,000
Fuels Revolving Line [Member] | GAFI [Member]
Line of Credit Facility, Maximum Borrowing Capacity							50,000,000
Carbon Revolving Line [Member] | ACCI [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 50,000,000
Third Eye Capital [Member] | Mr. McAfee [Member]
Net Amount at Risk by Product and Guarantee, Net Amount at Risk													8,000,000
Third Eye Capital [Member] | Warrants in Association With Amendment No. 27 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				80,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 2
Third Eye Capital [Member] | Revolving Credit Facility [Member]
Debt Instrument, Face Amount									$ 18,000,000
Long-Term Debt, Total													21,900,000
Debt Issuance Costs, Net													$ 900,000
Third Eye Capital [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage													22.25%
Debt Instrument, Basis Spread on Variable Rate									13.75%
Third Eye Capital [Member] | Acquisition Term Notes [Member]
Debt Instrument, Face Amount									$ 15,000,000
Third Eye Capital [Member] | Revolving Notes Series B [Member]
Long-Term Debt, Total													$ 54,800,000
Debt Issuance Costs, Net													$ 400,000
Third Eye Capital [Member] | Revolving Notes Series B [Member] | Prime Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage													22.25%
Debt Instrument, Basis Spread on Variable Rate				13.75%
Third Eye Capital [Member] | Reserve Liquidity Facility [Member]
Line of Credit Facility, Current Borrowing Capacity													$ 85,000,000
Debt Instrument, Interest Rate, Stated Percentage													30.00%
Long-Term Debt, Total													$ 0
Term Loan [Member] | Third Eye Capital [Member]
Debt Instrument, Face Amount									7,200,000
Revenue Participation Term Notes [Member] | Third Eye Capital [Member]
Debt Instrument, Face Amount									$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage													5.00%
Revenue Participation Term Notes [Member] | Third Eye Capital [Member] | AAFK [Member]
Long-Term Debt, Total													$ 12,100,000
Debt Issuance Costs, Net													$ 81,000
Amendment No. 22 [Member] | Third Eye Capital [Member]
Debt Instrument, Fee Amount																							$ 100,000
Amendment No. 23 [Member] | Third Eye Capital [Member]
Debt Instrument, Fee Amount																						$ 100,000
Amendment No. 24 [Member] | Third Eye Capital [Member]
Debt Instrument, Fee Amount																			$ 300,000
Debt Instrument, Extension Fee, Percent of Note Indebtedness																			1.00%
Amendment No. 25 [Member] | Third Eye Capital [Member]
Debt Instrument, Fee Amount																	$ 100,000
Amendment No. 26 [Member] | Third Eye Capital [Member]
Debt Instrument, Fee Amount															$ 100,000
Debt Instrument, Minimum Production Requirement (Gallon) | gal															10
Amendment No. 27 [Member] | Third Eye Capital [Member]
Debt Instrument, Fee Amount				$ 500,000
Debt Instrument, Extension Fee, Percent of Note Indebtedness				1.00%
Amendment No 28 [Member] | Third Eye Capital [Member] | Subsequent Event [Member]
Debt Instrument, Fee Amount											$ 100,000
Reserve Liquidity Facility [Member] | Third Eye Capital [Member]
Debt Instrument, Face Amount								$ 18,000,000
Debt Instrument, Term (Year)								1 year
Line of Credit Facility, Maximum Borrowing Capacity																										$ 70,000,000
Line of Credit Facility, Current Borrowing Capacity																									$ 40,000,000
Debt Instrument, Non-refundable Standby Fee, Percent of Difference Between Principal Amount and the Commitment								2.00%
Non Refundable Fees								$ 500,000
Reserve Liquidity Facility [Member] | Third Eye Capital [Member] | Subsequent Event [Member]
Debt Instrument, Fee Amount											500,000
Line of Credit Facility, Maximum Borrowing Capacity											$ 85,000,000	$ 85,000,000
Reserve Liquidity Facility Paid Monthly in Arrears [Member] | Third Eye Capital [Member]
Debt Instrument, Interest Rate, Stated Percentage								30.00%
Reserve Liquidity Facility if Event of Default Occurred and Continues [Member] | Third Eye Capital [Member]
Debt Instrument, Interest Rate, Stated Percentage								40.00%
Term Notes [Member] | Third Eye Capital [Member]
Debt Instrument, Interest Rate, Stated Percentage													14.00%
Long-Term Debt, Total													$ 7,200,000
Debt Issuance Costs, Net													45,000
Acquisition Term Notes [Member] | Third Eye Capital [Member]
Long-Term Debt, Total													26,800,000
Debt Issuance Costs, Net													184,000
Acquisition Term Notes [Member] | Third Eye Capital [Member] | Aemetis Facility Keyes, Inc. [Member]
Debt Instrument, Redemption Fee													$ 7,500,000
Acquisition Term Notes [Member] | Third Eye Capital [Member] | Prime Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage													19.25%
Debt Instrument, Basis Spread on Variable Rate									10.75%
Fuels Revolving Line [Member] | GAFI [Member]
Debt Instrument, Interest Rate, Stated Percentage							10.00%						14.50%
Long-Term Debt, Total													$ 33,900,000
Debt Issuance Costs, Net													$ 1,300,000
Fuels Revolving Line [Member] | Prime Rate [Member] | GAFI [Member]
Debt Instrument, Basis Spread on Variable Rate							6.00%
Carbon Revolving Line [Member] | ACCI [Member]
Debt Instrument, Interest Rate, Stated Percentage							8.00%						12.50%
Long-Term Debt, Total													$ 25,200,000
Debt Issuance Costs, Net													1,700,000
Carbon Revolving Line [Member] | Prime Rate [Member] | ACCI [Member]
Debt Instrument, Basis Spread on Variable Rate							4.00%
Cilion Shareholder Seller Notes Payable [Member]
Debt Instrument, Face Amount									$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage									3.00%
Long-Term Debt, Total													7,000,000
Debt, Long-Term and Short-Term, Combined Amount													7,028,000					6,821,000
Subordinated Notes [Member] | AAFK [Member]
Debt Instrument, Fee Amount																															$ 2,500,000	$ 900,000
Debt Instrument Fee Rate																															10.00%
Debt Extension Fee, Percentage																															10.00%
Short-Term Debt													17,600,000					15,900,000
Subordinated Notes 1 [Member]
Short-Term Debt													17,625,000					15,931,000
Subordinated Notes 1 [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee			$ 90,000		$ 90,000
Subordinated Notes 1 [Member] | Subsequent Event [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee	$ 90,000
Subordinated Notes 2 [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee			$ 250,000		$ 250,000
Subordinated Notes 2 [Member] | Subsequent Event [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee	$ 250,000
EB5 Phase I Notes [Member]
Debt Instrument, Face Amount										$ 500,000
Debt Instrument, Term (Year)										4 years
Long-Term Debt, Total													37,900,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																													$ 30
Debt Instrument, Amount Released From Escrow													35,500,000
Debt Instrument, Amount Remaining Funded to Escrow													500,000
EB5 Phase I Notes [Member] | Scenario, Plan [Member]
Debt Instrument, Face Amount																														$ 50,000,000
EB5 Phase I Notes [Member] | Minimum [Member]
Debt Instrument, Investment Raised Per Investor																											$ 500,000
EB5 Phase I Funding [Member]
Debt Instrument, Face Amount										$ 36,000,000
EB5 Phase I Funding [Member] | Maximum [Member]
Debt Instrument, Face Amount										$ 36,000,000
EB5 Phase II Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage																												3.00%
Debt Instrument, Amount Remaining Funded to Escrow													46,800,000
Debt Instrument, Principal Amount Sold													4,000,000
Debt, Long-Term and Short-Term, Combined Amount													4,300,000
EB5 Phase II Notes [Member] | Maximum [Member]
Debt Instrument, Minimum Investment Raised Per Investor																												$ 900,000
Debt Instrument, Investment Raised Per Investor																											900,000
Aggregate Principal Amount																											$ 50,800,000
EB5 Phase II Notes [Member] | Minimum [Member]
Debt Instrument, Minimum Investment Raised Per Investor																												$ 500,000
Secunderabad Oils [Member]
Debt Instrument, Interest Rate, Stated Percentage																					18.00%
Short-Term Debt													3,800,000					0
Debt Agreement, Maximum Borrowing Capacity																					$ 1,880,000
Leo Edibles & Fats Limited [Member]
Debt Agreement, Maximum Borrowing Capacity																				$ 1,270,000
IndusInd Bank and HDFC Bank Secured Loans [Member]
Short-Term Debt													0					0
IndusInd Bank and HDFC Bank Secured Loans [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage																8.00%
IndusInd Bank and HDFC Bank Secured Loans [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage																6.00%
Construction Loan Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage						9.25%
Long-Term Debt, Total													25,100,000					0
Debt, Long-Term and Short-Term, Combined Amount													41,024,000					19,820,000
Debt Agreement, Maximum Borrowing Capacity						$ 25,000,000
Construction Loan Agreement [Member] | US Treasury (UST) Interest Rate [Member]
Debt Instrument, Basis Spread on Variable Rate						5.00%
Construction Loan Agreement 2 [Member]
Debt Instrument, Interest Rate, Stated Percentage		8.75%
Long-Term Debt, Total													16,800,000					0
Debt Issuance Costs, Net													800,000					$ 0
Debt Agreement, Maximum Borrowing Capacity		$ 25,000,000
Construction Loan Agreement 2 [Member] | US Treasury (UST) Interest Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		5.00%
Financing Agreement For Capital Expenditures [Member]
Debt Instrument, Face Amount														$ 5,700,000
Short-Term Debt													2,000,000
Other Long-Term Debt, Noncurrent													$ 3,800,000

XML

Note 4 - Debt- Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt, Long-Term and Short-Term, Combined Amount	$ 294,721	$ 246,240
Short-Term Debt	23,443	36,754
Less current portion of debt	37,028	49,219
Total long term debt	257,693	197,021
Third Eye Capital Term Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	7,159	7,141
Third Eye Capital Revolving Credit Facility [Member]
Debt, Long-Term and Short-Term, Combined Amount	20,922	60,602
Revolving Notes Series B [Member]
Debt, Long-Term and Short-Term, Combined Amount	54,412	0
Third Eye Capital Revenue Participation Term Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	12,011	11,963
Third Eye Capital Acquisition Term Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	26,655	26,578
Third Eye Capital Fuels Revolving Line [Member]
Debt, Long-Term and Short-Term, Combined Amount	32,511	27,410
Third Eye Capital Carbon Revolving Line [Member]
Debt, Long-Term and Short-Term, Combined Amount	23,486	22,710
Construction Loan Agreement [Member]
Debt, Long-Term and Short-Term, Combined Amount	41,024	19,820
Cilion Shareholder Seller Notes Payable [Member]
Debt, Long-Term and Short-Term, Combined Amount	7,028	6,821
Subordinated Notes 1 [Member]
Short-Term Debt	17,625	15,931
EB-5 Promissory Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	42,211	41,404
Working capital Loan [Member]
Short-Term Debt	3,827	0
Term Loan On Equipment Purchase [Member]
Debt, Long-Term and Short-Term, Combined Amount	$ 5,850	$ 5,860

XML

Note 4 - Debt - Maturities of Long-term Debt (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 37,028
2025	181,464
2026	37,912
2027	4,128
2028	2,108
There after	37,545
Total debt	300,185
Debt issuance costs	(5,464)
Total debt, net of debt issuance costs	$ 294,721

XML

Note 5 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	May 06, 2022	Jun. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 24, 2019
Estimated Litigation Liability, Current					$ 6,200
Litigation Settlement, Amount Awarded to Other Party	$ 4,800
Gain (Loss) Related to Litigation Settlement		$ 1,400	$ (0)	$ 1,400
Payments for Legal Settlements		$ 4,800
Minimum [Member]
Lease Term (Year)			1 year
Maximum [Member]
Lease Term (Year)			13 years

XML

Note 5 - Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating lease expense	$ 722	$ 673
Short term lease expense	223	176
Variable lease expense	93	91
Total operating lease cost	1,038	940
Amortization of right-of-use assets	121	179
Interest on lease liabilities	340	310
Total finance lease cost	461	489
Operating cash flows used in operating leases	668	766
Operating cash flows used in finance leases	340	310
Financing cash flows used in finance leases	$ 428	$ 481

XML

Note 5 - Commitments and Contingencies - Non-cash Flow Information Related to ROU Asset and Lease Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accretion of the lease liability	$ 249	$ 340
Amortization of right-of-use assets	$ 293	$ 333
Operating leases (in years) (Year)	4 years 2 months 12 days	5 years 2 months 12 days
Finance leases (in years) (Year)	13 years	14 years
Operating leases	14.10%	14.20%
Finance leases	13.20%	13.20%

XML

Note 5 - Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating lease right-of-use assets	$ 2,056	$ 2,449
Current portion of operating lease liability	406	338
Operating lease liability	1,783	2,189
Total operating lease liabilities	2,189	2,527
Total finance lease liabilities	2,717
Property, Plant and Equipment [Member]
Property and equipment, at cost	2,889	3,045
Accumulated depreciation	(228)	(112)
Property and equipment, net	2,661	2,933
Other Current Liabilities [Member]
Other current liability	30	71
Other Noncurrent Liabilities [Member]
Other long term liabilities	2,687	2,911
Other Liabilities [Member]
Total finance lease liabilities	$ 2,717	$ 2,982

XML

Note 5 - Commitments and Contingencies - Maturities of Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
2024, Operating leases	$ 682
2024, Finance leases	179
2025, Operating leases	681
2025, Finance leases	168
2026, Operating leases	626
2026, Finance leases	145
2027, Operating leases	645
2027, Finance leases	145
2028, Operating leases	272
2028, Finance leases	145
Thereafter, Operating leases	0
Thereafter, Finance leases	10,105
Total lease payments, Operating leases	2,906
Total lease payments, Finance leases	10,887
Less imputed interest, Operating leases	(717)
Less imputed interest, Finance leases	(8,170)
Total operating lease liability	2,189	$ 2,527
Total finance lease liability	$ 2,717

XML

Note 5 - Commitments and Contingencies - Lease Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lease income	$ 2,075	$ 1,255

XML

Note 5 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 948
2025	773
2026	562
2027	508
2028	508
There after	635
Total future lease commitments	$ 3,934

XML

Note 6 - Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity (Details Textual) - USD ($)									12 Months Ended		14 Months Ended	15 Months Ended	17 Months Ended	44 Months Ended
	Nov. 08, 2023	Oct. 06, 2023	Aug. 31, 2023	May 31, 2023	Feb. 08, 2023	Jan. 01, 2023	Aug. 08, 2022	Dec. 20, 2018	Dec. 31, 2023	Dec. 31, 2022	Dec. 24, 2024	Aug. 31, 2024	May 31, 2024	Aug. 08, 2022	Feb. 08, 2024
Payments for Repurchase of Redeemable Convertible Preferred Stock									$ 30,000,000	$ (0)
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent									113,200,000	116,000,000
Assets									243,406,000	207,114,000
California Dairy Renewable Natural Gas [Member]
Assets									92,794,000	77,714,000
California Dairy Renewable Natural Gas [Member] | Asset Pledged as Collateral [Member] | Aemetis Biogas LLC [Member] | Preferred Units Series A [Member]
Assets									$ 90,300,000
Carbon Revolving Line [Member]
Extinguishment of Debt, Gain (Loss), Net of Tax							$ (49,400,000)
Common Units [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)								5,000,000
Preferred Units Series A [Member]
Common Units Authorized (in shares)								11,000,000
Preferred Units, Authorized (in shares)								6,000,000
Preferred Unit Dividend Rate Per Dollar Amount (in dollars per share)								$ 0.5
Conversion of Stock, Shares Issued (in shares)								1,200,000	5,000,000
Maximum Number of Shares (in shares)								5,000,000
Redeemable Noncontrolling Interest, Equity, Preferred, Redemption Value per Unit (in dollars per share)								$ 15
Free Cash Flow Generated by ABGL								75.00%	100.00%
Redeemable Noncontrolling Interest Equity Redemption Value, Total								$ 90,000,000
Fees and Commission Transfer Agent								900,000
Debt Instrument, Collateral Amount								$ 30,000,000
Preferred Units Series A [Member] | First Tranche [Member]
Preferred Units, Issued (in shares)							3,200,000							3,200,000
Preferred Units Issued Value														$ 16,000,000
Preferred Units Series A [Member] | Second Tranche [Member
Preferred Units, Issued (in shares)							2,800,000							2,800,000
Preferred Units Issued Value														$ 14,000,000
Stock Redeemed or Called During Period, Shares (in shares)														20,000
Preferred Units Redeemed, Value														$ 300,000
Preferred Units Series A [Member] | Third Eye Capital [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)								6,000,000
Series A Preferred Stocks [Member]
Common Units Issued (in shares)								6,000,000
Common Units Issuance Value (in dollars per share)								$ 5
Proceeds from Issuance of Common Units								$ 30,000,000
PUPA Second Amendment [Member]
Preferred Units Issued Value							$ 116,000,000			$ 116,000,000
PUPA Second Amendment [Member] | Forecast [Member]
Preferred Units Issued Value													$ 159,000,000
PUPA Second Amendment [Member] | ABGL [Member]
Preferred Units Issued Value						$ 125,000,000	$ 106,000,000
PUPA Third Amendment [Member]
Preferred Units Issued Value				$ 127,200,000
Payments for Repurchase of Redeemable Convertible Preferred Stock		$ 30,000,000
Proceeds from Sale of Income Tax Credits		$ 55,200,000
PUPA Third Amendment [Member] | Forecast [Member]
Preferred Units Issued Value												$ 171,700,000
PUPA Third Amendment [Member] | ABGL [Member]
Preferred Units Issued Value			$ 135,000,000
PUPA Fourth Amendment [Member]
Preferred Units Issued Value	$ 110,600,000
Preferred Stock, Redemption Amount	108,000,000
Closing Fee	$ 5,500,000
PUPA Fourth Amendment [Member] | Subsequent Event [Member]
Closing Fee															$ 5,500,000
PUPA Fourth Amendment [Member] | Forecast [Member]
Increase in Carrying Amount of Redeemable Preferred Stock											$ 130,000,000
PUPA Fifth Amendment [Member]
Preferred Units Issued Value					$ 111,000,000
PUPA Fifth Amendment [Member] | Subsequent Event [Member]
Preferred Stock, Redemption Amount															$ 111,000,000

XML

Note 7 - Stockholders' Equity (Details Textual) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common Stock, Shares Authorized (in shares)	80,000,000	80,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Preferred Units, Authorized (in shares)	65,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	10
Preferred Stock, Shares Outstanding (in shares)	0

XML

Note 7 - Stockholders' Equity - Schedule of Stock by Class (Details) - shares shares in Thousands	Dec. 31, 2023	Dec. 31, 2022
Series B Preferred Stock, Authorized (in shares)	65,000
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Series B Preferred Stock [Member]
Series B Preferred Stock, Authorized (in shares)	7,235
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Undesignated [Member]
Series B Preferred Stock, Authorized (in shares)	57,765
Series B Preferred Stock, Shares Issued (in shares)	0	0

XML

Note 8 - Warrants to Purchase Common Stocks (Details Textual) - $ / shares	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 11.7	$ 15.92	$ 2.59
Warrants and Rights Outstanding, Term (Year)	5 years 9 months 7 days	7 years 5 months 23 days	4 years 11 months 12 days
Warrants to Purchase Common Stock [Member] | Vendor [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.5
Warrants and Rights Outstanding, Term (Year)	2 years
Stock Issued During Period, Warrants Exercised (in shares)	62,293
Warrants to Purchase Common Stock [Member] | Senior Lenders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	160,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants to Purchase Common Stock, Modification [Member] | Senior Lenders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 10.2
Warrants and Rights Outstanding, Term (Year)	3 years
Class of Warrant or Right, Number of Additional Securities Called by Warrants or Rights (in shares)	25,000
Warrants Issued to Subordinated Debt Holders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	226,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.01
Warrants and Rights Outstanding, Term (Year)	2 years

XML

Note 8 - Warrants to Purchase Common Stock - Fair Value Assumptions (Details)	Dec. 31, 2023 $ / shares yr	Dec. 31, 2022 $ / shares yr
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0385	0.0175
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.179	1.5141
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	5	3
Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	1.62	10.47
Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	4.13	11.29
Fair Value per Warrant on Grant Date [Member]
Warrants and Rights Outstanding, Measurement Input	3.92	9.68

XML

Note 8 - Warrants to Purchase Common Stock - Schedule of Warrants or Rights (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Outstanding, warrants (in shares)	355	55
Outstanding, Weighted - Average Exercise Price (in dollars per share)	$ 15.92	$ 2.59
Outstanding, Average Remaining Term in Years (Year)	5 years 9 months 7 days	7 years 5 months 23 days	4 years 11 months 12 days
Granted, warrants (in shares)	511	527
Granted, Weighted - Average Exercise Price (in dollars per share)	$ 1.62	$ 10.47
Exercised, warrants (in shares)	(336)	(227)
Exercised, Weighted - Average Exercise Price (in dollars per share)	$ 0.83	$ 0.01
Outstanding, warrants (in shares)	530	355
Outstanding, Weighted - Average Exercise Price (in dollars per share)	$ 11.7	$ 15.92

XML

Note 9 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Aug. 26, 2021	Apr. 25, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021	Jul. 01, 2021	Mar. 31, 2016
Share Price (in dollars per share)			$ 5.24	$ 3.96
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)			5,526,000	4,694,000
Share-Based Payment Arrangement, Expense			$ 7.7	$ 6.4
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 7.3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 6 months
The 2019 Stock Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)							4,558,621
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage Increase in Shares Available for Issuance Based on Common stock Outstanding	4.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Measurement Input, Shares (in shares)	2,541,823
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			244,000
Share Price (in dollars per share)			$ 3.6	$ 10.97
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)			5,526,000	4,694,000		3,763,000
The 2019 Stock Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				89,000
The 2019 Stock Plan [Member] | Restricted Stock [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			244,000	89,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value (in dollars per share)			$ 3.75	$ 10.92
The 2019 Stock Plan [Member] | Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)			1,300,000	1,300,000
The 2019 Stock Plan [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)					10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					3 years
Inducement Equity Plan Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)								100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)			0

XML

Note 9 - Stock-based Compensation - Schedule of Share-based Payment Award (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance, outstanding (in shares)	4,694
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.63
Balance, outstanding (in shares)	5,526	4,694
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.42	$ 4.63
The 2019 Stock Plan [Member]
Balance, Shares Available for Grant (in shares)	65	42
Balance, outstanding (in shares)	4,694	3,763
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.63	$ 2.29
Authorized, shares (in shares)	1,644	1,338
Options Granted, shares (in shares)	(1,278)	(1,307)
Options Granted, shares (in shares)	1,278	1,307
Options Granted, Weighted-Average Exercise Price (in dollars per share)	$ 3.6	$ 10.97
RSAs Granted, shares (in shares)	(244)
Exercised, outstanding (in shares)	(177)	(295)
Exercised, Weighted-Average Exercise Price (in dollars per share)	$ 1.83	$ 0.93
Forfeited/expired, shares available (in shares)	269	81
Forfeited/expired, outstanding (in shares)	(269)	(81)
Forfeited/expired, Weighted-Average Exercise Price (in dollars per share)	$ 5.93	$ 11.63
Balance, Shares Available for Grant (in shares)	456	65
Balance, outstanding (in shares)	5,526	4,694
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.42	$ 4.63
The 2019 Stock Plan [Member] | Restricted Stock [Member]
RSAs Granted, shares (in shares)		(89)

XML

Note 9 - Stock-Based Compensation - Share-Based Compensation Arrangement by Share-Based Payment Award, Options Vested and Expected to Vest, Outstanding, and Exercisable (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		24 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Vested and Exercisable, number of shares (in shares)		3,986	3,170
Vested and Exercisable, weighted average exercise price (in dollars per share)		$ 3.58	$ 2.46
Vested and Exercisable, remaining contractual term (Year)		6 years 5 months 19 days	6 years 11 months 23 days
Vested and Exercisable, aggregate intrinsic value	[1]	$ 11,695	$ 7,419
Unvested, number of share (in shares)		1,540	1,524
Unvested, weighted average exercise price (in dollars per share)		$ 6.55	$ 9.13
Unvested, remaining contractual term (Year)		8 years 8 months 1 day	8 years 9 months 21 days
Unvested, aggregate intrinsic value	[1]	$ 1,621	$ 647
Number of shares (in shares)		5,526	4,694
Weighted average exercise price (in dollars per share)		$ 4.42	$ 4.63
Remaining contractual term (Year)		7 years 14 days	7 years 6 months 29 days
Aggregate intrinsic value	[1]	$ 13,316	$ 8,066

[1] Intrinsic value based on the $5.24 and $3.96 closing price of Aemetis, Inc. common stock on December 31, 2023 and 2022 respectively, as reported on the NASDAQ Exchange.

XML

Note 9 - Stock-based Compensation - Fair Value Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Market value per share on grant date (in dollars per share)	$ 5.24	$ 3.96
The 2019 Stock Plan [Member]
Dividend-yield	0.00%	0.00%
Risk-free interest rate	3.86%	2.03%
Expected volatility	124.62%	117.21%
Expected life (years) (Year)	7 years	7 years
Market value per share on grant date (in dollars per share)	$ 3.6	$ 10.97
Fair value per share on grant date (in dollars per share)	$ 3.29	$ 9.71

XML

Note 10 - Agreements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jul. 01, 2022
Prepaid Expense, Current	$ 3,347	$ 4,248
Marketing Expense	1,500	2,900
Shipping and Handling Costs	1,700	3,300
Results of Operations, Transportation Costs	3,300	5,300
Forward Sales Commitments [Member]
Other Commitment	0
Operating Agreement with Gemini Edibles and Fats India Private Limited [Member]
Debt Agreement, Maximum Borrowing Capacity			$ 12,700
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Accounts Payable	0	0
J.D. Heiskell [Member]
Prepaid Expense, Current	$ 0	$ 2,400

XML

Note 10 - Agreements - Schedule of Working Capital Agreement Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Accounts payable	32,132	26,168
J.D. Heiskell [Member]
Accounts receivable	1,073	0
Accounts payable	1,207	27
Ethanol Sales [Member] | J.D. Heiskell [Member]
Revenues	77,359	0
Wet Distiller's Grains Sales [Member] | J.D. Heiskell [Member]
Revenues	21,963	50,930
CDO and CDS [Member] | J.D. Heiskell [Member]
Revenues	3,296	10,168
Corn Purchases [Member] | J.D. Heiskell [Member]
Corn purchases	$ 83,128	$ 191,401

XML

Note 11 - Segment Information (Details Textual) gal in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2023 gal	Dec. 31, 2022
Number of Reportable Segments		3
California Ethanol [Member]
GallonPerYear (Gallon)		65
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales [Member]
Number of Major Customers		1	1
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales [Member] | Customer One [Member]
Concentration Risk, Percentage		100.00%
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member]
Number of Major Customers			1
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member] | Customer One [Member]
Concentration Risk, Percentage			73.00%
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member] | Customer Two [Member]
Concentration Risk, Percentage			26.00%
India Biodiesel [Member]
GallonPerYear (Gallon)		60
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer One [Member]
Concentration Risk, Percentage		47.00%	48.00%
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer Two [Member]
Concentration Risk, Percentage		25.00%	29.00%
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer Three [Member]
Concentration Risk, Percentage		23.00%	12.00%
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Sales of Biogas [Member]
Number of Major Customers		1
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Sales of Biogas [Member] | Customer One [Member]
Concentration Risk, Percentage		100.00%
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | D3 RIN Credits [Member]
Number of Major Customers	1
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | D3 RIN Credits [Member] | Customer One [Member]
Concentration Risk, Percentage	98.00%

XML

Note 11 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Gross profit (loss)	2,017	(5,535)
Interest expense, including amortization of debt fees	39,519	28,770
Accretion and other expenses of Series A preferred units	25,313	9,888
Income tax expense (benefit)	(53,736)	1,053
Capital expenditures	33,119	39,157
Depreciation	6,933	5,535
Total Assets	243,406	207,114
Loss on debt extinguishment	0	49,386
Intersegment Eliminations [Member]
Revenues	0	1,002
California Ethanol [Member]
Revenues	104,068	228,194
Gross profit (loss)	(6,602)	(13,017)
Interest expense, including amortization of debt fees	25,258	20,637
Accretion and other expenses of Series A preferred units	0	0
Income tax expense (benefit)	0	0
Capital expenditures	5,695	8,399
Depreciation	3,995	4,148
Total Assets	67,991	66,794
Loss on debt extinguishment		0
California Ethanol [Member] | Intersegment Eliminations [Member]
Revenues	0	0
California Dairy Renewable Natural Gas [Member]
Revenues	5,455	208
Gross profit (loss)	(331)	(778)
Interest expense, including amortization of debt fees	2,809	742
Accretion and other expenses of Series A preferred units	25,313	9,888
Income tax expense (benefit)	(55,159)	6
Capital expenditures	24,744	22,884
Depreciation	2,116	615
Total Assets	92,794	77,714
Loss on debt extinguishment		49,386
California Dairy Renewable Natural Gas [Member] | Intersegment Eliminations [Member]
Revenues	0	1,002
India Biodiesel [Member]
Revenues	77,194	28,111
Gross profit (loss)	8,950	8,273
Interest expense, including amortization of debt fees	447	119
Accretion and other expenses of Series A preferred units	0	0
Income tax expense (benefit)	1,416	1,040
Capital expenditures	1,281	129
Depreciation	576	650
Total Assets	34,769	16,120
Loss on debt extinguishment		0
India Biodiesel [Member] | Intersegment Eliminations [Member]
Revenues	0	0
Other Segments [Member]
Revenues	0	0
Gross profit (loss)	0	(13)
Interest expense, including amortization of debt fees	11,005	7,272
Accretion and other expenses of Series A preferred units	0	0
Income tax expense (benefit)	7	7
Capital expenditures	1,399	7,745
Depreciation	246	122
Total Assets	47,852	46,486
Loss on debt extinguishment		0
Other Segments [Member] | Intersegment Eliminations [Member]
Revenues	$ 0	$ 0

XML

Note 11 - Segment Information - Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Elimination of intersegment revenues	0	(1,002)
Operating Segments [Member]
Revenues	$ 186,717	$ 257,515

XML

Note 12 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Expense	$ 7,700	$ 6,400
Mr. McAfee [Member]
Accrued Liabilities, Current	175
Various Board Members [Member]
Share-Based Payment Arrangement, Expense	400	400
Employment Agreements and Expense Reimbursements [Member] | Mr. McAfee [Member]
Related Party Transaction, Amounts of Transaction	400
Accrued Liabilities	400
One-time Guarantee Fee [Member] | Mr. McAfee [Member]
Related Party Transaction, Amounts of Transaction	350
Board Compensation Fees [Member] | Various Board Members [Member]
Related Party Transaction, Amounts of Transaction	$ 300	$ 300

XML

Note 13 - Income Tax (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Liabilities, Net, Total	$ 735	$ 810
Undistributed Earnings of Foreign Subsidiaries	1,300	$ 2,500
Alcohol and Cellulosic Biofuel Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,500
Carbon Oxide Sequestration Credit Carryforward [Member]
Tax Credit Carryforward, Amount	6,700
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 253,000
Domestic Tax Authority [Member] | Minimum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2027
Domestic Tax Authority [Member] | Maximum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2043
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 336,000
State and Local Jurisdiction [Member] | Minimum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2027
State and Local Jurisdiction [Member] | Maximum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2042

XML

Note 13 - Income Tax - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal tax expense, current	$ (55,164)	$ 0
State and Local tax expense, current	13	13
Foreign tax expense, current	1,489	230
Total tax expense, current	(53,662)	243
Federal tax expense, deferred	0	0
State and Local tax expense, deferred	0	0
Foreign tax expense, deferred	(74)	810
Income tax (benefit) expense	$ (53,736)	$ 1,053

XML

Note 13 - Income Tax - Schedule of Income Before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
United States	$ (107,191)	$ (112,959)
Foreign	7,035	6,254
Loss before income taxes	$ (100,156)	$ (106,705)

XML

Note 13 - Income Tax - Schedule of Effective Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income tax benefit at the federal statutory rate	$ (21,033)	$ (22,408)
State tax benefit	(999)	(496)
Sale of tax credits	(55,164)	0
Foreign tax differential	11	168
Stock-based compensation	2,048	295
Interest Expense	92	58
GILTI Inclusion	0	1,126
Prior year true-ups	(18,031)	55
Non-includible US Entities	0	13,499
Other	67	46
Credits	(869)	(2,373)
Valuation Allowance	40,142	11,083
Income tax (benefit) expense	$ (53,736)	$ 1,053
Effective Tax Rate	53.65%	(0.99%)

XML

Note 13 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Organizational Costs, Start-up and Intangible Assets	$ 34,217	$ 2,309
Stock Based Compensation	1,239	1,842
NOLs, Unabsorbed Depreciation and R&D Credits C/F's	67,621	68,201
Interest expense carryover	29,066	22,374
Accrued Expenses	2,249	2,001
Operating Lease Liability	1,282	1,512
Other, net	248	113
Total Deferred Tax Assets	144,118	105,679
Valuation Allowance	(135,354)	(95,214)
Net Deferred Tax Assets	8,764	10,465
Right of Use Asset	(1,230)	(1,477)
Property, Plant & Equipment	(8,266)	(9,788)
Other, net	(3)	(10)
Total Deferred Tax Liabilities	(9,499)	(11,275)
Net Deferred Tax Liabilities	(735)	(810)
Ethanol Credits [Member]
Deffered tax assets, tax credit carryforwards	1,500	1,500
Carbon Oxide Sequestration Credit Carryforward [Member]
Deffered tax assets, tax credit carryforwards	$ 6,696	$ 5,827

XML

Note 13 - Income Tax - Open Tax Years by Major Tax Jurisdiction (Details)	12 Months Ended
	Dec. 31, 2023
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Open tax year	2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
State and Local Jurisdiction [Member]
Open tax year	2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Foreign Tax Authority [Member] | Ministry of Finance, India [Member]
Open tax year	2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Foreign Tax Authority [Member] | Mauritius Revenue Authority [Member]
Open tax year	2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

XML

Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 2,667	$ 4,313
Prepaid expenses	3,347	4,248
Other current assets	3,462	3,653
Total current assets	36,400	18,136
Property, plant and equipment, net	195,108	180,441
Total Assets	243,406	207,114
Accounts payable	32,132	26,168
Other current liabilities	10,302	8,474
Total current liabilities	84,389	88,281
Operating lease liability	2,189	2,527
Total long term liabilities	375,994	320,687
Common stock	41	36
Additional paid-in capital	264,058	232,546
Accumulated deficit	(475,405)	(428,985)
Accumulated other comprehensive loss	(5,671)	(5,452)
Total stockholders' deficit	(216,977)	(201,854)
Total liabilities & stockholders' deficit	243,406	207,114
Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member]
Mandatorily redeemable Series B convertible preferred	4,521	4,082
Parent Company [Member]
Cash and cash equivalents	1,454	286
Receivables due from subsidiaries	110,083	98,780
Prepaid expenses	437	611
Other current assets	12	7
Total current assets	111,986	99,684
Investment in subsidiary, net of advances	14,499	8,106
Property, plant and equipment, net	149	135
Other assets	2,096	2,377
Total Assets	128,730	110,302
Accounts payable	3,633	2,934
Other current liabilities	5,031	4,269
Total current liabilities	13,185	11,285
Operating lease liability	1,716	2,047
Subsidiary obligation in excess of investment	330,806	298,824
Total long term liabilities	332,522	300,871
Common stock	41	36
Additional paid-in capital	264,058	232,546
Accumulated deficit	(475,405)	(428,985)
Accumulated other comprehensive loss	(5,671)	(5,452)
Total stockholders' deficit	(216,977)	(201,854)
Total liabilities & stockholders' deficit	128,730	110,302
Parent Company [Member] | Series B Preferred Stock [Member]
Series B Preferred convertible stock	0	1
Parent Company [Member] | Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member]
Mandatorily redeemable Series B convertible preferred	4,521	4,082
Parent Company [Member] | Aemetis Property Keyes, Inc. [Member]
Investment in subsidiary, net of advances	1,556	1,274
Parent Company [Member] | Aemetis International, Inc. [Member]
Investment in subsidiary, net of advances	12,059	6,659
Parent Company [Member] | Aemetis Advanced Products Riverbank, Inc. [Member]
Investment in subsidiary, net of advances	638	173
Parent Company [Member] | AE Advanced Products Keyes, Inc. [Member]
Investment in subsidiary, net of advances	246	0
Subsidiary obligation in excess of investment	0	270
Parent Company [Member] | AE Advanced Fuels, Inc. [Member]
Subsidiary obligation in excess of investment	220,571	177,856
Parent Company [Member] | Aemetis Americas, Inc. [Member]
Subsidiary obligation in excess of investment	202	205
Parent Company [Member] | Aemetis Biofuels, Inc. [Member]
Subsidiary obligation in excess of investment	2,721	2,738
Parent Company [Member] | Aemetis Technologies, Inc. [Member]
Subsidiary obligation in excess of investment	4,868	4,716
Parent Company [Member] | Aemetis Health Products, Inc. [Member]
Subsidiary obligation in excess of investment	2,084	2,076
Parent Company [Member] | Goodland Advanced Fuels, Inc. [Member]
Subsidiary obligation in excess of investment	22,982	16,869
Parent Company [Member] | Aemetis Biogas LLC [Member]
Subsidiary obligation in excess of investment	70,471	91,292
Parent Company [Member] | Aemetis Carbon Capture, Inc. [Member]
Subsidiary obligation in excess of investment	5,895	2,323
Parent Company [Member] | Aemetis Properties Riverbank, Inc. [Member]
Subsidiary obligation in excess of investment	$ 1,012	$ 479

XML

Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Selling, general and administrative expenses	$ 39,266	$ 28,686
Operating loss	(37,401)	(34,401)
Interest expense	39,519	28,770
Debt related fees and amortization expense	6,524	7,363
Other income	(2,077)	(14,340)
Income tax expense (benefit)	(53,736)	1,053
Net loss	(46,420)	(107,758)
Comprehensive loss	(46,639)	(108,860)
Parent Company [Member]
Equity in subsidiary losses	(25,370)	(91,561)
Selling, general and administrative expenses	19,218	15,203
Operating loss	(44,588)	(106,764)
Interest expense	1,073	806
Debt related fees and amortization expense	781	1,581
Other income	(30)	(1,400)
Loss before income taxes	(46,412)	(107,751)
Income tax expense (benefit)	8	7
Net loss	(46,420)	(107,758)
Foreign currency translation adjustment	(219)	(1,102)
Comprehensive loss	$ (46,639)	$ (108,860)

XML

Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Net loss		$ (46,420)	$ (107,758)
Share-based compensation		7,660	6,410
Depreciation		6,933	5,535
Debt related fees and amortization expense		6,524	7,363
Gain on litigation	$ (1,400)	0	(1,400)
Warrants issued for working capital agreement		409	0
Prepaid expenses		(1,838)	(1,777)
Accounts payable		13,726	2,183
Accrued interest expense		23,558	15,501
Other liabilities		(1,757)	(10,125)
Net cash provided by (used in) operating activities		13,825	(22,866)
Capital expenditures		(33,119)	(39,157)
Net cash used in investing activities		(23,687)	(31,306)
Proceeds from the exercise of stock options		133	206
Proceeds from issuance of common stock in equity offering		21,718	11,987
Net cash provided by financing activities		9,094	53,633
Net change in cash and cash equivalents for period		(719)	(752)
Cash, cash equivalents, and restricted cash at beginning of period		6,999	7,751
Cash, cash equivalents, and restricted cash at end of period		6,280	6,999
Income taxes paid		20	10
Fair value of warrants issued to subordinated debt holders		1,278	1,939
Fair value of stock issued to a related party for guarantee fees		0	2,012
Fair value of warrants issued to lender for debt issuance costs		318	3,158
Fair value of stock issued to lender		0	1,335
Parent Company [Member]
Net loss		(46,420)	(107,758)
Share-based compensation		7,660	6,410
Depreciation		51	29
Debt related fees and amortization expense		782	1,776
Subsidiary portion of net losses		25,370	91,561
Gain on litigation		0	(1,400)
Warrants issued for working capital agreement		409	0
Prepaid expenses		608	(111)
Accounts payable		699	(90)
Accrued interest expense		785	778
Other liabilities		85	(4,625)
Other assets		(276)	(207)
Net cash provided by (used in) operating activities		(10,911)	(13,001)
Capital expenditures		(65)	(128)
Subsidiary advances, net		(9,707)	1,222
Net cash used in investing activities		(9,772)	1,094
Proceeds from the exercise of stock options		133	206
Proceeds from issuance of common stock in equity offering		21,718	11,987
Net cash provided by financing activities		21,851	12,193
Net change in cash and cash equivalents for period		1,168	286
Cash, cash equivalents, and restricted cash at beginning of period		286	0
Cash, cash equivalents, and restricted cash at end of period		1,454	286
Income taxes paid		7	7
Fair value of warrants issued to subordinated debt holders		1,278	1,939
Fair value of stock issued to a related party for guarantee fees		0	2,012
Fair value of warrants issued for capital expenditures		318	0
Fair value of warrants issued to lender for debt issuance costs		0	3,158
Fair value of stock issued to lender		$ 0	$ 1,335

XML

Note 15 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Feb. 08, 2023	Mar. 06, 2020	Mar. 25, 2024	Mar. 22, 2024	Jan. 01, 2024	Dec. 31, 2023	Jul. 01, 2023	Jan. 01, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 14, 2021	Jan. 09, 2012	Jan. 06, 2012
Warrants and Rights Outstanding, Term (Year)						5 years 9 months 7 days			7 years 5 months 23 days	4 years 11 months 12 days
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 11.7			$ 15.92	$ 2.59
Line of Credit [Member] | Required Credit Agreement to Satisfy Units Redemption Obligation [Member]
Debt Instrument, Term (Year)	12 months
Line of Credit Facility, Maximum Borrowing Capacity	$ 111,000
PUPA Fifth Amendment [Member]
Preferred Units Issued Value	$ 111,000
AAFK [Member] | Warrants in Connection With Subordinated Notes [Member]
Warrants and Rights Outstanding, Term (Year)							2 years	2 years				2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0.01	$ 0.01				$ 0.01
Subsequent Event [Member] | AAFK [Member] | Warrants in Connection With Subordinated Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					113
Warrants and Rights Outstanding, Term (Year)					2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.01
Subordinated Notes [Member] | AAFK [Member]
Debt Instrument, Fee Amount												$ 2,500	$ 900
Subordinated Notes [Member] | Subsequent Event [Member]
Equity Financing					$ 25,000
Subordinated Notes 1 [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee							$ 90	$ 90
Subordinated Notes 1 [Member] | Subsequent Event [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee					90
Subordinated Notes 2 [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee							$ 250	$ 250
Subordinated Notes 2 [Member] | Subsequent Event [Member] | AAFK [Member]
Debt Instrument, Cash Extension Fee					$ 250
Reserve Liquidity Facility [Member] | Third Eye Capital [Member]
Debt Instrument, Term (Year)		1 year
Line of Credit Facility, Maximum Borrowing Capacity											$ 70,000
Reserve Liquidity Facility [Member] | Subsequent Event [Member] | Third Eye Capital [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 85,000	$ 85,000
Debt Instrument, Fee Amount			500
Amendment No 28 [Member] | Subsequent Event [Member] | Third Eye Capital [Member]
Debt Instrument, Fee Amount			$ 100

XML

Note 16 - Liquidity (Details Textual) - Third Eye Capital [Member] - Reserve Liquidity Facility [Member] - USD ($) $ in Millions	Mar. 25, 2024	Mar. 22, 2024	Mar. 14, 2021
Line of Credit Facility, Maximum Borrowing Capacity			$ 70
Subsequent Event [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 85	$ 85